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The contents of this doctoral dissertation titled “Metabolomics: A Promising Tool to Improve the 
Understanding of the Developmental Origins of Obesity and Metabolic Disease” are dedicated to 
each pediatric patient I see in my practice as a Registered Dietitian. My patients provide the 
inspiration to create innovative solutions to address the complex pathophysiology of obesity and 
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The prevalence of obesity and type 2 diabetes continues to rise in the pediatric and adult 
population. This increase in metabolic disease may be partially due to programming during 
sensitive periods of development. Metabolomics is a powerful tool to identify molecular 
biomarkers and mechanistic insights into adverse health outcomes. This dissertation describes 
the use of metabolomic profiling to define the metabolic environment in two human cohorts, 
during gestation and the pubertal transition, and relate them mechanistically to growth and 
metabolism outcomes.  
Lipidomic profiles performed on first trimester maternal plasma (M1), delivery maternal plasma 
(M3), and infant umbilical cord plasma (CB) in 106 mother-infant dyads showed selective 
transport of long-chain polyunsaturated fatty acids (PUFA) as well as lysophosphatidylcholine 
(LysoPC) and lysophosphatidylethanolamine (LysoPE) into CB. Using linear models, CB 
LysoPC and LysoPE groups were positively associated with birth weight, a commonly assessed 
indicator of gestational implications on fetal growth. M1 PUFA containing triglycerides and 
phospholipids appear to modulate the levels of the CB lysophospholipids related to BW. 
Furthermore, epigenome-wide DNA methylation was measured in CB leukocytes to determine 
how the maternal lipidome across gestation may influence fetal programming. M3 saturated 
LysoPCs and LysoPEs were associated with differential methylation in CpG islands within genes 
pertaining to cell proliferation and growth. These results highlight the influence of the maternal 
lipidome on the infant epigenome.  
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A growing body of evidence suggests a relationship between the metabolome and metabolic 
health in adults, however, less is known in children and adolescents in the pubertal transition, 
who have changing hormonal patterns and accumulation of muscle and fat tissue. Using 
untargeted metabolomics, metabolites associated with BMI z-score include positive associations 
with diglycerides among girls and positive associations with branched chain and aromatic amino 
acids in boys. In contrast to that found in adults, medium-chain acylcarnitines were inversely 
associated with insulin resistance (IR), suggesting less imbalance in the delivery and oxidation of 
substrates in adolescents, perhaps due to the increased substrate utilization to fuel tissue and 
linear growth. Path analysis identified metabolites that underlie the relationship between energy-
adjusted macronutrient intake with IR. Carbohydrate intake is positively associated with IR 
through decreases in intermediates of β-oxidation, while fat intake is positively associated with 
IR through increases in extra-mitochondrial fatty acid metabolism, the latter identified by 
accumulation of dicarboxylic fatty acids. Thus, biomarkers of IR and mitochondrial oxidative 
capacity may depend on the relative nutrient mix and an individual’s intrinsic mitochondrial 
metabolism.  
These studies demonstrate the ability to generate inferential hypotheses about metabolism by 
acquiring high dimensional metabolomics data. The suggested modulation of uptake of 
lysophospholipids into the developing fetus, potentially influencing birth weight, by PUFAs 
exposure in the first trimester could be tested in larger cohorts or experimentally by timed PUFA 
intake. Longitudinal follow-up is needed to identify if fetal programming, via the establishment 
of DNA methylation patterns at birth, influences risk of adult metabolic disease. During 
adolescence, our findings confirm and extend associations between the metabolome with obesity 
and IR, emphasizing sex-specific differences due to variations in muscle and fat tissue 
xvii 
 
accumulation in puberty. These results suggest that adolescents prone to IR have an increase in 
selection of carbohydrates for fuel, exacerbated by elevated habitual carbohydrate consumption. 
Using controlled feeding studies, intrinsic differences in mitochondrial metabolism and the 





CHAPTER 1                                                                                                                           
Introduction 
Obesity and Type 2 Diabetes: A Growing Public Health Challenge. 
One of the top public health crises our world currently is challenged by is the increase in the 
prevalence of obesity. Between 1980 and 2014, the worldwide prevalence of obesity has more 
than doubled (1). In the United States, 39.8% of adults have obesity and 18.5% of children and 
adolescents aged 2-19 years have obesity (2). The high prevalence of obesity is increasing in 
both developed and developing nations (3). Higher levels of obesity are found in people with 
lower socioeconomic status, less education, and within Hispanic and non-Hispanic black (4).   
Obesity is defined by excessive growth of adipose tissue depots, typically due to an imbalance 
between energy intake and the energetic needs of an individual. The obesity pandemic is related 
to increased intake of calorically dense foods, in particular highly processed foods, paired with 
increases in sedentary activity (5). Through the incorporation of genome-wide analyses, common 
genetic variants of obesity risk have been identified (6). Depending on the population studied, 
the genetic influence of obesity varies from 40-70% (7,8). Common genes associated with 
obesity have previously been reviewed highlighting 190 known associated loci, accounting for 
<10% of obesity risk (6). Therefore, genetics alone cannot explain the rise in obesity prevalence 
and it is clear that the interaction between environmental factors and genetic variants influences 
the risk of disease.  
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In parallel to the obesity pandemic, the global prevalence of type 2 diabetes (T2D) has rapidly 
increased over the past four decades (9). In a study including 180 countries, the global 
prevalence of T2D in people ages 20-79 years was 8.8% in 2015 (10). The burden of diabetes 
influences low-income and middle-income countries more than high-income countries with the 
highest T2D trends in Polynesia and Micronesia followed by Melanesia, the Middle East, and 
northern Africa (9). Epidemiologic studies link T2D with obesity, including the Nurses’ Health 
Study (11), suggesting that T2D risk increases with higher BMI. Studies highlight the 
importance of fat distribution in the development to T2D. Visceral adiposity, rather than 
subcutaneous adiposity, contributes to T2D, potentially due to lipid accumulation around key 
internal organs including the liver (12). The increased ability to store excess lipids in 
subcutaneous adipose tissue is hypothesized to be protective from developing T2D (13). 
T2D development is associated with a fall in the production of the hormone insulin. Insulin is an 
anabolic hormone produced by β-cells of the pancreas in the fed state to maintain blood glucose 
homeostasis. Insulin binds to insulin receptors on the cell surface, inducing autophosphorylation 
of the insulin receptors and stimulating a signaling cascade to maintain glucose homeostasis (14). 
The regulatory effect of the insulin transduction pathway differs by cell type – stimulating uptake 
of glucose in myocytes and adipocytes, inhibiting glucose release in hepatocytes, promoting lipid 
synthesis and storage in hepatocytes and adipocytes, and stimulating protein synthesis and 
inhibiting protein degradation in myocytes (14).  
The origins of T2D begin as tissues become resistant, or non-responsive, to insulin signaling. To 
compensate, pancreatic β-cells increase the production of insulin to lower blood glucose levels. 
Overtime, the resistance to insulin action paired with an intrinsic susceptibility to dysfunction 
and death of β-cells to produce leads to inadequate insulin secretion for the prevailing insulin 
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sensitivity (15). Indeed, genes attributing to the development of type 2 diabetes seem to be 
primarily associated with β-cell development, signaling, and failure to compensate for increased 
demands (16). Without the production of insulin, blood glucose homeostasis is not maintained. 
Elevations in the blood glucose level is paired with increases in free fatty acids (FFA), 
triglycerides (TG), and LDL-cholesterol (LDL-C) (17). The gold standard for measuring insulin 
resistance is a hyperinsulinemic-euglycemic clamp (18), however, estimates can be obtained 
through the homeostatic model assessment of insulin resistance (HOMA-IR) or through a 
frequently sampled intravenous glucose tolerance test (FSIVGTT). Systemic changes in glucose 
homeostasis are a result of impaired insulin action on multiple metabolically active organs, 
including skeletal muscle, the liver, and adipose tissue. Although the complete mechanisms in 
the pathogenesis of T2D are not yet fully understood, researchers are beginning to describe how 
tissues become insulin resistant, highlighting the connection between obesity and T2D (19).  
This dissertation describes the use of metabolomic profiling to define the metabolic environment 
in two human cohorts, during gestation and the pubertal transition, and relate them 
mechanistically to growth and metabolism outcomes, potentially highlight risk of developing 
metabolic diseases (Figure 1.1). To address this objective, we incorporated untargeted 
metabolomics and lipidomics techniques to two human cohorts; the Michigan Mother-Infant 
Pairs (MMIP) cohort and the Early Life Exposure in Mexico to ENvironmental Toxicants 
(ELEMENT) cohort (Figure 1.2). During gestation, the maternal lipidome was related to the 
infant birth weight and the umbilical CB lipidome to determine how nutrient exposure influences 
fetal growth. Additionally, we assessed the influence of the maternal lipidome on establishing 
infant umbilical CB leukocyte DNA methylation patterns, providing insight on fetal 
programming via epigenetic mechanisms. Lastly, during adolescence, we determined how the 
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metabolome is associated with insulin resistance, which may be exacerbated by habitual dietary 
intake. The remainder of this chapter will focus the developmental origins of susceptibility to 
type 2 diabetes on the application of metabolomics to probe the potential biology underlying risk 
for insulin resistance and diabetes.  
The Developmental Origins of Obesity and Metabolic Disease.  
Both external and internal exposures may influence the trajectory of development and alter 
disease risk in adult life. The Developmental Origins of Health and Disease (DOHaD) field 
describes how insults during the gestational and postnatal periods can permanently program an 
individual altering their risk of human disease during adulthood (20). David Barker and his 
colleagues were the original pioneers of the DOHaD approach which originated from their 
epidemiological studies of infant and adult mortality published in The Lancet (21–23). These 
findings generated the Fetal Origins Hypothesis, which proposes that the gestational period has a 
significant impact on an individual’s health and wellbeing in adulthood. Barker demonstrated 
that the fetus is not immune to harmful exposures and events that happen during gestation can 
impact future health in adulthood.  
The DOHaD approach acknowledges that an organism will adapt to best fit its external 
environment to increase chance of survival. Developmental plasticity describes the ability of a 
given genotype to produce differing phenotypes in response to environmental cues (24). 
Plasticity can be evolutionary advantageous as environmental cues can influence structural 
changes to enhance the survival of the organism within the extant environment. Sensitive periods 
of development denote times when environmental insults have a larger effect than the same 
exposure during other periods. Examples of sensitive periods include in utero, newborn, infancy, 
and puberty. Infant birth weight (BW) is the most common health outcome studied to determine 
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if the maternal intrauterine environment influences the development of the fetus. Both low and 
high BW have been associated with increased T2D rates, proposing a U-shaped curve with 
higher T2D rates in both tails of the distributions (25,26). 
Maternal nutrient availability and offspring health outcomes 
The origins of the DOHaD field began in the 1900s, as scientists were collecting experimental 
evidence that manipulating pregnant animals can alter the phenotype of the offspring (27). 
Famines during World War II provided rare experiments to observe how conditions during 
gestational development influenced offspring (28). The strongest evidence of the influence of 
exposures during gestation occurred in Rotterdam and The Hague, two cities in the western 
Netherlands that experienced a well-documented famine after a railway strike during World War 
II. From November 1944 through February 1945, the German occupants limited rations to 400-
800 calories/day for all people, including pregnant women. After the complete restriction, the 
Netherlands returned back to their complete diet relatively quickly. The Dutch Hunger Winter 
created a controlled human cohort of intrauterine deprivation and long-term health implications 
(29). This study and others (30,31) have revealed implications of exposure timing, as some 
pregnant women were exposed to the famine in early gestation, while others exposed in late 
gestation. Nutrient restriction in utero during the first trimester was associated with elevated rates 
of obesity, altered lipid profiles, and cardiovascular disease (32). Exposure to famine in the third 
trimester was associated with lower birth weight and lower rates of adult obesity (32) as well as 
decreased glucose tolerance (33). Additionally, prenatal famine exposure in the first trimester 
was associated to differentially methylated DNA regions related to genes involved in growth and 
metabolism (34), suggesting the influence of famine of the epigenome. Epidemiologic studies 
have identified outcomes from other cohorts of individuals exposed to famine across the entire 
6 
 
gestational period demonstrating increased risk of adult T2D and hyperglycemia (35) and 
hypertension (36). Stemming from results of famine studies, dietary manipulation studies during 
pregnancy have demonstrated changes in the risk of adult metabolic disease among offspring 
(37). These studies have demonstrated the nutrient factors, including energy intake, fatty acids 
(37,38), protein (39,40), micronutrients (41), and vitamins, including folic acid (42), have 
profound influence on fetal programming, varying by timing of exposure.  
Maternal phenotypes and offspring metabolic health  
Studies have demonstrated that maternal phenotypes influence the offspring development. There 
is an increase in pregnant women that are overweight or obese, which influences both maternal 
and infant health. Maternal obesity during pregnancy is associated with an increased risk of 
gestational diabetes mellitus (GDM) and elevated infant fat mass and birth weight at delivery as 
well as an increase in adult risk of obesity and insulin resistance (43). During pregnancy, both 
excessive and inadequate maternal gestational weight gain influence maternal and infant 
outcomes (44). In 2009, the Institute of Medicine (IOM) issued guidelines on gestational weight 
gain for optimal maternal and infant health based on pre-pregnancy BMI (45). Independent of 
pre-pregnancy BMI, women who gained more weight than the IOM recommendations had 
newborns with increased risk of childhood adiposity, hypertension and insulin resistance (46). 
Additionally, women who gained less weight than the IOM recommendations had newborns with 
increased risk of hypertension and insulin resistance (46). These results suggest that pre-
pregnancy BMI and GWG have distinct pathways influencing offspring’s risk of metabolic 
health.    
The Pima Indians from the Gila River Indian Community of Arizona are a population with a high 
prevalence of diabetes and obesity that have been followed in a longitudinal study since the 
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1960s (47). Through this group of people, the effect of maternal T2D on offspring health has 
been assessed. During adolescence, the offspring of diabetic mothers weighed 140% more than 
their desirable weight, directly relating maternal diabetes to offspring obesity (48). Interestingly, 
maternal diabetes was predictive of obesity in adolescence, independent of maternal pre-
pregnancy BMI and infant birth weight (49). From these studies, the Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) study began; a renowned study assessing the influence of 
mild maternal glycemia with adverse pregnancy outcomes (50). The HAPO study demonstrated 
that maternal hyperglycemia, even at levels below the GDM diagnosis threshold, were associated 
with large-for-gestational-age offspring (51). Exposure to elevated glucose levels in utero is 
associated with childhood adiposity, independent of maternal BMI (52). At childhood, offspring 
exposed to untreated GDM during pregnancy are more insulin resistance with limited β-cell 
compensation (53).   
A Systems Biology Approach Utilizing Metabolomics Techniques  
As analytical techniques and computational methods are advancing, there is an opportunity to 
classify the complexity of a biological system at the molecular, cellular, and organismal level. 
The field of systems biology is a collaboration between chemist, biologists, mathematicians, 
physicists, and engineers incorporating multiple omics approaches (e.g. genomics, epigenomics, 
transcriptomics, proteomics, and metabolomics) (54). Applying these omics techniques creates a 
holistic approach in the study of a biological system. As omics technologies are becoming more 
accessible, the incorporation of multi-omics techniques in a research design presents 
computational challenges and difficulties in interpretations of the findings. Despite these 
complexities, systems biology approaches are being applied to understand the development and 
progression of disease states.  
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Metabolomics is the analysis of the chemical reactions within cells, tissues, or biological 
systems. Metabolites are small molecular weight compounds (<1,500 Da) that are both 
intermediates and products of metabolism. Each metabolite plays a critical role in keeping cells 
healthy and functioning properly, including providing substrates for energy production, 
participating in cell signaling, and regulating enzymes through inhibiting or stimulating their 
activity. The metabolome varies between individuals due to age (55) and dietary intake (56), as 
well as biological differences in individual phenotypes based on genetics, epigenetics, and the 
external environmental. Analytical chemistry instrumentation is used for metabolomics assays. A 
common platform couples a separation method, such as gas chromatography, liquid 
chromatography, or capillary electrophoresis, with mass spectrometry (MS) to ionize and detect 
the compounds within the sample. Another method called nuclear magnetic resonance (NMR) 
spectroscopy can detect metabolites through the application of magnetic fields to measure the re-
emitted electromagnetic radiation from nuclei with the sample. Targeted metabolomics 
approaches use standards to quantitatively measure specific groups of metabolites of interest, 
generally favored for hypothesis-driven approaches. Untargeted metabolomics detects all low 
molecular weight compounds in a biological sample, known as the metabolome, generally 
favored for hypothesis-generating approaches. Challenges in untargeted metabolomics include 
the large number of unannotated “features” that may be redundant or a fragmentation of the 
ionization techniques.  
Classifying the metabolome of different cell-types and tissue-types is important to understand 
localized influences of a disease-state (57). However, many biological samples require invasive 
procedures to obtain, such as biopsies. Blood is a commonly used biological fluid for 
metabolomics analyses, as it requires minimally invasive procedures and has the potential to 
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reflect the complex interplay of many tissues within the human body. There is a desire to classify 
differential metabolites in a disease state in blood, potentially identifying biomarkers to assess in 
other populations. Plasma is the liquid in which blood cells are suspended and is obtained when 
anti-coagulants are introduced. If anti-coagulants are not introduced, the blood is allowed to clot 
and the supernatant fluid is called the serum. Slight differences have been observed between the 
serum and plasma metabolome (58), however similar biological and clinical associations have 
been seen.   
The metabolome is the complete set of small-molecular weight compounds in a sample, 
composed of amino acids, organic acids, nucleic acids, fatty acids, sugars, amines, vitamins, co-
factors, and exogenous chemicals, such as drugs or food additives. Multiple databases are 
available for compound identification and classification of metabolites including the Human 
Metabolome Database (HMDB) (59), KEGG (60), Lipid Maps (61), and Metlin (62). Each 
metabolite contributes to the human body in different ways. Nucleic acids and amino acids are 
the building blocks for DNA, RNA, and proteins. Carbohydrates are a major source of energy 
during the fed state and can be stored in tissues, primarily liver and muscle as glycogen. Lipids 
are the most structurally diverse and abundant metabolites in human plasma (63). The main 
groups of lipids are fatty acyls, glycerolipids, phospholipids, sphingolipids, and sterol lipids (61). 
Each lipid group will be discussed below.  
Fatty acyls are the fundamental category of lipids, including fatty acids, eicosanoids, fatty 
alcohols, and esters. The basic structure of a fatty acid is a hydrocarbon chain with a terminal 
carboxyl group, varying in chain length and the number of double bonds. The terminal carboxyl 
group can be substituted for an alcohol group, forming a fatty alcohol. The structure of fatty 
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acids determines their biological functions, including energy storage, signal-transduction, and 
lipid synthesis.  
The highest proportion of total lipids in the plasma is within the glycerolipids class, which is 
comprised of monoglycerides, diglycerides, and triglycerides. Glycerolipids are composed of a 
glycerol backbone with one, two, or three fatty acyl groups. These lipids are transported through 
the body via lipoproteins to be distributed to tissues. In adipose tissue, glycerolipids are the main 
energy storage. Plasma glycerolipid levels change based on the fasted or fed state (63). Elevated 
triglycerides can results from an unhealthy diet, pregnancy, weight gain, genetics, and the use of 
some medications (64). Hypertriglyceridemia is a common risk factor for cardiovascular disease 
(64).  
Phospholipids are the main component of cell membranes, containing a glycerol backbone with 
two fatty acyl tails attached with ester linkages to the sn-1 and sn-2 carbons and a polar molecule 
attached to the sn-3 carbon. Typically, a polyunsaturated fatty acid tail is attached to the sn-2 
position. The human body has a wide variety of phospholipids differing by organelle and cell 
type (65). This diversity suggests specificity in phospholipid’s involvement in many 
physiological processes; although it is uncertain how cell-specific phospholipid composition is 
established and maintained. Phospholipids can be converted to each other rapidly, suggesting the 
high correlation between many types of phospholipids. The simplest phospholipid is 
phosphatidic acid, with a phosphate group attached to the sn-3 carbon. Phosphatidic acid is a 
precursor for other lipid synthesis and is rapidly converted to diglyceride molecules for cell 
signaling (65). Phosphatidylcholine is the most abundant phospholipid in the cell, comprising 40-
50% of total phospholipids within all organelles (65), and contains a choline head-group. 
Phosphatidylethanolamine N-methyltransferase (PEMT) converts a phosphatidylethanolamine 
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lipid to a phosphatidylcholine via the addition of three methyl groups. Phosphatidylethanolamine 
is enriched in the inner membrane of the mitochondria, comprising 35-40% of total 
phospholipids (65). Additional polar head groups attaching to the phosphate group on the sn-3 
carbon include glycerol (phosphatidylglycerol), inositol (phosphatidylinositol), and serine 
(phosphatidylserine) among other combinations.  
The fatty acyl group on the sn-1 carbon of a phospholipid can be altered. The hydrolysis of the 
fatty acyl group on the sn-1 carbon forms a lysophospholipid, a lipid class important for cell 
signaling. Plasmalogens contain a fatty alcohol radical and a cis double bond at the sn-1 carbon. 
Plasmalogens are named by the polar head-group in the sn-3 position making the most abundant 
plasmenyl-phosphatidylcholine and plasmenyl-phosphatidylethanolamine (66). Because 
polyunsaturated fatty acids are typically attached to the sn-2 carbon, plasmalogens are 
considered reservoirs of polyunsaturated fatty acids in membranes (67).  
Sphingolipids contain a polar head group, known as an amino alcohol called a sphingosine, and 
two nonpolar tails. Variations in the r-group attached to the oxygen on the sphingosine determine 
its class. A sphingolipid with a hydrogen R-group is called a ceramide, which can participate in a 
variety of cell signaling. A sphingolipid with a phosphocholine R-group is called a 
sphingomyelin, which is found in cell membranes in the myelin sheath at high abundance.  
Sterols contain one hydroxyl group on a 4-ring structure. The most abundant sterol in human 
plasma is cholesterol, existing in both free and fatty acyl-esterified forms. Sterols are precursors 
to vitamin and steroid hormone synthesis and are components of the cell membrane.  
12 
 
Using the Metabolome to Classify the Intrauterine Environment  
The maternal metabolome has been used to obtain an objective measurement of the metabolic 
environment in which the developing fetus is exposed. Changes in the maternal metabolome 
across gestation occur to support the developing needs to the fetus (68), suggesting the 
importance of analyzing multiple measures of the metabolome across gestation. The application 
of metabolomics to developmental studies can identify changes in maternal nutrient availability 
across pregnancy (69,70) while identifying how maternal characteristics, such as pre-pregnancy 
BMI (71–73), hyperglycemia (74,75), and other lifestyle/clinical factors (76), influence nutrient 
availability and alter fetal growth, typically measured by birth weight. Using a targeted 
metabolomics approach, our research group previously reported an increase in plasma long-chain 
fatty acids and corresponding long-chain acylcarnitines in maternal plasma from first trimester to 
term, supporting rapid fetal growth (77). The metabolome of the maternal plasma across 
gestation can be paired with the metabolome of infant umbilical cord blood. Maternal metabolite 
levels, placental transfer, and interaction with other metabolites, such as inhibition by 
competition or metabolite-induced changes in placental transport activity, can all affect the 
relative levels of the umbilical cord blood metabolome.   
Metabolomics analyses have been applied to identify trimester-specific maternal metabolites 
associated with infant birth weight and adiposity (71,72,74,78,79), accounting for maternal 
characteristics such as pre-pregnancy BMI (72). The metabolome from cord blood has been 
correlated with BW finding positive associations with branched chain amino acids (80), AC 
(81,82), and phosphatidylcholines (PC) (82,83) along with inverse associations with TGs (81). 
Other studies have found that cord blood lysophosphatidylcholine (LysoPC) metabolites with 
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varying chain length and saturation are positively associated with newborn BW (83–85), as well 
as with weight at 6 months of age (83). 
Intrauterine Influences on the Epigenome   
There is growing evidence that epigenetic mechanisms are an important contributor to 
developmental programming (86). Epigenetics is defined as mitotically heritable changes in gene 
expression that occur without altering the DNA sequence. Two epigenetic modifications include 
DNA methylation and alterations to chromatin folding via histone modifications. DNA 
methylation is the most extensively studied epigenetic modification. Methyl-groups are 
covalently attached to the 5’ carbon of a cytosine, commonly preceding a guanine, generating a 
5-methylcytosine. Across most tissues, 70% of CpG sites are methylated (87). Regions in the 
genome with high CpG site frequency are called CpG islands, which are often located at the 5’ 
promotor of genes. In general, transcriptionally active genes have unmethylated CpG islands 
upstream of the promoter. Another way that genes are regulated is through altering chromatin 
structure, the complex of DNA and its histone protein. Histone proteins can be modified through 
methylation, phosphorylation, acetylation, and ubiquitination; impacting gene expression 
through either promoting or preventing transcription factor binding. Other epigenetic 
mechanisms with a potential role in the development of disease include noncoding RNAs (86).   
The ability to modify the epigenome through a variety of mechanisms allows for control of gene 
expression in a cellular and tissue-specific manner. Epigenetic responses fluctuate between 
different cell-types, allowing for specificity in gene expression dependent upon localization. 
Modifications can remain present through cell divisions (mitosis) and, although rare, may last for 
multiple generations (meiosis) (88), highlighting the inter-generational heritability of epigenetic 
modifications. During mammalian development, genome-wide epigenetic reprogramming erases 
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epigenetic marks, followed by the establishment of a new set of marks (89). As an individual 
develops, the epigenome is vulnerable to insults. One particularly vulnerable period is during 
embryogenesis, where DNA synthesis rates are high and establishing the epigenome is crucial 
for normal development (90). 
During sensitive periods of development, environmental exposures have the capability to 
influence the epigenome and protect or predispose an organism to disease development. A well-
known example of maternal diet influencing epigenetic changes in the offspring is found in the 
viable yellow Agouti (Avy) mouse model (91). The agouti gene encodes the agouti-signaling 
protein, which is responsible for distributing melanin pigment. During development, the agouti 
gene is expressed in the skin modulating hair color. In mice, the wild type agouti allele (A) 
produces a brown phenotype. The viable yellow mutation (Avy) expression differs from the wild 
type because the agouti gene is ectopically expressed across all tissues during the lifespan of the 
mouse, not just during development. The Avy metastable epiallele, an allele in which epigenetic 
regulation is established during early development and highly maintained throughout mitotic 
divisions, is formed from an insertion of an intracisternal A-particle (IAP) upstream of the 
transcription site (92). The methylation of the IAP influences the phenotype of the mouse. When 
the IAP is unmethylated, there is an increase in transcription of the agouti gene, resulting in mice 
with yellow fur that are obese, hyperinsulinemic, hyperglycemic, and have an increased risk of 
cancer (92). A fully methylated IAP produces healthy brown mice. The viable yellow Agouti 
(Avy) mouse model has been used across multiple types of studies assessing how nutrition 
influences the offspring development. Maternal diets supplemented with methyl donors, such a 
folic acid, increase the methylation of the IAP insert in the Agouti (Avy) gene, reducing its 
expression (91).   
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Alterations in maternal nutrition during gestation in the form of under- or over-nutrition, protein 
restriction, alterations in fat type, sugar content, and micronutrients have induced epigenetic 
changes in the offspring (93,94). Polyunsaturated fatty acids are thought to influence DNA 
methylation via directly influencing enzymes responsible for methylation and/or contributing to 
one carbon metabolism via choline from phosphatidylcholine. During pregnancy, clinical trials 
have supplemented polyunsaturated fatty acids finding conflicting results, potentially due to 
timing in gestation and cell-type analyzed (95,96). DNA methylation is dependent upon 
micronutrient intake providing substrates (folate, methionine, choline, and betaine) and co-
factors (vitamins B12, B6, and B2) for one carbon metabolism (97). Additionally, maternal 
hyperglycemia (98) and body composition (99) have been analyzed for associations with infant 
DNA methylation.  
Metabolomics provides an objective and quantifiable measurement of how the maternal 
environment influences the offspring epigenome. Previous work from our group (77) provided 
some of the first evidence for a relationship between specific metabolites in the maternal plasma 
across gestation with DNA methylation in umbilical cord blood leukocytes. The correlations 
were quantified between a targeted group of metabolites with global methylation (LINE-1) and 
methylation at candidate loci including ESR1, PPARα, IGF2, and H19, which have previously 
been associated with growth and future cardiovascular disease risk (100–102). The results 
revealed significant correlations of essential fatty acids, conditionally essential fatty acids, 
medium-chain acylcarnitines, and long-chain acylcarnitines in maternal first trimester and term 
blood with DNA methylation in infant cord blood at LINE1, ESR1, and PPARα (77). A recent 
study (103) assessed how the maternal lipidome at ~26 weeks gestation influences DNA 
methylation in umbilical cord blood cells.  These results found that maternal phospholipids and 
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lysophospholipids were associated with methylation, suggesting the importance of that lipids 
fraction in establishing methylation patterns.  
Mitochondrial Dysfunction in the Pathogenesis of Obesity and Metabolic Disease  
Mitochondrial dysfunction has been identified as a key component in the pathogenesis of T2D as 
connections between the mitochondria and insulin resistance were first identified over 40 years 
ago (104). The mitochondria is the site for β-oxidation; the main pathway of fatty acid oxidation 
(105). This organelle produces the majority of a cell’s ATP through the oxidation of glucose, 
amino acids, and fatty acids and oxidative phosphorylation in the electron transport chain within 
the mitochondrial matrix. As insulin is the predominant hormone involved in fuel metabolism, 
altered mitochondrial function has been discussed as the cause, the consequence, and a non-
related correlation with insulin resistance (106–108).  
To begin to understand the role of mitochondria in insulin resistance, it is necessary to consider 
how the mitochondria responds to different energy substrates. Humans possess the capability to 
oxidize carbohydrates and fat for energy production. Oxidation of each fuel does not occur in 
isolation, but rather, occurs simultaneously. There is a reciprocal relationship between the 
utilization of carbohydrates and fat (109). The steady-state of this relationship is dictated by (1) 
the fasted or fed state, (2) being at rest or during exercise, and (3) the availability of substrates.  
Being able to shift between oxidizing carbohydrates and fat is evolutionary advantageous for 
humans, allowing for the metabolic response to fluctuations in energy supply and demand.   
The reciprocal relationship between carbohydrate and fat oxidation was established by Randle et 
al. in the 1960s (110). It was observed that in skeletal muscle, there is competition between 
selecting carbohydrates or fat for energy production in the fasted and fed states, dependent upon 
the presence of free fatty acids (110). These experiments found that elevated plasma free fatty 
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acids increased fatty acid oxidation and decreased glucose oxidation (110). During a fast, 
skeletal muscle in lean individuals relies mainly on lipid metabolism, as originally observed by 
Andres et al. (111). Later experiments identified that elevated fatty acid oxidation increased the 
production of acetyl-CoA, citrate, and glucose-6-phosphate, which reduced glucose oxidation via 
the inhibition of pyruvate dehydrogenase, phosphofructokinase, and hexokinase (112). In 
contrary, in the fed state when glucose availability increases, fatty acid oxidation is suppressed 
via the inhibition of carnitine palmitoyltransferase 1 (CPT1) by malonyl-CoA (113). The elegant 
transition between fatty acid and carbohydrate oxidation in the fasted and fed state is controlled 
by a variety of endocrine and metabolic signals (114).    
In the fed state, metabolic adaptations must occur to respond to fluctuations in the supply of 
carbohydrates and fat to produce energy. An organism’s ability to select fuel for energy 
production depending on environmental demand is defined as metabolic flexibility, coined by 
Kelley et al. in 1999 (115). Metabolic flexibility is related to the metabolic health of an 
organism. For instance, Kelley et al. observed differences in adaptations to fuel preference 
between obese individuals with insulin resistance and lean individuals in both the fasting state 
and after an insulin infusion (115). At rest during fasting, Kelley et al. found that obese 
individuals with insulin resistance have a lesser reliance on fatty acid oxidation than lean 
individuals. Upon insulin infusion, obese individuals with insulin resistance were not able to 
reduce fatty acid oxidation and did not increase glucose oxidation in comparison to lean 
individuals. Kelley classified obese individuals with insulin resistance as having a state of 
metabolic inflexibility (112).  
In insulin resistance, skeletal muscle has an increase in fatty acid uptake (116) paired with a 
decreased mitochondrial oxidative capacity, measured by enzymatic activity (107,117,118) and 
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rates of fatty acid oxidation (119,120). In adults, these alterations leads to lipotoxicity and 
incomplete fatty acid oxidation with increases in acylcarnitine intermediates (121) and 
incompletely oxidized fatty acids (122,123). Levels of intramyocellular lipids are positively 
associated with worsening insulin resistance, independent of obesity (124) and observed in 
muscles of multiple fiber types (125). Incompletely oxidized fatty acids are partitioned towards 
the synthesis of other metabolites that have been linked to insulin signaling such as 
diacylglycerols, triglycerides, and ceramides (126). These lipids may impair insulin signaling 
through other mechanisms including activation of the diacylglycerol-protein kinase C pathway 
(126). Overall, the obese and insulin resistant state is marked by alterations in fuel selection, 
metabolic flexibility, and oxidative capacity. 
Metabolite Biomarkers of Obesity and Insulin Resistance 
Metabolomics has been used to identify biomarkers of obesity (127) and insulin resistance (128), 
increasing the understanding of the pathogenesis. Obesity and insulin resistance alter the 
oxidative capacity and metabolic fate of a subset of essential amino acids (129). Branched chain 
amino acids (BCAA), leucine, isoleucine, and valine, and their metabolites and carnitines esters 
are elevated with obesity, insulin resistance, and T2D, first demonstrated 50 years ago (130). 
Elevated plasma BCAAs are associated with an increased risk for T2D (131,132). Risk of 
becoming insulin resistant is increased with the presence of genetic polymorphisms near the 
PPM2 gene (encoding for branched chain ketoacid dehydrogenase [BCKDH] phosphate), which 
alters BCAA metabolism (133). Individuals with insulin resistance have decreased BCAA 
catabolism in hepatocytes and adipocytes, leading to the accumulation of plasma BCAAs and 
their metabolites (134). Excess BCAAs may contribute to insulin resistance via activation of 
mTORC1 signaling, though this remains controversial (135). Additional amino acids that are 
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elevated with obesity and insulin resistance include sulfur-containing methionine and cysteine 
(136,137) and the aromatic amino acids tyrosine and phenylalanine (130,137).  
Metabolomics analyses have revealed significant associations between fatty acid oxidation 
intermediates, such as acylcarnitines, and insulin resistance. The carnitine shuttle transports fatty 
acyl-CoAs into the mitochondria via their carnitine ester through carnitine palmitoyltransferase 1 
(CPT1), which regulates fatty acid oxidation flux (138). Once inside the inner mitochondrial 
membrane, carnitine palmitoyltransferase 2 (CPT2) transports the acylcarnitine into the 
mitochondrial matrix converting it back to free carnitine and the fatty acyl-CoA. In adults with 
obesity and insulin resistance, there is an imbalance between entry of acyl-CoA into the 
mitochondria and fatty acid oxidation rates, resulting in elevated acylcarnitines (121) and 
incompletely oxidized FA (122,123). Skeletal muscle insulin resistance is associated with 
increased acylcarnitine accumulation in the muscle or circulation (123,139). These results lead to 
the hypothesis that if fatty acid oxidation rates outpace the TCA cycle, there will be an 
accumulation of fatty acid oxidation intermediates, which may influence insulin resistance.  
Risk of adult obesity and insulin resistance will be classified during adolescence; a period 
physical transition marked by the onset of puberty. Pediatric studies highlight differences in the 
fluctuations of the metabolome with obesity and insulin resistance compared to adults. BCAAs 
and their short-chain acylcarnitine metabolites, propionylcarnitine and butyrylcarnitine, have 
been consistently increased in obese adolescents (140–142). However, studies are inconsistent 
regarding the relationship between BCAA and insulin resistance in adolescents with findings 
reporting positive associations (140–142), inverse associations (143), and sex differences (144–
146) which may be due to differences in analytical methodologies as well as the variability in the 
size and characteristic in study populations. Some metabolomics analyses in youth have also 
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identified divergent associations of metabolite levels and metabolic phenotypes compared to 
those observed in adults. In contrast to adults, free fatty acids were not associated with BMI or 
insulin resistance at 15 years of age (147,148). Additionally, lower levels of fatty acid oxidation 
intermediates, such as dicarboxylic fatty acids (141) and medium chain acylcarnitines (143), 
were reported in children with T2D and obesity. These results suggest less imbalance in the 
delivery and oxidation of substrates in these individuals, perhaps due to the increased substrate 
utilization to fuel tissue and linear growth in the pubertal period. Sex differences may be 
explained by changes in muscle and fat mass accompanied by puberty.    
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Specific Aims and Hypotheses 
The Developmental Origins of Health and Disease hypothesis suggests that exposures during 
sensitive periods of development have the potential to cause permanent changes in metabolic 
pathways increasing the risk of obesity and insulin resistance (149). The aim of this 
dissertation was to classify the metabolic environment using metabolomics during sensitive 
periods of early development to identify alterations in the risk of developing obesity, insulin 
resistance, and metabolic diseases. Our goal was to define the potential metabolite mediators 
that are associated with alterations in metabolism arising during fetal development that persist 
into adolescence. To achieve this goal, we determined the metabolome’s relationship to the 
development and metabolic state of infants and adolescents through the following Specific Aims: 
SPECIFIC AIM 1: Determine the dynamic changes in the maternal lipidome during 
pregnancy and identify maternal nutrient exposures that are critical for the modulation of 
birthweight and the umbilical cord blood lipidome using the Michigan Mother-Infant Pairs 
cohort. To determine the timing and effect of maternal nutrients on offspring development, 
untargeted lipidomics profiling of mother-infant dyads was performed in plasma samples 
collected from maternal first trimester (M1) and delivery (M3) and infant umbilical cord blood 
plasma (CB). Fluctuations in the metabolome across pregnancy were identified, inferring the role 
of placenta transport proteins. We classified maternal and CB lipids associated with maternal 
characteristics and infant birth weight, considering sex differences. We identified maternal lipids 
that may modulate the CB lipidome that is related to birth weight.   
SPECIFIC AIM 2: Investigate how the maternal lipidome relates to infant DNA 
methylation patterns to understand how nutrient exposures influence epigenetic 
programming. DNA methylation in CB leukocytes was assessed using the Infinium 
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MethylationEPIC (EPIC) bead array. Using empirical Bayes modeling, we analyzed how the 
maternal lipidome (M1 and M3) influences infant DNA methylation, highlighting differential 
methylation in genes associated with lipid metabolism and adiposity.  
SPECIFIC AIM 3: Expand on the relationship between the metabolome with obesity and 
insulin resistance during the pubertal period, defining sex-specific alterations using the 
Early Life Exposure in Mexico to ENvironmental Toxicants cohort. To assess the metabolite 
alterations that are related to metabolic health, untargeted metabolomics profiling of adolescents 
was performed using serum samples. Using linear models, the relationship between the 
metabolome with obesity and insulin resistance was quantified, assessing sex-specific alterations 
given differences in pubertal hormones and the accumulation of muscle and fat tissue. We 
determined if recalled dietary intake could provide additional information on the underlying 
difference in metabolism that leads to insulin resistance.   
After the completion of these studies, we have developed an initial model for how intrauterine 
exposure can lead to altered metabolism in later life. Confirmation that specific metabolite 
patterns are associated with postnatal risk for metabolic disease, we may have the opportunity to 
modify intrauterine nutrient exposure through diet to modulate the long-term risks of the 
offspring      
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Figure 1.1. Study Objective. Classification of the metabolic environment during sensitive 
periods of development to identify alterations in the risk of developing obesity, type 2 diabetes, 





Figure 1.2. Study cohort. To classify the metabolic environment during development, we will 
incorporate untargeted metabolomics and lipidomics techniques to two human cohorts; the 
Michigan Mother-Infant Pairs (MMIP) cohort and the Early Life Exposure in Mexico to 
ENvironmental Toxicants (ELEMENT) cohort. The novelty of this dissertation is the 
incorporation of multiple metabolome measurements with the epigenome to gain a broader 
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CHAPTER 2                                                                                                                         
Maternal Lipid Levels across Pregnancy Impact the Umbilical Cord Blood Lipidome and 
Infant Birth Weight 
Abstract 
Major alterations in metabolism occur during pregnancy enabling the mother to provide adequate 
nutrients to support infant development, affecting birth weight (BW) and potentially long-term 
risk of obesity and cardiometabolic disease. We classified dynamic changes in the maternal 
lipidome during pregnancy and identified lipids associated with Fenton BW z-score and the 
umbilical cord blood (CB) lipidome. Lipidomics was performed on first trimester maternal 
plasma (M1), delivery maternal plasma (M3), and CB plasma in 106 mother-infant dyads. Shifts 
in the maternal and CB lipidome were consistent with the selective transport of long-chain 
polyunsaturated fatty acids (PUFA) as well as lysophosphatidylcholine (LysoPC) and 
lysophosphatidylethanolamine (LysoPE) species into CB. Partial correlation networks 
demonstrated fluctuations in correlations between lipid groups at M1, M3, and CB, signifying 
differences in lipid metabolism. Using linear models, LysoPC and LysoPE groups in CB were 
positively associated with BW. M1 PUFA containing triglycerides (TG) and phospholipids were 
correlated with CB LysoPC and LysoPE species and total CB polyunsaturated TGs. These results 
indicate that early gestational maternal lipid levels influence the CB lipidome and its relationship 
with BW, suggesting an opportunity to modulate maternal diet and improve long-term offspring 




The Developmental Origins of Health and Disease (DOHaD) theory describes how insults during 
early life can permanently program the fetus/offspring, altering their risk of adult chronic disease 
(1). To adapt to the intrauterine environment (i.e. maternal nutrient supply), structural changes 
and functional modifications occur in fetal organs and tissues to ensure survival of the newborn, 
indicative of their developmental plasticity (2). Barker and Osmond developed this hypothesis in 
response to observations from the Dutch Famine birth cohort, a well-documented famine in the 
Netherlands during World War II. Within this cohort, nutrient restriction in utero in the first 
trimester was associated with increased risk of obesity, dyslipidemia and cardiovascular disease, 
while restriction in the third trimester was associated with decreased risk of metabolic disease 
independent of birth weight (BW) (3), affirming existence of distinct susceptibility windows for 
producing differing outcomes. Infant BW is the most common health outcome studied to 
determine if the maternal intrauterine environment influences the development of the fetus. Both 
low and high BW have been associated with an increased risk of obesity and cardiometabolic 
diseases, including type 2 diabetes (T2D) (4, 5). 
In recent years, profiling of small molecular weight compounds in a biological sample by 
metabolomics has been used to obtain an objective measurement of the metabolic environment in 
which the developing fetus is exposed. Metabolite levels are influenced by dietary intake (6) and 
can both reflect and influence changes in metabolism (7). The application of metabolomics to 
developmental studies can identify changes in maternal nutrient availability across pregnancy 
(8–11). Using a targeted metabolomics approach, we previously reported an increase in plasma 
long-chain fatty acids and corresponding long-chain acylcarnitines (AC) in maternal plasma 
from first trimester to term (10). These results reflect the increase in lipolysis during late-
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gestation to fuel rapid fetal growth. Using a larger cohort and a comprehensive lipidomics 
platform, we aim to expand our previous findings and detail changes in phospholipids, ceramides 
(Cer), cholesteryl esters (CE), and triglycerides (TG) during pregnancy.  
Metabolomics analyses have been applied to identify trimester-specific maternal metabolites 
associated with infant BW and adiposity (12–16), accounting for maternal characteristics such as 
pre-pregnancy BMI (13). Maternal metabolite levels, placental transfer, and interaction with 
other metabolites, such as inhibition by competition or metabolite-induced changes in placental 
transport activity, can all affect the relative levels of the umbilical cord blood (CB) metabolome. 
The CB metabolome is influenced by maternal characteristics such as pre-pregnancy BMI (17, 
18).  
The metabolome from CB has been correlated with BW finding positive associations with 
branched chain amino acids (19), AC (18, 20), and phosphatidylcholines (PC) (20, 21) along 
with inverse associations with TGs (18). Other studies have found that CB 
lysophosphatidylcholine (LysoPC) metabolites with varying chain length and saturation are 
positively associated with newborn BW (21–23), as well as with weight at 6 months of age (21). 
However, what remains unclear is how the maternal lipidome influences that establishment of 
CB lipids related to BW. In this study we profiled 573 lipid species in 106 mother-infant dyads 
from maternal first trimester (M1) and delivery blood (M3) as well as umbilical CB. We confirm 
the strong association of CB lysophospholipids (LysoPL) and BW. In addition, we find that 
maternal first trimester and delivery plasma lipid profiles seem to influence the levels of CB 
LysoPLs. Some of these effects appear to have sex-specific influences in the developing fetus 
(24). The results of this study indicate that starting in early gestation, the maternal metabolite 
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environment may have an important effect on offspring weight and potentially, long-term 
cardiometabolic risk, consistent with developmental origins of health and disease (1). 
Subjects and Methods 
Study Population. The subjects used in this study are part of the Michigan Maternal Infant Pair 
(MMIP) birth cohort study (2010-present). Briefly, pregnant women were recruited at their first 
prenatal appointment between 8 and 14 weeks of gestation. Eligibility criteria for MMIP were: 
age between 18 and 42 years old, had a spontaneously conceived singleton pregnancy, and 
intended to deliver at the University of Michigan Hospital. A subset of MMIP participants from 
among these were chosen for lipidomics measures. Criteria for inclusion for the current study 
include the mother-infant pairs having complete demographic, survey and health information at 
their initial study visit and availability of all biospecimen at all-time points from mother and 
child. Study procedures were approved by the UM Medical School Institutional Review Board, 
and all participants provided written informed consent.  
During the initial study visit at 8-14 week of pregnancy, participants provided a blood sample 
(M1) and anthropometry information (weight and height) to calculate an estimated baseline 
BMI. Information obtained at delivery include maternal weight for calculating gestational weight 
gain (GWG) from the initial visit. Maternal venous blood samples (M3) and cord blood (CB) 
samples via venipuncture from the umbilical cord were collected. Physician measured 
anthropometry was adjusted for gestation age and infant sex using Fenton growth curves for BW 
(25) and growth curves developed by the Canadian Institute of Health Research for head 
circumference (26). All 106 mother-infant pairs met additional inclusion criteria for this study 
including infant BW greater than 2500 grams, maternal BMI > 18.5, full term, and no pregnancy 
complications (i.e. gestational diabetes mellitus). Study design represented in Figure 2.1. 
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Lipidomics sample preparation. Metabolomics analysis were conducted by the Michigan 
Regional Comprehensive Metabolomics Resource Core. Maternal plasma (M1 and M3) samples 
were stored at -80°C prior to analysis. Lipids were extracted using a modified Bligh-Dyer 
Method (27). At room temperature, the extraction used water/methanol/dichloromethane (2:2:2, 
v/v/v) after spiking internal standards. The organic layer was collected, dried under nitrogen, and 
resuspended in 100μL of Buffer B (10:90 acetonitrile/isopropyl alcohol) with 10mM Na4OAc. 
Lipid extracts were analyzed using a lipid chromatography tandem mass spectrometry platform 
(28)    
Shotgun lipidomics analysis. Lipid extracts were injected into a 1.8 μm particle 50 x 2.1 mm 
internal diameter Waters Acquity HSS T3 column (Waters, Milford, MA) and heated to 55°C. 
For chromatography, a linear gradient using solvents was created over the 20 minute total run 
time. Solvent A contained acetonitrile/water (40:60, v/v) with 10mM ammonium acetate. Solvent 
B contained acetonitrile/water/isopropanol (10:5:85, v/v/v) with 10 mM ammonium acetate. For 
the first ten minutes, a 60% Solvent A and 40% Solvent B was used.  For the next seven minutes, 
the gradient increased in a linear fashion to 100% Solvent B. For the final three minutes, the 
gradient switched back to 60% Solvent B and 40% Solvent A. The flow rate used for these 
experiments was 0.4 mL/min and the injection volume was 5μL. The column was equilibrated 
for three minutes before the next injection and run at a flow rate of 0.400uL/min for a total run 
time of 20 min. Samples were ionized in positive and negative ionization model using a Triple 
TOF 5600 (AB Sciex, Concord Canada).  Pooled human plasma samples and pooled 
experimental samples were randomized and ran for quality control (29).   
From detected features, lipids were classified using LIPIDBLAST (30), a computer generated 
tandem mass spectral library containing 119,200 compounds from 26 lipid classes. Raw feature 
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data files with mass and retention time were searched against LIPIDBLAST using Multiquant 
1.1.0.26 (ABsciex, Concord, Canada) (31). Lipid compounds were excluded with (1) a relative 
standard deviation greater than 40% in the pooled samples and/or (2) less than 70% presence in 
the samples. Missing data were imputed using the K-nearest neighbor method. After processing, 
573 lipids from multiple lipid classes were identified (Table 2.1). All lipids will be mentioned 
with the nomenclature as X:Y, where X is the length of the carbon chain and Y, the number of 
double bonds.   
Statistics. Prior to the main analysis, we examined differences in maternal and newborn 
characteristics stratified by sex of the newborn. Pearson chi-square tests were used to identify 
sex-differences in categorical variables. Paired t-tests were used to identify sex-differences in 
continuous variables.  
To observe changes in the lipid profile across pregnancy, raw peak intensities of each lipid were 
standardized (mean=0, standard deviation=1) across M1, M3, and CB. Paired t-tests were used to 
identify differences in raw peak intensities of individual lipids between M1-M3, to represent 
change in maternal metabolome during pregnancy, and M3-CB, to represent transfer of lipids 
through the placenta. We calculated FC for M1-M3 (log2[M3/M1]) and for M3-CB 
(log2[CB/M3]) to quantify change between time points (α=0.05/573). Using Pearson’s 
correlations, the correlations between individual lipids within time points was measured. 
Due to biological constraints on metabolism, many metabolites are highly correlated. In 
response, we created lipid groups separating individual lipids by class and number of double 
bonds, yielding 41 groups (Table S2.1). To create lipid group scores, unsupervised Principal 
Component Analysis was run retaining the first principal component, accounting for the largest 
portion of variance using PROC FACTOR in SAS. Within the principal component, each lipid 
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receives a factor loading, which is the correlation coefficient between the lipid and the 
component. Score were created by (1) multiplying the lipid factor loading by the lipid 
standardized peak intensity and (2) adding together these values for all lipids within a lipid 
group, using PROC SCORE in SAS. Mother-infant dyads received lipid group scores for M1, 
M3, and CB, separately. Using Debiased Sparse Partial Correlations, the correlations between 
lipid groups within time points was measured. As this is an exploratory analysis, we present 
correlations that have an adjusted p-value<0.2.  
Linear regression was used to classify the relationship between maternal baseline BMI and GWG 
with M1, M3, and CB lipid groups, adjusting for sex, parity, maternal age, and gestational age 
(unadjusted p-value<0.05). Linear regression was used to identify M1, M3, and CB lipid groups 
associated with Fenton BW z-score, adjusting for sex, parity, maternal age, gestational age, 
maternal baseline BMI, and GWG (unadjusted p-value<0.05). Sex-stratified models were run. 
Furthermore, linear models were used to explore sex differences between individual CB 
triglycerides (mean 0, standard deviation 1) and Fenton BW z-score, stratified by infant sex and 
adjusted for parity, maternal age, gestational age, maternal baseline BMI, and GWG (unadjusted 
p-value<0.05). Non-parametric regression curves were plotted to classify how the relationship 
between TGs and BW is related to the number of double bonds in TGs. CB lipid groups 
associated with BW were correlated with M1 and M3 individual lipids and lipid groups to 
determine if maternal lipids modulate the levels with CB, using Pearson Correlations (p<0.05).  
Unless otherwise state, all statistical analyses were performed using SAS 9.4 (Cary, North 
Carolina). Figures were created using GraphPad Prism version 7.4 (La Jolla, California). 
Results 
Subject Demographics  
43 
 
Women were recruited during the first trimester and followed through delivery (Figure 2.1). 
Average maternal age at their first trimester visit was 32.1 ± 3.6 years and the majority of 
women had a lean baseline BMI (62%) (Table 2.2). On average, women gained 13.2±5.2 kg 
between the baseline visit and term and 72% of infants were born vaginally. Offspring analysis 
was stratified by males (n=51) and females (n=55). We observed no significant difference in 
Fenton BW percentile between males and females.  
Maternal BMI was inversely associated with gestational weight gain (GWG) (r2 = 0.18, 
p<0.001), indicating that leaner women gained more weight during pregnancy (Figure S2.1a). In 
contrast, maternal BMI was positively associated with Fenton BW percentile (r2=0.06, p=0.014) 
(Figure S2.1b); and while not significant, maternal GWG trended towards a positive association 
with Fenton BW percentile (r2=0.03, p=0.070) (Figure S2.1c).  
Fluctuations in the Lipidome between M1, M3, and CB  
We next examined the changes in the plasma lipidome across pregnancy (M1 to M3) and 
between maternal delivery plasma and cord blood (M3 to CB), the latter as a potential surrogate 
for placental transfer and fetal exposure. Figure 2.2a displays a Heatmap of lipids organized by 
class with individual lipid peak intensities normalized across M1, M3, and CB. Figures 2.2b and 
Table S2.2 show fold changes (FC) of lipids from M1 to M3. Figure 2.2c and Table S2.3 shows 
FC of lipids between M3 and CB. Most classes of lipids increased in levels from M1 to M3, 
consistent with previous observations of generalized increase in lipoproteins and associated 
lipids with advancing pregnancy (8,32). A subset of lipid species was reduced in M3 compared 
to M1 including polyunsaturated CEs and a variety of LysoPC and LysoPE species. Most of the 
polyunsaturated fatty acid (PUFA) containing lipids that were lower in M3 were significantly 
increased in CB plasma (Figure 2.2a, 2.2c). In addition, several lipid species that are statistically 
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unchanged from M1 to M3 were higher in CB compared to M3, including SM and TG enriched 
in PUFAs. These results are consistent with the known specific transfer of PUFAs across the 
placenta to the fetus (33), perhaps mediated by LysoPLs (see below) (34).  
Pearson Correlations of Individual Lipids within Each Time-Point  
Networks were generated for individual lipids at M1 (Figure 2.3), M3 (Figure 2.4), and CB 
(Figure 2.5) using Pearson’s correlations. In maternal plasma, clusters of lipid classes were 
observed between (1) TGs, DGs, PCs, and PEs; (2) Cers and SMs; (3) PL-PC and PL-PE; and (4) 
LysoPCs and LysoPEs. FFA and AC tended to cluster by themselves, independent of the other 
lipid networks. Interestingly, in CB plasma, individual lipids all clustered together  
Partial Correlation Network of Lipid Groups within Each Time-Point  
Given the specific patterns within lipid classes containing PUFAs, lipid clusters were created by 
grouping lipids based on a priori knowledge of lipid class and the number of double bonds in 
each lipid species, resulting in 41 groups at each time point (Table S2.1). Using a Debiased 
Sparse Partial Correlation algorithm (35), we estimated partial correlation networks for lipid 
groups within M1, M3, and CB, using an adjusted p-value less than 0.2 (Figure 2.6). At each 
time point, the majority of correlations were positive, signifying the connectivity of lipids across 
classes. In particular, multiple positive correlations were observed between (1) TGs, DGs, and 
phospholipids; (2) Cers and SMs; (3) PL-PC and PL-PE; and (4) LysoPCs and LysoPEs. Most 
positive correlations occurred between lipid groups containing lipids with similar number of 
double bonds. CEs are correlated with a variety of lipid classes including LysoPCs, 
phospholipids, DGs, SMs, and TGs; potentially suggesting their interaction with a variety of 
lipid metabolic pathways. Noteworthy, in M1, M3, and CB, CE-poly is inversely associated with 
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DG-mono and, excluding M1, with TG-mono. Both M3 and CB have more significant 
correlations than M1 (Figure 2.6), potentially due to the increase in maternal lipolysis and 
delivery fatty acids to the fetal circulation during late gestation, resulting in proportional 
distribution to different lipids species.  
Relationship between Maternal Characteristics with the Maternal and Cord Blood Lipidome 
The next objective was to assess the relationship between maternal characteristics, baseline BMI 
and GWG, and the lipidome at M1, M3, and CB. At each time point, multiple lipid classes were 
associated with BMI and GWG, adjusting for sex, maternal age, parity, and gestational age. 
Maternal BMI was inversely associated with PCs and PEs and was positively associated with 
SM-mono and SM-poly at both M1 and M3 (Figure S2.2). In CB, saturated PGs and SM-poly 
are positively associated with maternal BMI, while CE displayed inverse correlations. 
Associations of GWG with lipid groups were largely in the opposite direction, due to the inverse 
correlation between BMI and GWG (Figure S2.1a). GWG was positively associated with 
LysoPC and LysoPE clusters at both M1 and M3, independent of the number of double bonds in 
the fatty acid tails (Figure S2.3). GWG was inversely associated with SM-mono and SM-poly at 
both M1 and M3. Few associations between GWG and CB lipids groups were observed.  
Relationship between Maternal and Cord Blood Lipidome and Birth Weight  
As infant BW is associated with obesity and future cardiometabolic risk (4,5), we sought to 
identify maternal and CB lipid groups associated with Fenton BW z-score using linear 
regression, adjusting for sex, maternal age, parity, gestational age, GWG, and BMI (Figure 2.7). 




In the combined model, the early gestation lipidome (M1) was not associated with infant BW in 
the combined model, however, M1 lipid groups were associated with BW in males in the sex-
stratified models (Figure 2.7A) displaying positive associations with saturated free fatty acids 
(FFA) and negative associations with CER-mono, CER-poly, PC-mono, SM-sat, and SM-mono. 
Within M3, significant positive correlations were observed between BW and DG-sat, LysoPE-
sat, PL-PC-sat, SM-mono, SM-poly, and TG-sat (Figure 2.7B). The direction of these 
associations was consistent within males and females, however in the sex-stratified models, the 
relationship reached significance in females, but not in males.  
Within the CB, all LysoPC and LysoPE lipids groups are positively associated with BW, 
independent of the number of double bonds and was consistent in both male and female infants 
(Figure 2.7C). Additionally, CB DG-poly and TG-poly are inversely associated with BW, driven 
by female infants, and CE-poly is inversely associated with BW, driven by male infants. In 
response to the unique relationship between CB TG-poly and BW, sex-stratified regression 
models determined the relationship between individual CB TGs (97 triglycerides) and Fenton 
BW z-score, adjusting for maternal age, parity, gestational age, GWG, and BMI. Figure 2.8 
represents the beta coefficients from the sex-stratified models, plotted by the number of double 
bonds in the TGs. Observing non-linear trends, we used non-parametric regression to fit 
polynomial lines to each curve, emphasizing the evident sex differences in the relationship 
between polyunsaturated TGs and BW, again driven by females.  
Influence of Maternal Lipidome on Cord Blood Lysophospholipids  
Our results indicated that CB LysoPLs of varying chain length and number of double bonds are 
elevated in the CB compared to M3 (Figure 2.2) and are significantly associated with BW, 
independent of sex (Figure 2.7). To assess if maternal lipids during pregnancy can influence the 
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level of CB LysoPLs, M1 and M3 lipidome was correlated with individual CB LysoPCs and 
LysoPEs, as well as the score of LysoPC and LysoPE subgroups (Sat, Mono and Poly) and the 
score of all LysoPLs (LysoPL-total). Figure 2.9 displays a Heatmap of lipids from M1 and M3 
that are significantly correlated with the CB LysoPL-total group. In M1, 13 lipids positively 
correlated, and 47 lipids inversely correlated with CB total LysoPL levels. Lipids with a positive 
correlation include AC 18:0 and LysoPC species (16:0, 17:0, 18:0, 19:0, and 20:0), as well as the 
saturated LysoPC lipid group. Lipids with an inverse correlation mainly include individual lipids 
and lipid groups with PUFA containing DG, PC, phosphatidylethanolamine (PE), and TGs, 
suggesting that early maternal levels of PUFAs within multiple lipid class modulate levels of CB 
LysoPL-total.  
In M3, 34 lipids were positively correlated, and 7 lipids were inversely correlated with CB 
LysoPL levels. M3 saturated LysoPC and LysoPE lipid groups, as well as individual LysoPL, are 
positively associated with CB LysoPL-total, proposing that higher M3 levels results in higher CB 
levels. CER and SM containing saturated and monounsaturated TGs are positively associated 
with CB LysoPL-total. Interesting, inverse associations were observed between M3 LysoPE 20:3 
and 22:5 with CB LysoPL-total, suggesting differences based on the fatty acid tail.  
Most correlations between the significant M1 and M3 individual lipids and individual CB 
LysoPCs and LysoPEs were in the same direction as CB LysoPL-total. Subtle variations in the 
correlation patterns are observed for LysoPC 18:2, 18:3, 20:5, and 26:4 and LysoPE 18:2, 20:3, 
20:4, 22:6, and 24:0, potentially suggesting differences in how the maternal lipidome modulates 
these CB polyunsaturated LysoPL.  
Influence of the Maternal Lipidome on Cord Blood Polyunsaturated Triglycerides  
48 
 
The apparent preferential transfer of lipids containing PUFAs into the CB (Figure 2.2) and an 
inverse association between Fenton BW z-score and CB lipid groups containing PUFAs (Figure 
2.7 and 2.8) prompted us to determine if maternal lipids might modulate the levels of PUFA in 
CB. The M1 and M3 lipidome was correlated with CB TGs. Figure 2.10 displays a Heatmap of 
lipids from M1 and M3 that are significantly correlated with the CB TG-poly group. A variety of 
M1 PUFA containing lipids, including PC, PL-PC, DG, and TG, are positively associated with 
CB TG-poly. In M3, there are positive correlations between PCs and PEs, 75% of these 
phospholipids contained PUFAs, with CB TG-poly, suggesting the mobilization of PUFAs 
within PCs and PEs to the placenta for transport. Lastly, M3 monounsaturated and 
polyunsaturated SM are inversely associated with CB TG-poly, noting that these lipids were 
found to be positively associated with maternal BMI (Figure S2.2) and Fenton BW z-score 
(Figure 2.7).  
Discussion 
Using a comprehensive lipidomics platform including almost six hundred lipid species, this 
study objectively classified the maternal metabolic environment during the first trimester and at 
delivery, as well as the infant lipidome, reflecting infant metabolism. We found dynamic shifts in 
the maternal lipidome across pregnancy and evidence for selective transfer of lipids containing 
PUFA from maternal to fetal circulation. We further identified associations between the lipidome 
and BW, emphasizing the inverse correlations observed with CB DGs and TGs containing 
PUFAs and positive correlations observed with CB LysoPL. Lastly, we identified maternal lipids 
that may modulate CB lipid levels influential in growth.  
Early in gestation, insulin sensitivity is enhanced to increase maternal energy storage (36). 
However, as pregnancy advances, maternal insulin resistance increases with elevations in lipid 
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parameters such as lipoproteins, TGs, and total cholesterol to support the necessary metabolic 
changes for pregnancy maintenance and fetal growth (8). Of the 573 lipid species analyzed, 35% 
were significantly increased while only 10% were decreased in M3 compared to M1 (Figure 
2.2b). Between M1 and M3, we observed higher levels of PC, PE, DG, CER, SM, TG, and FFA, 
many containing fatty acids with 16-18 carbons. The majority of lipids species reduced in M3 are 
increased in CB and are enriched in long-chain PUFAs, suggesting specific transfer of these 
entities across the placenta to the fetus to provide LC-PUFAs to support brain development (37). 
While several studies have demonstrated the apparent transfer of individual PUFAs into the fetal 
circulation during the later stages of pregnancy (33,38,39), our study is the first to document the 
transfer of a wide variety of lipid species containing LC-PUFA including CE, LysoPL, TG, and 
SM as well as free LC-PUFA.  
The transport of PUFA from maternal circulation to the fetus is dependent upon fetal 
requirements of PUFAs, which increase during late gestation. PUFAs such as arachidonic acid 
(20:4n-6) (AA) and docosahexaenoic acid (22:6n-3) (DHA) are essential for establishing cell 
membranes in the brain and retina (40). Within the maternal liver, these fatty acids are derived 
from the essential fatty acids (EFA) linoleic acid and alpha-linolenic acid via elongation by liver 
Δ5 and Δ6 desaturases. Fetal supply of very LC-PUFAs is dependent on placental transfer 
because placenta lacks the enzymes Δ5 and Δ6 desaturases (41) and the fetus only has limited 
desaturase activity (42).  
Correlations between the maternal and CB lipidome can infer the role of transport proteins. Our 
results suggest that starting early in gestation, M1 PUFA levels within PC, PL-PC, DG, and TG 
are positively associated with CB TG-poly (Figure 2.10). Therefore, maternal PUFA levels early 
in gestation are crucial to establish infant PUFA levels. Since there is no evidence of direct 
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placental transport of TG from maternal to fetal circulation (43), these results suggest a diversion 
of PUFAs from the maternal TG pool with re-esterification in CB TGs. This diversion could 
occur during hepatic TG elongation and desaturation of EFAs, with increased esterification of 
PUFA or by TG lipolysis in placenta and selective uptake of PUFA at the maternal-fetal 
interface (44,45). Maternal fatty acids are transported to the fetus across the placenta via a 
variety of fatty acid transport proteins as well as passive diffusion (46).  
Using 13C-labeled fatty acids administered to women 12-hours prior to scheduled Cesarean 
delivery, Gil-Sánchez et al. demonstrated that the esterification of fatty acids into different lipid 
fractions influences placental transfer to the fetus (46). In maternal plasma at the time of 
delivery, 13C-fatty acid enrichment was detected with the incorporation of saturated fatty acid 
13C-palmitate and monounsaturated fatty acid 13C-oleate in TGs while the PUFAs 13C-linoleic 
and 13C-DHA were found in both TGs and phospholipids (46). Within the placenta, 90% of 
labeled FA were found in the phospholipid fraction with significant enrichment of 13C-DHA in 
CB compared to both maternal and placental samples. These results suggest that the 
incorporation of essential PUFA into maternal phospholipids may be important for placental 
transfer at the end of gestation. Our results found M3 polyunsaturated FA within PCs and PEs, 
rather than DGs and TGs, are positively associated with CB TG-poly (Figure 2.10), supporting 
the importance of the phospholipid fraction in the transfer of PUFA late in gestation. 
Our results indicated a sexual dimorphic effect of CB DG- and TG-poly with BW, with a larger 
effect seen in the females (Figure 2.7 and 2.8). Previous studies that have looked at the effect of 
PUFA supplementation during pregnancy on infant BW have yielded mixed results (47), 
potentially due to differences in gestation length, baseline characteristics of the participants, and 
source, timing, and dose of n-3 PUFA supplement. PUFAs supplementation has been associated 
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with longer gestation and an increase in fetal weight, especially in women at risk for intrauterine 
growth retardation (48). However, O’Tierney-Ginn, et al. (49) found that total CB saturated fatty 
acids was positively associated with high skinfold thickness at birth (but not birthweight BMI z-
score), as well as increased BMI-z trajectory in early infancy, while PUFA levels were inversely 
correlated with BMI-z trajectory. Hauner, et al. (50) demonstrated that dietary n-3 LC-PUFA 
supplementation of women had no effect on BW in randomized trial of 208 women but had a 
larger effect on the gene expression profile in female placentas. Sedlmeier, et al. observed 
placental gene expression to be more responsive to maternal omega-3 supplementation in 
females than males (51). The reason for the sexually dimorphic differences is not yet clear.  
We observed a positive association between CB LysoPE and LysoPCs and Fenton BW z-score 
(Figure 2.7), independent of the chain length and the number of double bonds. This confirms 
findings from other studies that CB LysoPCs with varying chain length and saturation are 
positively associated with newborn BW (21–23), as well as with weight at age 6 months (21). 
The associations between LysoPL and BW were not as apparent in M1 and M3, with an 
exception being M3 LysoPE-sat are positively associated with BW (Figure 2.7). Additionally, 
we found that maternal GWG is positively associated with M1 and M3 LysoPC and LysoPE 
lipid groups of varying number of double bonds, suggesting an influence of maternal 
characteristics during pregnancy on LysoPL (Figure S2.3).  
Recently, the Major Facilitator Super Family Domain Containing 2a (MFSD2a) protein has been 
proposed as a NA+-dependent LysoPL transporter in the brain (52) and placenta (53). This 
transporter provides a mechanism for the active transport of LysoPL from maternal plasma, 
consistent with our study findings that (1) LysoPC and LysoPE are depleted in maternal plasma 
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and elevated in CB (Figure 2.2) and (2) M1 and M3 LysoPLs, mainly containing saturated FA, 
are positively correlated with total CB LysoPL levels (Figure 2.9).  
Since the sn-2 position of phospholipids tend to be occupied by PUFAs (54), it has been 
hypothesized that specific placental endothelial lipases cleave sn-1 fatty acids, allowing transport 
of the PUFA-containing LysoPL to the fetal circulation, perhaps enhancing delivery to the 
developing fetal brain (34,55). An intriguing possibility suggested by our data is that there is an 
interaction between PUFA during development and later transfer of LysoPL to the fetus. We see 
a significant inverse association of PUFA-containing lipids M1 and LysoPC levels in the CB of 
infants and conversely, a positive association of M1 (and M3) lipids enriched in saturated fatty 
acids (Figure 2.9). This might imply early programming of LysoPL transport capacity. Control 
of MFSD2a expression in placenta has not been established, but is potentially regulated by diet. 
In mice, cortical and subcortical brain MFSD2a levels increased in rodents fed a high fat diet, 
with PUFA-containing diets having a greater effect at lower concentrations than a lard-
containing diet (56). Additionally, MFSD2a expression in placenta is positively correlated with 
CB DHA levels (53), supporting its role in PUFA transport and implying it responds to the levels 
of DHA.  
Of interest, polyunsaturated SM are decreased between M3 and CB (Figure 2.2), suggesting that 
maternal late gestation SM may be (1) directly transferred to the fetus to provide PUFAs or (2) 
converted into LysoPL, the preferential transfer method of PUFAs. Multiple significant 
correlations were observed between M3 SM and the CB lipidome. CB polyunsaturated TGs are 
inversely correlated with M3 SM-mono and SM-poly individual lipids and lipid groups (Figure 
2.10), suggesting that elevated late gestation polyunsaturated SM may result in lower levels of 
polyunsaturated containing TG in the CB. Supporting these results, we found that M3 SM-mono 
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and M3 SM-poly are positively associated with maternal baseline BMI (Figure S2.3) and 
positively associated with newborn BW (Figure 2.7). These results suggest that inability to 
convert SM to transfer the monounsaturated and polyunsaturated fatty acids across the placenta 
results in less favorable fetal development, potentially linked to maternal BMI. Lastly, M3 
saturated and monounsaturated SM were positively associated with CB LysoPL-total levels. 
These results highlight the importance of the SM lipid fraction during gestation, which 
potentially is related to the pathogenesis of obesity, T2D, and various metabolic diseases (57).  
Conclusion 
The finding that the lipids that show the greatest differences between maternal and fetal 
circulation at term are also associated with BW is a novel finding in these studies and suggests a 
complex interaction between PUFA intake, incorporation into specific lipid subtypes and 
transport to the developing fetus. Future longitudinal studies with a larger sample size are desired 
to assess if changing the maternal metabolic environment to a more favorable lipidome will 
improve infant outcomes. Collection of maternal dietary intake can help elucidate the 
relationship between nutrient intake and blood concentrations of very long-chain FA, as the 
metabolome doesn’t solely represent dietary intake, but rather a combination of genetics, diet, 
and phenotypes. Maternal blood collection at delivery may not be representative of the metabolic 
states during the third trimester due to the stress of parturition, although we observed no 
differences in lipidome components based on route of delivery. Collecting multiple blood 
samples throughout pregnancy will help to further classify lipidome changes throughout 
pregnancy. Collection of placenta samples and quantifying gene expression of key transport 




Jennifer L. LaBarre, Muraly Puttabyatappa, Peter X.K. Song, Jaclyn M. Goodrich, Ling Zhou, 
Thekkelnaycke M. Rajendiran, Tanu Soni, Steven E. Domino, Marjorie C. Treadwell, Dana C. 
Dolinoy, Vasantha Padmanabhan, and Charles F. Burant 
Acknowledgements 
We would like to acknowledge Samantha Milewski and Steven Rogers for help with recruitment, 
processing of samples, and retrieval of clinical data. 
Funding Support  
University of Michigan NIEHS/EPA Children’s Environmental Health and Disease Prevention 
Center P01 ES022844/RD 83543601 (VP, DCD, PS, JG), NIH Children’s Health Exposure 
Analysis Resource (CHEAR), 1U2C ES026553 (DD, JG, CFB), Michigan Lifestage 
Environmental Exposures and Disease (M-LEEaD) NIEHS Core Center P30 ES017885 (VP, 
DCD, JG, PS, CFB), NIH/NIEHS UG3 OD023285 (VP, DCD), Molecular Phenotyping Core, 
Michigan Nutrition and Obesity Center P30 DK089503 (CFB, DCD) and Michigan Regional 
Metabolomics Resource Core R24 DK097153 (CFB), Ruth L. Kirschstein Institutional Training 
Grant from the NIEHS T32 ES007062 (MP) and The A. Alfred Taubman Research Institute 
(CFB). 
Study Approval 
The MMIP study was approved by the University of Michigan Institutional Review Board 
(HUM00017941). Written informed consent was received from all participants and all plasma 















Trimester of Pregnancy 
Delivery and Birth  
1 2 3 
Recruitment 
and Consent  
Maternal blood 






Lipidomics was conducted on maternal first trimester (M1), term (M3) and cord blood (CB) 
plasma (n=106). Maternal and infant phenotypes were collected throughout the study.  
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Table 2.1. Lipid species class, abbreviation, and number of lipids annotated from lipidomics 
analysis. 
Lipid Class Abbreviation Number 
acylcarnitine AC 6 
ceramide CER 51 
cholesteryl ester CE 13 
diacylglycerol DG 30 
free fatty acid  FFA 16 
glucosylceramidase GlcCer 9 
lysophosphatidylcholine LysoPC 29 
lysophosphatidylethanolamine LysoPE 9 
phosphatidic acid PA 4 
phosphatidylcholine PC 96 
phosphatidylethanolamine PE 44 
plasmenyl-phosphatidylcholine PL-PC 54 
plasmenyl-phosphatidylethanolamine PL-PE 36 
phosphatidylglycerol PG 8 
phosphatidylinositol PI 12 
phosphatidylserine PS 2 
sphingomyelin SM 65 





Table S2.1. Lipid group classifications. Lipidomics dataset was collapsed into groups of lipids based on the lipid class and the number 
of double bonds within the fatty acid tails. A list of the individual lipids within each group are reported. 
Lipid Group Lipid Species 
AC Acylcarnitine 16:0, Acylcarnitine 18:0, Acylcarnitine 24:0, Acylcarnitine 26:0, Acylcarnitine 18:1, Acylcarnitine 18:2 
CE 16:0 CE, 18:0 CE, 16:1 CE, 17:1 CE, 18:1 CE 
CE-poly 18:2 CE, 18:3 CE, 20:3 CE, 20:4 CE, 22:4 CE, 20:5 CE, 22:5 CE, 22:6 CE 
CER-sat 
Cer[NDS] 34:0, Cer[NDS] 36:0, Cer[NDS] 38:0, Cer[NDS] 40:0, Cer[NDS] 41:0, Cer[NDS] 42:0, Cer[EODS] 53:0, Cer[NP] 34:0, 
Cer[NP] 40:0, Cer[NP] 42:0,  
CER-mono 
Cer[NS] 32:1, Cer[NS] 33:1, Cer[NS] 34:1, Cer[NS] 35:1, Cer[NS] 36:1, Cer[NS] 37:1, Cer[NS] 38:1, Cer[NS] 39:1, Cer[NS] 40:1, 
Cer[NS] 41:1, Cer[NS] 42:1, Cer[NS] 43:1, Cer[NS] 44:1, Cer[AS] 41:1, Cer[EODS] 49:1, Cer[NP] 42:1 
CER-poly 
Cer[NS] 34:2, Cer[NS] 36:2, Cer[NS] 38:2, Cer[NS] 39:2, Cer[NS] 40:2, Cer[NS] 41:2, Cer[NS] 42:2, Cer[NS] 43:2, Cer[AS] 42:2, 
Cer[EODS] 57:2, Cer[NS] 41:3, Cer[NS] 42:3, Cer[NS] 43:3, Cer[NS] 33:4, Cer[NS] 37:4 
DG-sat DG 30:0, DG 31:0, DG 32:0, DG 33:0, DG 34:0, DG 36:0, DG 38:0, DG 30:1, DG 32:1, DG 33:1, DG 35:1, DG 36:1, DG 38:1 
DG-mono DG 32:2, DG 34:2, DG 35:2, DG 36:2, DG 38:2, DG 34:3, DG 35:3, DG 36:3, DG 38:3 
DG-poly DG 36:4, DG 38:4, DG 36:5, DG 38:5, DG 38:6, DG 38:7, DG 40:7, DG 40:8 
FFA-sat FFA18:0, FFA16:0, FFA20:0, FFA22:0, FFA24:0 
FFA-mono FFA18:1, FFA20:1, FFA22:1, FFA24:1 
FFA-poly FFA18:2, FFA20:2, FFA22:2, FFA24:2, FFA22:3, FFA24:3, FFA20:4 
GlcCer 
GlcCer[NS] 32:1, GlcCer[NS] 34:1, GlcCer[NS] 38:1, GlcCer[NS] 40:1, GlcCer[NS] 41:1, GlcCer[NS] 42:1, GlcCer[NS] 43:1, 
GlcCer[NS] 41:2, GlcCer[NS] 42:2 
LysoPC-sat 
LysoPC 14:0, LysoPC 15:0, LysoPC 16:0, LysoPC 17:0, LysoPC 18:0, LysoPC 19:0, LysoPC 20:0, LysoPC 22:0, LysoPC 24:0, 
LysoPC 26:0 
LysoPC-mono LysoPC 16:1, LysoPC 17:1, LysoPC 18:1, LysoPC 19:1, LysoPC 20:1, LysoPC 24:1, LysoPC 26:1 
LysoPC-poly 
LysoPC 18:2, LysoPC 20:2, LysoPC 26:2, LysoPC 18:3, LysoPC 20:3, LysoPC 20:4, LysoPC 22:4, LysoPC 24:4, LysoPC 26:4, 
LysoPC 20:5, LysoPC 22:5, LysoPC 22:6 
LysoPE-sat LysoPE 16:0, LysoPE 18:0, LysoPE 24:0 
LysoPE-poly LysoPE 18:2, LysoPE 20:3, LysoPE 20:4, LysoPE 22:5, LysoPE 22:6 
PC-sat 
PC 22:0, PC 23:0, PC 24:0, PC 26:0, PC 28:0, PC 29:0, PC 30:0, PC 31:0, PC 32:0, PC 33:0, PC 34:0, PC 36:0, PC 40:0, PC 25:1, 
PC 26:1, PC 28:1, PC 30:1, PC 31:1, PC 32:1, PC 33:1, PC 34:1, PC 35:1, PC 36:1, PC 37:1, PC 38:1, PC 40:1, PC 42:1 
PC-mono 
PC 30:2, PC 31:2, PC 32:2, PC 33:2, PC 34:2, PC 35:2, PC 36:2, PC 37:2, PC 38:2, PC 40:2, PC 42:2, PC 44:2, PC 30:3, PC 32:3, 
PC 33:3, PC 34:3, PC 35:3, PC 36:3, PC 37:3, PC 38:3, PC 39:3, PC 40:3, PC 42:3, PC 44:3 
PC-poly 
PC 40:10, PC 42:10, PC 42:11, PC 32:4, PC 34:4, PC 35:4, PC 36:4, PC 37:4, PC 38:4, PC 39:4, PC 40:4, PC 42:4, PC 44:4, PC 
46:4, PC 34:5, PC 35:5, PC 36:5, PC 37:5, PC 38:5, PC 39:5, PC 40:5, PC 41:5, PC 42:5, PC 44:5, PC 46:5, PC 35:6, PC 36:6, PC 
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37:6, PC 38:6, PC 39:6, PC 40:6, PC 41:6, PC 42:6, PC 44:6, PC 35:7, PC 36:7, PC 37:7, PC 38:7, PC 39:7, PC 40:7, PC 42:7, PC 
40:8, PC 42:8, PC 40:9, PC 42:9 
PE-sat PE 30:0, PE 32:0, PE 33:0, PE 34:0, PE 35:0, PE 36:0, PE 32:1, PE 33:1, PE 34:1, PE 35:1, PE 36:1, PE 38:1 
PE-mono PE 32:2, PE 33:2, PE 34:2, PE 35:2, PE 36:2, PE 37:2, PE 38:2, PE 40:2, PE 34:3, PE 35:3, PE 36:3, PE 37:3, PE 38:3 
PE-poly 
PE 42:10, PE 34:4, PE 35:4, PE 36:4, PE 37:4, PE 38:4, PE 40:4, PE 36:5, PE 37:5, PE 38:5, PE 40:5, PE 36:6, PE 37:6, PE 38:6, 
PE 39:6, PE 40:6, PE 38:7, PE 40:7, PE 40:8 
PG-sat PG 32:0, PG 33:0, PG 34:0, PG 36:0, PG 32:1, PG 34:1 
PG-mono PG 34:2, PG 36:2 
PI-sat PI 34:1, PI 36:1 
PI-mono PI 34:2, PI 36:2, PI 36:3, PI 38:3 
PI-poly PI 36:4, PI 38:4, PI 38:5, PI 40:5, PI 38:6, PI 40:6 
PLPC-sat 
PL-PC 24:0, PL-PC 26:0, PL-PC 30:0, PL-PC 32:0, PL-PC 34:0, PL-PC 35:0, PL-PC 36:0, PL-PC 40:0, PL-PC 42:0, PL-PC 32:1, PL-
PC 34:1, PL-PC 35:1, PL-PC 36:1, PL-PC 37:1, PL-PC 40:1, PL-PC 42:1, PL-PC 44:1 
PLPC-mono 
PL-PC 34:2, PL-PC 35:2, PL-PC 36:2, PL-PC 37:2, PL-PC 40:2, PL-PC 42:2, PL-PC 44:2, PL-PC 34:3, PL-PC 35:3, PL-PC 36:3, PL-
PC 37:3, PL-PC 38:3, PL-PC 40:3, PL-PC 42:3, PL-PC 43:3, PL-PC 44:3 
PLPC-poly 
PL-PC 34:4, PL-PC 36:4, PL-PC 37:4, PL-PC 38:4, PL-PC 40:4, PL-PC 41:4, PL-PC 42:4, PL-PC 43:4, PL-PC 44:4, PL-PC 46:4, PL-
PC 36:5, PL-PC 38:5, PL-PC 39:5, PL-PC 40:5, PL-PC 42:5, PL-PC 44:5, PL-PC 36:6, PL-PC 37:6, PL-PC 38:6, PL-PC 40:6, PL-PC 
44:6 
PLPE-sat PL-PE 32:0, PL-PE 32:1, PL-PE 34:1, PL-PE 35:1, PL-PE 36:1, PL-PE 38:1, PL-PE 40:1 
PLPE-mono 
PL-PE 32:2, PL-PE 34:2, PL-PE 35:2, PL-PE 36:2, PL-PE 37:2, PL-PE 38:2, PL-PE 40:2, PL-PE 34:3, PL-PE 36:3, PL-PE 38:3, PL-PE 
40:3 
PLPE-poly 
PL-PE 34:4, PL-PE 35:4, PL-PE 36:4, PL-PE 37:4, PL-PE 38:4, PL-PE 39:4, PL-PE 40:4, PL-PE 42:4, PL-PE 36:5, PL-PE 37:5, PL-PE 
38:5, PL-PE 40:5, PL-PE 36:6, PL-PE 37:6, PL-PE 38:6, PL-PE 39:6, PL-PE 40:6, PL-PE 42:6 
SM-sat 
SM 30:0, SM 32:0, SM 33:0, SM 34:0, SM 36:0, SM 38:0, SM 40:0, SM 41:0, SM 29:1, SM 30:1, SM 31:1, SM 32:1, SM 33:1, 
SM 34:1, SM 35:1, SM 36:1, SM 37:1, SM 38:1, SM 39:1, SM 40:1, SM 41:1, SM 42:1, SM 43:1, SM 44:1 
SM-mono 
SM 30:2, SM 32:2, SM 33:2, SM 34:2, SM 35:2, SM 36:2, SM 37:2, SM 38:2, SM 39:2, SM 40:2, SM 41:2, SM 42:2, SM 43:2, 
SM 44:2, SM 34:3, SM 36:3, SM 38:3, SM 39:3, SM 40:3, SM 41:3, SM 42:3, SM 43:3, SM 44:3 
SM-poly 
SM 36:4, SM 38:4, SM 40:4, SM 42:4, SM 43:4, SM 44:4, SM 45:4, SM 38:5, SM 40:5, SM 42:5, SM 44:5, SM 47:5, SM 35:6, 
SM 42:6, SM 44:6, SM 42:7, SM 43:7, SM 44:7 
TG-sat 
TG 36:0, TG 38:0, TG 39:0, TG 40:0, TG 41:0, TG 42:0, TG 43:0, TG 44:0, TG 45:0, TG 46:0, TG 47:0, TG 48:0, TG 49:0, TG 
50:0, TG 51:0, TG 52:0, TG 53:0, TG 54:0, TG 56:0, TG 40:1, TG 42:1, TG 44:1, TG 45:1, TG 46:1, TG 47:1, TG 48:1, TG 49:1, 
TG 50:1, TG 51:1, TG 52:1, TG 53:1, TG 54:1, TG 55:1, TG 56:1, TG 58:1, TG 62:1, TG 42:2, TG 44:2, TG 46:2, TG 47:2, TG 




TG 42:3, TG 46:3, TG 47:3, TG 48:3, TG 49:3, TG 50:3, TG 51:3, TG 52:3, TG 53:3, TG 54:3, TG 55:3, TG 56:3, TG 58:3, TG 
48:4, TG 50:4, TG 51:4, TG 52:4, TG 53:4, TG 54:4, TG 56:4, TG 58:4, TG 50:5, TG 51:5, TG 52:5, TG 53:5, TG 54:5, TG 56:5, 
TG 58:5 
TG-poly 
TG 50:6, TG 52:6, TG 54:6, TG 56:6, TG 58:6, TG 54:7, TG 56:7, TG 58:7, TG 54:8, TG 56:8, TG 58:8, TG 56:9, TG 58:9, TG 
56:10, TG 58:10, TG 60:10, TG 58:11, TG 60:11, TG 60:12, TG 62:12, TG 62:14 
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Table 2.2. Characteristics of the MMIP participants, stratified by sex (n=106). 
  
Categorical Variables  
All Males Females 
p-valueA  
n (%)  n (%) n (%) 
Parity  
0 33 (31%) 16 (31%) 17 (31%) 
0.988 
1 45 (42%) 21 (41%) 24 (44%) 
2 21 (20%) 11 (22%) 10 (18%) 
≥3 7 (7%) 3 (6%) 4 (7%) 
Baseline BMI (kg/m²) 
18.5-24.9 64 (62%) 30 (61%) 34 (63%) 
0.5037 
25.0-29.9 18 (17%) 11 (22%) 7 (13%) 
30.0-34.9 12 (12%) 4 (8%) 8 (15%) 
≥ 35.0 9 (9%) 4 (8%) 5 (9%) 
Delivery Mode  
Vaginal  76 (72%) 35 (69%) 41 (75%) 
0.4992 
Caesarean Section  30 (28%) 16 (31%) 14 (25%) 
Continuous Variables  
All Males Females 
p-valueB  
mean±SD (n) mean±SD (n) mean±SD (n) 
Maternal Baseline Characteristics 
Age (years) 32.1±3.6 32.4±4.1 31.7±3.2 0.3233 
Weight (kg) 71.1±17.6 69.4±13.9 72.6±20.4 0.3465 
Height (cm)  165±7 (103) 165±6 (49) 165±7 (54) 0.8589 
BMI (kg/m²) 25.8±6.0 (103) 25.4±5.3 (49) 26.2±6.6 (54) 0.5238 
Maternal and Newborn Delivery Characteristics  
Gestation age (days) 278±7 278±8 278±6 0.9812 
GWG (kg) 13.2±5.2 13.9±4.5 12.6±5.8 0.2058 
Birth weight (g)  3510±436 (105) 3638±467 3390±370 (54) 0.0032 
Fenton BW z-score 0.09±0.87 (105) 0.20±0.95 -0.01±0.78 (54) 0.2055 
Fenton BW percentile  53.1±26.1 (105) 56.0±28.2 50.4±23.8 (54) 0.2701 
Head Circumference (cm) 35±1 (101) 35.2±1.2 (48) 34.7±1.3 (53) 0.049 
Fenton HC z-score 0.10±0.86 (101) 0.16±0.72 (48) 0.04±0.96 (53) 0.4847 
Fenton HC percentile  52.5±25.5 (101) 54.9±22.9 (48) 50.4±27.6 (53) 0.3749 
Values are n(%) or mean±SD. Stratified by males (n=51) and females (n=55). ARepresents 
Pearson's chi-square test for categorical variables. BRepresents paired t-test for continuous 
variables.  If sample size differs, mean±SD (n). 
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(A) Maternal baseline BMI is inversely associated with gestational weight gain (r2 0.18, 
P<0.001). (B) Maternal baseline BMI is positively associated with Fenton BW percentile (r2 
0.06, p=0.0014). (C) Maternal gestational weight gain is trending towards a positive 
association with Fenton BW percentile (r2 0.03, p=0.070).  


























































A B C 
62 
 



















































    
A 
B C 
 (A) Heat Map of standardized peak intensity for individual lipids (mean 0, standard deviation 
1). Lipids are grouped by lipid class with increasing total chain length and double bond from 
left to right in each lipid class. (B) Differences between M1 and M3 lipidome using log2FC. 
Lipids that are greater in M1 than M3 have a positive log2FC. Of the 573 lipid species 
analyzed, 35% were significantly increased and 10% were decreased (Bonferroni adjusted, 
α=0.05/573). (C) Differences between M3 and CB lipidome using log2FC. Of the 573 lipid 
species analyzed, 10% were significantly increased and 61% were decreased (Bonferroni 
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Table S2.2. Comparison of M1-M3 lipid raw peak intensities. Paired t-tests identified 
differences in raw peak intensities of individual plasma lipids between M1 to M3. The fold 
change between lipids in M1 and M3 was calculated by log2(M3/M1), where a positive FC 
indicates increases in that lipid between M1 and M3 and a negative FC indicates decreases in 
that lipid between M1 and M3. Significance highlighted in red (Bonferroni adjusted, 
α=0.05/573). 
Metabolite 
M1 M3 M1 M3 t-test 
Mean Std dev Mean Std dev log2(M3/M1) p-value -log10(p-value) 
FFA(16:0) 5.68E+07 8.07E+06 7.06E+07 1.39E+07 0.314 3.46E-16 15.461 
FFA(18:0) 6.89E+07 5.46E+06 7.23E+07 7.23E+06 0.071 1.13E-04 3.948 
FFA(18:1) 2.37E+07 1.42E+07 5.46E+07 2.45E+07 1.203 3.16E-23 22.501 
FFA(18:2) 1.62E+07 8.75E+06 3.37E+07 1.50E+07 1.055 1.29E-20 19.889 
FFA(20:0) 1.99E+06 2.46E+05 2.10E+06 3.40E+05 0.083 4.17E-03 2.380 
FFA(20:1) 4.66E+05 2.38E+05 1.34E+06 6.81E+05 1.526 3.46E-27 26.461 
FFA(20:2) 4.17E+05 2.33E+05 9.58E+05 4.24E+05 1.199 4.63E-24 23.335 
FFA(20:4) Arachidonic acid 1.45E+06 6.69E+05 1.73E+06 6.73E+05 0.260 2.22E-03 2.653 
FFA(22:0) 5.59E+05 1.43E+05 6.46E+05 2.71E+05 0.208 3.99E-03 2.399 
FFA(22:1) 1.41E+05 4.34E+04 2.58E+05 1.57E+05 0.871 3.09E-12 11.510 
FFA(22:2) 3.64E+04 1.30E+04 8.29E+04 3.39E+04 1.186 3.01E-29 28.521 
FFA(22:3) 4.85E+04 1.69E+04 8.90E+04 3.17E+04 0.877 2.20E-24 23.657 
FFA(24:0) 3.76E+05 1.53E+05 3.86E+05 1.73E+05 0.039 6.47E-01 0.189 
FFA(24:1) 2.62E+05 6.80E+04 3.83E+05 1.08E+05 0.548 7.64E-19 18.117 
FFA(24:2) 7.47E+04 2.29E+04 1.21E+05 3.54E+04 0.690 4.02E-23 22.396 
FFA(24:3) 1.23E+04 4.71E+03 1.72E+04 6.76E+03 0.487 3.69E-09 8.433 
16:0 Cholesteryl ester 4.57E+04 1.20E+04 4.72E+04 1.76E+04 0.046 4.75E-01 0.324 
16:1 Cholesteryl ester 2.22E+04 1.04E+04 3.32E+04 1.51E+04 0.582 2.96E-09 8.528 
17:1 Cholesteryl ester 6.55E+03 2.87E+03 7.14E+03 2.74E+03 0.123 1.32E-01 0.881 
18:0 Cholesteryl ester 1.89E+04 8.57E+03 1.78E+04 7.35E+03 -0.083 3.38E-01 0.471 
18:1 Cholesteryl ester 5.79E+05 1.19E+05 6.98E+05 1.59E+05 0.269 3.76E-09 8.424 
18:2 Cholesteryl ester 3.30E+06 5.46E+05 3.19E+06 6.38E+05 -0.048 1.91E-01 0.720 
18:3 Cholesteryl ester 1.15E+04 2.65E+04 9.06E+03 2.09E+04 -0.339 4.65E-01 0.333 
20:3 Cholesteryl ester 3.50E+05 8.97E+04 3.10E+05 8.99E+04 -0.175 1.37E-03 2.863 
20:4 Cholesteryl ester 1.48E+04 9.05E+03 1.67E+04 1.00E+04 0.175 1.47E-01 0.832 
20:5 Cholesteryl ester 9.86E+04 7.82E+04 5.35E+04 5.23E+04 -0.883 1.63E-06 5.789 
22:4 Cholesteryl ester 1.52E+04 5.45E+03 1.17E+04 4.62E+03 -0.384 6.65E-07 6.177 
22:5 Cholesteryl ester 4.07E+04 1.25E+04 3.39E+04 1.24E+04 -0.263 1.03E-04 3.985 
22:6 Cholesteryl ester 2.33E+05 8.96E+04 1.77E+05 8.09E+04 -0.398 3.11E-06 5.507 
Acylcarnitine 16:0 6.54E+04 2.02E+04 6.95E+04 2.48E+04 0.089 1.81E-01 0.741 
Acylcarnitine 18:0 3.10E+04 1.05E+04 2.88E+04 1.39E+04 -0.108 1.89E-01 0.723 
Acylcarnitine 18:1 1.22E+05 5.05E+04 1.32E+05 5.46E+04 0.111 1.79E-01 0.747 
Acylcarnitine 18:2 7.63E+04 3.84E+04 7.12E+04 3.93E+04 -0.100 3.40E-01 0.469 
Acylcarnitine 24:0 1.82E+03 1.08E+03 1.86E+03 9.37E+02 0.031 7.77E-01 0.109 
Acylcarnitine 26:0 2.69E+03 1.69E+03 2.53E+03 1.42E+03 -0.090 4.47E-01 0.350 
Cer[NDS] 34:0 1.07E+05 2.19E+04 1.20E+05 2.95E+04 0.168 2.68E-04 3.572 
Cer[NDS] 36:0 3.58E+04 1.20E+04 7.37E+04 2.97E+04 1.042 4.28E-26 25.369 
Cer[NDS] 38:0 3.60E+03 1.19E+03 5.22E+03 1.99E+03 0.536 1.19E-11 10.924 
Cer[NDS] 40:0 3.17E+05 1.07E+05 5.04E+05 1.39E+05 0.667 1.86E-22 21.731 
Cer[NDS] 41:0 2.10E+04 6.63E+03 3.03E+04 8.43E+03 0.532 1.61E-16 15.792 
Cer[NDS] 42:0 5.53E+04 1.80E+04 8.59E+04 2.46E+04 0.637 1.55E-20 19.809 
Cer[NDS] 42:1 3.19E+05 8.69E+04 4.38E+05 1.19E+05 0.454 1.85E-14 13.732 
Cer[NS] 32:1 3.63E+04 1.06E+04 3.90E+04 1.14E+04 0.102 7.91E-02 1.102 
Cer[NS] 33:1 2.97E+04 6.80E+03 2.79E+04 8.19E+03 -0.095 6.88E-02 1.163 
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Cer[NS] 33:4 3.42E+03 2.51E+03 3.45E+03 2.51E+03 0.011 9.38E-01 0.028 
Cer[NS] 34:1 1.59E+04 3.85E+03 2.09E+04 5.73E+03 0.398 1.56E-12 11.806 
Cer[NS] 34:2 2.34E+04 6.03E+03 2.49E+04 7.48E+03 0.088 1.18E-01 0.928 
Cer[NS] 35:1 1.53E+07 1.62E+06 1.37E+07 1.52E+06 -0.161 2.35E-12 11.630 
Cer[NS] 36:1 1.34E+05 3.17E+04 2.18E+05 6.55E+04 0.705 2.21E-25 24.655 
Cer[NS] 36:2 2.02E+04 5.61E+03 2.62E+04 9.87E+03 0.375 1.45E-07 6.839 
Cer[NS] 37:1 6.74E+04 1.52E+04 8.99E+04 3.30E+04 0.416 1.11E-09 8.956 
Cer[NS] 37:4 1.80E+04 8.47E+03 1.51E+04 6.43E+03 -0.258 4.64E-03 2.334 
Cer[NS] 38:1 2.14E+05 5.79E+04 3.19E+05 8.17E+04 0.576 6.52E-22 21.186 
Cer[NS] 38:2 2.88E+04 7.67E+03 4.12E+04 1.20E+04 0.514 1.77E-16 15.751 
Cer[NS] 39:1 2.70E+05 7.50E+04 3.53E+05 9.12E+04 0.386 8.94E-12 11.049 
Cer[NS] 39:2 3.59E+04 1.12E+04 4.50E+04 1.32E+04 0.326 1.88E-07 6.727 
Cer[NS] 40:1 1.24E+06 3.51E+05 1.76E+06 4.98E+05 0.508 4.65E-16 15.333 
Cer[NS] 40:2 2.29E+05 6.42E+04 2.95E+05 7.92E+04 0.365 2.34E-10 9.630 
Cer[NS] 41:1 8.06E+04 2.31E+04 1.06E+05 2.94E+04 0.401 1.66E-11 10.779 
Cer[NS] 41:2 4.06E+05 1.04E+05 4.99E+05 1.31E+05 0.298 3.08E-08 7.512 
Cer[NS] 41:3 5.03E+04 1.54E+04 6.46E+04 2.18E+04 0.362 9.47E-08 7.024 
Cer[NS] 42:1 3.19E+05 8.69E+04 4.38E+05 1.19E+05 0.454 1.85E-14 13.732 
Cer[NS] 42:2 1.43E+06 3.51E+05 1.95E+06 4.83E+05 0.441 4.24E-16 15.373 
Cer[NS] 42:3 8.38E+03 2.99E+03 1.10E+04 4.27E+03 0.389 6.82E-07 6.166 
Cer[NS] 43:1 6.74E+05 2.14E+05 6.77E+05 2.27E+05 0.006 9.28E-01 0.032 
Cer[NS] 43:2 1.56E+04 5.20E+03 1.63E+04 5.83E+03 0.065 3.48E-01 0.458 
Cer[NS] 43:3 7.39E+03 2.98E+03 1.02E+04 3.55E+03 0.459 3.96E-09 8.402 
Cer[NS] 44:1 2.63E+04 5.83E+03 2.62E+04 7.21E+03 -0.009 8.51E-01 0.070 
Cer[AS] 41:1 2.26E+04 9.70E+03 3.75E+04 1.71E+04 0.726 3.98E-13 12.401 
Cer[AS] 42:2 8.56E+04 2.81E+04 9.28E+04 3.52E+04 0.116 1.02E-01 0.990 
Cer[EODS] 49:1 4.93E+03 2.44E+03 8.42E+03 3.86E+03 0.772 1.87E-13 12.727 
Cer[EODS] 53:0 1.03E+04 3.45E+03 7.86E+03 2.90E+03 -0.386 1.06E-07 6.976 
Cer[EODS] 57:2 9.93E+03 3.94E+03 9.66E+03 4.45E+03 -0.040 6.41E-01 0.193 
Cer[NP] 34:0 5.17E+03 2.63E+03 4.12E+03 1.99E+03 -0.328 1.18E-03 2.930 
Cer[NP] 40:0 6.95E+04 2.58E+04 7.25E+04 2.53E+04 0.061 3.94E-01 0.404 
Cer[NP] 42:0 1.12E+05 3.24E+04 1.07E+05 3.07E+04 -0.062 2.78E-01 0.557 
Cer[NP] 42:1 6.83E+04 2.58E+04 6.41E+04 2.34E+04 -0.092 2.14E-01 0.670 
GlcCer[NS] 32:1 3.15E+03 1.60E+03 3.77E+03 1.69E+03 0.256 7.17E-03 2.145 
GlcCer[NS] 34:1 1.43E+05 3.15E+04 1.92E+05 5.62E+04 0.426 2.00E-13 12.699 
GlcCer[NS] 38:1 8.90E+03 4.03E+03 1.19E+04 3.71E+03 0.418 5.68E-08 7.245 
GlcCer[NS] 40:1 1.90E+05 5.23E+04 2.47E+05 7.97E+04 0.380 3.48E-09 8.459 
GlcCer[NS] 41:1 1.56E+04 4.32E+03 1.84E+04 5.62E+03 0.237 7.59E-05 4.120 
GlcCer[NS] 41:2 8.91E+03 4.44E+03 1.15E+04 5.62E+03 0.368 2.55E-04 3.593 
GlcCer[NS] 42:1 5.01E+04 1.29E+04 6.22E+04 1.56E+04 0.310 4.44E-09 8.352 
GlcCer[NS] 42:2 3.98E+04 8.63E+03 4.67E+04 1.24E+04 0.231 4.40E-06 5.357 
GlcCer[NS] 43:1 6.97E+03 4.72E+03 7.32E+03 3.69E+03 0.071 5.46E-01 0.263 
MG 26:4 2.53E+04 7.84E+03 2.82E+04 9.60E+03 0.157 1.63E-02 1.786 
DG 30:0 9.81E+03 1.07E+04 1.92E+04 1.69E+04 0.969 2.57E-06 5.591 
DG 30:1 5.04E+03 4.75E+03 7.92E+03 6.32E+03 0.651 2.36E-04 3.628 
DG 31:0 2.56E+03 2.31E+03 4.10E+03 2.47E+03 0.680 4.77E-06 5.321 
DG 32:0 2.57E+04 2.42E+04 7.25E+04 5.16E+04 1.496 4.77E-15 14.321 
DG 32:1 3.57E+04 2.92E+04 8.35E+04 5.58E+04 1.225 2.70E-13 12.569 
DG 32:2 1.56E+04 1.04E+04 2.62E+04 1.35E+04 0.746 1.10E-09 8.959 
DG 33:0 3.24E+03 2.15E+03 5.29E+03 2.92E+03 0.709 2.10E-08 7.677 
DG 33:1 6.15E+03 4.88E+03 1.15E+04 6.45E+03 0.901 1.13E-10 9.946 
DG 34:0 2.57E+04 1.47E+04 4.58E+04 2.29E+04 0.835 8.80E-13 12.056 
DG 34:2 1.39E+05 7.30E+04 3.33E+05 1.56E+05 1.257 2.19E-24 23.660 
DG 34:3 3.50E+04 1.82E+04 6.81E+04 2.90E+04 0.961 2.10E-19 18.678 
DG 35:1 6.72E+03 3.75E+03 1.18E+04 5.17E+03 0.812 2.52E-14 13.599 
65 
 
DG 35:2 7.43E+03 3.41E+03 1.36E+04 6.14E+03 0.869 1.45E-16 15.840 
DG 35:3 4.03E+03 2.12E+03 6.92E+03 3.10E+03 0.780 1.28E-13 12.894 
DG 36:0 1.17E+04 3.30E+03 1.31E+04 3.47E+03 0.167 2.38E-03 2.623 
DG 36:1 4.31E+04 2.17E+04 8.75E+04 4.14E+04 1.023 6.93E-19 18.159 
DG 36:2 2.14E+05 8.10E+04 4.33E+05 2.02E+05 1.015 1.61E-20 19.792 
DG 36:3 2.49E+05 9.74E+04 4.97E+05 2.38E+05 0.996 2.80E-19 18.553 
DG 36:4 1.65E+05 7.44E+04 2.68E+05 1.15E+05 0.704 2.90E-13 12.538 
DG 36:5 1.99E+04 1.04E+04 2.72E+04 1.26E+04 0.447 8.37E-06 5.077 
DG 38:0 1.91E+03 1.05E+03 2.18E+03 1.29E+03 0.192 9.33E-02 1.030 
DG 38:1 8.37E+03 4.37E+03 1.00E+04 5.02E+03 0.257 1.24E-02 1.907 
DG 38:2 9.77E+03 3.62E+03 2.18E+04 8.99E+03 1.158 4.64E-28 27.334 
DG 38:3 1.33E+04 4.85E+03 2.52E+04 9.48E+03 0.918 6.15E-24 23.211 
DG 38:4 2.09E+04 7.51E+03 3.53E+04 1.28E+04 0.756 1.68E-19 18.775 
DG 38:5 3.91E+04 2.01E+04 6.20E+04 2.42E+04 0.664 1.96E-12 11.708 
DG 38:6 3.47E+04 1.92E+04 5.16E+04 2.16E+04 0.572 7.70E-09 8.114 
DG 38:7 4.72E+03 3.52E+03 5.74E+03 4.20E+03 0.282 5.64E-02 1.249 
DG 40:7 1.39E+04 8.78E+03 2.38E+04 1.38E+04 0.775 2.41E-09 8.619 
DG 40:8 6.18E+03 4.52E+03 9.19E+03 6.13E+03 0.572 6.62E-05 4.179 
LysoPC 14:0 3.99E+04 1.99E+04 2.54E+04 1.39E+04 -0.652 3.78E-09 8.423 
LysoPC 15:0 5.10E+04 1.94E+04 2.80E+04 1.18E+04 -0.868 6.30E-21 20.201 
LysoPC 16:0 5.11E+06 1.26E+06 3.79E+06 1.21E+06 -0.433 2.58E-13 12.589 
LysoPC 16:1 9.38E+04 4.87E+04 6.13E+04 3.52E+04 -0.615 7.06E-08 7.151 
LysoPC 17:0 1.71E+06 1.72E+05 1.59E+06 1.36E+05 -0.102 1.38E-07 6.861 
LysoPC 17:1 2.28E+04 7.89E+03 1.45E+04 5.35E+03 -0.654 1.62E-16 15.790 
LysoPC 18:0 3.87E+06 1.24E+06 2.50E+06 1.85E+06 -0.628 1.43E-09 8.844 
LysoPC 18:1 1.81E+06 5.76E+05 1.09E+06 5.57E+05 -0.730 3.46E-17 16.461 
LysoPC 18:2 2.12E+06 9.32E+05 8.57E+05 3.15E+05 -1.309 1.62E-29 28.791 
LysoPC 18:3 2.71E+04 1.22E+04 1.50E+04 6.29E+03 -0.851 1.14E-16 15.943 
LysoPC 19:0 3.41E+04 8.11E+03 2.59E+04 8.42E+03 -0.397 9.64E-12 11.016 
LysoPC 19:1 1.08E+04 3.58E+03 7.28E+03 4.33E+03 -0.573 5.56E-10 9.255 
LysoPC 20:0 2.18E+04 7.88E+03 1.35E+04 6.94E+03 -0.696 2.77E-14 13.558 
LysoPC 20:1 3.83E+04 1.54E+04 2.61E+04 1.76E+04 -0.556 1.86E-07 6.730 
LysoPC 20:2 2.99E+04 1.01E+04 1.85E+04 1.04E+04 -0.692 5.50E-14 13.260 
LysoPC 20:3 2.20E+05 8.09E+04 1.29E+05 6.79E+04 -0.771 3.46E-16 15.461 
LysoPC 20:4 5.37E+05 2.00E+05 2.78E+05 1.99E+05 -0.947 8.73E-18 17.059 
LysoPC 20:5 1.28E+05 7.98E+04 7.71E+04 5.79E+04 -0.736 2.23E-07 6.652 
LysoPC 22:0 9.32E+03 4.06E+03 6.36E+03 3.83E+03 -0.552 1.28E-07 6.894 
LysoPC 22:4 1.93E+04 8.41E+03 1.33E+04 9.91E+03 -0.544 2.89E-06 5.539 
LysoPC 22:5 3.69E+04 1.45E+04 2.24E+04 1.22E+04 -0.718 2.18E-13 12.662 
LysoPC 22:6 1.06E+05 4.29E+04 6.59E+04 2.97E+04 -0.691 9.88E-14 13.005 
LysoPC 24:0 1.60E+04 5.61E+03 1.13E+04 4.50E+03 -0.504 1.21E-10 9.916 
LysoPC 24:1 5.54E+03 2.03E+03 3.98E+03 1.61E+03 -0.477 2.75E-09 8.561 
LysoPC 24:4 1.71E+03 1.13E+03 1.66E+03 1.05E+03 -0.038 7.65E-01 0.116 
LysoPC 26:0 4.15E+03 1.86E+03 2.58E+03 1.46E+03 -0.682 1.08E-10 9.968 
LysoPC 26:1 3.10E+03 1.43E+03 2.29E+03 1.25E+03 -0.435 1.91E-05 4.718 
LysoPC 26:2 1.97E+03 1.02E+03 1.50E+03 9.88E+02 -0.391 8.22E-04 3.085 
LysoPC 26:4 3.24E+03 1.33E+03 3.44E+03 1.53E+03 0.087 3.10E-01 0.508 
LysoPE 16:0 1.55E+05 6.14E+04 1.55E+05 6.77E+04 -0.004 9.63E-01 0.016 
LysoPE 18:0 8.39E+04 2.66E+04 8.77E+04 4.12E+04 0.064 4.27E-01 0.369 
LysoPE 18:1 1.95E+05 8.73E+04 1.46E+05 6.46E+04 -0.424 4.32E-06 5.364 
LysoPE 18:2 2.06E+05 1.18E+05 1.02E+05 4.49E+04 -1.011 3.51E-15 14.454 
LysoPE 20:3 3.49E+04 1.69E+04 2.02E+04 1.07E+04 -0.790 1.06E-12 11.974 
LysoPE 20:4 1.67E+05 6.62E+04 8.94E+04 3.36E+04 -0.897 1.35E-21 20.870 
LysoPE 22:5 4.24E+04 1.93E+04 3.50E+04 1.80E+04 -0.279 3.97E-03 2.401 
LysoPE 22:6 6.29E+04 2.52E+04 5.04E+04 1.80E+04 -0.320 4.62E-05 4.335 
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LysoPE 24:0 9.07E+03 3.88E+03 7.91E+03 4.07E+03 -0.198 3.39E-02 1.469 
PA 34:1 9.75E+03 7.24E+03 9.89E+03 6.66E+03 0.020 8.89E-01 0.051 
PA 34:2 1.64E+04 5.27E+03 1.35E+04 4.59E+03 -0.281 2.84E-05 4.546 
PA 36:4 9.95E+03 3.41E+03 9.76E+03 4.57E+03 -0.028 7.30E-01 0.137 
PA 38:6 7.13E+03 4.15E+03 7.91E+03 3.48E+03 0.150 1.40E-01 0.854 
PC 22:0 1.59E+03 1.41E+03 1.35E+03 1.31E+03 -0.237 1.99E-01 0.701 
PC 23:0 1.85E+03 1.21E+03 2.02E+03 1.22E+03 0.126 3.13E-01 0.505 
PC 24:0 4.10E+03 4.20E+03 2.87E+03 2.12E+03 -0.516 7.52E-03 2.124 
PC 25:1 2.28E+03 3.17E+03 1.50E+03 1.35E+03 -0.600 2.16E-02 1.666 
PC 26:0 1.28E+04 1.35E+04 9.75E+03 7.57E+03 -0.395 4.20E-02 1.377 
PC 26:1 1.73E+03 1.39E+03 1.29E+03 1.05E+03 -0.422 1.04E-02 1.984 
PC 28:0 8.03E+04 7.80E+04 9.11E+04 6.28E+04 0.182 2.69E-01 0.570 
PC 28:1 8.05E+03 6.91E+03 7.82E+03 5.30E+03 -0.043 7.79E-01 0.109 
PC 29:0 2.40E+04 1.60E+04 2.65E+04 1.47E+04 0.139 2.49E-01 0.604 
PC 30:0 1.64E+05 7.27E+04 1.90E+05 7.95E+04 0.208 1.56E-02 1.806 
PC 30:1 1.25E+05 7.92E+04 1.83E+05 1.18E+05 0.547 4.07E-05 4.390 
PC 30:2 1.72E+04 1.46E+04 1.77E+04 1.04E+04 0.040 7.81E-01 0.107 
PC 30:3 1.29E+04 9.52E+03 1.32E+04 6.80E+03 0.040 7.52E-01 0.124 
PC 31:0 8.26E+04 3.49E+04 7.40E+04 2.69E+04 -0.160 4.37E-02 1.360 
PC 31:1 4.51E+04 2.32E+04 6.01E+04 2.94E+04 0.412 5.75E-05 4.241 
PC 31:2 2.26E+05 8.75E+04 6.02E+05 2.24E+05 1.411 1.60E-38 37.796 
PC 32:0 1.68E+06 2.75E+05 1.92E+06 2.82E+05 0.195 1.45E-09 8.837 
PC 32:1 1.61E+06 6.87E+05 2.54E+06 9.93E+05 0.662 9.78E-14 13.010 
PC 32:2 1.36E+06 5.07E+05 1.90E+06 6.89E+05 0.481 6.26E-10 9.203 
PC 32:3 4.11E+04 2.06E+04 5.38E+04 2.72E+04 0.388 1.71E-04 3.766 
PC 32:4 1.80E+04 9.48E+03 2.19E+04 1.06E+04 0.279 5.62E-03 2.250 
PC 33:0 1.12E+05 3.65E+04 1.13E+05 3.21E+04 0.010 8.73E-01 0.059 
PC 33:1 8.58E+04 4.12E+04 1.01E+05 3.96E+04 0.237 6.33E-03 2.198 
PC 33:2 5.05E+05 1.75E+05 1.01E+06 3.15E+05 1.004 1.96E-33 32.708 
PC 33:3 3.83E+04 1.32E+04 4.32E+04 1.43E+04 0.174 1.00E-02 1.999 
PC 34:0 4.29E+05 1.14E+05 5.48E+05 2.09E+05 0.356 5.40E-07 6.267 
PC 34:1 1.99E+06 1.21E+06 3.89E+06 2.85E+06 0.964 1.64E-09 8.784 
PC 34:2 1.05E+07 1.92E+07 8.78E+07 2.18E+08 3.068 3.38E-04 3.471 
PC 34:3 3.37E+06 8.83E+05 4.51E+06 1.16E+06 0.417 8.90E-14 13.051 
PC 34:4 4.91E+05 2.05E+05 5.28E+05 2.02E+05 0.104 1.91E-01 0.720 
PC 34:5 1.11E+04 8.95E+03 9.07E+03 7.99E+03 -0.287 8.74E-02 1.058 
PC 35:1 3.78E+04 2.42E+04 3.47E+04 1.01E+04 -0.121 2.34E-01 0.631 
PC 35:2 1.06E+05 5.47E+04 1.14E+05 5.57E+04 0.099 3.20E-01 0.495 
PC 35:3 2.56E+05 5.62E+04 2.22E+05 4.20E+04 -0.209 9.09E-07 6.041 
PC 35:4 3.41E+05 1.00E+05 2.94E+05 8.74E+04 -0.212 3.82E-04 3.418 
PC 35:5 2.97E+04 1.89E+04 2.69E+04 1.67E+04 -0.143 2.53E-01 0.596 
PC 35:6 3.24E+05 1.32E+05 6.11E+05 1.79E+05 0.916 1.15E-29 28.938 
PC 35:7 1.28E+04 6.29E+03 2.64E+04 1.07E+04 1.042 3.56E-23 22.449 
PC 36:0 1.38E+05 3.98E+04 1.48E+05 4.18E+04 0.101 7.41E-02 1.130 
PC 36:1 3.31E+06 9.70E+05 4.02E+06 1.07E+06 0.280 9.13E-07 6.040 
PC 36:2 4.42E+05 7.54E+05 7.46E+05 1.48E+06 0.756 6.00E-02 1.222 
PC 36:3 2.90E+06 5.33E+05 3.29E+06 6.56E+05 0.179 5.40E-06 5.268 
PC 36:4 3.39E+06 8.01E+05 3.52E+06 7.26E+05 0.051 2.43E-01 0.615 
PC 36:5 2.18E+04 6.35E+04 1.34E+04 3.57E+04 -0.700 2.38E-01 0.623 
PC 36:6 2.56E+05 1.13E+05 2.71E+05 1.26E+05 0.083 3.61E-01 0.443 
PC 36:7 5.00E+04 1.61E+04 4.55E+04 1.24E+04 -0.135 2.51E-02 1.600 
PC 37:1 3.78E+04 1.43E+04 3.79E+04 1.22E+04 0.003 9.63E-01 0.016 
PC 37:2 5.18E+04 3.34E+04 5.13E+04 3.66E+04 -0.013 9.21E-01 0.036 
PC 37:3 7.08E+04 3.42E+04 6.88E+04 3.05E+04 -0.042 6.49E-01 0.188 
PC 37:4 6.32E+05 2.21E+05 4.73E+05 1.74E+05 -0.419 2.11E-08 7.676 
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PC 37:5 9.04E+04 3.49E+04 1.79E+05 5.53E+04 0.987 7.36E-32 31.133 
PC 37:6 1.70E+05 6.28E+04 1.49E+05 5.64E+04 -0.195 9.11E-03 2.040 
PC 37:7 5.07E+04 2.20E+04 8.81E+04 2.84E+04 0.798 1.04E-21 20.981 
PC 38:1 5.42E+04 1.49E+04 5.84E+04 1.49E+04 0.107 4.19E-02 1.378 
PC 38:2 1.48E+05 3.85E+04 1.51E+05 4.51E+04 0.036 5.19E-01 0.285 
PC 38:3 1.18E+06 3.13E+05 1.10E+06 2.54E+05 -0.100 4.49E-02 1.348 
PC 38:4 1.21E+07 2.62E+06 9.57E+06 2.38E+06 -0.337 4.83E-12 11.316 
PC 38:5 8.91E+05 2.14E+05 8.46E+05 2.05E+05 -0.075 1.20E-01 0.922 
PC 38:6 1.18E+07 3.38E+06 1.20E+07 3.04E+06 0.023 6.70E-01 0.174 
PC 38:7 1.41E+05 5.15E+04 1.65E+05 5.24E+04 0.227 8.81E-04 3.055 
PC 39:3 3.37E+04 1.17E+04 3.03E+04 1.10E+04 -0.154 2.90E-02 1.538 
PC 39:4 9.13E+04 2.26E+04 7.48E+04 2.36E+04 -0.288 4.64E-07 6.334 
PC 39:5 3.76E+03 4.20E+03 3.90E+03 5.10E+03 0.054 8.22E-01 0.085 
PC 39:6 2.06E+05 7.64E+04 1.49E+05 5.71E+04 -0.469 3.25E-09 8.488 
PC 39:7 2.12E+04 8.48E+03 1.81E+04 6.38E+03 -0.228 2.93E-03 2.534 
PC 40:0 3.98E+03 2.10E+03 4.83E+03 3.48E+03 0.281 3.15E-02 1.502 
PC 40:1 1.20E+04 6.27E+03 1.32E+04 6.40E+03 0.139 1.67E-01 0.777 
PC 40:2 3.82E+04 2.49E+04 4.37E+04 2.78E+04 0.193 1.32E-01 0.878 
PC 40:3 6.18E+04 2.86E+04 6.68E+04 2.66E+04 0.112 1.89E-01 0.724 
PC 40:4 1.49E+05 5.06E+04 1.46E+05 3.56E+04 -0.032 5.90E-01 0.229 
PC 40:5 2.61E+05 7.93E+04 2.57E+05 6.99E+04 -0.023 6.88E-01 0.163 
PC 40:6 2.67E+06 7.44E+05 2.39E+06 6.05E+05 -0.160 3.02E-03 2.520 
PC 40:7 9.51E+04 2.64E+04 8.81E+04 2.03E+04 -0.112 2.98E-02 1.526 
PC 40:8 2.32E+05 5.99E+04 2.05E+05 4.74E+04 -0.179 3.22E-04 3.492 
PC 40:9 1.44E+04 6.30E+03 1.38E+04 6.02E+03 -0.067 4.39E-01 0.358 
PC 40:10 3.06E+04 8.89E+03 2.50E+04 7.74E+03 -0.291 1.97E-06 5.705 
PC 41:5 1.19E+04 9.14E+03 1.15E+04 1.03E+04 -0.038 8.19E-01 0.087 
PC 41:6 1.87E+04 8.05E+03 1.55E+04 7.24E+03 -0.266 3.08E-03 2.512 
PC 42:1 1.29E+04 1.03E+04 1.51E+04 2.06E+04 0.225 3.30E-01 0.481 
PC 42:2 1.81E+04 1.02E+04 1.71E+04 1.05E+04 -0.078 5.02E-01 0.299 
PC 42:3 1.85E+04 1.19E+04 1.93E+04 1.32E+04 0.059 6.52E-01 0.186 
PC 42:4 1.47E+04 7.62E+03 1.73E+04 1.09E+04 0.241 4.11E-02 1.386 
PC 42:5 4.65E+04 1.41E+04 6.18E+04 1.93E+04 0.409 3.65E-10 9.438 
PC 42:6 5.08E+04 1.73E+04 5.40E+04 1.62E+04 0.088 1.66E-01 0.780 
PC 42:7 4.94E+04 1.86E+04 4.44E+04 1.79E+04 -0.154 4.78E-02 1.320 
PC 42:8 2.81E+04 9.27E+03 2.19E+04 6.56E+03 -0.360 5.62E-08 7.250 
PC 42:9 2.99E+04 1.03E+04 3.26E+04 1.01E+04 0.122 6.10E-02 1.215 
PC 42:10 5.13E+04 1.99E+04 7.00E+04 2.78E+04 0.448 5.59E-08 7.253 
PC 42:11 1.11E+04 3.96E+03 8.85E+03 3.94E+03 -0.320 7.05E-05 4.152 
PC 44:2 3.07E+03 1.69E+03 3.58E+03 2.78E+03 0.222 1.07E-01 0.971 
PC 44:3 1.62E+03 9.88E+02 1.69E+03 8.60E+02 0.057 6.10E-01 0.215 
PC 44:4 1.50E+04 1.01E+04 1.44E+04 9.18E+03 -0.062 6.34E-01 0.198 
PC 44:5 9.51E+03 7.25E+03 8.86E+03 5.99E+03 -0.103 4.73E-01 0.325 
PC 44:6 4.52E+03 2.51E+03 4.30E+03 2.24E+03 -0.071 5.07E-01 0.295 
PC 46:4 1.87E+03 1.66E+03 1.65E+03 9.69E+02 -0.179 2.44E-01 0.613 
PC 46:5 1.16E+03 6.62E+02 1.22E+03 9.34E+02 0.071 5.97E-01 0.224 
PE 30:0 1.03E+04 7.85E+03 1.53E+04 9.99E+03 0.571 7.44E-05 4.128 
PE 32:0 2.08E+04 1.03E+04 2.95E+04 1.04E+04 0.502 5.00E-09 8.301 
PE 32:1 6.62E+04 3.84E+04 1.81E+05 1.18E+05 1.446 5.98E-18 17.223 
PE 32:2 1.14E+04 6.31E+03 3.00E+04 1.63E+04 1.401 2.23E-22 21.651 
PE 33:0 9.31E+03 3.80E+03 8.46E+03 3.93E+03 -0.137 1.13E-01 0.946 
PE 33:1 1.50E+04 6.70E+03 2.67E+04 1.08E+04 0.830 7.37E-18 17.132 
PE 33:2 1.47E+04 7.15E+03 3.50E+04 1.43E+04 1.253 7.23E-29 28.141 
PE 34:0 3.63E+06 3.90E+05 3.39E+06 3.90E+05 -0.096 2.07E-05 4.683 
PE 34:1 9.46E+04 3.91E+04 2.56E+05 7.33E+04 1.439 1.07E-50 49.971 
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PE 34:2 1.26E+06 4.28E+05 2.91E+06 8.93E+05 1.203 1.10E-41 40.957 
PE 34:3 2.94E+05 1.67E+05 1.07E+06 5.21E+05 1.858 1.25E-33 32.904 
PE 34:4 1.00E+04 5.61E+03 1.82E+04 8.32E+03 0.859 8.46E-15 14.072 
PE 35:0 1.46E+04 8.57E+03 1.66E+04 1.05E+04 0.186 1.30E-01 0.885 
PE 35:1 2.49E+04 1.33E+04 3.93E+04 1.94E+04 0.660 1.55E-09 8.809 
PE 35:2 8.06E+04 3.14E+04 1.52E+05 5.08E+04 0.912 2.23E-26 25.651 
PE 35:3 1.66E+04 7.70E+03 2.70E+04 1.05E+04 0.698 2.91E-14 13.536 
PE 35:4 2.79E+04 1.28E+04 5.29E+04 2.21E+04 0.921 9.99E-20 19.000 
PE 36:0 6.36E+04 1.58E+04 5.99E+04 1.77E+04 -0.086 1.10E-01 0.960 
PE 36:1 4.51E+05 1.76E+05 8.77E+05 2.56E+05 0.960 2.13E-32 31.672 
PE 36:2 5.05E+05 1.75E+05 1.01E+06 3.15E+05 1.004 1.96E-33 32.708 
PE 36:3 1.35E+06 4.76E+05 2.35E+06 6.55E+05 0.798 1.05E-27 26.980 
PE 36:4 1.65E+06 5.88E+05 2.99E+06 7.34E+05 0.862 3.04E-34 33.517 
PE 36:5 3.39E+05 2.16E+05 7.35E+05 4.43E+05 1.114 1.57E-14 13.804 
PE 36:6 1.06E+04 5.98E+03 2.35E+04 1.23E+04 1.142 1.50E-18 17.824 
PE 37:2 2.31E+04 9.38E+03 3.48E+04 1.22E+04 0.592 2.32E-13 12.634 
PE 37:3 3.04E+04 1.19E+04 4.11E+04 1.44E+04 0.435 1.42E-08 7.848 
PE 37:4 1.01E+05 3.20E+04 1.51E+05 4.12E+04 0.587 1.87E-19 18.728 
PE 37:5 6.38E+04 1.96E+04 6.41E+04 2.08E+04 0.007 9.13E-01 0.039 
PE 37:6 7.32E+04 4.42E+04 1.54E+05 6.70E+04 1.076 1.10E-20 19.960 
PE 38:1 3.46E+04 1.67E+04 4.47E+04 1.78E+04 0.370 2.92E-05 4.534 
PE 38:2 8.85E+04 2.55E+04 1.20E+05 3.73E+04 0.439 1.17E-11 10.932 
PE 38:3 4.86E+05 1.87E+05 7.88E+05 2.79E+05 0.697 2.39E-17 16.621 
PE 38:4 5.19E+05 1.36E+05 9.21E+05 2.19E+05 0.826 2.37E-38 37.626 
PE 38:5 2.48E+05 7.58E+04 4.42E+05 1.20E+05 0.834 4.69E-32 31.328 
PE 38:6 3.24E+05 1.32E+05 6.11E+05 1.79E+05 0.916 1.15E-29 28.938 
PE 38:7 6.38E+04 3.21E+04 1.50E+05 6.01E+04 1.232 9.52E-29 28.021 
PE 39:6 7.47E+04 3.27E+04 1.02E+05 3.48E+04 0.444 2.48E-08 7.606 
PE 40:2 6.70E+03 3.90E+03 6.84E+03 4.46E+03 0.029 8.12E-01 0.091 
PE 40:4 1.05E+05 5.53E+04 1.61E+05 7.98E+04 0.611 1.60E-08 7.795 
PE 40:5 3.99E+05 1.42E+05 7.35E+05 2.15E+05 0.881 5.03E-30 29.299 
PE 40:6 1.31E+06 5.44E+05 2.26E+06 6.80E+05 0.785 3.64E-23 22.438 
PE 40:7 3.89E+05 1.78E+05 7.11E+05 2.29E+05 0.868 1.08E-23 22.966 
PE 40:8 8.89E+04 3.10E+04 1.41E+05 4.64E+04 0.663 3.02E-18 17.520 
PE 42:10 5.86E+03 3.39E+03 7.82E+03 4.25E+03 0.418 2.52E-04 3.599 
PL-PC 24:0 4.61E+03 1.96E+03 3.41E+03 2.83E+03 -0.435 4.08E-04 3.389 
PL-PC 26:0 2.59E+03 1.69E+03 2.19E+03 1.64E+03 -0.241 8.25E-02 1.083 
PL-PC 30:0 1.29E+04 5.65E+03 1.09E+04 5.67E+03 -0.240 1.18E-02 1.930 
PL-PC 32:0 9.44E+04 2.66E+04 1.03E+05 4.53E+04 0.127 9.04E-02 1.044 
PL-PC 32:1 3.85E+04 2.76E+04 4.20E+04 2.76E+04 0.124 3.63E-01 0.440 
PL-PC 34:0 5.59E+05 1.65E+05 6.26E+05 1.25E+05 0.163 9.99E-04 3.001 
PL-PC 34:1 4.77E+05 1.39E+05 4.77E+05 1.65E+05 0.000 9.96E-01 0.002 
PL-PC 34:2 1.00E+06 2.84E+05 8.45E+05 2.27E+05 -0.247 1.33E-05 4.875 
PL-PC 34:3 2.81E+04 1.03E+04 2.75E+04 9.83E+03 -0.034 6.40E-01 0.194 
PL-PC 34:4 3.13E+03 1.72E+03 3.67E+03 2.31E+03 0.228 5.72E-02 1.243 
PL-PC 35:0 1.86E+04 4.99E+03 1.99E+04 5.59E+03 0.101 6.67E-02 1.176 
PL-PC 35:1 1.06E+04 4.37E+03 1.32E+04 6.17E+03 0.324 3.55E-04 3.450 
PL-PC 35:2 5.83E+04 2.22E+04 5.12E+04 1.99E+04 -0.186 1.60E-02 1.796 
PL-PC 35:3 1.65E+04 8.36E+03 1.26E+04 5.50E+03 -0.395 6.39E-05 4.194 
PL-PC 36:0 7.42E+04 2.12E+04 8.51E+04 2.25E+04 0.196 3.92E-04 3.406 
PL-PC 36:1 3.02E+05 8.09E+04 3.14E+05 7.47E+04 0.060 2.36E-01 0.628 
PL-PC 36:2 3.17E+05 1.07E+05 2.87E+05 1.01E+05 -0.143 3.74E-02 1.427 
PL-PC 36:3 1.68E+06 3.67E+05 1.45E+06 2.81E+05 -0.211 7.83E-07 6.106 
PL-PC 36:4 1.14E+06 3.13E+05 9.89E+05 2.07E+05 -0.207 4.04E-05 4.394 
PL-PC 36:5 6.84E+04 3.31E+04 6.57E+04 2.99E+04 -0.058 5.36E-01 0.271 
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PL-PC 36:6 2.18E+04 7.49E+03 2.35E+04 6.92E+03 0.105 9.63E-02 1.016 
PL-PC 37:1 1.36E+04 4.48E+03 1.53E+04 4.88E+03 0.164 1.13E-02 1.948 
PL-PC 37:2 1.06E+04 4.08E+03 1.12E+04 4.32E+03 0.079 3.04E-01 0.517 
PL-PC 37:3 1.35E+04 5.41E+03 1.46E+04 4.60E+03 0.106 1.37E-01 0.864 
PL-PC 37:4 8.98E+04 3.32E+04 7.11E+04 2.17E+04 -0.337 2.30E-06 5.638 
PL-PC 37:6 1.66E+05 6.23E+04 2.05E+05 6.36E+04 0.305 1.07E-05 4.972 
PL-PC 38:3 9.36E+05 2.01E+05 8.78E+05 2.49E+05 -0.091 6.66E-02 1.177 
PL-PC 38:4 9.85E+05 2.66E+05 8.94E+05 2.78E+05 -0.141 1.50E-02 1.824 
PL-PC 38:5 9.67E+04 2.50E+04 9.21E+04 2.31E+04 -0.069 1.74E-01 0.760 
PL-PC 38:6 1.66E+05 6.20E+04 1.57E+05 5.12E+04 -0.078 2.67E-01 0.574 
PL-PC 39:5 3.04E+04 1.28E+04 2.78E+04 1.32E+04 -0.128 1.50E-01 0.823 
PL-PC 40:0 5.27E+04 3.08E+04 6.05E+04 3.15E+04 0.199 6.93E-02 1.159 
PL-PC 40:1 8.58E+03 4.71E+03 9.10E+03 3.82E+03 0.085 3.78E-01 0.422 
PL-PC 40:2 1.99E+04 5.70E+03 2.16E+04 5.70E+03 0.117 3.20E-02 1.494 
PL-PC 40:3 5.85E+04 2.34E+04 6.17E+04 2.61E+04 0.077 3.49E-01 0.458 
PL-PC 40:4 3.11E+05 1.09E+05 3.39E+05 9.67E+04 0.124 5.05E-02 1.297 
PL-PC 40:5 2.35E+05 6.80E+04 2.72E+05 8.40E+04 0.214 4.45E-04 3.351 
PL-PC 40:6 1.98E+05 6.30E+04 2.00E+05 6.24E+04 0.011 8.66E-01 0.062 
PL-PC 41:4 2.70E+04 1.99E+04 3.89E+04 2.04E+04 0.528 2.53E-05 4.597 
PL-PC 42:0 2.55E+04 1.55E+04 2.69E+04 2.25E+04 0.081 5.79E-01 0.237 
PL-PC 42:1 2.67E+04 1.36E+04 2.45E+04 1.55E+04 -0.122 2.80E-01 0.553 
PL-PC 42:2 1.52E+05 1.07E+05 1.67E+05 1.15E+05 0.138 3.16E-01 0.500 
PL-PC 42:3 6.60E+04 2.58E+04 6.71E+04 2.47E+04 0.023 7.61E-01 0.119 
PL-PC 42:4 2.80E+05 1.74E+05 3.47E+05 1.96E+05 0.311 8.83E-03 2.054 
PL-PC 42:5 1.40E+05 5.04E+04 1.30E+05 4.43E+04 -0.113 1.06E-01 0.974 
PL-PC 43:3 1.08E+04 6.39E+03 1.11E+04 5.70E+03 0.043 6.94E-01 0.159 
PL-PC 43:4 1.10E+04 4.90E+03 1.01E+04 5.17E+03 -0.116 2.22E-01 0.654 
PL-PC 44:1 9.38E+03 8.70E+03 8.72E+03 1.05E+04 -0.105 6.19E-01 0.209 
PL-PC 44:2 4.36E+04 2.28E+04 4.52E+04 2.66E+04 0.053 6.35E-01 0.197 
PL-PC 44:3 9.00E+04 4.30E+04 8.82E+04 5.36E+04 -0.029 7.92E-01 0.101 
PL-PC 44:4 3.09E+05 1.53E+05 3.20E+05 1.40E+05 0.053 5.65E-01 0.248 
PL-PC 44:5 2.73E+05 8.85E+04 2.54E+05 8.36E+04 -0.104 1.11E-01 0.956 
PL-PC 44:6 1.04E+05 4.49E+04 1.06E+05 3.74E+04 0.022 7.76E-01 0.110 
PL-PC 46:4 5.62E+04 3.48E+04 5.81E+04 3.52E+04 0.049 6.88E-01 0.162 
PL-PE 32:0 2.47E+04 7.51E+03 2.91E+04 9.89E+03 0.238 3.15E-04 3.502 
PL-PE 32:1 1.57E+04 5.19E+03 1.66E+04 5.13E+03 0.081 2.00E-01 0.700 
PL-PE 32:2 9.58E+03 4.46E+03 1.23E+04 8.09E+03 0.357 3.07E-03 2.513 
PL-PE 34:1 2.73E+05 7.03E+04 3.02E+05 7.28E+04 0.142 4.37E-03 2.360 
PL-PE 34:2 5.78E+05 1.58E+05 6.67E+05 2.08E+05 0.207 5.42E-04 3.266 
PL-PE 34:3 2.41E+04 9.61E+03 2.57E+04 1.18E+04 0.095 2.67E-01 0.573 
PL-PE 34:4 2.44E+04 1.08E+04 3.69E+04 5.66E+04 0.595 2.67E-02 1.573 
PL-PE 35:1 2.18E+04 9.03E+03 2.56E+04 8.77E+03 0.229 2.45E-03 2.611 
PL-PE 35:2 4.89E+04 1.83E+04 4.58E+04 1.76E+04 -0.095 2.10E-01 0.679 
PL-PE 35:4 2.20E+04 1.11E+04 2.16E+04 2.90E+04 -0.025 9.00E-01 0.046 
PL-PE 36:1 2.26E+05 8.75E+04 2.59E+05 7.82E+04 0.196 4.32E-03 2.365 
PL-PE 36:2 7.21E+05 1.98E+05 8.49E+05 2.54E+05 0.234 6.75E-05 4.171 
PL-PE 36:3 8.63E+05 2.06E+05 8.46E+05 1.97E+05 -0.030 5.28E-01 0.277 
PL-PE 36:4 2.11E+06 6.14E+05 1.94E+06 4.68E+05 -0.118 2.84E-02 1.546 
PL-PE 36:5 1.46E+05 1.17E+05 1.21E+05 1.15E+05 -0.274 1.14E-01 0.944 
PL-PE 36:6 2.54E+04 1.35E+04 3.67E+04 1.73E+04 0.532 2.66E-07 6.576 
PL-PE 37:2 1.57E+04 6.27E+03 1.87E+04 6.50E+03 0.250 8.51E-04 3.070 
PL-PE 37:4 1.99E+05 8.29E+04 1.38E+05 4.80E+04 -0.528 4.53E-10 9.344 
PL-PE 37:5 4.19E+04 2.41E+04 3.82E+04 2.28E+04 -0.133 2.53E-01 0.596 
PL-PE 37:6 2.38E+04 1.08E+04 2.97E+04 1.90E+04 0.321 5.77E-03 2.239 
PL-PE 38:1 4.17E+04 3.79E+04 5.05E+04 3.98E+04 0.275 1.03E-01 0.988 
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PL-PE 38:2 1.15E+05 3.74E+04 1.39E+05 4.80E+04 0.275 6.35E-05 4.197 
PL-PE 38:3 5.14E+05 1.60E+05 5.33E+05 1.52E+05 0.050 3.96E-01 0.402 
PL-PE 38:4 4.85E+05 1.83E+05 4.49E+05 1.39E+05 -0.112 1.07E-01 0.969 
PL-PE 38:5 2.66E+06 6.87E+05 2.34E+06 5.17E+05 -0.187 1.50E-04 3.825 
PL-PE 38:6 1.65E+06 4.85E+05 1.87E+06 4.78E+05 0.178 1.24E-03 2.906 
PL-PE 39:4 5.15E+04 1.92E+04 4.49E+04 1.50E+04 -0.196 6.16E-03 2.211 
PL-PE 39:6 1.09E+05 3.72E+04 1.14E+05 3.42E+04 0.070 2.73E-01 0.564 
PL-PE 40:1 1.61E+04 7.83E+03 1.85E+04 8.95E+03 0.202 3.73E-02 1.429 
PL-PE 40:2 3.82E+04 1.35E+04 4.55E+04 1.67E+04 0.251 5.88E-04 3.230 
PL-PE 40:3 1.26E+05 4.37E+04 1.25E+05 3.12E+04 -0.010 8.67E-01 0.062 
PL-PE 40:4 3.87E+05 1.12E+05 3.88E+05 1.02E+05 0.000 9.94E-01 0.003 
PL-PE 40:5 5.01E+05 1.45E+05 5.50E+05 1.26E+05 0.132 1.03E-02 1.986 
PL-PE 40:6 1.66E+05 6.23E+04 2.05E+05 6.36E+04 0.305 1.07E-05 4.972 
PL-PE 42:4 7.49E+04 3.02E+04 7.04E+04 2.35E+04 -0.090 2.22E-01 0.654 
PL-PE 42:6 1.05E+05 4.11E+04 1.36E+05 4.77E+04 0.372 1.03E-06 5.988 
PG 32:0 8.05E+03 4.14E+03 9.91E+03 6.93E+03 0.300 1.84E-02 1.736 
PG 32:1 3.55E+03 1.85E+03 4.70E+03 2.51E+03 0.402 2.17E-04 3.664 
PG 33:0 3.48E+04 1.21E+04 3.05E+04 1.13E+04 -0.193 7.30E-03 2.136 
PG 34:0 4.72E+06 7.29E+05 3.87E+06 7.75E+05 -0.285 2.70E-14 13.568 
PG 34:1 4.93E+04 1.49E+04 8.81E+04 2.89E+04 0.839 1.50E-26 25.823 
PG 34:2 1.56E+04 5.81E+03 2.08E+04 7.34E+03 0.410 5.18E-08 7.286 
PG 36:0 7.34E+04 2.86E+04 5.97E+04 1.23E+04 -0.298 9.76E-06 5.011 
PG 36:2 9.73E+04 3.14E+04 1.46E+05 5.07E+04 0.588 4.57E-15 14.340 
PI 34:1 7.04E+04 3.45E+04 1.23E+05 4.98E+04 0.800 3.41E-16 15.467 
PI 34:2 7.86E+04 4.24E+04 1.19E+05 4.30E+04 0.599 5.95E-11 10.226 
PI 36:1 7.01E+04 3.39E+04 9.89E+04 4.84E+04 0.497 1.07E-06 5.970 
PI 36:2 3.69E+05 1.85E+05 5.12E+05 1.70E+05 0.475 1.46E-08 7.836 
PI 36:3 8.82E+04 5.07E+04 1.05E+05 3.70E+04 0.247 7.37E-03 2.132 
PI 36:4 8.89E+04 4.16E+04 1.00E+05 3.94E+04 0.170 4.76E-02 1.322 
PI 38:3 7.72E+05 4.67E+05 8.35E+05 3.38E+05 0.114 2.58E-01 0.588 
PI 38:4 1.10E+06 4.29E+05 1.06E+06 3.54E+05 -0.050 4.87E-01 0.312 
PI 38:5 8.44E+04 3.71E+04 8.16E+04 2.97E+04 -0.048 5.49E-01 0.260 
PI 38:6 2.00E+04 1.08E+04 2.27E+04 1.14E+04 0.182 7.72E-02 1.112 
PI 40:5 9.35E+04 3.82E+04 1.07E+05 3.85E+04 0.192 1.24E-02 1.907 
PI 40:6 7.18E+04 3.38E+04 9.38E+04 3.76E+04 0.386 1.18E-05 4.929 
PS 36:1 8.23E+04 3.73E+04 1.66E+05 6.08E+04 1.015 5.50E-26 25.260 
PS 38:4 1.35E+04 1.94E+04 1.60E+04 9.77E+03 0.249 2.30E-01 0.638 
SM 29:1 2.44E+03 1.13E+03 2.18E+03 8.45E+02 -0.160 6.38E-02 1.196 
SM 30:0 6.26E+03 3.19E+03 7.00E+03 3.28E+03 0.161 9.71E-02 1.013 
SM 30:1 6.19E+04 2.08E+04 6.85E+04 2.25E+04 0.145 2.87E-02 1.542 
SM 30:2 7.68E+03 3.47E+03 7.05E+03 2.52E+03 -0.125 1.28E-01 0.892 
SM 31:1 3.97E+04 1.42E+04 4.17E+04 1.49E+04 0.070 3.21E-01 0.494 
SM 32:0 7.04E+04 2.50E+04 9.13E+04 3.70E+04 0.375 2.77E-06 5.558 
SM 32:1 1.35E+06 3.67E+05 1.73E+06 4.72E+05 0.354 6.63E-10 9.179 
SM 32:2 1.62E+05 4.44E+04 1.78E+05 4.71E+04 0.135 1.23E-02 1.909 
SM 33:0 6.21E+04 1.79E+04 7.74E+04 2.32E+04 0.318 1.90E-07 6.721 
SM 33:1 4.68E+05 1.39E+05 5.44E+05 1.84E+05 0.218 8.01E-04 3.096 
SM 33:2 2.74E+04 8.41E+03 3.18E+04 1.01E+04 0.212 8.14E-04 3.089 
SM 34:0 2.63E+05 8.26E+04 3.45E+05 1.04E+05 0.393 1.26E-09 8.898 
SM 34:1 2.70E+06 4.07E+05 3.41E+06 7.58E+05 0.339 2.38E-15 14.624 
SM 34:2 2.01E+06 4.27E+05 2.67E+06 5.44E+05 0.409 6.06E-19 18.217 
SM 34:3 1.41E+04 5.00E+03 1.77E+04 5.72E+03 0.323 2.96E-06 5.529 
SM 35:1 1.39E+06 2.22E+05 1.07E+06 2.12E+05 -0.376 1.28E-21 20.894 
SM 35:2 3.30E+04 1.23E+04 3.56E+04 1.56E+04 0.109 1.82E-01 0.741 
SM 35:6 4.31E+03 2.74E+03 5.58E+03 3.29E+03 0.372 2.59E-03 2.586 
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SM 36:0 5.74E+04 1.85E+04 8.36E+04 2.30E+04 0.542 6.36E-17 16.196 
SM 36:1 2.20E+06 4.68E+05 2.75E+06 5.96E+05 0.327 9.74E-13 12.011 
SM 36:2 1.20E+06 3.09E+05 1.48E+06 4.16E+05 0.303 7.36E-08 7.133 
SM 36:3 1.58E+05 4.76E+04 2.01E+05 6.01E+04 0.342 4.33E-08 7.364 
SM 36:4 3.16E+04 7.64E+03 3.48E+04 8.72E+03 0.138 5.25E-03 2.280 
SM 37:1 1.65E+05 7.19E+04 1.84E+05 8.26E+04 0.158 7.36E-02 1.133 
SM 37:2 5.11E+04 1.56E+04 4.73E+04 1.49E+04 -0.110 7.51E-02 1.124 
SM 38:0 1.63E+05 3.76E+04 2.16E+05 4.94E+04 0.403 8.36E-16 15.078 
SM 38:1 2.46E+05 1.09E+05 3.24E+05 1.48E+05 0.401 1.67E-05 4.778 
SM 38:2 5.86E+05 1.22E+05 5.99E+05 1.54E+05 0.030 5.25E-01 0.280 
SM 38:3 5.11E+04 1.90E+04 5.13E+04 1.73E+04 0.005 9.42E-01 0.026 
SM 38:4 2.02E+04 8.26E+03 2.53E+04 8.87E+03 0.326 2.19E-05 4.659 
SM 38:5 1.56E+04 6.44E+03 1.63E+04 7.30E+03 0.068 4.29E-01 0.368 
SM 39:1 2.20E+05 6.58E+04 2.53E+05 7.11E+04 0.200 6.08E-04 3.216 
SM 39:2 1.34E+05 3.08E+04 1.40E+05 3.29E+04 0.068 1.44E-01 0.842 
SM 39:3 5.32E+04 1.30E+04 4.76E+04 1.35E+04 -0.160 2.48E-03 2.605 
SM 40:0 2.53E+05 6.68E+04 3.10E+05 6.20E+04 0.293 8.29E-10 9.081 
SM 40:1 1.91E+06 3.93E+05 2.92E+06 4.31E+06 0.612 1.71E-02 1.767 
SM 40:2 1.91E+06 1.03E+06 2.06E+06 1.02E+06 0.115 2.63E-01 0.581 
SM 40:3 2.43E+05 8.05E+04 2.64E+05 7.22E+04 0.117 5.26E-02 1.279 
SM 40:4 3.69E+04 1.02E+04 3.90E+04 1.21E+04 0.079 1.81E-01 0.743 
SM 40:5 2.17E+04 8.37E+03 3.23E+04 9.63E+03 0.573 2.76E-15 14.559 
SM 41:0 1.74E+05 4.30E+04 2.18E+05 4.67E+04 0.328 1.08E-11 10.968 
SM 41:1 1.28E+06 2.58E+05 1.45E+06 2.61E+05 0.176 5.57E-06 5.254 
SM 41:2 7.52E+05 1.19E+05 7.43E+05 1.34E+05 -0.017 6.10E-01 0.215 
SM 41:3 1.76E+05 4.03E+04 1.86E+05 4.44E+04 0.079 9.13E-02 1.040 
SM 42:1 1.91E+06 4.22E+05 2.26E+06 5.43E+05 0.240 4.95E-07 6.305 
SM 42:2 3.79E+06 6.13E+05 1.14E+07 2.91E+07 1.593 7.37E-03 2.133 
SM 42:3 2.42E+06 4.58E+05 2.80E+06 6.13E+05 0.207 1.07E-06 5.970 
SM 42:4 3.40E+05 8.52E+04 3.68E+05 1.10E+05 0.116 3.66E-02 1.436 
SM 42:5 8.54E+04 3.69E+04 1.50E+05 7.90E+04 0.815 6.95E-13 12.158 
SM 42:6 4.89E+04 2.10E+04 7.78E+04 3.32E+04 0.668 1.34E-12 11.874 
SM 42:7 2.13E+04 9.33E+03 3.02E+04 1.42E+04 0.506 1.66E-07 6.779 
SM 43:1 4.34E+04 1.48E+04 4.80E+04 1.69E+04 0.145 3.79E-02 1.422 
SM 43:2 1.82E+05 5.42E+04 1.69E+05 5.61E+04 -0.105 9.43E-02 1.026 
SM 43:3 6.38E+04 1.73E+04 5.97E+04 2.13E+04 -0.095 1.29E-01 0.888 
SM 43:4 1.42E+04 9.96E+03 1.40E+04 1.05E+04 -0.024 8.67E-01 0.062 
SM 43:7 1.04E+04 4.09E+03 1.18E+04 5.21E+03 0.174 3.83E-02 1.417 
SM 44:1 1.36E+04 6.16E+03 1.32E+04 4.71E+03 -0.034 6.78E-01 0.169 
SM 44:2 9.18E+03 4.58E+03 9.90E+03 5.42E+03 0.110 2.95E-01 0.531 
SM 44:3 4.04E+04 1.98E+04 3.73E+04 2.23E+04 -0.116 2.80E-01 0.553 
SM 44:4 1.96E+04 9.00E+03 1.85E+04 9.77E+03 -0.082 4.03E-01 0.394 
SM 44:5 1.97E+04 7.85E+03 2.90E+04 1.83E+04 0.558 2.86E-06 5.544 
SM 44:6 1.23E+04 6.37E+03 2.10E+04 1.40E+04 0.775 1.79E-08 7.748 
SM 44:7 6.45E+03 4.04E+03 7.69E+03 4.55E+03 0.254 3.69E-02 1.432 
SM 45:4 1.35E+04 7.58E+03 1.38E+04 8.08E+03 0.031 7.86E-01 0.105 
SM 47:5 1.15E+04 7.91E+03 1.38E+04 2.00E+04 0.260 2.78E-01 0.556 
TG 36:0 7.49E+04 2.07E+05 4.95E+04 9.20E+04 -0.598 2.48E-01 0.605 
TG 38:0 1.43E+05 3.36E+05 7.93E+04 1.68E+05 -0.854 8.06E-02 1.094 
TG 39:0 2.15E+04 2.68E+04 1.44E+04 1.26E+04 -0.575 1.49E-02 1.827 
TG 40:0 2.49E+05 4.71E+05 1.41E+05 2.69E+05 -0.822 4.13E-02 1.384 
TG 40:1 1.11E+05 1.69E+05 1.02E+05 1.29E+05 -0.123 6.62E-01 0.179 
TG 41:0 3.41E+04 4.68E+04 2.18E+04 2.02E+04 -0.641 1.45E-02 1.840 
TG 42:0 3.59E+05 5.33E+05 2.47E+05 3.28E+05 -0.542 6.59E-02 1.181 
TG 42:1 3.00E+05 4.12E+05 2.55E+05 3.66E+05 -0.237 3.98E-01 0.401 
72 
 
TG 42:2 1.60E+05 1.94E+05 1.63E+05 2.08E+05 0.027 9.15E-01 0.039 
TG 42:3 2.93E+04 2.83E+04 3.90E+04 3.61E+04 0.412 3.09E-02 1.510 
TG 43:0 4.56E+04 5.92E+04 3.19E+04 2.48E+04 -0.515 2.94E-02 1.531 
TG 44:0 3.53E+05 4.08E+05 3.22E+05 2.88E+05 -0.133 5.23E-01 0.282 
TG 44:1 6.00E+05 6.84E+05 5.99E+05 6.06E+05 -0.002 9.92E-01 0.003 
TG 44:2 3.44E+05 3.53E+05 3.41E+05 3.15E+05 -0.012 9.49E-01 0.023 
TG 45:0 4.99E+04 5.88E+04 3.98E+04 2.60E+04 -0.326 1.08E-01 0.967 
TG 45:1 7.03E+04 7.58E+04 7.05E+04 5.02E+04 0.006 9.75E-01 0.011 
TG 46:0 4.04E+05 3.57E+05 5.16E+05 3.05E+05 0.354 1.48E-02 1.829 
TG 46:1 1.00E+06 9.21E+05 1.30E+06 1.05E+06 0.382 2.59E-02 1.586 
TG 46:2 8.30E+05 6.66E+05 1.01E+06 6.95E+05 0.283 5.58E-02 1.254 
TG 46:3 3.00E+05 2.28E+05 3.35E+05 2.10E+05 0.158 2.50E-01 0.602 
TG 47:0 5.08E+04 5.17E+04 5.17E+04 2.89E+04 0.026 8.71E-01 0.060 
TG 47:1 1.15E+05 1.12E+05 1.29E+05 7.43E+04 0.160 3.01E-01 0.521 
TG 47:2 1.01E+05 7.45E+04 1.17E+05 5.76E+04 0.214 7.81E-02 1.107 
TG 47:3 4.43E+04 2.62E+04 6.13E+04 2.50E+04 0.471 2.37E-06 5.625 
TG 48:0 5.08E+05 3.37E+05 8.43E+05 3.43E+05 0.731 1.26E-11 10.901 
TG 48:1 2.06E+06 1.33E+06 3.28E+06 1.67E+06 0.674 1.30E-08 7.887 
TG 48:2 2.06E+06 1.10E+06 3.05E+06 1.42E+06 0.571 3.70E-08 7.432 
TG 48:3 1.18E+06 6.35E+05 1.47E+06 6.83E+05 0.309 2.02E-03 2.694 
TG 48:4 4.53E+05 2.90E+05 4.81E+05 2.48E+05 0.085 4.60E-01 0.337 
TG 49:0 6.36E+04 4.66E+04 7.75E+04 3.19E+04 0.287 1.17E-02 1.933 
TG 49:1 2.49E+05 1.65E+05 3.34E+05 1.34E+05 0.426 5.14E-05 4.289 
TG 49:2 2.62E+05 1.32E+05 3.44E+05 1.21E+05 0.394 3.97E-06 5.401 
TG 49:3 1.30E+05 5.20E+04 1.71E+05 5.47E+04 0.394 7.34E-08 7.134 
TG 50:0 6.10E+05 3.42E+05 1.05E+06 3.43E+05 0.789 6.85E-18 17.165 
TG 50:1 3.48E+06 1.57E+06 6.72E+06 1.81E+06 0.949 1.17E-31 30.933 
TG 50:2 4.83E+06 1.60E+06 8.03E+06 1.93E+06 0.734 3.61E-29 28.443 
TG 50:3 3.52E+06 1.05E+06 5.39E+06 1.36E+06 0.616 3.15E-23 22.502 
TG 50:4 1.65E+06 5.48E+05 2.20E+06 6.47E+05 0.411 2.95E-10 9.530 
TG 50:5 3.86E+05 1.68E+05 4.72E+05 1.74E+05 0.290 3.25E-04 3.488 
TG 50:6 8.33E+04 4.92E+04 9.27E+04 3.78E+04 0.154 1.22E-01 0.913 
TG 51:1 2.33E+05 1.29E+05 3.57E+05 1.27E+05 0.615 2.53E-11 10.597 
TG 51:2 5.30E+05 1.70E+05 7.12E+05 1.99E+05 0.427 1.23E-11 10.909 
TG 51:3 1.31E+04 9.40E+03 1.61E+04 1.12E+04 0.301 3.41E-02 1.467 
TG 51:4 2.34E+05 5.56E+04 2.72E+05 6.88E+04 0.215 1.94E-05 4.712 
TG 51:5 9.15E+04 3.74E+04 9.64E+04 3.45E+04 0.076 3.18E-01 0.497 
TG 52:0 3.18E+05 1.62E+05 4.87E+05 1.62E+05 0.616 9.11E-13 12.040 
TG 52:1 2.43E+06 9.93E+05 3.98E+06 1.15E+06 0.712 4.49E-21 20.348 
TG 52:2 8.74E+06 1.87E+06 1.29E+07 2.47E+06 0.556 6.75E-31 30.171 
TG 52:4 7.73E+06 2.17E+06 1.07E+07 2.66E+06 0.465 4.18E-16 15.379 
TG 52:5 2.36E+06 7.60E+05 3.13E+06 9.51E+05 0.404 7.17E-10 9.145 
TG 52:6 5.15E+05 2.00E+05 6.16E+05 2.15E+05 0.258 5.14E-04 3.289 
TG 53:0 5.42E+04 2.24E+04 5.09E+04 1.68E+04 -0.091 2.22E-01 0.654 
TG 53:1 1.00E+05 5.09E+04 1.39E+05 5.36E+04 0.470 1.95E-07 6.709 
TG 53:2 3.12E+05 8.98E+04 4.53E+05 1.42E+05 0.536 1.73E-15 14.762 
TG 53:3 3.86E+05 8.44E+04 4.32E+05 1.15E+05 0.164 9.49E-04 3.023 
TG 53:4 1.78E+04 1.25E+04 2.19E+04 1.27E+04 0.304 1.72E-02 1.764 
TG 53:5 1.15E+05 3.08E+04 1.17E+05 2.69E+04 0.025 6.12E-01 0.213 
TG 54:0 8.28E+04 4.96E+04 1.07E+05 4.94E+04 0.367 5.26E-04 3.279 
TG 54:1 5.81E+05 3.50E+05 8.30E+05 3.51E+05 0.513 5.57E-07 6.254 
TG 54:2 1.92E+06 7.31E+05 2.67E+06 8.45E+05 0.481 3.88E-11 10.411 
TG 54:3 2.90E+06 9.43E+05 3.16E+06 8.10E+05 0.127 2.83E-02 1.548 
TG 54:4 3.76E+06 1.22E+06 3.85E+06 9.54E+05 0.035 5.39E-01 0.268 
TG 54:5 3.40E+06 1.21E+06 3.54E+06 1.02E+06 0.061 3.39E-01 0.470 
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TG 54:6 2.17E+06 9.75E+05 2.37E+06 8.75E+05 0.129 1.12E-01 0.951 
TG 54:7 7.75E+05 4.09E+05 8.54E+05 4.07E+05 0.140 1.59E-01 0.798 
TG 54:8 1.69E+05 9.03E+04 1.75E+05 9.19E+04 0.045 6.69E-01 0.174 
TG 55:1 2.04E+04 1.28E+04 3.17E+04 1.57E+04 0.631 4.07E-08 7.391 
TG 55:2 3.92E+04 1.65E+04 5.49E+04 1.89E+04 0.486 7.84E-10 9.106 
TG 55:3 5.28E+04 1.53E+04 7.08E+04 2.33E+04 0.423 2.53E-10 9.597 
TG 56:0 1.14E+04 1.04E+04 1.73E+04 1.23E+04 0.606 1.85E-04 3.733 
TG 56:1 8.09E+04 8.13E+04 1.16E+05 8.56E+04 0.524 2.24E-03 2.649 
TG 56:2 1.69E+05 1.32E+05 2.58E+05 1.36E+05 0.614 2.32E-06 5.635 
TG 56:3 2.32E+05 1.27E+05 3.33E+05 1.29E+05 0.520 3.57E-08 7.448 
TG 56:4 2.62E+05 7.50E+04 3.12E+05 8.00E+04 0.249 6.20E-06 5.208 
TG 56:5 5.58E+05 1.38E+05 5.65E+05 1.26E+05 0.016 7.32E-01 0.136 
TG 56:6 7.94E+05 2.13E+05 7.81E+05 1.81E+05 -0.024 6.32E-01 0.199 
TG 56:7 9.08E+05 3.17E+05 1.03E+06 3.58E+05 0.175 1.23E-02 1.911 
TG 56:8 5.90E+05 2.59E+05 6.79E+05 2.85E+05 0.202 1.86E-02 1.731 
TG 56:9 1.70E+05 8.65E+04 1.73E+05 8.41E+04 0.024 8.07E-01 0.093 
TG 56:10 2.83E+04 2.02E+04 2.65E+04 2.02E+04 -0.098 5.03E-01 0.298 
TG 58:1 2.38E+04 3.33E+04 3.49E+04 3.38E+04 0.551 1.70E-02 1.770 
TG 58:2 6.69E+04 1.21E+05 9.33E+04 9.77E+04 0.479 8.20E-02 1.086 
TG 58:3 5.57E+04 7.91E+04 8.44E+04 7.43E+04 0.600 6.96E-03 2.157 
TG 58:4 3.76E+04 2.38E+04 5.88E+04 2.57E+04 0.646 2.29E-09 8.639 
TG 58:5 6.87E+04 2.43E+04 1.25E+05 4.30E+04 0.868 5.19E-25 24.285 
TG 58:6 1.14E+05 3.56E+04 1.55E+05 4.67E+04 0.451 5.62E-12 11.250 
TG 58:7 1.80E+05 6.57E+04 2.08E+05 7.25E+04 0.202 4.79E-03 2.319 
TG 58:8 2.34E+05 9.61E+04 2.47E+05 1.03E+05 0.074 3.67E-01 0.435 
TG 58:9 2.12E+05 1.03E+05 2.08E+05 9.06E+04 -0.021 8.15E-01 0.089 
TG 58:10 1.37E+05 7.90E+04 1.33E+05 6.60E+04 -0.049 6.47E-01 0.189 
TG 58:11 3.89E+04 2.98E+04 3.72E+04 3.01E+04 -0.067 6.68E-01 0.175 
TG 60:10 4.46E+04 2.39E+04 4.14E+04 2.12E+04 -0.108 3.02E-01 0.519 
TG 60:11 4.57E+04 3.07E+04 4.57E+04 2.99E+04 0.000 9.98E-01 0.001 
TG 60:12 3.50E+04 3.21E+04 3.67E+04 3.47E+04 0.072 6.97E-01 0.156 
TG 62:1 1.93E+03 4.73E+03 2.33E+03 4.20E+03 0.274 5.12E-01 0.291 
TG 62:12 1.03E+04 8.51E+03 1.08E+04 8.37E+03 0.075 6.35E-01 0.197 





Table S2.3. Comparison of M3-CB lipid raw peak intensities. Paired t-tests identified 
differences in raw peak intensities of individual plasma lipids between M3 to CB. The fold 
change between lipids in M3 and CB was calculated by log2(CB/M3), where a positive FC 
indicates increases in that lipid between M3 and CB and a negative FC indicates decreases in that 
lipid between M3 and CB. Significance highlighted in red (Bonferroni adjusted, α=0.05/573). 
Metabolite 
M3 CB M3 CB t-test 
Mean  Std dev Mean  Std dev log2(CB/M3) p-value -log10(p-value) 
FFA(16:0) 7.06E+07 1.39E+07 6.08E+07 1.22E+07 -0.217 3.89E-09 8.410 
FFA(18:0) 7.23E+07 7.23E+06 6.83E+07 1.13E+07 -0.083 6.06E-05 4.218 
FFA(18:1) 5.46E+07 2.45E+07 2.18E+07 9.47E+06 -1.324 5.17E-29 28.287 
FFA(18:2) 3.37E+07 1.50E+07 1.43E+07 6.64E+06 -1.232 7.54E-27 26.123 
FFA(20:0) 2.10E+06 3.40E+05 1.86E+06 3.80E+05 -0.178 6.75E-08 7.171 
FFA(20:1) 1.34E+06 6.81E+05 3.65E+05 1.28E+05 -1.880 6.52E-34 33.185 
FFA(20:2) 9.58E+05 4.24E+05 4.79E+05 1.87E+05 -1.001 3.69E-22 21.433 
FFA(20:4) Arachidonic acid 1.73E+06 6.73E+05 2.61E+06 1.77E+06 0.590 1.24E-05 4.908 
FFA(22:0) 6.46E+05 2.71E+05 4.64E+05 1.45E+05 -0.477 1.82E-09 8.741 
FFA(22:1) 2.58E+05 1.57E+05 1.19E+05 4.13E+04 -1.118 1.61E-16 15.792 
FFA(22:2) 8.29E+04 3.39E+04 5.86E+04 2.78E+04 -0.499 8.39E-07 6.076 
FFA(22:3) 8.90E+04 3.17E+04 1.56E+05 6.06E+04 0.810 4.24E-19 18.372 
FFA(24:0) 3.86E+05 1.73E+05 3.73E+05 1.09E+05 -0.049 3.45E-01 0.462 
FFA(24:1) 3.83E+05 1.08E+05 3.24E+05 9.86E+04 -0.243 1.16E-05 4.937 
FFA(24:2) 1.21E+05 3.54E+04 1.62E+05 5.02E+04 0.425 4.50E-10 9.347 
FFA(24:3) 1.72E+04 6.76E+03 4.08E+04 1.46E+04 1.245 7.19E-35 34.144 
16:0 Cholesteryl ester 4.72E+04 1.76E+04 4.50E+04 2.03E+04 -0.068 8.88E-01 0.052 
16:1 Cholesteryl ester 3.32E+04 1.51E+04 6.15E+04 4.11E+04 0.887 2.88E-13 12.540 
17:1 Cholesteryl ester 7.14E+03 2.74E+03 7.54E+03 3.13E+03 0.079 3.77E-01 0.424 
18:0 Cholesteryl ester 1.78E+04 7.35E+03 2.84E+04 1.42E+04 0.670 1.49E-10 9.827 
18:1 Cholesteryl ester 6.98E+05 1.59E+05 4.44E+05 1.15E+05 -0.652 3.31E-31 30.480 
18:2 Cholesteryl ester 3.19E+06 6.38E+05 1.15E+06 3.77E+05 -1.477 6.08E-75 74.216 
18:3 Cholesteryl ester 9.06E+03 2.09E+04 2.87E+03 4.94E+03 -1.658 4.15E-03 2.382 
20:3 Cholesteryl ester 3.10E+05 8.99E+04 3.82E+05 9.38E+04 0.300 9.52E-07 6.021 
20:4 Cholesteryl ester 1.67E+04 1.00E+04 9.32E+03 8.05E+03 -0.843 2.14E-07 6.670 
20:5 Cholesteryl ester 5.35E+04 5.23E+04 4.13E+04 4.71E+04 -0.371 3.27E-01 0.485 
22:4 Cholesteryl ester 1.17E+04 4.62E+03 1.95E+04 6.98E+03 0.737 4.07E-17 16.391 
22:5 Cholesteryl ester 3.39E+04 1.24E+04 7.05E+04 2.22E+04 1.056 1.38E-35 34.861 
22:6 Cholesteryl ester 1.77E+05 8.09E+04 2.87E+05 1.10E+05 0.697 5.82E-14 13.235 
Acylcarnitine 16:0 6.95E+04 2.48E+04 1.10E+05 4.37E+04 0.666 1.04E-15 14.985 
Acylcarnitine 18:0 2.88E+04 1.39E+04 3.10E+04 1.69E+04 0.107 3.94E-01 0.405 
Acylcarnitine 18:1 1.32E+05 5.46E+04 1.04E+05 6.00E+04 -0.345 3.72E-04 3.429 
Acylcarnitine 18:2 7.12E+04 3.93E+04 8.88E+04 4.97E+04 0.318 8.42E-03 2.074 
Acylcarnitine 24:0 1.86E+03 9.37E+02 1.15E+03 3.77E+05 -0.690 2.28E-01 0.643 
Acylcarnitine 26:0 2.53E+03 1.42E+03 1.89E+03 7.42E+03 -0.423 7.19E-01 0.144 
Cer[NDS] 34:0 1.20E+05 2.95E+04 1.32E+05 4.24E+04 0.135 4.09E-03 2.389 
Cer[NDS] 36:0 7.37E+04 2.97E+04 7.24E+04 1.03E+05 -0.024 2.21E-01 0.655 
Cer[NDS] 38:0 5.22E+03 1.99E+03 5.68E+03 3.86E+03 0.123 2.56E-02 1.592 
Cer[NDS] 40:0 5.04E+05 1.39E+05 2.94E+05 9.79E+04 -0.774 3.12E-28 27.506 
Cer[NDS] 41:0 3.03E+04 8.43E+03 1.26E+04 4.59E+03 -1.271 2.49E-48 47.604 
Cer[NDS] 42:0 8.59E+04 2.46E+04 8.64E+04 2.94E+04 0.009 6.42E-01 0.193 
Cer[NDS] 42:1 4.38E+05 1.19E+05 1.19E+05 6.62E+04 -1.877 1.23E-62 61.911 
Cer[NS] 32:1 3.90E+04 1.14E+04 1.36E+04 6.31E+03 -1.519 1.47E-50 49.833 
Cer[NS] 33:1 2.79E+04 8.19E+03 3.21E+04 1.24E+04 0.205 8.26E-03 2.083 
Cer[NS] 33:4 3.45E+03 2.51E+03 3.07E+03 1.29E+05 -0.166 1.88E-01 0.726 
Cer[NS] 34:1 2.09E+04 5.73E+03 9.68E+03 8.34E+03 -1.112 2.90E-21 20.538 
Cer[NS] 34:2 2.49E+04 7.48E+03 1.75E+04 9.27E+03 -0.508 3.82E-10 9.418 
Cer[NS] 35:1 1.37E+07 1.52E+06 1.83E+07 3.43E+06 0.425 1.51E-25 24.822 
Cer[NS] 36:1 2.18E+05 6.55E+04 9.40E+04 3.96E+04 -1.215 1.64E-40 39.785 
Cer[NS] 36:2 2.62E+04 9.87E+03 2.05E+04 8.98E+03 -0.358 1.61E-05 4.793 
Cer[NS] 37:1 8.99E+04 3.30E+04 5.31E+04 1.39E+04 -0.759 4.32E-22 21.364 
Cer[NS] 37:4 1.51E+04 6.43E+03 6.05E+04 2.32E+04 2.005 7.52E-48 47.124 
Cer[NS] 38:1 3.19E+05 8.17E+04 7.21E+04 4.33E+04 -2.146 5.37E-72 71.270 
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Cer[NS] 38:2 4.12E+04 1.20E+04 1.90E+04 1.04E+04 -1.114 7.88E-32 31.104 
Cer[NS] 39:1 3.53E+05 9.12E+04 6.63E+04 3.65E+04 -2.412 2.82E-78 77.550 
Cer[NS] 39:2 4.50E+04 1.32E+04 1.40E+04 7.30E+03 -1.684 4.55E-53 52.342 
Cer[NS] 40:1 1.76E+06 4.98E+05 3.35E+05 2.32E+05 -2.393 8.99E-70 69.046 
Cer[NS] 40:2 2.95E+05 7.92E+04 9.43E+04 3.99E+04 -1.646 7.45E-60 59.128 
Cer[NS] 41:1 1.06E+05 2.94E+04 1.46E+04 1.11E+04 -2.869 2.50E-78 77.602 
Cer[NS] 41:2 4.99E+05 1.31E+05 1.19E+05 5.51E+04 -2.063 4.53E-72 71.344 
Cer[NS] 41:3 6.46E+04 2.18E+04 2.51E+04 1.15E+04 -1.367 7.07E-41 40.151 
Cer[NS] 42:1 4.38E+05 1.19E+05 1.19E+05 6.87E+04 -1.877 5.72E-61 60.242 
Cer[NS] 42:2 1.95E+06 4.83E+05 5.64E+05 2.43E+05 -1.786 4.30E-69 68.367 
Cer[NS] 42:3 1.10E+04 4.27E+03 5.71E+03 6.93E+03 -0.943 5.09E-08 7.293 
Cer[NS] 43:1 6.77E+05 2.27E+05 2.13E+05 9.93E+04 -1.664 1.25E-48 47.902 
Cer[NS] 43:2 1.63E+04 5.83E+03 5.95E+03 4.37E+03 -1.452 1.39E-31 30.856 
Cer[NS] 43:3 1.02E+04 3.55E+03 6.00E+03 2.43E+03 -0.760 5.16E-19 18.287 
Cer[NS] 44:1 2.62E+04 7.21E+03 2.15E+04 7.92E+03 -0.285 4.68E-04 3.330 
Cer[AS] 41:1 3.75E+04 1.71E+04 8.72E+03 3.36E+05 -2.102 6.87E-01 0.163 
Cer[AS] 42:2 9.28E+04 3.52E+04 2.13E+04 1.22E+04 -2.124 6.64E-50 49.178 
Cer[EODS] 49:1 8.42E+03 3.86E+03 3.20E+03 1.89E+03 -1.398 8.10E-27 26.091 
Cer[EODS] 53:0 7.86E+03 2.90E+03 1.28E+04 3.81E+03 0.706 1.27E-21 20.895 
Cer[EODS] 57:2 9.66E+03 4.45E+03 3.63E+03 4.43E+03 -1.413 3.88E-17 16.411 
Cer[NP] 34:0 4.12E+03 1.99E+03 2.44E+03 7.06E+03 -0.757 2.38E-01 0.623 
Cer[NP] 40:0 7.25E+04 2.53E+04 1.95E+04 1.31E+04 -1.898 4.11E-47 46.386 
Cer[NP] 42:0 1.07E+05 3.07E+04 2.96E+04 1.43E+04 -1.856 3.00E-61 60.522 
Cer[NP] 42:1 6.41E+04 2.34E+04 2.52E+04 1.06E+04 -1.345 3.29E-37 36.483 
GlcCer[NS] 32:1 3.77E+03 1.69E+03 1.39E+03 1.08E+03 -1.441 1.48E-25 24.828 
GlcCer[NS] 34:1 1.92E+05 5.62E+04 6.05E+04 2.50E+04 -1.669 2.19E-56 55.660 
GlcCer[NS] 38:1 1.19E+04 3.71E+03 5.24E+03 2.23E+03 -1.183 8.76E-38 37.057 
GlcCer[NS] 40:1 2.47E+05 7.97E+04 5.42E+04 2.52E+04 -2.188 1.06E-61 60.974 
GlcCer[NS] 41:1 1.84E+04 5.62E+03 3.91E+03 2.17E+03 -2.233 1.29E-63 62.889 
GlcCer[NS] 41:2 1.15E+04 5.62E+03 4.07E+03 2.70E+03 -1.500 3.08E-26 25.512 
GlcCer[NS] 42:1 6.22E+04 1.56E+04 3.38E+04 1.02E+04 -0.878 9.08E-37 36.042 
GlcCer[NS] 42:2 4.67E+04 1.24E+04 2.55E+04 8.61E+03 -0.873 1.52E-34 33.819 
GlcCer[NS] 43:1 7.32E+03 3.69E+03 3.84E+03 3.30E+03 -0.930 5.93E-10 9.227 
MG 26:4 2.82E+04 9.60E+03 1.77E+04 6.37E+03 -0.667 4.52E-17 16.345 
DG 30:0 1.92E+04 1.69E+04 3.70E+03 3.23E+03 -2.377 4.07E-17 16.391 
DG 30:1 7.92E+03 6.32E+03 1.75E+03 2.67E+03 -2.180 5.67E-16 15.246 
DG 31:0 4.10E+03 2.47E+03 1.82E+03 1.18E+03 -1.174 2.52E-15 14.599 
DG 32:0 7.25E+04 5.16E+04 1.46E+04 1.99E+04 -2.310 1.06E-20 19.976 
DG 32:1 8.35E+04 5.58E+04 1.70E+04 1.68E+05 -2.299 1.13E-02 1.948 
DG 32:2 2.62E+04 1.35E+04 5.03E+03 1.01E+05 -2.378 4.26E-01 0.371 
DG 33:0 5.29E+03 2.92E+03 2.17E+03 1.11E+03 -1.285 1.01E-19 18.997 
DG 33:1 1.15E+04 6.45E+03 2.67E+03 2.37E+03 -2.105 1.44E-28 27.842 
DG 34:0 4.58E+04 2.29E+04 1.85E+04 9.80E+03 -1.304 8.87E-23 22.052 
DG 34:2 3.33E+05 1.56E+05 6.04E+04 4.52E+04 -2.464 7.13E-43 42.147 
DG 34:3 6.81E+04 2.90E+04 1.58E+04 1.03E+04 -2.112 4.55E-43 42.342 
DG 35:1 1.18E+04 5.17E+03 2.72E+03 1.59E+03 -2.116 2.66E-42 41.574 
DG 35:2 1.36E+04 6.14E+03 2.82E+03 3.33E+05 -2.268 2.85E-01 0.545 
DG 35:3 6.92E+03 3.10E+03 1.53E+03 1.15E+03 -2.174 4.91E-41 40.309 
DG 36:0 1.31E+04 3.47E+03 1.13E+04 1.60E+04 -0.218 9.04E-01 0.044 
DG 36:1 8.75E+04 4.14E+04 1.99E+04 1.55E+04 -2.138 1.38E-37 36.861 
DG 36:2 4.33E+05 2.02E+05 7.17E+04 5.57E+04 -2.595 3.29E-44 43.483 
DG 36:3 4.97E+05 2.38E+05 6.35E+04 4.86E+04 -2.969 3.37E-46 45.472 
DG 36:4 2.68E+05 1.15E+05 4.58E+04 3.29E+04 -2.550 1.13E-48 47.946 
DG 36:5 2.72E+04 1.26E+04 7.46E+03 4.70E+03 -1.865 1.45E-35 34.839 
DG 38:0 2.18E+03 1.29E+03 1.53E+03 3.20E+03 -0.516 4.90E-01 0.309 
DG 38:1 1.00E+04 5.02E+03 2.73E+03 1.70E+03 -1.871 7.37E-32 31.133 
DG 38:2 2.18E+04 8.99E+03 3.15E+03 4.41E+03 -2.791 4.74E-47 46.324 
DG 38:3 2.52E+04 9.48E+03 8.01E+03 6.31E+03 -1.652 8.82E-37 36.054 
DG 38:4 3.53E+04 1.28E+04 2.04E+04 2.13E+04 -0.792 1.32E-09 8.881 
DG 38:5 6.20E+04 2.42E+04 2.80E+04 2.04E+05 -1.147 7.22E-01 0.142 
DG 38:6 5.16E+04 2.16E+04 2.54E+04 1.89E+04 -1.021 3.41E-16 15.467 
DG 38:7 5.74E+03 4.20E+03 3.65E+03 3.45E+03 -0.652 1.46E-03 2.837 
DG 40:7 2.38E+04 1.38E+04 1.38E+04 9.38E+03 -0.792 1.88E-08 7.725 
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DG 40:8 9.19E+03 6.13E+03 5.53E+03 3.62E+03 -0.733 8.60E-07 6.066 
LysoPC 14:0 2.54E+04 1.39E+04 4.28E+04 1.52E+04 0.751 3.14E-17 16.503 
LysoPC 15:0 2.80E+04 1.18E+04 2.76E+04 1.06E+04 -0.019 7.25E-01 0.140 
LysoPC 16:0 3.79E+06 1.21E+06 3.75E+06 1.18E+06 -0.015 5.55E-01 0.255 
LysoPC 16:1 6.13E+04 3.52E+04 2.61E+05 8.48E+04 2.091 5.46E-56 55.263 
LysoPC 17:0 1.59E+06 1.36E+05 1.63E+06 2.82E+05 0.037 6.88E-01 0.162 
LysoPC 17:1 1.45E+04 5.35E+03 2.55E+04 7.75E+03 0.813 5.30E-26 25.276 
LysoPC 18:0 2.50E+06 1.85E+06 1.97E+06 7.39E+05 -0.343 4.28E-03 2.369 
LysoPC 18:1 1.09E+06 5.57E+05 1.55E+06 4.69E+05 0.506 3.83E-09 8.417 
LysoPC 18:2 8.57E+05 3.15E+05 1.47E+06 4.84E+05 0.775 1.92E-20 19.716 
LysoPC 18:3 1.50E+04 6.29E+03 2.69E+04 7.91E+03 0.839 1.73E-24 23.763 
LysoPC 19:0 2.59E+04 8.42E+03 2.56E+04 8.37E+03 -0.016 5.31E-01 0.275 
LysoPC 19:1 7.28E+03 4.33E+03 7.47E+03 3.02E+03 0.037 8.20E-01 0.086 
LysoPC 20:0 1.35E+04 6.94E+03 1.15E+04 3.80E+03 -0.222 1.10E-02 1.958 
LysoPC 20:1 2.61E+04 1.76E+04 1.88E+04 6.19E+03 -0.474 9.33E-05 4.030 
LysoPC 20:2 1.85E+04 1.04E+04 3.23E+04 1.24E+04 0.807 4.84E-15 14.316 
LysoPC 20:3 1.29E+05 6.79E+04 5.36E+05 1.75E+05 2.059 2.63E-55 54.580 
LysoPC 20:4 2.78E+05 1.99E+05 1.85E+06 6.44E+05 2.734 1.55E-60 59.811 
LysoPC 20:5 7.71E+04 5.79E+04 9.50E+04 5.31E+04 0.301 3.93E-02 1.406 
LysoPC 22:0 6.36E+03 3.83E+03 5.09E+03 3.04E+03 -0.322 4.39E-02 1.358 
LysoPC 22:4 1.33E+04 9.91E+03 3.78E+04 6.30E+04 1.509 3.49E-07 6.457 
LysoPC 22:5 2.24E+04 1.22E+04 5.23E+04 1.99E+04 1.219 2.81E-28 27.551 
LysoPC 22:6 6.59E+04 2.97E+04 1.73E+05 5.89E+04 1.397 1.68E-39 38.774 
LysoPC 24:0 1.13E+04 4.50E+03 1.35E+04 3.71E+03 0.253 1.47E-04 3.833 
LysoPC 24:1 3.98E+03 1.61E+03 6.06E+03 2.06E+05 0.605 1.52E-01 0.817 
LysoPC 24:4 1.66E+03 1.05E+03 6.45E+03 2.51E+04 1.959 8.66E-04 3.063 
LysoPC 26:0 2.58E+03 1.46E+03 8.25E+03 7.06E+03 1.675 7.74E-18 17.111 
LysoPC 26:1 2.29E+03 1.25E+03 5.25E+03 3.94E+03 1.195 8.98E-16 15.047 
LysoPC 26:2 1.50E+03 9.88E+02 3.95E+03 1.45E+03 1.393 1.02E-35 34.991 
LysoPC 26:4 3.44E+03 1.53E+03 6.39E+03 2.56E+04 0.894 1.02E-02 1.991 
LysoPE 16:0 1.55E+05 6.77E+04 1.28E+05 4.68E+04 -0.273 3.38E-04 3.472 
LysoPE 18:0 8.77E+04 4.12E+04 5.51E+04 1.64E+04 -0.672 2.24E-12 11.650 
LysoPE 18:1 1.46E+05 6.46E+04 9.01E+04 3.11E+04 -0.693 2.23E-14 13.652 
LysoPE 18:2 1.02E+05 4.49E+04 1.04E+05 4.05E+04 0.017 8.95E-01 0.048 
LysoPE 20:3 2.02E+04 1.07E+04 5.71E+04 2.20E+05 1.502 1.98E-03 2.704 
LysoPE 20:4 8.94E+04 3.36E+04 3.23E+05 1.23E+05 1.851 1.64E-45 44.785 
LysoPE 22:5 3.50E+04 1.80E+04 7.44E+04 2.99E+05 1.090 6.95E-03 2.158 
LysoPE 22:6 5.04E+04 1.80E+04 1.53E+05 5.94E+04 1.607 3.66E-44 43.436 
LysoPE 24:0 7.91E+03 4.07E+03 8.04E+03 4.32E+03 0.023 4.06E-01 0.392 
PA 34:1 9.89E+03 6.66E+03 8.59E+03 4.74E+03 -0.203 2.04E-01 0.690 
PA 34:2 1.35E+04 4.59E+03 8.23E+03 3.30E+03 -0.715 1.96E-17 16.708 
PA 36:4 9.76E+03 4.57E+03 7.08E+03 5.22E+03 -0.463 1.48E-03 2.829 
PA 38:6 7.91E+03 3.48E+03 4.24E+03 2.24E+03 -0.901 1.12E-15 14.949 
PC 22:0 1.35E+03 1.31E+03 1.50E+03 9.51E+03 0.161 1.43E-01 0.844 
PC 23:0 2.02E+03 1.22E+03 1.68E+03 9.87E+04 -0.268 1.81E-01 0.743 
PC 24:0 2.87E+03 2.12E+03 1.76E+03 1.54E+04 -0.705 5.14E-01 0.289 
PC 25:1 1.50E+03 1.35E+03 1.67E+03 2.23E+05 0.156 1.55E-01 0.810 
PC 26:0 9.75E+03 7.57E+03 2.54E+03 1.94E+05 -1.939 3.97E-01 0.401 
PC 26:1 1.29E+03 1.05E+03 7.91E+02 6.12E+03 -0.706 5.80E-01 0.237 
PC 28:0 9.11E+04 6.28E+04 1.89E+04 1.29E+04 -2.266 2.04E-24 23.691 
PC 28:1 7.82E+03 5.30E+03 2.17E+03 4.91E+03 -1.849 1.39E-11 10.857 
PC 29:0 2.65E+04 1.47E+04 7.26E+03 1.99E+04 -1.865 6.52E-11 10.186 
PC 30:0 1.90E+05 7.95E+04 1.22E+05 5.60E+04 -0.638 4.11E-12 11.386 
PC 30:1 1.83E+05 1.18E+05 5.21E+04 2.97E+04 -1.813 5.52E-23 22.258 
PC 30:2 1.77E+04 1.04E+04 3.17E+03 5.27E+03 -2.485 2.18E-26 25.662 
PC 30:3 1.32E+04 6.80E+03 4.30E+03 2.48E+03 -1.624 5.97E-28 27.224 
PC 31:0 7.40E+04 2.69E+04 7.50E+04 1.95E+05 0.021 1.45E-01 0.840 
PC 31:1 6.01E+04 2.94E+04 2.45E+04 3.23E+04 -1.293 3.35E-12 11.475 
PC 31:2 6.02E+05 2.24E+05 7.64E+04 9.43E+04 -2.978 7.38E-58 57.132 
PC 32:0 1.92E+06 2.82E+05 1.96E+06 5.50E+05 0.033 9.05E-01 0.043 
PC 32:1 2.54E+06 9.93E+05 1.98E+06 6.41E+05 -0.361 2.97E-07 6.527 
PC 32:2 1.90E+06 6.89E+05 2.00E+05 1.84E+05 -3.249 7.10E-64 63.149 
PC 32:3 5.38E+04 2.72E+04 8.91E+03 6.81E+03 -2.594 3.60E-39 38.443 
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PC 32:4 2.19E+04 1.06E+04 1.11E+04 4.37E+03 -0.976 1.94E-18 17.712 
PC 33:0 1.13E+05 3.21E+04 8.48E+04 3.30E+04 -0.412 1.39E-09 8.858 
PC 33:1 1.01E+05 3.96E+04 3.06E+04 1.81E+04 -1.726 7.63E-41 40.117 
PC 33:2 1.01E+06 3.15E+05 8.49E+04 1.56E+05 -3.575 5.42E-71 70.266 
PC 33:3 4.32E+04 1.43E+04 9.80E+03 6.83E+03 -2.139 1.33E-55 54.875 
PC 34:0 5.48E+05 2.09E+05 4.21E+05 1.36E+05 -0.382 6.19E-08 7.208 
PC 34:1 3.89E+06 2.85E+06 8.24E+05 3.95E+05 -2.239 1.05E-22 21.977 
PC 34:2 8.78E+07 2.18E+08 5.95E+06 1.33E+07 -3.883 1.47E-04 3.834 
PC 34:3 4.51E+06 1.16E+06 6.66E+05 5.60E+05 -2.759 7.68E-79 78.115 
PC 34:4 5.28E+05 2.02E+05 7.45E+04 5.15E+04 -2.827 9.13E-58 57.039 
PC 34:5 9.07E+03 7.99E+03 2.09E+03 4.36E+04 -2.114 8.24E-01 0.084 
PC 35:1 3.47E+04 1.01E+04 1.50E+04 2.98E+04 -1.208 1.88E-07 6.726 
PC 35:2 1.14E+05 5.57E+04 2.91E+04 2.58E+04 -1.965 1.60E-32 31.795 
PC 35:3 2.22E+05 4.20E+04 9.25E+04 2.87E+04 -1.260 5.01E-69 68.301 
PC 35:4 2.94E+05 8.74E+04 1.18E+05 3.74E+04 -1.314 8.56E-49 48.068 
PC 35:5 2.69E+04 1.67E+04 6.42E+03 4.29E+03 -2.067 3.91E-26 25.408 
PC 35:6 6.11E+05 1.79E+05 2.33E+05 1.25E+05 -1.389 1.69E-44 43.773 
PC 35:7 2.64E+04 1.07E+04 5.45E+03 3.16E+05 -2.274 5.08E-01 0.295 
PC 36:0 1.48E+05 4.18E+04 1.08E+05 3.67E+04 -0.456 3.86E-13 12.414 
PC 36:1 4.02E+06 1.07E+06 2.18E+06 6.37E+05 -0.884 6.05E-37 36.218 
PC 36:2 7.46E+05 1.48E+06 1.72E+05 2.01E+06 -2.115 2.20E-01 0.657 
PC 36:3 3.29E+06 6.56E+05 1.47E+06 3.61E+05 -1.159 5.35E-66 65.271 
PC 36:4 3.52E+06 7.26E+05 2.38E+06 6.53E+05 -0.561 7.09E-27 26.150 
PC 36:5 1.34E+04 3.57E+04 9.62E+03 1.62E+04 -0.478 3.57E-01 0.447 
PC 36:6 2.71E+05 1.26E+05 5.30E+04 3.25E+04 -2.353 4.61E-42 41.336 
PC 36:7 4.55E+04 1.24E+04 1.22E+04 6.76E+05 -1.901 3.66E-01 0.436 
PC 37:1 3.79E+04 1.22E+04 2.21E+04 9.09E+03 -0.779 9.70E-22 21.013 
PC 37:2 5.13E+04 3.66E+04 3.33E+04 2.46E+04 -0.626 1.04E-04 3.984 
PC 37:3 6.88E+04 3.05E+04 4.35E+04 2.17E+04 -0.663 1.56E-11 10.807 
PC 37:4 4.73E+05 1.74E+05 3.55E+05 1.47E+05 -0.412 8.78E-08 7.057 
PC 37:5 1.79E+05 5.53E+04 3.94E+04 5.17E+04 -2.188 4.50E-46 45.347 
PC 37:6 1.49E+05 5.64E+04 4.81E+04 1.63E+04 -1.630 1.25E-43 42.903 
PC 37:7 8.81E+04 2.84E+04 2.73E+04 1.54E+04 -1.690 2.90E-49 48.538 
PC 38:1 5.84E+04 1.49E+04 2.87E+04 2.76E+04 -1.024 8.01E-16 15.096 
PC 38:2 1.51E+05 4.51E+04 1.28E+05 1.75E+05 -0.241 9.65E-01 0.015 
PC 38:3 1.10E+06 2.54E+05 1.27E+06 2.81E+05 0.212 5.09E-05 4.293 
PC 38:4 9.57E+06 2.38E+06 1.57E+07 3.50E+06 0.714 9.46E-33 32.024 
PC 38:5 8.46E+05 2.05E+05 4.86E+05 1.48E+05 -0.799 4.43E-35 34.354 
PC 38:6 1.20E+07 3.04E+06 9.43E+06 2.73E+06 -0.348 7.92E-11 10.101 
PC 38:7 1.65E+05 5.24E+04 4.74E+04 2.90E+04 -1.803 7.84E-52 51.106 
PC 39:3 3.03E+04 1.10E+04 3.12E+04 1.22E+05 0.041 1.46E-01 0.836 
PC 39:4 7.48E+04 2.36E+04 8.30E+04 3.55E+04 0.151 7.37E-02 1.132 
PC 39:5 3.90E+03 5.10E+03 2.50E+03 9.98E+03 -0.642 9.05E-01 0.043 
PC 39:6 1.49E+05 5.71E+04 1.11E+05 4.10E+04 -0.421 2.41E-07 6.618 
PC 39:7 1.81E+04 6.38E+03 1.34E+04 5.88E+04 -0.438 5.89E-01 0.230 
PC 40:0 4.83E+03 3.48E+03 2.70E+03 2.29E+06 -0.839 1.62E-01 0.790 
PC 40:1 1.32E+04 6.40E+03 7.86E+03 1.02E+04 -0.744 4.42E-04 3.355 
PC 40:2 4.37E+04 2.78E+04 2.05E+04 1.56E+04 -1.089 5.89E-12 11.230 
PC 40:3 6.68E+04 2.66E+04 4.92E+04 2.40E+05 -0.440 5.11E-01 0.292 
PC 40:4 1.46E+05 3.56E+04 1.26E+05 3.94E+04 -0.214 3.15E-05 4.502 
PC 40:5 2.57E+05 6.99E+04 2.07E+05 7.56E+04 -0.311 3.17E-07 6.498 
PC 40:6 2.39E+06 6.05E+05 2.86E+06 9.08E+05 0.263 4.05E-05 4.392 
PC 40:7 8.81E+04 2.03E+04 4.43E+04 1.10E+04 -0.990 2.56E-49 48.592 
PC 40:8 2.05E+05 4.74E+04 1.38E+05 3.91E+04 -0.571 5.48E-23 22.261 
PC 40:9 1.38E+04 6.02E+03 7.63E+03 4.96E+03 -0.852 1.21E-13 12.917 
PC 40:10 2.50E+04 7.74E+03 1.70E+04 1.05E+05 -0.560 5.62E-01 0.250 
PC 41:5 1.15E+04 1.03E+04 8.14E+03 5.80E+03 -0.505 6.32E-03 2.200 
PC 41:6 1.55E+04 7.24E+03 1.48E+04 1.23E+05 -0.068 1.80E-01 0.744 
PC 42:1 1.51E+04 2.06E+04 7.33E+03 6.90E+03 -1.042 8.76E-04 3.058 
PC 42:2 1.71E+04 1.05E+04 8.63E+03 6.28E+03 -0.988 2.18E-10 9.661 
PC 42:3 1.93E+04 1.32E+04 1.40E+04 1.52E+04 -0.459 6.72E-02 1.173 
PC 42:4 1.73E+04 1.09E+04 1.54E+04 2.12E+05 -0.167 1.87E-01 0.727 
PC 42:5 6.18E+04 1.93E+04 3.65E+04 1.69E+05 -0.757 8.85E-01 0.053 
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PC 42:6 5.40E+04 1.62E+04 3.19E+04 5.15E+05 -0.760 3.28E-01 0.484 
PC 42:7 4.44E+04 1.79E+04 2.36E+04 8.20E+03 -0.914 2.28E-22 21.642 
PC 42:8 2.19E+04 6.56E+03 3.00E+04 9.06E+04 0.456 2.01E-02 1.698 
PC 42:9 3.26E+04 1.01E+04 2.55E+04 4.64E+04 -0.355 7.76E-01 0.110 
PC 42:10 7.00E+04 2.78E+04 3.24E+04 4.28E+04 -1.114 5.06E-10 9.296 
PC 42:11 8.85E+03 3.94E+03 1.02E+04 9.33E+06 0.197 1.58E-01 0.801 
PC 44:2 3.58E+03 2.78E+03 1.87E+03 1.84E+04 -0.939 6.58E-01 0.182 
PC 44:3 1.69E+03 8.60E+02 1.64E+03 2.44E+05 -0.045 1.58E-01 0.802 
PC 44:4 1.44E+04 9.18E+03 1.71E+04 9.27E+03 0.248 3.03E-02 1.519 
PC 44:5 8.86E+03 5.99E+03 9.57E+03 1.54E+04 0.112 9.46E-02 1.024 
PC 44:6 4.30E+03 2.24E+03 7.34E+03 2.96E+03 0.772 3.77E-16 15.424 
PC 46:4 1.65E+03 9.69E+02 2.60E+03 9.09E+04 0.653 1.29E-01 0.890 
PC 46:5 1.22E+03 9.34E+02 1.52E+03 9.10E+04 0.321 1.48E-01 0.830 
PE 30:0 1.53E+04 9.99E+03 3.56E+03 3.08E+03 -2.101 1.43E-23 22.846 
PE 32:0 2.95E+04 1.04E+04 2.20E+04 1.45E+04 -0.424 2.99E-05 4.524 
PE 32:1 1.81E+05 1.18E+05 5.31E+04 1.38E+05 -1.766 2.52E-09 8.599 
PE 32:2 3.00E+04 1.63E+04 3.98E+03 7.87E+04 -2.911 5.19E-02 1.285 
PE 33:0 8.46E+03 3.93E+03 1.06E+04 3.23E+04 0.323 4.21E-02 1.376 
PE 33:1 2.67E+04 1.08E+04 7.70E+03 4.61E+03 -1.795 4.26E-40 39.371 
PE 33:2 3.50E+04 1.43E+04 3.32E+03 5.70E+03 -3.397 4.97E-53 52.304 
PE 34:0 3.39E+06 3.90E+05 3.85E+06 6.61E+05 0.183 4.14E-07 6.382 
PE 34:1 2.56E+05 7.33E+04 5.39E+04 3.25E+05 -2.250 5.42E-07 6.266 
PE 34:2 2.91E+06 8.93E+05 2.85E+05 4.25E+05 -3.350 2.02E-71 70.695 
PE 34:3 1.07E+06 5.21E+05 5.64E+04 1.37E+05 -4.242 1.36E-48 47.867 
PE 34:4 1.82E+04 8.32E+03 3.56E+03 4.28E+03 -2.353 4.69E-37 36.329 
PE 35:0 1.66E+04 1.05E+04 1.67E+04 2.26E+04 0.010 2.44E-01 0.613 
PE 35:1 3.93E+04 1.94E+04 1.59E+04 1.04E+04 -1.303 3.22E-22 21.492 
PE 35:2 1.52E+05 5.08E+04 1.70E+04 1.75E+04 -3.156 3.33E-67 66.478 
PE 35:3 2.70E+04 1.05E+04 4.62E+03 4.85E+03 -2.547 4.34E-49 48.362 
PE 35:4 5.29E+04 2.21E+04 7.40E+03 1.72E+04 -2.837 3.75E-38 37.426 
PE 36:0 5.99E+04 1.77E+04 6.19E+04 1.45E+04 0.048 6.36E-01 0.197 
PE 36:1 8.77E+05 2.56E+05 1.03E+05 1.57E+05 -3.085 1.09E-68 67.964 
PE 36:2 1.01E+06 3.15E+05 8.49E+04 1.58E+05 -3.575 1.27E-70 69.895 
PE 36:3 2.35E+06 6.55E+05 2.91E+05 3.35E+05 -3.013 2.94E-75 74.532 
PE 36:4 2.99E+06 7.34E+05 8.58E+05 4.50E+05 -1.803 6.13E-67 66.212 
PE 36:5 7.35E+05 4.43E+05 7.97E+04 1.78E+05 -3.204 2.53E-32 31.598 
PE 36:6 2.35E+04 1.23E+04 2.89E+03 3.32E+03 -3.023 9.82E-40 39.008 
PE 37:2 3.48E+04 1.22E+04 8.15E+03 6.56E+03 -2.093 3.70E-50 49.432 
PE 37:3 4.11E+04 1.44E+04 1.24E+04 1.24E+05 -1.731 3.25E-01 0.489 
PE 37:4 1.51E+05 4.12E+04 4.13E+04 5.76E+04 -1.874 5.48E-35 34.262 
PE 37:5 6.41E+04 2.08E+04 4.55E+04 1.19E+05 -0.494 8.40E-01 0.075 
PE 37:6 1.54E+05 6.70E+04 1.65E+04 2.65E+05 -3.223 1.67E-04 3.778 
PE 38:1 4.47E+04 1.78E+04 1.49E+04 8.31E+03 -1.591 2.85E-37 36.545 
PE 38:2 1.20E+05 3.73E+04 3.39E+04 1.95E+04 -1.824 2.26E-53 52.645 
PE 38:3 7.88E+05 2.79E+05 2.52E+05 1.30E+05 -1.642 5.51E-45 44.259 
PE 38:4 9.21E+05 2.19E+05 2.70E+05 2.64E+05 -1.770 1.56E-46 45.808 
PE 38:5 4.42E+05 1.20E+05 1.19E+05 6.05E+04 -1.898 6.56E-65 64.183 
PE 38:6 6.11E+05 1.79E+05 2.33E+05 1.24E+05 -1.389 1.44E-44 43.841 
PE 38:7 1.50E+05 6.01E+04 2.32E+04 1.83E+04 -2.691 5.34E-53 52.272 
PE 39:6 1.02E+05 3.48E+04 2.46E+04 1.17E+04 -2.048 2.72E-55 54.565 
PE 40:2 6.84E+03 4.46E+03 5.84E+03 1.09E+04 -0.227 7.75E-01 0.111 
PE 40:4 1.61E+05 7.98E+04 7.32E+04 3.95E+04 -1.133 2.94E-20 19.532 
PE 40:5 7.35E+05 2.15E+05 1.81E+05 1.09E+05 -2.025 1.77E-61 60.752 
PE 40:6 2.26E+06 6.80E+05 5.70E+05 2.89E+05 -1.987 4.89E-61 60.310 
PE 40:7 7.11E+05 2.29E+05 1.19E+05 8.74E+04 -2.580 1.54E-64 63.812 
PE 40:8 1.41E+05 4.64E+04 5.32E+04 3.51E+05 -1.404 2.31E-01 0.637 
PE 42:10 7.82E+03 4.25E+03 1.05E+04 1.62E+04 0.422 7.72E-03 2.112 
PL-PC 24:0 3.41E+03 2.83E+03 4.80E+03 5.29E+04 0.493 9.24E-02 1.034 
PL-PC 26:0 2.19E+03 1.64E+03 3.58E+03 2.09E+03 0.708 1.31E-08 7.884 
PL-PC 30:0 1.09E+04 5.67E+03 1.57E+04 2.15E+04 0.526 7.53E-04 3.123 
PL-PC 32:0 1.03E+05 4.53E+04 1.06E+05 3.54E+04 0.043 9.67E-01 0.014 
PL-PC 32:1 4.20E+04 2.76E+04 3.45E+04 2.49E+04 -0.284 6.74E-02 1.171 
PL-PC 34:0 6.26E+05 1.25E+05 3.24E+05 1.09E+05 -0.949 1.34E-47 46.874 
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PL-PC 34:1 4.77E+05 1.65E+05 1.45E+05 8.19E+04 -1.714 2.21E-46 45.655 
PL-PC 34:2 8.45E+05 2.27E+05 1.79E+05 9.73E+04 -2.241 5.59E-73 72.252 
PL-PC 34:3 2.75E+04 9.83E+03 1.42E+04 5.46E+03 -0.954 1.07E-26 25.972 
PL-PC 34:4 3.67E+03 2.31E+03 1.27E+03 4.74E+03 -1.525 7.32E-04 3.136 
PL-PC 35:0 1.99E+04 5.59E+03 9.32E+03 1.91E+04 -1.095 2.67E-05 4.573 
PL-PC 35:1 1.32E+04 6.17E+03 4.90E+03 4.75E+03 -1.433 1.90E-20 19.722 
PL-PC 35:2 5.12E+04 1.99E+04 1.13E+04 7.25E+03 -2.176 5.40E-49 48.268 
PL-PC 35:3 1.26E+04 5.50E+03 1.08E+04 4.44E+03 -0.224 1.34E-02 1.872 
PL-PC 36:0 8.51E+04 2.25E+04 2.64E+04 1.73E+05 -1.686 4.11E-02 1.386 
PL-PC 36:1 3.14E+05 7.47E+04 8.28E+04 3.91E+04 -1.925 3.86E-74 73.413 
PL-PC 36:2 2.87E+05 1.01E+05 1.57E+05 8.64E+04 -0.866 4.89E-20 19.311 
PL-PC 36:3 1.45E+06 2.81E+05 1.26E+06 2.48E+05 -0.206 3.31E-08 7.481 
PL-PC 36:4 9.89E+05 2.07E+05 8.88E+05 2.18E+05 -0.155 1.34E-04 3.874 
PL-PC 36:5 6.57E+04 2.99E+04 4.48E+04 2.43E+04 -0.551 2.13E-08 7.672 
PL-PC 36:6 2.35E+04 6.92E+03 1.25E+04 4.40E+03 -0.911 5.70E-31 30.244 
PL-PC 37:1 1.53E+04 4.88E+03 8.32E+03 3.89E+03 -0.877 1.51E-23 22.821 
PL-PC 37:2 1.12E+04 4.32E+03 4.75E+03 2.73E+03 -1.232 1.05E-28 27.978 
PL-PC 37:3 1.46E+04 4.60E+03 9.86E+03 5.51E+03 -0.564 9.02E-11 10.045 
PL-PC 37:4 7.11E+04 2.17E+04 4.50E+04 3.23E+04 -0.660 1.24E-08 7.906 
PL-PC 37:6 2.05E+05 6.36E+04 6.56E+04 3.79E+05 -1.641 2.05E-02 1.689 
PL-PC 38:3 8.78E+05 2.49E+05 6.88E+05 5.15E+05 -0.352 4.21E-04 3.376 
PL-PC 38:4 8.94E+05 2.78E+05 5.73E+05 1.50E+05 -0.642 2.05E-21 20.688 
PL-PC 38:5 9.21E+04 2.31E+04 5.46E+04 1.37E+04 -0.755 1.46E-33 32.837 
PL-PC 38:6 1.57E+05 5.12E+04 1.60E+05 4.18E+04 0.026 9.39E-01 0.028 
PL-PC 39:5 2.78E+04 1.32E+04 2.11E+04 2.99E+05 -0.400 2.35E-01 0.630 
PL-PC 40:0 6.05E+04 3.15E+04 2.56E+04 2.02E+04 -1.239 1.35E-18 17.868 
PL-PC 40:1 9.10E+03 3.82E+03 4.63E+03 2.74E+03 -0.974 3.81E-19 18.419 
PL-PC 40:2 2.16E+04 5.70E+03 9.83E+03 1.83E+04 -1.137 4.56E-07 6.341 
PL-PC 40:3 6.17E+04 2.61E+04 2.73E+04 9.53E+03 -1.176 3.37E-28 27.473 
PL-PC 40:4 3.39E+05 9.67E+04 1.58E+05 5.37E+04 -1.098 2.58E-40 39.589 
PL-PC 40:5 2.72E+05 8.40E+04 1.68E+05 4.55E+04 -0.699 2.32E-23 22.635 
PL-PC 40:6 2.00E+05 6.24E+04 1.05E+05 3.20E+04 -0.930 2.05E-32 31.687 
PL-PC 41:4 3.89E+04 2.04E+04 2.52E+04 2.70E+05 -0.626 3.77E-01 0.424 
PL-PC 42:0 2.69E+04 2.25E+04 1.20E+04 9.58E+03 -1.169 1.29E-09 8.891 
PL-PC 42:1 2.45E+04 1.55E+04 1.34E+04 1.40E+04 -0.870 9.37E-07 6.028 
PL-PC 42:2 1.67E+05 1.15E+05 7.54E+04 6.54E+04 -1.149 1.19E-11 10.924 
PL-PC 42:3 6.71E+04 2.47E+04 3.21E+04 3.59E+04 -1.062 2.30E-12 11.638 
PL-PC 42:4 3.47E+05 1.96E+05 1.45E+05 1.01E+05 -1.259 1.51E-17 16.821 
PL-PC 42:5 1.30E+05 4.43E+04 5.56E+04 2.46E+04 -1.223 9.34E-36 35.030 
PL-PC 43:3 1.11E+04 5.70E+03 5.29E+03 8.46E+06 -1.071 1.61E-01 0.794 
PL-PC 43:4 1.01E+04 5.17E+03 7.55E+03 4.04E+03 -0.422 3.40E-04 3.468 
PL-PC 44:1 8.72E+03 1.05E+04 2.90E+03 2.72E+03 -1.587 2.14E-07 6.669 
PL-PC 44:2 4.52E+04 2.66E+04 1.94E+04 1.49E+04 -1.223 4.10E-16 15.387 
PL-PC 44:3 8.82E+04 5.36E+04 4.34E+04 2.76E+04 -1.024 3.79E-13 12.421 
PL-PC 44:4 3.20E+05 1.40E+05 1.59E+05 8.36E+04 -1.014 1.15E-20 19.940 
PL-PC 44:5 2.54E+05 8.36E+04 1.22E+05 5.60E+04 -1.062 1.79E-31 30.746 
PL-PC 44:6 1.06E+05 3.74E+04 6.05E+04 3.39E+05 -0.805 9.82E-01 0.008 
PL-PC 46:4 5.81E+04 3.52E+04 3.98E+04 2.09E+04 -0.546 5.54E-06 5.256 
PL-PE 32:0 2.91E+04 9.89E+03 1.67E+04 1.42E+04 -0.806 5.81E-10 9.236 
PL-PE 32:1 1.66E+04 5.13E+03 1.35E+04 2.51E+05 -0.295 2.02E-01 0.694 
PL-PE 32:2 1.23E+04 8.09E+03 2.56E+03 2.88E+03 -2.258 9.24E-24 23.034 
PL-PE 34:1 3.02E+05 7.28E+04 2.18E+05 1.00E+05 -0.472 1.50E-11 10.823 
PL-PE 34:2 6.67E+05 2.08E+05 9.27E+04 8.18E+04 -2.848 6.30E-69 68.201 
PL-PE 34:3 2.57E+04 1.18E+04 5.51E+03 7.54E+04 -2.224 1.81E-01 0.742 
PL-PE 34:4 3.69E+04 5.66E+04 4.45E+03 6.44E+04 -3.053 4.84E-03 2.315 
PL-PE 35:1 2.56E+04 8.77E+03 9.95E+03 5.57E+03 -1.361 1.07E-36 35.970 
PL-PE 35:2 4.58E+04 1.76E+04 6.47E+03 8.04E+03 -2.822 3.51E-52 51.454 
PL-PE 35:4 2.16E+04 2.90E+04 4.03E+03 1.58E+04 -2.423 2.55E-06 5.594 
PL-PE 36:1 2.59E+05 7.82E+04 8.49E+04 5.88E+04 -1.606 1.72E-45 44.764 
PL-PE 36:2 8.49E+05 2.54E+05 9.47E+04 9.25E+04 -3.164 8.32E-75 74.080 
PL-PE 36:3 8.46E+05 1.97E+05 2.36E+05 1.10E+05 -1.844 5.96E-73 72.225 
PL-PE 36:4 1.94E+06 4.68E+05 9.64E+05 3.96E+05 -1.009 2.31E-40 39.637 
PL-PE 36:5 1.21E+05 1.15E+05 2.02E+04 3.00E+04 -2.580 1.23E-15 14.909 
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PL-PE 36:6 3.67E+04 1.73E+04 1.08E+04 7.27E+03 -1.761 4.43E-32 31.353 
PL-PE 37:2 1.87E+04 6.50E+03 3.60E+03 6.90E+03 -2.374 2.83E-36 35.548 
PL-PE 37:4 1.38E+05 4.80E+04 6.28E+04 2.74E+04 -1.135 1.18E-30 29.927 
PL-PE 37:5 3.82E+04 2.28E+04 1.36E+04 7.89E+03 -1.495 2.15E-20 19.668 
PL-PE 37:6 2.97E+04 1.90E+04 9.74E+03 1.34E+04 -1.608 3.75E-14 13.426 
PL-PE 38:1 5.05E+04 3.98E+04 1.16E+04 7.03E+03 -2.120 3.07E-19 18.512 
PL-PE 38:2 1.39E+05 4.80E+04 2.78E+04 2.18E+04 -2.318 1.03E-55 54.986 
PL-PE 38:3 5.33E+05 1.52E+05 1.67E+05 8.21E+04 -1.677 1.47E-55 54.833 
PL-PE 38:4 4.49E+05 1.39E+05 1.87E+05 9.04E+04 -1.265 1.92E-39 38.717 
PL-PE 38:5 2.34E+06 5.17E+05 8.07E+05 3.15E+05 -1.534 2.65E-68 67.577 
PL-PE 38:6 1.87E+06 4.78E+05 8.38E+05 2.98E+05 -1.155 9.01E-48 47.046 
PL-PE 39:4 4.49E+04 1.50E+04 2.64E+04 2.98E+04 -0.765 1.10E-05 4.959 
PL-PE 39:6 1.14E+05 3.42E+04 4.72E+04 1.86E+04 -1.276 6.74E-44 43.171 
PL-PE 40:1 1.85E+04 8.95E+03 5.86E+03 3.99E+03 -1.663 3.87E-30 29.413 
PL-PE 40:2 4.55E+04 1.67E+04 1.42E+04 3.75E+04 -1.683 2.72E-10 9.566 
PL-PE 40:3 1.25E+05 3.12E+04 8.61E+04 2.64E+05 -0.538 6.99E-01 0.155 
PL-PE 40:4 3.88E+05 1.02E+05 2.59E+05 1.42E+05 -0.584 3.07E-13 12.512 
PL-PE 40:5 5.50E+05 1.26E+05 1.92E+05 1.95E+05 -1.518 1.28E-34 33.891 
PL-PE 40:6 2.05E+05 6.36E+04 6.56E+04 2.55E+04 -1.641 1.40E-53 52.854 
PL-PE 42:4 7.04E+04 2.35E+04 5.05E+04 1.32E+05 -0.478 6.89E-01 0.162 
PL-PE 42:6 1.36E+05 4.77E+04 4.44E+04 1.87E+04 -1.609 7.41E-46 45.130 
PG 32:0 9.91E+03 6.93E+03 6.54E+03 4.48E+03 -0.601 1.89E-04 3.724 
PG 32:1 4.70E+03 2.51E+03 2.19E+03 7.65E+03 -1.100 6.01E-02 1.221 
PG 33:0 3.05E+04 1.13E+04 3.00E+04 2.30E+05 -0.025 2.48E-01 0.606 
PG 34:0 3.87E+06 7.75E+05 4.98E+06 1.08E+06 0.364 1.41E-13 12.852 
PG 34:1 8.81E+04 2.89E+04 1.71E+04 1.41E+04 -2.369 4.13E-59 58.384 
PG 34:2 2.08E+04 7.34E+03 4.59E+03 5.74E+03 -2.179 1.67E-42 41.778 
PG 36:0 5.97E+04 1.23E+04 1.18E+05 4.67E+04 0.982 8.79E-27 26.056 
PG 36:2 1.46E+05 5.07E+04 3.45E+04 2.31E+04 -2.083 2.24E-52 51.650 
PI 34:1 1.23E+05 4.98E+04 2.20E+04 4.14E+04 -2.481 2.64E-36 35.579 
PI 34:2 1.19E+05 4.30E+04 1.88E+04 1.52E+04 -2.665 1.32E-58 57.881 
PI 36:1 9.89E+04 4.84E+04 1.62E+04 1.72E+04 -2.610 5.25E-40 39.280 
PI 36:2 5.12E+05 1.70E+05 4.43E+04 1.27E+05 -3.531 5.50E-57 56.260 
PI 36:3 1.05E+05 3.70E+04 3.51E+04 1.56E+04 -1.578 1.52E-44 43.819 
PI 36:4 1.00E+05 3.94E+04 7.91E+04 3.14E+04 -0.339 6.81E-06 5.167 
PI 38:3 8.35E+05 3.38E+05 3.76E+05 1.72E+05 -1.153 3.39E-28 27.470 
PI 38:4 1.06E+06 3.54E+05 6.19E+05 2.39E+05 -0.780 1.32E-22 21.879 
PI 38:5 8.16E+04 2.97E+04 4.61E+04 2.50E+04 -0.823 1.71E-16 15.768 
PI 38:6 2.27E+04 1.14E+04 1.33E+04 2.05E+04 -0.772 2.19E-03 2.659 
PI 40:5 1.07E+05 3.85E+04 6.11E+04 3.24E+04 -0.807 8.69E-17 16.061 
PI 40:6 9.38E+04 3.76E+04 3.45E+04 1.41E+04 -1.443 2.76E-36 35.559 
PS 36:1 1.66E+05 6.08E+04 4.04E+04 3.04E+04 -2.042 4.72E-48 47.326 
PS 38:4 1.60E+04 9.77E+03 3.21E+04 1.08E+06 1.000 2.15E-01 0.667 
SM 29:1 2.18E+03 8.45E+02 9.17E+02 7.86E+03 -1.251 8.11E-01 0.091 
SM 30:0 7.00E+03 3.28E+03 4.33E+03 5.53E+03 -0.693 1.75E-03 2.756 
SM 30:1 6.85E+04 2.25E+04 1.73E+04 9.99E+03 -1.982 3.35E-54 53.475 
SM 30:2 7.05E+03 2.52E+03 3.39E+03 1.80E+03 -1.055 7.05E-25 24.152 
SM 31:1 4.17E+04 1.49E+04 1.04E+04 5.88E+03 -1.998 2.48E-50 49.605 
SM 32:0 9.13E+04 3.70E+04 5.61E+04 3.94E+04 -0.702 5.43E-09 8.265 
SM 32:1 1.73E+06 4.72E+05 4.26E+05 2.09E+05 -2.022 3.89E-68 67.410 
SM 32:2 1.78E+05 4.71E+04 7.44E+04 1.94E+05 -1.257 3.32E-05 4.479 
SM 33:0 7.74E+04 2.32E+04 2.00E+04 5.03E+04 -1.954 2.60E-18 17.584 
SM 33:1 5.44E+05 1.84E+05 1.81E+05 7.03E+04 -1.590 5.46E-48 47.263 
SM 33:2 3.18E+04 1.01E+04 9.84E+03 4.65E+03 -1.691 1.80E-50 49.745 
SM 34:0 3.45E+05 1.04E+05 2.26E+05 1.02E+05 -0.607 2.20E-15 14.658 
SM 34:1 3.41E+06 7.58E+05 1.64E+06 4.62E+05 -1.061 1.74E-53 52.759 
SM 34:2 2.67E+06 5.44E+05 1.20E+06 3.82E+05 -1.148 1.60E-59 58.796 
SM 34:3 1.77E+04 5.72E+03 6.24E+03 6.23E+04 -1.502 5.53E-01 0.257 
SM 35:1 1.07E+06 2.12E+05 2.33E+06 5.32E+05 1.119 2.05E-56 55.689 
SM 35:2 3.56E+04 1.56E+04 1.72E+04 3.24E+04 -1.049 2.30E-05 4.639 
SM 35:6 5.58E+03 3.29E+03 2.99E+03 2.63E+03 -0.902 6.81E-08 7.167 
SM 36:0 8.36E+04 2.30E+04 1.32E+05 5.41E+04 0.665 1.86E-14 13.729 
SM 36:1 2.75E+06 5.96E+05 2.37E+06 5.25E+05 -0.220 4.93E-08 7.308 
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SM 36:2 1.48E+06 4.16E+05 1.70E+06 4.72E+05 0.204 2.42E-03 2.617 
SM 36:3 2.01E+05 6.01E+04 5.46E+04 3.37E+04 -1.877 5.15E-55 54.288 
SM 36:4 3.48E+04 8.72E+03 1.81E+04 6.04E+03 -0.943 4.16E-40 39.381 
SM 37:1 1.84E+05 8.26E+04 1.12E+05 4.65E+04 -0.711 3.10E-13 12.509 
SM 37:2 4.73E+04 1.49E+04 4.27E+04 1.33E+04 -0.150 9.15E-03 2.039 
SM 38:0 2.16E+05 4.94E+04 2.97E+05 9.73E+04 0.460 8.66E-12 11.063 
SM 38:1 3.24E+05 1.48E+05 2.59E+05 1.25E+05 -0.323 7.71E-04 3.113 
SM 38:2 5.99E+05 1.54E+05 8.04E+05 1.92E+05 0.425 1.19E-13 12.924 
SM 38:3 5.13E+04 1.73E+04 4.78E+04 1.27E+06 -0.102 2.69E-01 0.570 
SM 38:4 2.53E+04 8.87E+03 1.54E+04 7.30E+03 -0.712 1.35E-14 13.869 
SM 38:5 1.63E+04 7.30E+03 2.72E+04 1.52E+04 0.734 5.47E-12 11.262 
SM 39:1 2.53E+05 7.11E+04 1.25E+05 1.48E+05 -1.016 6.84E-12 11.165 
SM 39:2 1.40E+05 3.29E+04 6.65E+04 2.16E+04 -1.075 2.53E-49 48.597 
SM 39:3 4.76E+04 1.35E+04 4.02E+04 1.15E+04 -0.244 8.24E-06 5.084 
SM 40:0 3.10E+05 6.20E+04 3.14E+05 7.62E+04 0.023 9.95E-01 0.002 
SM 40:1 2.92E+06 4.31E+06 1.16E+06 4.16E+05 -1.334 3.37E-05 4.472 
SM 40:2 2.06E+06 1.02E+06 1.56E+06 1.25E+06 -0.400 1.03E-03 2.989 
SM 40:3 2.64E+05 7.22E+04 1.92E+05 5.10E+04 -0.459 5.69E-16 15.245 
SM 40:4 3.90E+04 1.21E+04 6.54E+04 1.79E+04 0.746 9.76E-27 26.011 
SM 40:5 3.23E+04 9.63E+03 3.34E+04 1.19E+04 0.049 3.17E-01 0.499 
SM 41:0 2.18E+05 4.67E+04 8.92E+04 3.68E+04 -1.291 3.52E-58 57.453 
SM 41:1 1.45E+06 2.61E+05 3.43E+05 1.58E+05 -2.079 3.66E-95 94.437 
SM 41:2 7.43E+05 1.34E+05 3.09E+05 9.86E+04 -1.265 1.15E-70 69.939 
SM 41:3 1.86E+05 4.44E+04 1.18E+05 3.37E+04 -0.660 1.00E-28 27.998 
SM 42:1 2.26E+06 5.43E+05 1.48E+06 6.11E+05 -0.608 8.14E-20 19.090 
SM 42:2 1.14E+07 2.91E+07 2.81E+06 9.60E+05 -2.025 2.38E-03 2.623 
SM 42:3 2.80E+06 6.13E+05 1.96E+06 4.20E+05 -0.509 3.54E-25 24.451 
SM 42:4 3.68E+05 1.10E+05 5.16E+05 1.32E+05 0.488 1.00E-14 14.000 
SM 42:5 1.50E+05 7.90E+04 1.58E+05 4.87E+04 0.074 4.99E-01 0.302 
SM 42:6 7.78E+04 3.32E+04 8.62E+04 3.42E+04 0.148 3.51E-02 1.455 
SM 42:7 3.02E+04 1.42E+04 2.03E+04 3.80E+05 -0.572 3.56E-01 0.449 
SM 43:1 4.80E+04 1.69E+04 2.98E+04 1.04E+04 -0.685 5.69E-18 17.245 
SM 43:2 1.69E+05 5.61E+04 1.04E+05 3.28E+04 -0.697 9.56E-21 20.020 
SM 43:3 5.97E+04 2.13E+04 5.39E+04 1.65E+04 -0.149 1.73E-02 1.761 
SM 43:4 1.40E+04 1.05E+04 1.87E+04 2.20E+04 0.414 5.59E-02 1.252 
SM 43:7 1.18E+04 5.21E+03 7.37E+03 4.16E+03 -0.677 2.14E-10 9.669 
SM 44:1 1.32E+04 4.71E+03 1.91E+04 3.33E+05 0.530 1.10E-01 0.959 
SM 44:2 9.90E+03 5.42E+03 1.20E+04 8.47E+03 0.280 4.68E-03 2.330 
SM 44:3 3.73E+04 2.23E+04 5.14E+04 2.55E+04 0.463 4.06E-05 4.391 
SM 44:4 1.85E+04 9.77E+03 4.40E+04 3.05E+04 1.253 1.66E-17 16.780 
SM 44:5 2.90E+04 1.83E+04 4.46E+04 1.73E+04 0.623 5.32E-11 10.274 
SM 44:6 2.10E+04 1.40E+04 2.69E+04 1.18E+05 0.358 6.13E-02 1.213 
SM 44:7 7.69E+03 4.55E+03 1.14E+04 5.57E+03 0.566 1.49E-06 5.828 
SM 45:4 1.38E+04 8.08E+03 7.03E+03 1.72E+04 -0.976 1.34E-02 1.872 
SM 47:5 1.38E+04 2.00E+04 6.52E+03 6.24E+04 -1.076 9.68E-01 0.014 
TG 36:0 4.95E+04 9.20E+04 1.63E+04 3.06E+04 -1.601 5.05E-04 3.297 
TG 38:0 7.93E+04 1.68E+05 1.82E+04 3.42E+04 -2.124 4.50E-04 3.347 
TG 39:0 1.44E+04 1.26E+04 5.23E+03 2.93E+04 -1.465 4.93E-02 1.307 
TG 40:0 1.41E+05 2.69E+05 1.41E+04 2.88E+04 -3.320 3.72E-06 5.429 
TG 40:1 1.02E+05 1.29E+05 8.62E+03 2.23E+04 -3.558 6.00E-12 11.222 
TG 41:0 2.18E+04 2.02E+04 4.83E+03 2.85E+05 -2.177 5.58E-01 0.253 
TG 42:0 2.47E+05 3.28E+05 1.80E+04 4.04E+04 -3.775 1.73E-11 10.763 
TG 42:1 2.55E+05 3.66E+05 1.55E+04 5.47E+04 -4.035 5.71E-10 9.244 
TG 42:2 1.63E+05 2.08E+05 1.02E+04 6.01E+05 -4.000 1.99E-01 0.702 
TG 42:3 3.90E+04 3.61E+04 4.25E+03 4.06E+03 -3.199 5.01E-19 18.300 
TG 43:0 3.19E+04 2.48E+04 7.89E+03 8.71E+03 -2.016 2.17E-17 16.664 
TG 44:0 3.22E+05 2.88E+05 3.91E+04 6.43E+04 -3.039 6.94E-19 18.159 
TG 44:1 5.99E+05 6.06E+05 5.30E+04 8.92E+04 -3.498 4.13E-17 16.384 
TG 44:2 3.41E+05 3.15E+05 2.53E+04 4.69E+04 -3.752 3.29E-20 19.483 
TG 45:0 3.98E+04 2.60E+04 1.24E+04 9.16E+03 -1.682 4.79E-20 19.320 
TG 45:1 7.05E+04 5.02E+04 1.46E+04 1.32E+04 -2.273 1.29E-22 21.890 
TG 46:0 5.16E+05 3.05E+05 1.12E+05 1.02E+05 -2.203 1.14E-28 27.945 
TG 46:1 1.30E+06 1.05E+06 2.23E+05 2.10E+05 -2.550 7.03E-21 20.153 
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TG 46:2 1.01E+06 6.95E+05 1.38E+05 1.84E+05 -2.868 1.61E-26 25.792 
TG 46:3 3.35E+05 2.10E+05 3.72E+04 7.53E+04 -3.172 4.45E-30 29.352 
TG 47:0 5.17E+04 2.89E+04 2.00E+04 1.80E+04 -1.372 1.91E-16 15.719 
TG 47:1 1.29E+05 7.43E+04 3.93E+04 2.38E+04 -1.713 5.85E-25 24.233 
TG 47:2 1.17E+05 5.76E+04 2.82E+04 1.39E+05 -2.058 7.35E-07 6.134 
TG 47:3 6.13E+04 2.50E+04 1.01E+04 9.73E+03 -2.596 1.83E-48 47.739 
TG 48:0 8.43E+05 3.43E+05 3.15E+05 1.71E+05 -1.419 6.36E-33 32.196 
TG 48:1 3.28E+06 1.67E+06 9.31E+05 5.71E+05 -1.817 2.82E-31 30.549 
TG 48:2 3.05E+06 1.42E+06 7.91E+05 5.16E+05 -1.950 2.13E-36 35.671 
TG 48:3 1.47E+06 6.83E+05 3.01E+05 2.15E+05 -2.287 6.87E-41 40.163 
TG 48:4 4.81E+05 2.48E+05 9.12E+04 5.75E+04 -2.399 1.38E-37 36.860 
TG 49:0 7.75E+04 3.19E+04 3.51E+04 3.75E+04 -1.143 5.76E-14 13.239 
TG 49:1 3.34E+05 1.34E+05 1.01E+05 4.94E+04 -1.721 4.84E-41 40.315 
TG 49:2 3.44E+05 1.21E+05 1.07E+05 5.21E+04 -1.683 1.76E-46 45.753 
TG 49:3 1.71E+05 5.47E+04 4.42E+04 2.49E+04 -1.954 3.45E-56 55.462 
TG 50:0 1.05E+06 3.43E+05 4.20E+05 2.34E+05 -1.327 1.78E-36 35.750 
TG 50:1 6.72E+06 1.81E+06 3.12E+06 1.56E+06 -1.537 2.13E-52 51.671 
TG 50:2 8.03E+06 1.93E+06 1.73E+06 9.45E+05 -1.363 2.20E-59 58.658 
TG 50:3 5.39E+06 1.36E+06 5.91E+05 3.44E+05 -1.644 1.24E-58 57.906 
TG 50:4 2.20E+06 6.47E+05 1.30E+05 7.47E+04 -1.896 1.53E-46 45.816 
TG 50:5 4.72E+05 1.74E+05 2.51E+04 1.88E+04 -1.863 1.85E-38 37.732 
TG 50:6 9.27E+04 3.78E+04 3.46E+05 1.15E+05 -1.883 6.11E-38 37.214 
TG 51:1 3.57E+05 1.27E+05 1.18E+05 7.87E+04 -1.605 7.36E-39 38.133 
TG 51:2 7.12E+05 1.99E+05 2.12E+05 9.52E+04 -1.747 6.56E-61 60.183 
TG 51:3 1.61E+04 1.12E+04 4.07E+03 7.51E+03 -1.985 1.78E-15 14.751 
TG 51:4 2.72E+05 6.88E+04 7.14E+04 4.75E+04 -1.927 1.42E-62 61.847 
TG 51:5 9.64E+04 3.45E+04 3.03E+04 1.56E+04 -1.669 7.90E-45 44.103 
TG 52:0 4.87E+05 1.62E+05 1.70E+05 9.24E+04 -1.515 1.89E-43 42.724 
TG 52:1 3.98E+06 1.15E+06 1.32E+06 6.69E+05 -1.591 4.46E-53 52.351 
TG 52:2 1.29E+07 2.47E+06 4.17E+06 1.86E+06 -1.623 7.68E-76 75.114 
TG 52:4 1.07E+07 2.66E+06 2.49E+06 1.34E+06 -2.102 1.28E-74 73.893 
TG 52:5 3.13E+06 9.51E+05 9.07E+05 4.58E+05 -1.786 2.63E-56 55.580 
TG 52:6 6.16E+05 2.15E+05 2.58E+05 2.01E+05 -1.257 5.41E-25 24.267 
TG 53:0 5.09E+04 1.68E+04 4.92E+04 1.99E+04 -0.050 3.65E-01 0.438 
TG 53:1 1.39E+05 5.36E+04 3.65E+04 1.95E+04 -1.928 2.33E-46 45.632 
TG 53:2 4.53E+05 1.42E+05 1.19E+05 5.33E+04 -1.932 5.09E-59 58.294 
TG 53:3 4.32E+05 1.15E+05 1.23E+05 7.00E+04 -1.813 7.49E-61 60.126 
TG 53:4 2.19E+04 1.27E+04 7.36E+03 5.96E+04 -1.574 1.53E-01 0.816 
TG 53:5 1.17E+05 2.69E+04 5.23E+04 2.37E+04 -1.164 3.29E-46 45.483 
TG 54:0 1.07E+05 4.94E+04 3.87E+04 4.38E+04 -1.463 1.25E-19 18.903 
TG 54:1 8.30E+05 3.51E+05 2.26E+05 1.98E+05 -1.875 8.62E-37 36.064 
TG 54:2 2.67E+06 8.45E+05 7.82E+05 4.67E+05 -1.774 1.02E-51 50.992 
TG 54:3 3.16E+06 8.10E+05 1.26E+06 5.93E+05 -1.331 3.02E-50 49.519 
TG 54:4 3.85E+06 9.54E+05 1.42E+06 2.93E+06 -1.439 3.19E-11 10.496 
TG 54:5 3.54E+06 1.02E+06 1.53E+06 6.48E+05 -1.216 3.13E-43 42.505 
TG 54:6 2.37E+06 8.75E+05 1.17E+06 4.94E+05 -1.012 3.67E-27 26.436 
TG 54:7 8.54E+05 4.07E+05 5.22E+05 2.68E+05 -0.711 1.31E-11 10.883 
TG 54:8 1.75E+05 9.19E+04 1.20E+05 6.82E+04 -0.539 1.13E-06 5.948 
TG 55:1 3.17E+04 1.57E+04 7.70E+03 5.69E+03 -2.039 2.14E-34 33.670 
TG 55:2 5.49E+04 1.89E+04 1.22E+04 1.04E+04 -2.170 9.14E-51 50.039 
TG 55:3 7.08E+04 2.33E+04 2.12E+04 8.20E+04 -1.740 2.98E-06 5.526 
TG 56:0 1.73E+04 1.23E+04 4.02E+03 1.70E+05 -2.110 7.98E-01 0.098 
TG 56:1 1.16E+05 8.56E+04 1.81E+04 5.21E+06 -2.688 2.90E-01 0.538 
TG 56:2 2.58E+05 1.36E+05 4.67E+04 7.21E+04 -2.465 1.83E-32 31.736 
TG 56:3 3.33E+05 1.29E+05 8.99E+04 6.23E+04 -1.887 3.24E-43 42.489 
TG 56:4 3.12E+05 8.00E+04 2.15E+05 9.82E+04 -0.535 1.23E-14 13.911 
TG 56:5 5.65E+05 1.26E+05 5.46E+05 2.27E+05 -0.048 2.87E-01 0.542 
TG 56:6 7.81E+05 1.81E+05 8.57E+05 3.27E+05 0.134 9.21E-02 1.036 
TG 56:7 1.03E+06 3.58E+05 1.08E+06 4.65E+05 0.081 4.62E-01 0.335 
TG 56:8 6.79E+05 2.85E+05 6.72E+05 3.72E+05 -0.015 7.20E-01 0.143 
TG 56:9 1.73E+05 8.41E+04 1.74E+05 1.23E+05 0.009 4.39E-01 0.358 
TG 56:10 2.65E+04 2.02E+04 2.52E+04 1.38E+04 -0.070 5.75E-01 0.240 
TG 58:1 3.49E+04 3.38E+04 5.99E+03 2.32E+04 -2.541 7.48E-12 11.126 
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TG 58:2 9.33E+04 9.77E+04 1.22E+04 7.43E+04 -2.929 2.30E-09 8.637 
TG 58:3 8.44E+04 7.43E+04 1.30E+04 3.36E+04 -2.700 9.39E-17 16.027 
TG 58:4 5.88E+04 2.57E+04 1.98E+04 2.90E+04 -1.572 2.07E-18 17.684 
TG 58:5 1.25E+05 4.30E+04 6.68E+04 5.25E+04 -0.909 4.48E-15 14.348 
TG 58:6 1.55E+05 4.67E+04 1.31E+05 5.30E+04 -0.245 3.38E-04 3.471 
TG 58:7 2.08E+05 7.25E+04 2.35E+05 8.22E+04 0.180 1.75E-02 1.757 
TG 58:8 2.47E+05 1.03E+05 3.27E+05 1.22E+05 0.408 1.39E-06 5.858 
TG 58:9 2.08E+05 9.06E+04 2.96E+05 1.19E+05 0.508 2.80E-08 7.552 
TG 58:10 1.33E+05 6.60E+04 1.98E+05 9.25E+04 0.579 3.65E-08 7.438 
TG 58:11 3.72E+04 3.01E+04 4.91E+04 8.27E+04 0.402 1.39E-02 1.858 
TG 60:10 4.14E+04 2.12E+04 1.06E+05 4.83E+05 1.361 6.54E-03 2.185 
TG 60:11 4.57E+04 2.99E+04 1.23E+05 2.07E+05 1.432 1.41E-06 5.850 
TG 60:12 3.67E+04 3.47E+04 8.94E+04 6.04E+04 1.284 2.69E-14 13.570 
TG 62:1 2.33E+03 4.20E+03 3.98E+02 1.29E+04 -2.548 8.30E-01 0.081 
TG 62:12 1.08E+04 8.37E+03 3.16E+04 1.70E+04 1.548 3.28E-23 22.484 





Figure 2.3. Pearson correlation of maternal first trimester plasma lipidome. 
  
Pearson’s correlation between individual lipids from M1. Network 
created using “organic layout” in Cytoscape. Positive correlations are 
depicted using red edges. Inverse correlations are depicted using 
green edges. Correlations represented have an r-value > 0.5 or < -0.5. 





















Figure 2.4. Pearson correlation of maternal delivery plasma lipidome. 
  
Pearson’s correlation between individual lipids from M3. Network 
created using “organic layout” in Cytoscape. Positive correlations are 
depicted using red edges. Inverse correlations are depicted using 
green edges. Correlations represented have an r-value > 0.5 or < -0.5. 





















Figure 2.5. Pearson correlation of cord blood lipidome. 
  
Pearson’s correlation between individual lipids from CB. Network 
created using “organic layout” in Cytoscape. Positive correlations are 
depicted using red edges. Inverse correlations are depicted using 
green edges. Correlations represented have an r-value > 0.5 or < -0.5. 





















Figure 2.6. Correlation between lipid groups differs between maternal and cord blood samples. 
 
  
The relationship between lipid 
groups was estimated using 
Debiased Sparse Partial Correlations 
within (A) M1 (48 edges), (B) M3 
(63 edges), and (C) CB (60 edges). 
Colors of nodes depict class of lipid. 
Shapes of nodes depict number of 
double bonds. Positive correlations 
are depicted using red edges. Inverse 
correlations are depicted using green 
edges. Weight of the edges signifies 
a more significant correlation. Edges 
represented have an adjusted p-value 

























Figure S2.2. Associations between maternal and cord blood lipid groups with maternal BMI at 
baseline.  
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Regression models estimated the linear relationship between maternal BMI at baseline and 
(A) maternal first trimester, (B) maternal term, and (C) cord blood lipid groups, adjusting for 
sex, maternal age, parity, and gestational age. Beta coefficients plotted as white bars (β±SE) 
with significance depicted as gray stripped bars (unadjusted p-value α=0.05).  
         combined  
         combined (significant)  
 
Legend  
A  B  C  
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Figure S2.3. Associations between maternal and cord blood lipid groups with maternal 
gestational weight gain. 
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Regression models estimated the linear relationship between maternal GWG (kg) and (A) 
maternal first trimester, (B) maternal term, and (C) cord blood lipid groups, adjusting for sex, 
maternal age, parity, and gestational age. Beta coefficients plotted as white bars (β±SE) with 
significance depicted as gray stripped bars (unadjusted p-value α=0.05).  
 
A  B  C  
         combined  





 Figure 2.7. Distinct maternal and cord blood lipid groups are related to birth weight.   
 
 
   
           combined  
         combined (significant)  
● males  
X males (significant)  
● females 
X females (significant) 
Legend  Regression models estimated the linear relationship between 
lipid groups from (A) maternal first trimester, (B) maternal 
term, and (C) cord blood and Fenton BW z-score, adjusting for 
sex, maternal age, parity, gestational age, baseline BMI, and 
GWG. For the combined model, beta coefficients plotted as 
gray bars (β±SE) with significance depicted as gray stripped 
bars (α=0.05). Sex stratified models were run. For males, beta 
coefficients are plotted as blue dots (β±SE) with significance 
depicted as blue “X” (α=0.05).  For females, beta coefficients 
are plotted as red dots (β±SE) with significance depicted as red 
“X” (α=0.05).   
A  B  C  
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Figure 2.8. Association between triglycerides and birth weight in male and female infants. 
 














































A  B  
Regression models estimated the linear relationship between cord blood individual 
triglycerides and Fenton BW z-score in (A) males and (B) females, adjusting for maternal age, 
parity, gestational age, baseline BMI, and GWG. Beta coefficients are plotted by the number 
of double bonds in the fatty acid tails of the TGs. Significant TGs are marked in red (α=0.05). 
Non-parametric regression fit polynomial lines for each plot.  
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  The association between maternal individual lipids and lipid groups with CB LysoPCs, 
LysoPEs, and total LysoPLs was classified using Pearson’s correlations. Maternal lipids 
listed were significantly correlated with the lipid group CB LysoPL-total (unadjusted p-value 
α=0.05), suggesting they may modulate CB lysophospholipid levels. Maternal lipids (rows) 
are broken down by positive and inverse associations. Cord blood lysophospholipids 
(columns) are ordered by increasing chain length and number of double bonds. CB lipids 
groups LysoPC-sat, LysoPC-mono, LysoPC-poly, LysoPE-sat, LysoPE-poly, LysoPC-total, 
































































































































































































































































































































































































































































































































The association between maternal individual lipids and lipid groups with CB TGs was 
classified using Pearson’s correlations. Maternal lipids listed were significantly correlated 
with the lipid group CB TG-poly (unadjusted p-value α=0.05), suggesting they may 
modulate CB polyunsaturated TG levels. Maternal lipids (rows) are broken down by positive 
and inverse associations. Cord blood triglycerides (columns) are ordered by increasing chain 
length and number of double bonds. CB lipids groups TG-sat, TG-mono, and TG-poly are 
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CHAPTER 3                                                                                                                               
Lipidome across Pregnancy Influences the Programming of Umbilical Cord Blood 
Leukocyte DNA Methylation. 
Abstract 
The maternal metabolic environment may influence DNA methylation levels in the developing 
fetus, with potential long-term health consequences in the offspring via epigenetic programming. 
The lipidome provides a comprehensive assessment of maternal lipid levels across gestation. 
Untargeted shotgun lipidomics was performed on first trimester maternal plasma (M1) and 
delivery maternal plasma (M3) in 106 mothers from the Michigan Mother-Infant Pair (MMIP) 
cohort. Infant cord blood (CB) leukocyte DNA methylation was profiled using the Infinium 
MethylationEPIC (EPIC) bead array. Using empirical Bayes modeling, we classified differential 
methylation at CpG sites in relation to maternal lipid groups, adjusting for CB blood cell types, 
sex, and batch effects. M3 saturated lysophosphatidylcholine (LysoPC) was associated with 45 
differentially methylated CpG sites and M3 saturated lysophosphatidylethanolamine (LysoPE) 
was associated with 18 differentially methylated CpG sites. Most of the differentially methylated 
CpG sites had increased DNA methylation. Many of the differentially methylated CpG sites were 
localized in CpG islands, including 64% of CpG sites associated with M3 saturated LysoPC and 
50% of CpG sites associated with M3 saturated LysoPE. Biological pathways pertaining to 
differentially methylated CpG sites associated with M3 saturated LysoPCs were involved in cell 
proliferation and growth. The results of this analysis highlighted the influence of late gestation 
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maternal lipid levels on the infant epigenome. Future analyses will assess expression of genes 
with differential methylation.  
Introduction 
The Developmental Origins of Health and Disease (DOHaD) theory postulates that insults during 
early life can permanently program the fetus/offspring, influencing long-term health outcomes 
(1). During gestation, the maternal metabolic environment may alter DNA methylation levels in 
the fetus, potentially shifting the developmental trajectory of the offspring via epigenetic 
programming. Profiling the maternal metabolome and lipidome, the low-molecular weight lipid 
intermediates in metabolism, provides an objective view of maternal nutrient availability during 
pregnancy. Changes in the maternal metabolome across gestation occur to support the 
developing needs of the fetus (2) and are influenced by maternal characteristics such as obesity 
(3–5) and dietary intake (6). Irregular fluctuations in the maternal metabolome may influence the 
development of the offspring by causing structural changes in fetal organs and tissues to adapt to 
the intrauterine environment and prepare for the external environment (7).  
We have previously assessed the relationship between the maternal lipidome with the umbilical 
cord blood (CB) lipidome (LaBarre et al, submitted). The umbilical CB lipidome is an 
approximate snapshot of the infant lipidome in circulation, presenting details on maternal lipid 
transfer across the placenta. Our results highlight the selective transport of polyunsaturated fatty 
acids (PUFA) and lysophospholipids (LysoPL) across the placenta into the umbilical CB to 
support fetal development. Additionally, CB lipid groups containing PUFAs and LysoPLs were 
associated with birth weight, a common outcome in DOHaD studies due to its association with 
cardiometabolic disease in adulthood (8,9). We identified maternal PUFAs in early gestation 
were vital for the establishment of umbilical CB lipids associated with birth weight. 
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There is growing evidence that epigenetic mechanisms are a major contributor to developmental 
programming (10). Epigenetics is defined as the mitotically heritable changes in gene expression 
that occur without altering the DNA sequence. The most extensively studied epigenetic 
modification is DNA methylation at CpG sites, short-hand for a cytosine and guanine base 
separated by a phosphate group. Methyl-groups are covalently attached to the 5’ carbon of a 
cytosine preceding a guanine, generating a 5-methylcytosine. Across most tissues, 70% of CpG 
sites are methylated (11). Regions in the genome with high CpG site frequency are called CpG 
islands, which are often located at the 5’ promotor of genes. The umbilical CB epigenome has 
previously been associated with maternal dietary intake (12) and maternal BMI (13), as well as 
infant birth weight (14). Details on the influence and timing of maternal exposures on the 
offspring DNA methylation patterns continues to be elucidated.   
Previous work from our group (15) provided some of the first evidence for a relationship 
between specific metabolites in the maternal plasma across gestation with DNA methylation in 
umbilical CB leukocytes. DNA methylation at key genes including ESR1, PPARα, IGF2, and 
H19, which have previously been associated with growth and future cardiovascular disease risk 
(16–18), was correlated with maternal essential fatty acids (FA) and acylcarnitines. A recent 
study (19) assessed how the maternal lipidome at ~26 weeks gestation influences DNA 
methylation in umbilical CB cells using the Infinium HumanMethylation450 (450K) assay. 
These results found that maternal phospholipids and lysophospholipids were associated with 
offspring DNA methylation, suggesting the importance of that lipids fraction in establishing 
methylation patterns.  
The objective of our analysis is to provide a deeper understanding of how the maternal lipidome 
at early gestation and delivery is related to altered DNA methylation patterns in umbilical CB 
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leukocytes. Our findings provide support that the maternal metabolic environment during 
gestation influences the infant epigenome, potentially by fetal programming. In particular, we 
focus our results and discussion on differential methylation in genes associated with lipid 
metabolism, growth, and metabolic disease. This analysis incorporates high-throughput shotgun 
lipidomics methodology, profiling 573 lipids, and genome-wide DNA methylation using the 
EPIC bead array, presenting a comprehensive view of developmental programming.  
Subjects and Methods 
Study population. Biological samples were analyzed from women and their offspring enrolled in 
the Michigan Mother Infant Pair (MMIP) cohort (2010-present), an ongoing birth cohort study 
based out of the University of Michigan (UM) Von Voigtlander Women’s Hospital. Recruitment 
of women took place during their initial prenatal appointment, between 8 and 14 weeks of 
gestation. Eligibility criteria includes women ages 18 to 42 years, a spontaneously conceived 
singleton pregnancy, and intention to deliver at the UM Hospital. For this analysis, a subset of 
mother-infant dyads was selected for lipidomics analyses and genome-wide DNA methylation 
using the EPIC bead array. Inclusion criteria for the current study include completed 
demographic, survey, and health information at the initial study visit and availability of all 
biospecimen for metabolomics and epigenomics analyses (n=100). Study procedures were 
approved by the UM Medical School Institutional Review Board, and all participants provided 
written informed consent, which includes consent for measures of lipidomics and DNA 
methylation. All participants were de-identified.   
During the initial study visit between 8 and 14 weeks of gestation, participants provided a blood 
sample (M1) and anthropometry information (weight and height) to calculate an estimated 
baseline BMI. Maternal venous blood samples (M3) was collected upon admittance at UM 
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Hospital for delivery, and cord blood (CB) samples were collected via venipuncture from the 
umbilical cord. All mother-infant dyads met additional inclusion criteria for this study, including 
infant birth weight greater than 2500 grams, maternal BMI greater than 18.5 kg/m2, and no 
pregnancy complications, such as gestational diabetes.   
Lipidomics Profiling. Untargeted shotgun lipidomics was performed as previously detailed (20) 
using reconstituted lipid extract from M1, M3, and CB plasma samples. Samples were ionized in 
positive and negative ionization model using a Triple TOF 5600 (AB Sciex, Concord Canada). 
Chromatographic peaks that represent features are detected using a modified version of existing 
commercial software (Agilent MassHunter Qualitative Analysis). Pooled human plasma samples 
and pooled experimental samples were randomized and ran for quality control (21). Detected 
features were excluded with (1) a relative standard deviation greater than 40% in the pooled 
samples and/or (2) less than 70% presence in the samples. Missing data were imputed using the 
K-nearest neighbor method.  
Lipids were classified using LIPIDBLAST, a computer generated tandem mass spectral library 
containing 119,200 compounds from 26 lipid classes (22). After processing, 573 lipids from 
multiple lipid classes were identified (Table 2.1). All lipids will be mentioned with the 
nomenclature as X:Y, where X is the length of the carbon chain and Y, the number of double 
bonds.  
DNA extraction. At the time of birth, infant umbilical CB was collected into PaxGene Blood 
DNA tubes (PreAnalytix). Samples were stored at -80°C until extraction. DNA was extracted 
from CB leukocytes using the PaxGene Blood DNA kit, following standard protocols. At the 
University of Michigan Advanced Genomics Core, DNA concentration and integrity were 
quantified using a Qubit Fluorometer and extracts with a concentration greater than 15 ng/μL 
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were selected for further analysis. Prior to DNA methylation analysis, approximately 500ng of 
input DNA per sample underwent bisulfite conversion using the EZ-96 DNA Methylation Kit 
(Zymo).  
Genome-wide DNA methylation analysis. DNA methylation analyses were performed by the 
University of Michigan Epigenomics Core. The Illumina Infinium MethylationEPIC (EPIC) 
bead array was used to quantify DNA methylation at ~850,000 CpG sites (Illumina Inc, San 
Diego, CA, USA), following standard protocols. The EPIC bead array detects at single-
nucleotide resolution and contains probes the hybridize to loci throughout the genome located 
within CpG islands, genes, transcription binding sites, open chromatin regions, and more. 
Umbilical CB samples were run in three experimental batches (sample plates), which are 
considered in the statistical models (23). 
DNA methylation data processing. Raw intensity probe data were processed using the 
Bioconductor minfi package 1.32.0 (24). The data were generated from reading a red or green 
signal, signifying if the probe hybridized to a methylated or unmethylated loci. After generation 
of the signal, a value β between 0 and 1 was provided as 
β=[methylated/(methylated+unmethylated)]. Quality of samples and probes was determined by 
evaluating infant estimated sex (via methylation values on the X and Y chromosomes) versus 
known sex (as recorded in medical record) and detection and intensity of probe signals. Samples 
that failed quality check were removed from analysis. The probes located on X and Y 
chromosomes were excluded from this analysis due to differences in probe intensities for sex 
chromosomes (25). After quality control, 804108 probes were available for analysis. β-values 
were converted logarithmically into M-values for statistical analysis. Although β-values are more 
intuitive for a biological interpretation, M-values are more statistically valid for analysis (26).  
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Statistical analysis.  
Maternal and infant background characteristics. 
Table 3.1 summarized maternal and infant population characteristics and estimated proportions 
of infant CB cell types. To estimate CB proportions of white blood cell types and nucleated red 
blood cells, we utilized a CB reference dataset (23). 
Creating lipid group scores.  
The lipidome is highly correlated due to lipids being metabolized by enzymes in a class-specific 
manner. For this analysis, the lipidome was grouped based on lipid class and the number of 
double bonds, yielding 41 groups (Table S2.1). Lipid groups were scored for each mother-infant 
dyad using unsupervised Principal Component Analysis. The first principal component was 
retained, accounting for the largest portion of variance (PROC FACTOR, SAS 9.4 Cary, North 
Carolina). Within the principal component, each lipid received a factor loading, which is the 
correlation coefficient between the lipid and the component. Participant scores were created by 
(1) multiplying the lipid factor loading by the lipid standardized peak intensity and (2) adding 
together these values for all lipids within a lipid group (PROC SCORE, SAS 9.4 Cary, North 
Carolina). Lipid scores were considered outliers and removed if exceeding ±3 standard 
deviations from the mean score. While these values may be biologically relevant, including 
outliers into the analysis increases risk of false discovery, detecting CpG sites associated with 
participant variation, rather than the lipid group (27).  
Identification of differentially methylated CpG sites and regions. 
This analysis sought to identify differential methylation in CB leukocytes associated with the 
maternal (M1 and M3) lipidome. Differentially methylated sites were classified fitting linear 
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models using empirical Bayes methodology from the Bioconductor package limma, version 
3.42.0 (28). Models were adjusted for sex, EPIC bead array sample plate, and estimated 
proportions of nucleated red blood cells (nRBC) and B-cells. Results were adjusted for multiple 
hypothesis testing using the Benjamini-Hochberg method with an FDR threshold for significance 
of 0.05 (29). Differentially methylated regions (DMR) were identified by the R Bioconductor 
package DMRcate, version 2.0.0. All DMRs contained at least two CpG sites and were 
considered significant with an adjusted p-value threshold of 0.05 using the Stouffer’s method.  
Path analysis.  
Biological pathways associated with differentially methylated genes were classified. To avoid 
bias when performing gene ontology with methylation data (30), we used the gometh function in 
the R package missMethyl, version 1.20.0 (31), to classify enriched gene ontologies (GO) (32) 
and KEGG (33) pathways. Pathway analysis was conducted separately for the following lipids 
groups with multiple significant CpG sites; M3 LysoPC-sat and LysoPE-sat. Differentially 
methylated CpG sites with an FDR<0.1 were selected to classify enriched biological pathways. 
Gene ontologies and KEGG biological pathways were considered enriched with an FDR <0.05.  
All analyses were performed using R software, version 3.5.3 (The R Foundation for Statistical 
Computing). Figures were created using GraphPad Prism version 7.4 (La Jolla, California).  
Results 
Subject Demographics  
Maternal and infant population characteristics are reported in Table 3.1 (n=100). The majority of 
women were between 30-34 years with an average overweight baseline BMI (25.9 kg/m2). Most 
newborns were delivered vaginally (72%). There was a similar distribution of male and female 
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newborns (53 male, 47 female) with an average birth weight of approximately 3500 grams. Cord 
blood cell percentages estimated for CD4+T, CD8+T, B cells, granulocytes, monocytes, natural 
killer cells, and nRBCs are listed in Table 3.1.  
Relationship between maternal lipid groups with DNA methylation in infant cord blood 
leukocytes.  
Table 3.2 lists the number of CpG sites significantly associated with maternal lipid groups 
(FDR<0.05), adjusting for infant sex, sample plate, nRBC (%), and B cells (%). Significant sites 
are shown stratified by "increased" methylation and "decreased" methylation with increasing 
lipids. The majority of differentially methylated CpG sites were associated with maternal 
delivery lipid groups. Genes associated with differentially methylated sites are reported in Table 
3.3.  
In M1, only a few lipid groups were associated with single-CpG sites DNA methylation in CB 
leukocytes. Significant associations were observed between M1 LysoPC-sat and a CpG site in 
the shore of MPP5 (logFC= 0.12, probe ID cg07218192) (Table 3.3). Early gestation M1 PG-
mono is positively associated with a CpG site in the open sea of PPARGC1B (logFC=0.17, 
cg24968215) and a CpG site in the CpG island of TTC14 (logFC=0.15, cg14930059).  
In M3, the LysoPC-sat was associated with 45 differentially methylated CpG sites (Figure 3.1a) 
and LysoPE-sat was associated with 18 differentially methylated CpG sites (Figure 3.1b). Many 
of these CpG sites were located within CpG islands and shores (Figure 3.1c and d) and had 
increased DNA methylation. There was overlap in the CpG sites associated with M3 LysoPC-sat 
and LysoPE-sat including increased methylation at CpG sites related SLFN5 (cg23010414), 
HIST1H1D (cg15485323), and DBI (cg02325290) (Table 3.3). Increased methylation was 
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observed in the CpG island of Diazepam Binding Inhibitor/acyl-CoA binding protein (DBI) 
(Figure S3.1); a highly conserved gene that binds medium- and long-chain acyl-Coenzyme A 
esters and plays a role in lipid metabolism (36).  
M3 LysoPC-sat is associated with differential methylation in a variety of other genes related to 
metabolism and development (Table 3.3) including the CpG island of ATP5G1 (logFC=0.28, 
cg14103143), which encodes a subunit of mitochondrial ATP synthase; the south shore of COQ5 
(logFC=0.17, cg11075121), a mitochondrial gene that catalyzes the methylation in the COQ10 
synthetic pathways (37); CpG island of GABBR2 (logFC=0.25, cg11509404), which plays a role 
in coupling to G-proteins (38) and stimulates phospholipase A2, an enzyme that hydrolyzes 
phospholipids releasing the sn-2 FA; and the CpG island of PA2G4 (logFC=0.29, cg21001214), 
a gene encoding an RNA binding protein involved in growth regulation.  
In the DMR analysis, M3 LysoPE-sat was associated with increased methylation across 13 CpGs 
within the CpG island of FK506 binding protein prolyl isomerase 11 (FKBP11) (mean β FC = 
0.0064, Stouffer p-value=0.00047) (Table 3.4). No additional DMRs were observed.  
Pathway analysis of differentially methylated genes  
To further investigate the potential biological relevance of the results, pathway analysis was used 
to classify gene ontologies (GO) and KEGG pathways enriched in genes with differential 
methylation. Lipid groups selected for pathway analysis had multiple significant CpG hits 
including M3 LysoPC-sat and LysoPE-sat. Gene ontologies for biological processes (BP), 
cellular components (CC), and molecular function (MF) and KEGG biological pathways were 
classified. M3 LysoPC-sat was the only lipid group with significantly enriched gene ontologies 
(Table S3.1) and KEGG biological pathways (Table S3.2). The top ten significantly enriched 
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gene ontologies and biological pathways associated with M3 LysoPC-sat are reported in Figure 
3.2. From GO analysis, enriched ontologies include cell division (BP), regulation of transcription 
(BP), the nucleoplasm and nucleus (CC), and DNA, RNA, and protein binding (MF) (Figure 
3.2a-c). Multiple enriched KEGG pathways are related to cell proliferation including cell cycle, 
ribosome, human papillomavirus infection, viral carcinogenesis, mTOR signaling pathway, and 
pathways in cancer (Figure 3.2d).  
Discussion 
In this study using 100 mother-infant dyads from the MMIP cohort, we classified the relationship 
between the maternal lipidome at early gestation and delivery with DNA methylation profiles in 
CB leukocytes. An untargeted lipidomics platform quantified almost 600 lipids from a variety of 
lipid classes at M1 and M3. Measuring the maternal lipidome twice during gestation provided 
information on how lipid exposure may influence the infant epigenome based on the stage of 
fetal development. Our results indicate that M3 lysophospholipids with saturated FA tails are 
associated with differential DNA methylation within umbilical CB CpG sites within CpG islands 
and shores. These results highlight the importance of the late gestation maternal lipidome in 
programming the infant epigenome, emphasizing the relevance of specific lipid classes.  
Within the 41 lipid groups, M3 LysoPC-sat and LysoPE-sat were the main maternal lipid groups 
related to differential methylation in CB leukocytes. Most differentially methylated CpG sites 
associated with this lipid fraction were within CpG islands and shores, increasing the likelihood 
of potential relevance to programming infant gene expression (39). Both LysoPC-sat and 
LysoPE-sat were associated with changes in methylation of genes related to lipid metabolism, 
including increased methylation within the CpG island of DBI, the medium- and long-chain acyl-
CoA ester binding (36). Long-chain fatty acyl-CoAs play a role in a variety of cellular functions 
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(40) and are highly expressed in tissues with active lipid metabolism, such as the liver and 
adipose tissue (41), playing a role in the esterification of long-chain FA into triglycerides and 
phospholipids (42) as well as FA oxidation (43).  
In the DMR analysis, higher M3 LysoPE-sat was associated with increased DNA methylation 
across 13 CpG sites within the CpG island of FKBP11, a gene belonging to a family of FK506 
binding proteins. It has been suggested that FK506 binding proteins play a role in the regulation 
of mechanistic target of rapamycin (mTOR), a master regulator of cell growth (44). The FKBPs-
rapamycin complex binds to mTOR and prevents the binding of mTOR substrates (44). A recent 
study has demonstrated that the FKBP11 encoded protein, FK506-binding protein 11, mediates 
the stimulatory effect of XBP1 on the mTOR, leading to cell growth (45). 
The relevance of individual CpG site associations was determined using pathway analysis. M3 
LysoPC-sat was the only lipid group in maternal plasma with significant pathway enrichment, 
highlighting enriched cell proliferation and ribosomal metabolism/translation (Figure 3.2). 
Recent analyses by our group (LaBarre et al., submitted) have found that LysoPC and LysoPE 
are selectively depleted in maternal plasma at M3 and elevated in CB, suggesting selective 
transfer. We also noted that M1 and M3 LysoPLs, mainly containing saturated FA, are positively 
correlated with total CB LysoPL levels. A recently published study using the CHAMACOS 
cohort measured 92 lipids at ~26 weeks gestation and assessed the relationship between the 
maternal metabolome and DNA methylation in infant CB using the Infinium 450K Bead Chip 
(19). Their metabolomics platform consisted of diglyceride, phosphatidic acid, lysophospholipid, 
monoglyceride, phospholipid, sphingolipid, and triglyceride lipid classes mainly composed of 
FAs tails that are 16:0, 18:0, 18:1, or 20:4. They observed multiple lipids in maternal plasma 
were associated with infant DNA methylation including four phospholipids and four 
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lysophospholipids. They found that out of the 28 significant relationships observed, 22 had 
negative regression coefficients, signifying that increased maternal lipids are associated with 
decreased infant CB methylation. There was no overlap between the statistically significant CpG 
sites or related genes identified between our two analyses, potentially due to differences in the 
maternal metabolome measurement time and the DNA methylation array. In biological pathway 
analysis, the CHAMACOS cohort found significant differentially methylated genes were 
involved in biological pathways such as Huntington disease, pyruvate metabolism, and 
Parkinson disease. Both Huntington disease and Parkinson disease were significantly enriched 
pathways associated with M3 LysoPC-sat in our analysis (Table S3.2). Together with our 
results, these results emphasize the importance of the maternal lysophospholipid fraction in 
establishing the infant epigenome during mid-gestation to late gestation.  
Mechanisms expanding on the influence of maternal lysophospholipids on the infant epigenome 
are not clear. Lysophospholipids are formed from the rapid rearrangement and turnover of 
phospholipids in the cell membrane, known as the Land’s cycle (46). In this pathway, 
phosphatidylcholine in the cell membrane is deacylated by phospholipase A2 (PLA2) forming 
LysoPC (47). Reacylation of LysoPC mediated by lysophosphatidylcholine acyltransferase 
(LPCAT) allows for exchange of the sn-2 fatty acyl group, altering the composition of the 
cellular membrane in response to signals (47). Additionally, phosphatidylcholine is synthesized 
in the liver and secreted as components of very low density lipoprotein (VLDL), releasing 
LysoPCs into circulation by LPCAT (48). Once in the plasma, LysoPCs are bioactive molecules 
with diverse biological functions involved in cell proliferation, as previously demonstrated in 
cancer cells (49,50) and highlighted in our pathway enrichment analysis. Their role as signaling 
molecules may be related to metabolic health, as elevations in plasma LysoPCs have been 
114 
 
observed in obesity (51) and in type 2 diabetic subjects (52). Our previous study identified that 
CB lysophospholipids are positively associated with birth weight. Our results are confirmed by 
other studies demonstrating CB LysoPCs with varying chain length and saturation are positively 
associated with newborn BW (53–55), as well as with weight at age 6 months (53).  
It has been suggested that maternal lysophospholipids may influence the infant epigenome via 
the transport of choline to tissues (19). Choline is shuttled into a variety of pathways including 
acetylcholine synthesis, the production of phosphatidylcholine, and the production of betaine. 
Betaine is a source of methyl groups for the synthesis of methionine, the precursor to the 
principal methylating agent, S-adenosylmethioine. During pregnancy, the dynamics of choline 
metabolism shifts to increase production of phosphatidylcholine via the Kennedy pathway and 
the phosphatidylethanolamine N-methyltransferase pathway (56). Therefore, alterations in the 
levels of maternal lysophospholipids may alter the input of choline into the one carbon 
metabolism pathway, influencing DNA methylation. The discussion of the pregnancy lipidomics 
analysis from the CHAMACOS cohort explores this possibility (19). While lysophospholipids, 
in particular LysoPC, may contribute to methyl group donation for one-carbon metabolism, it is 
unknown why and how differential methylation is occurring in specific genes associated with 
cell proliferation. 
The majority of differentially methylated CpG sites were associated with the M3 lipidome, 
however a few M1 lipid groups were associated with CpG site methylation. Early gestation M1 
PG-mono was positively associated with a CpG site in the open sea of PPARGC1B. Peroxisome 
proliferator-activated receptors (PPAR) and the PPAR gamma co-activator 1 (PGC1) gene 
families have been previously associated with type 2 diabetes risk (57). In addition, the 
methylation of the PPARGC1B locus in peripheral blood cells was found to be inversely 
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associated to adherence to a Mediterranean diet (58), which in turn is associated with higher 
monounsaturated and lower polyunsaturated phospholipid levels (59–61). M1 LysoPC-sat was 
associated with increased methylation in a CpG site located in the shore of MPP5. MPP5 is a 
palmitoylated protein coding gene, which is a scaffolding protein in the outer membrane of 
retinal glial cells (34) and was found to be up-regulated in placenta villus cells of women with 
intrauterine growth retardation and severe preeclampsia (35).  
Previous analyses of the same cohort study (15) used a candidate gene approach to identify 
metabolite-DNA methylation associations in genes related to lipid metabolism and growth. 
Maternal very long-chain FA and acylcarnitines were the most consistently associated with DNA 
methylation. Our current analysis uses different metabolite extraction techniques, which made it 
unlikely to see similarities in the results. Future work will compare the maternal-infant dyads 
targeted metabolite profile to DNA methylation data from the EPIC bead array to identify genes 
related to lipid metabolism and growth with differential methylation.    
Conclusion 
Our findings provide support that the maternal metabolic environment during gestation, in 
particular lysophospholipids, influences the umbilical CB epigenome, potentially regulating gene 
expression. A novelty of this analysis was the incorporation of two ‘omics platforms; an 
untargeted lipidomics platform with measurements across gestation and the EPIC Bead Array. 
Multiple maternal measures across gestation determines how maternal lipids influence fetal 
programming during different periods of gestation. We acknowledge that maternal delivery 
plasma may not be a true reflect of late gestation lipids due to the stress of parturition. Maternal 
samples in this analysis were not fasted, presenting challenges in interpreting the results as the 
epigenome changes in the postprandial state (62). Therefore, infant CB methylation may be a 
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reflection of maternal fasted or fed state, rather than programming. Lastly, we acknowledge that 
CB leukocyte methylation may not be the relevant tissue for risk of cardiometabolic disease and 
additional epigenetic process may also be relevant, such as histone modifications. Future 
analyses will classify gene expression of relevant genes of interest.  
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 Table 3.1. Characteristics of the MMIP cohort (n=100 mother-infant pairs).   
 
  
Categorical variables N(%) 
maternal age  
25-29 25 (25%) 
30-34 54 (54%) 
35-45 21 (21%) 
newborn sex  
male 53 (53%) 
female 47 (47%) 
delivery route  
vaginal 72 (72%) 
caesarean section 28 (28%) 
 Continuous variables mean±SD (N) 
Maternal   
baseline BMI (kg/m²)  25.9±6.1 (97) 
gestational weight gain (kg) 13.2±5.3 
Newborn  
gestational age (days) 278±7 
birth weight (g) 3504±428 
white blood cell count (%)  
CD4+T 15.3.±6.0 
CD8+T 12.5±3.8 
B cells 8.6±3.2 
granulocytes  47.9±8.8 
monocytes 8.8±2.5 




Table 3.2. Number of significant differentially methylated CpG sites in umbilical cord blood 
leukocytes associated with maternal lipid groups. Differentially methylated sites were classified 
fitting linear models using empirical Bayes methodology. Models were adjusted for sex, EPIC 
bead array sample plate, nRBC, and Bcells. Results were adjusted for multiple hypothesis testing 
using the Benjamini-Hochberg method with an FDR threshold for significance of 0.05. Results 
reported as the number of CpG sites with significant differential methylation with M1 and M3 
lipid groups. Significant site counts are stratified by "Increased" methylation (in red) and 
"Decreased" methylation (in green).  
Lipid Cluster 
Maternal First Trimester (M1) Maternal Term (M3) 
Decreased Increased Decreased Increased 
AcylCN 0 0 0 0 
CE 0 0 0 0 
CE-poly 0 0 0 0 
CER-sat 0 0 0 0 
CER-mono 0 0 0 0 
CER-poly 0 0 0 0 
DG-sat 0 0 0 0 
DG-mono 0 0 0 0 
DG-poly 0 0 0 0 
FFA-sat 0 0 0 0 
FFA-mono 0 0 0 0 
FFA-poly 0 0 0 0 
GlcCer 0 0 0 0 
LysoPC-sat 0 1 2 43 
LysoPC-mono 0 0 0 0 
LysoPC-poly 0 0 0 1 
LysoPE-sat 0 0 0 18 
LysoPE-poly 0 0 0 0 
PC-sat 0 0 0 0 
PC-mono 0 0 0 0 
PC-poly 0 0 0 0 
PE-sat 0 0 0 0 
PE-mono 0 0 0 0 
PE-poly 0 0 0 0 
PG-sat 0 0 0 0 
PG-mono 0 3 0 0 
PI-sat 0 0 0 0 
PI-mono 0 0 0 0 
PI-poly 0 0 0 0 
PLPC-sat 0 0 0 0 
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PLPC-mono 0 0 0 0 
PLPC-poly 0 0 0 0 
PLPE-sat 0 0 0 0 
PLPE-mono 0 0 0 0 
PLPE-poly 0 0 0 0 
SM-sat 0 0 0 0 
SM-mono 0 0 0 0 
SM-poly 0 0 0 0 
TG-sat 0 0 0 0 
TG-mono 0 0 0 0 





Table 3.3. Classification of significant differentially methylated CpG sites in umbilical cord 
blood leukocytes associated with maternal lipid groups. Differentially methylated sitres were 
identified by fitting linear models using empirical Bayes methodology. Models were adjusted for 
sex, EPIC bead array sample plate, nRBC, and Bcells. Directionality indicated by log fold 
change. Results were adjusted for multiple hypothesis testing using the Benjamini-Hochberg 
method with an FDR threshold for significance of 0.05. The CpG site, chromosomal location, 
related gene, and relation to any CpG Island is reported. 
time 
point 







M1 LysoPC sat M1 cg07218192 chr14 MPP5 N-Shore 0.1196 0.0127 
M1 PG mono M1 cg24968215 chr5 PPARGC1B Open Sea 0.1717 0.0415 
M1 PG mono M1 cg14930059 chr3 TTC14 Island 0.1526 0.0415 
M1 PG mono M1 ch.19.23069863R chr19  Open Sea 0.3117 0.0415 
M3 LysoPC poly M3 cg01779447 chr6 IFITM4P N-Shore 0.1682 0.0122 
M3 LysoPC sat M3 cg15749322 chr11 ANKRD42 Island 0.3409 0.0471 
M3 LysoPC sat M3 cg14103143 chr17 ATP5G1 Island 0.2758 0.0471 
M3 LysoPC sat M3 cg21598517 chr19 B9D2 Island 0.1423 0.0471 
M3 LysoPC sat M3 cg00598747 chr19 B9D2 Island 0.1547 0.0471 
M3 LysoPC sat M3 cg19575351 chr6 C6orf141 Island 0.1247 0.0471 
M3 LysoPC sat M3 cg01382153 chr2 CCDC108 Island 0.1795 0.0471 
M3 LysoPC sat M3 cg11075121 chr12 COQ5 S-Shore 0.1683 0.0484 
M3 LysoPC sat M3 cg04410024 chr8 CRISPLD1 Island 0.1721 0.0471 
M3 LysoPC sat M3 cg02325290 chr2 DBI Island 0.1483 0.0471 
M3 LysoPC sat M3 cg01813748 chr18 DLGAP1-AS2 Open Sea 0.1760 0.0471 
M3 LysoPC sat M3 cg12709907 chr17 EFTUD2 Island 0.1664 0.0471 
M3 LysoPC sat M3 cg18071809 chr19 EID2B Island 0.1773 0.0471 
M3 LysoPC sat M3 cg22045228 chr2 ELMOD3 Island 0.1951 0.0471 
M3 LysoPC sat M3 cg01974100 chr14 FAM179B N-Shore 0.1529 0.0471 
M3 LysoPC sat M3 cg11509404 chr9 GABBR2 Island 0.2466 0.0471 
M3 LysoPC sat M3 cg07070542 chr7 GARS Island 0.1816 0.0471 
M3 LysoPC sat M3 cg15485323 chr6 HIST1H1D Open Sea 0.1722 0.0471 
M3 LysoPC sat M3 cg19060382 chr12 LOC253724 S-Shore 0.2293 0.0471 
M3 LysoPC sat M3 cg17434483 chr19 LOC729991-MEF2B S-Shore 0.1403 0.0471 
M3 LysoPC sat M3 cg25172519 chr6 MOXD1 Island 0.1668 0.0471 
M3 LysoPC sat M3 cg17775912 chr14 MTHFD1 Island 0.1542 0.0471 
M3 LysoPC sat M3 cg10326891 chr4 NUDT9 Island 0.2125 0.0471 
M3 LysoPC sat M3 cg21001214 chr12 PA2G4 Island 0.2869 0.0471 
M3 LysoPC sat M3 cg26431298 chr1 PRCC Island 0.2911 0.0496 
M3 LysoPC sat M3 cg17537899 chr3 RPL22L1 S-Shore 0.1982 0.0471 
M3 LysoPC sat M3 cg22842064 chr3 RPL22L1 Island 0.1667 0.0471 
M3 LysoPC sat M3 cg16696730 chr21 RSPH1 Island 0.2097 0.0471 
M3 LysoPC sat M3 cg19049809 chr17 SFRS1 S-Shore 0.1779 0.0471 
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M3 LysoPC sat M3 cg22398523 chr1 SH3BP5L Island 0.1501 0.0471 
M3 LysoPC sat M3 cg04696559 chr5 SKP2 Island 0.2191 0.0471 
M3 LysoPC sat M3 cg23013931 chr22 SLC25A17 N-Shore 0.1928 0.0471 
M3 LysoPC sat M3 cg23010414 chr17 SLFN5 Island 0.1801 0.0496 
M3 LysoPC sat M3 cg21151651 chr11 SPTY2D1 Island 0.2286 0.0471 
M3 LysoPC sat M3 cg25781123 chr3 THUMPD3 N-Shore 0.3710 0.0471 
M3 LysoPC sat M3 cg14210275 chr17 TMEM107 Island 0.1611 0.0471 
M3 LysoPC sat M3 cg14345069 chr4 UFSP2 Island 0.1598 0.0471 
M3 LysoPC sat M3 cg06356912 chr3 VILL N-Shore 0.2237 0.0471 
M3 LysoPC sat M3 cg21665057 chr3 WDR53 Island 0.1210 0.0471 
M3 LysoPC sat M3 cg22720041 chr19 ZNF229 Island 0.1516 0.0471 
M3 LysoPC sat M3 cg13468174 chr19 ZNF584 Island 0.1577 0.0471 
M3 LysoPC sat M3 cg17618194 chr7 ZNHIT1 S-Shore 0.2626 0.0471 
M3 LysoPC sat M3 ch.16.79494380F chr16  Open Sea 0.2426 0.0471 
M3 LysoPC sat M3 cg14205309 chr11  Open Sea -0.1555 0.0471 
M3 LysoPC sat M3 ch.4.74730522R chr4  Open Sea 0.1787 0.0471 
M3 LysoPC sat M3 cg26809926 chr7  Open Sea -0.1877 0.0471 
M3 LysoPE sat M3 cg08265188 chr12 ALG10 Island 0.5586 0.0338 
M3 LysoPE sat M3 cg22664986 chr11 ANKRD42 Island 0.2278 0.0364 
M3 LysoPE sat M3 cg12013332 chr12 BBS10 Island 0.2183 0.0338 
M3 LysoPE sat M3 cg12792102 chr5 BNIP1 Open Sea 0.2675 0.0364 
M3 LysoPE sat M3 cg19889500 chr14 DAD1 N-Shore 0.2409 0.0364 
M3 LysoPE sat M3 cg02325290 chr2 DBI Island 0.1488 0.0364 
M3 LysoPE sat M3 cg15485323 chr6 HIST1H1D Open Sea 0.1728 0.0364 
M3 LysoPE sat M3 cg16666115 chr6 MRPS18A S-Shore 0.1484 0.0338 
M3 LysoPE sat M3 cg16875280 chr19 OPA3 N-Shore 0.2928 0.0338 
M3 LysoPE sat M3 cg09367970 chr12 RAD51AP1 Island 0.1812 0.0338 
M3 LysoPE sat M3 cg04895581 chr8 RBM12B Island 0.2021 0.0372 
M3 LysoPE sat M3 cg05250654 chr2 RPS7 Island 0.2713 0.0364 
M3 LysoPE sat M3 cg16990505 chr14 SDCCAG1 S-Shore 0.1843 0.0364 
M3 LysoPE sat M3 cg23010414 chr17 SLFN5 Island 0.1969 0.0338 
M3 LysoPE sat M3 cg13045611 chr17 SUPT6H S-Shore 0.1908 0.0033 
M3 LysoPE sat M3 cg23093590 chr15  Island 0.2768 0.0338 
M3 LysoPE sat M3 cg07602492 chr1  S-Shore 0.1654 0.0364 




Table 3.4. Classification of differentially methylated regions in umbilical cord blood leukocytes 
associated with maternal lipid groups. Directionality indicated by βmax and βmin fold change. 
Significance denoted by a Stouffer p-value <0.05. Chromosome coordinates, number of 
differential CpG sites in the region, and related gene are reported.   
time 
point 














Figure 3.1. Maternal term saturated lysophospholipids are associated with differential DNA 
methylation in promoter regions of infant leukocyte genes. 
 
Differentially methylated CpG sites were classified fitting linear models using empirical Bayes 
methodology. Models were adjusted for sex, EPIC bead array sample plate, nRBC, and Bcells. 
Represented by Manhattan plots, (A) 45 CpG sites were significantly related to M3 LysoPC-sat 
and (B) 18 CpG probes were significantly related to M3 LysoPE-sat (FDR<0.05). Blue line 
signifies p-value=1e-5. Red line signifies p-value=6e-8. Differentially methylated CpG probes 
were classified by genomic location. Percentage of statistically significant CpG sites within the 
CpG Island, shore, shelf, and open sea reported for association with (C) M3 LysoPC-sat and (D) 





Figure S3.1. Maternal term saturated lysophospholipid levels are associated with differential 
DNA methylation within the CpG Island of Diazepam Binding Inhibitor, Acyl-CoA Binding 
Protein (DBI). 
 
Differentially methylated CpG sites were classified fitting linear models using empirical Bayes 
methodology. Models were adjusted for sex, EPIC bead array sample plate, nRBC, and Bcells. 
Both (A) M3 LysoPC-sat (logFC=0.15, FDR=0.047) and (B) M3 LysoPE-sat (logFC=0.15, 
FDR=0.036) are positively associated with methylation at a loci (probe ID cg02325290), residing 
within the CpG island of DBI. Relationship between proportion of DNA methylation at the site 




Table S3.1. Enriched gene ontologies (GO) from differentially methylated sites associated with 
M3 LysoPC-sat. Differentially methylated sites (FDR<0.1) were selected for pathway analysis. 
Gene ontologies are classified as "biological processes" (BP), "cellular component" (CC), or 
"molecular function" (MF). The number of genes within each pathway (N) and the number of 
genes differentially methylated (DE) are reported. Enriched pathways listed have an FDR<0.05. 
Gene 
Ontology ID 






GO:0005515 MF protein binding 9664 5966 80.300 2.87E-85 5.01E-81 
GO:0005654 CC nucleoplasm 3123 2179 69.100 9.09E-74 7.94E-70 
GO:0005829 CC cytosol 4871 3139 49.389 7.00E-54 4.08E-50 
GO:0005634 CC nucleus 4561 2861 44.915 2.78E-49 1.21E-45 
GO:0003723 MF RNA binding 1334 961 42.583 7.46E-47 2.61E-43 
GO:0005739 CC mitochondrion 1106 745 20.846 4.90E-25 1.43E-21 
GO:0005813 CC centrosome 447 348 17.969 4.30E-22 1.07E-18 
GO:0005737 CC cytoplasm 3433 2098 17.718 8.77E-22 1.92E-18 
GO:0003677 MF DNA binding 1329 831 11.979 5.41E-16 1.05E-12 
GO:0016020 CC membrane 1853 1185 11.468 1.95E-15 3.40E-12 
GO:0000981 MF 
DNA-binding transcription factor 
activity, RNA polymerase II-specific 
1537 967 10.698 1.26E-14 2.00E-11 
GO:0051301 BP cell division 344 256 10.138 5.00E-14 7.28E-11 
GO:0005743 CC mitochondrial inner membrane 383 255 8.339 3.41E-12 4.58E-09 
GO:0006357 BP 
regulation of transcription by RNA 
polymerase II 
917 575 7.818 1.22E-11 1.52E-08 
GO:0019901 MF protein kinase binding 401 292 7.370 3.67E-11 4.26E-08 
GO:0000122 BP 
negative regulation of transcription by 
RNA polymerase II 
707 481 7.370 3.90E-11 4.26E-08 
GO:0016607 CC nuclear speck 386 275 6.946 1.10E-10 1.13E-07 
GO:0045893 BP 
positive regulation of transcription, 
DNA-templated 
535 372 6.826 1.59E-10 1.49E-07 
GO:0046872 MF metal ion binding 2267 1352 6.826 1.62E-10 1.49E-07 
GO:0016032 BP viral process 366 259 6.491 3.70E-10 3.23E-07 
GO:0006412 BP translation 165 117 6.278 6.34E-10 5.27E-07 
GO:0006614 BP 
SRP-dependent cotranslational protein 
targeting to membrane 
89 70 6.143 9.07E-10 7.20E-07 
GO:0005524 MF ATP binding 1451 930 6.039 1.23E-09 9.14E-07 
GO:0048471 CC perinuclear region of cytoplasm 684 455 6.039 1.25E-09 9.14E-07 
GO:0008022 MF protein C-terminus binding 186 145 5.689 2.93E-09 2.05E-06 
GO:0016567 BP protein ubiquitination 419 286 5.632 3.47E-09 2.33E-06 
GO:0032991 CC protein-containing complex 592 389 5.539 4.46E-09 2.89E-06 
GO:0000398 BP mRNA splicing, via spliceosome 224 162 5.461 5.54E-09 3.46E-06 
GO:0000184 BP 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 
115 87 5.255 9.23E-09 5.56E-06 




positive regulation of transcription by 
RNA polymerase II 
975 624 5.038 1.64E-08 9.17E-06 
GO:0045892 BP 
negative regulation of transcription, 
DNA-templated 
485 323 5.038 1.68E-08 9.17E-06 
GO:0045296 MF cadherin binding 280 205 5.025 1.90E-08 9.43E-06 
GO:0001650 CC fibrillar center 131 105 5.025 1.90E-08 9.43E-06 
GO:0005925 CC focal adhesion 397 281 5.025 1.93E-08 9.43E-06 
GO:0006413 BP translational initiation 130 95 5.025 1.94E-08 9.43E-06 
GO:0000790 CC nuclear chromatin 167 128 4.720 4.03E-08 1.91E-05 
GO:0043161 BP 
proteasome-mediated ubiquitin-
dependent protein catabolic process 
133 105 4.659 4.81E-08 2.19E-05 
GO:0006366 BP transcription by RNA polymerase II 266 187 4.659 4.89E-08 2.19E-05 
GO:0016604 CC nuclear body 277 198 4.625 5.45E-08 2.37E-05 
GO:0008134 MF transcription factor binding 264 192 4.625 5.56E-08 2.37E-05 
GO:0006260 BP DNA replication 129 102 4.604 5.98E-08 2.49E-05 
GO:0019899 MF enzyme binding 345 238 4.517 7.64E-08 3.04E-05 
GO:0003735 MF structural constituent of ribosome 157 91 4.517 7.66E-08 3.04E-05 
GO:0005759 CC mitochondrial matrix 349 234 4.513 7.91E-08 3.07E-05 
GO:0005783 CC endoplasmic reticulum 850 524 4.455 9.23E-08 3.51E-05 
GO:0070125 BP mitochondrial translational elongation 86 66 4.370 1.15E-07 4.26E-05 
GO:0070126 BP mitochondrial translational termination 88 67 4.212 1.72E-07 6.14E-05 
GO:0006974 BP 
cellular response to DNA damage 
stimulus 
224 163 4.212 1.72E-07 6.14E-05 
GO:0003700 MF 
DNA-binding transcription factor 
activity 




579 379 4.074 2.46E-07 8.42E-05 
GO:0019083 BP viral transcription 109 79 4.003 2.95E-07 9.93E-05 
GO:0000086 BP G2/M transition of mitotic cell cycle 126 98 3.935 3.52E-07 1.16E-04 
GO:0001843 BP neural tube closure 76 65 3.870 4.16E-07 1.35E-04 
GO:0031965 CC nuclear membrane 234 167 3.752 5.57E-07 1.77E-04 
GO:0097711 BP 
ciliary basal body-plasma membrane 
docking 
95 76 3.614 7.80E-07 2.43E-04 
GO:1901796 BP 
regulation of signal transduction by p53 
class mediator 
131 101 3.600 8.18E-07 2.51E-04 
GO:0008380 BP RNA splicing 143 106 3.265 1.82E-06 5.43E-04 
GO:0006977 BP 
DNA damage response, signal 
transduction by p53 class mediator 
resulting in cell cycle arrest 
56 49 3.265 1.83E-06 5.43E-04 
GO:1901990 BP 
regulation of mitotic cell cycle phase 
transition 
80 65 3.243 1.96E-06 5.71E-04 
GO:0019904 MF protein domain specific binding 255 178 2.929 4.11E-06 1.18E-03 
GO:0022625 CC cytosolic large ribosomal subunit 52 40 2.909 4.37E-06 1.23E-03 
GO:0006511 BP 
ubiquitin-dependent protein catabolic 
process 
208 143 2.874 4.82E-06 1.34E-03 





dependent catabolic process 
81 63 2.742 6.73E-06 1.81E-03 
GO:0007049 BP cell cycle 248 170 2.683 7.88E-06 2.07E-03 
GO:0006397 BP mRNA processing 147 105 2.683 7.95E-06 2.07E-03 
GO:0004842 MF ubiquitin-protein transferase activity 224 158 2.671 8.30E-06 2.13E-03 
GO:0006364 BP rRNA processing 124 86 2.638 9.08E-06 2.30E-03 
GO:0044877 MF protein-containing complex binding 256 176 2.581 1.05E-05 2.62E-03 
GO:0060071 BP 
Wnt signaling pathway, planar cell 
polarity pathway 
88 70 2.563 1.11E-05 2.73E-03 
GO:0016579 BP protein deubiquitination 236 163 2.562 1.13E-05 2.74E-03 
GO:0003713 MF transcription coactivator activity 261 180 2.482 1.38E-05 3.30E-03 
GO:0000209 BP protein polyubiquitination 206 143 2.439 1.54E-05 3.64E-03 
GO:0006351 BP transcription, DNA-templated 101 77 2.421 1.64E-05 3.79E-03 
GO:0031625 MF ubiquitin protein ligase binding 270 187 2.421 1.65E-05 3.79E-03 
GO:0016363 CC nuclear matrix 106 82 2.375 1.86E-05 4.22E-03 
GO:0047485 MF protein N-terminus binding 106 81 2.333 2.07E-05 4.64E-03 
GO:0000978 MF 
RNA polymerase II proximal promoter 
sequence-specific DNA binding 
379 254 2.317 2.18E-05 4.81E-03 
GO:0005839 CC proteasome core complex 18 18 2.301 2.29E-05 5.00E-03 
GO:0005794 CC Golgi apparatus 820 514 2.299 2.33E-05 5.02E-03 
GO:0071013 CC catalytic step 2 spliceosome 80 62 2.299 2.35E-05 5.02E-03 
GO:0043488 BP regulation of mRNA stability 106 79 2.265 2.58E-05 5.44E-03 
GO:0035735 BP 
intraciliary transport involved in cilium 
assembly 
40 35 2.231 2.83E-05 5.88E-03 
GO:0043066 BP 
negative regulation of apoptotic 
process 
488 301 2.185 3.17E-05 6.53E-03 
GO:0005814 CC centriole 124 91 2.175 3.29E-05 6.68E-03 
GO:0030496 CC midbody 154 111 2.162 3.43E-05 6.88E-03 
GO:0048013 BP ephrin receptor signaling pathway 85 69 2.097 4.02E-05 7.99E-03 
GO:0006281 BP DNA repair 194 132 2.094 4.10E-05 8.06E-03 
GO:0005819 CC spindle 114 85 2.083 4.26E-05 8.27E-03 
GO:0005929 CC cilium 187 130 2.081 4.33E-05 8.30E-03 
GO:0042645 CC mitochondrial nucleoid 42 35 2.081 4.37E-05 8.30E-03 
GO:0030332 MF cyclin binding 28 26 2.060 4.64E-05 8.72E-03 
GO:0016236 BP macroautophagy 90 69 2.029 5.03E-05 9.36E-03 
GO:0006302 BP double-strand break repair 54 45 2.008 5.33E-05 9.81E-03 
GO:0006890 BP 
retrograde vesicle-mediated transport, 
Golgi to ER 
74 58 2.008 5.40E-05 9.83E-03 
GO:0051087 MF chaperone binding 91 68 2.002 5.53E-05 9.96E-03 
GO:0000278 BP mitotic cell cycle 90 69 1.993 5.69E-05 1.02E-02 
GO:0042802 MF identical protein binding 1041 626 1.979 5.95E-05 1.05E-02 
GO:0000922 CC spindle pole 112 84 1.970 6.13E-05 1.07E-02 
GO:0031146 BP 
SCF-dependent proteasomal ubiquitin-
dependent protein catabolic process 
68 54 1.944 6.58E-05 1.14E-02 
GO:0000139 CC Golgi membrane 585 372 1.895 7.43E-05 1.27E-02 
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GO:0006915 BP apoptotic process 538 333 1.895 7.50E-05 1.27E-02 
GO:0006468 BP protein phosphorylation 434 288 1.872 7.98E-05 1.34E-02 
GO:0016055 BP Wnt signaling pathway 179 129 1.870 8.10E-05 1.35E-02 
GO:0072686 CC mitotic spindle 66 52 1.859 8.39E-05 1.38E-02 
GO:0046982 MF protein heterodimerization activity 497 299 1.838 8.89E-05 1.45E-02 
GO:0017148 BP negative regulation of translation 61 48 1.811 9.55E-05 1.55E-02 
GO:0035035 MF histone acetyltransferase binding 26 24 1.792 1.01E-04 1.62E-02 
GO:0042795 BP 
snRNA transcription by RNA polymerase 
II 
70 53 1.755 1.11E-04 1.76E-02 
GO:0061418 BP 
regulation of transcription from RNA 
polymerase II promoter in response to 
hypoxia 
71 54 1.755 1.12E-04 1.76E-02 
GO:0000049 MF tRNA binding 47 39 1.720 1.22E-04 1.91E-02 
GO:0060271 BP cilium assembly 152 109 1.716 1.24E-04 1.92E-02 
GO:0005763 CC mitochondrial small ribosomal subunit 27 24 1.699 1.30E-04 2.00E-02 
GO:0003682 MF chromatin binding 326 215 1.633 1.53E-04 2.33E-02 
GO:0000781 CC chromosome, telomeric region 50 41 1.608 1.64E-04 2.46E-02 
GO:0006521 BP 
regulation of cellular amino acid 
metabolic process 
51 40 1.571 1.80E-04 2.69E-02 
GO:0006367 BP 
transcription initiation from RNA 
polymerase II promoter 
161 113 1.565 1.84E-04 2.72E-02 
GO:0071364 BP 
cellular response to epidermal growth 
factor stimulus 
43 37 1.559 1.88E-04 2.76E-02 
GO:0021766 BP hippocampus development 63 50 1.555 1.91E-04 2.79E-02 
GO:0005694 CC chromosome 113 81 1.520 2.11E-04 3.02E-02 
GO:0043065 BP positive regulation of apoptotic process 331 214 1.520 2.12E-04 3.02E-02 
GO:0006368 BP 
transcription elongation from RNA 
polymerase II promoter 
69 52 1.520 2.13E-04 3.02E-02 
GO:0005762 CC mitochondrial large ribosomal subunit 55 39 1.493 2.28E-04 3.21E-02 
GO:0014069 CC postsynaptic density 222 155 1.487 2.33E-04 3.26E-02 
GO:0000281 BP mitotic cytokinesis 48 39 1.473 2.43E-04 3.36E-02 
GO:0090090 BP 
negative regulation of canonical Wnt 
signaling pathway 
166 115 1.450 2.58E-04 3.54E-02 
GO:0005789 CC endoplasmic reticulum membrane 872 516 1.427 2.74E-04 3.74E-02 
GO:0000151 CC ubiquitin ligase complex 89 67 1.425 2.79E-04 3.76E-02 
GO:0005815 CC microtubule organizing center 142 102 1.425 2.82E-04 3.76E-02 
GO:0015630 CC microtubule cytoskeleton 122 88 1.425 2.83E-04 3.76E-02 
GO:1902036 BP 
regulation of hematopoietic stem cell 
differentiation 
68 53 1.425 2.84E-04 3.76E-02 
GO:0010389 BP 
regulation of G2/M transition of mitotic 
cell cycle 
79 59 1.422 2.88E-04 3.78E-02 
GO:0004672 MF protein kinase activity 186 130 1.422 2.90E-04 3.79E-02 
GO:0030426 CC growth cone 124 91 1.407 3.03E-04 3.92E-02 
GO:0001701 BP in utero embryonic development 168 118 1.378 3.26E-04 4.19E-02 
GO:0008284 BP positive regulation of cell proliferation 482 287 1.355 3.46E-04 4.42E-02 
GO:0030027 CC lamellipodium 175 124 1.347 3.56E-04 4.50E-02 
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GO:0042393 MF histone binding 99 73 1.346 3.58E-04 4.51E-02 
GO:0071889 MF 14-3-3 protein binding 30 27 1.346 3.61E-04 4.51E-02 
GO:0006888 BP ER to Golgi vesicle-mediated transport 144 100 1.320 3.86E-04 4.79E-02 




Table S3.2. Enriched KEGG pathways from differentially methylated sites associated with M3 
LysoPC-sat. Differentially methylated sites (FDR<0.1) within known genes were selected for 
pathway analysis. The number of genes within each pathway (N) and the number of genes 
differentially methylated (DE) are reported. Enriched pathways listed have an FDR<0.05. 






path:hsa04110 Cell cycle 124 102 7.004 2.95E-10 9.92E-08 
path:hsa03010 Ribosome 153 99 5.463 2.05E-08 3.45E-06 
path:hsa05165 Human papillomavirus infection 330 229 4.578 2.36E-07 2.64E-05 
path:hsa05203 Viral carcinogenesis 201 139 4.091 9.66E-07 8.12E-05 
path:hsa04150 mTOR signaling pathway 153 116 4.068 1.27E-06 8.56E-05 
path:hsa05200 Pathways in cancer 531 346 3.960 1.96E-06 1.10E-04 
path:hsa04218 Cellular senescence 160 118 3.741 3.78E-06 1.82E-04 
path:hsa03040 Spliceosome 135 97 3.704 4.71E-06 1.98E-04 
path:hsa04390 Hippo signaling pathway 154 116 3.572 7.18E-06 2.68E-04 
path:hsa04714 Thermogenesis 231 149 3.369 1.27E-05 4.28E-04 
path:hsa04144 Endocytosis 249 175 3.334 1.68E-05 4.64E-04 
path:hsa05220 Chronic myeloid leukemia 76 63 3.334 1.70E-05 4.64E-04 
path:hsa05205 Proteoglycans in cancer 204 147 3.334 1.79E-05 4.64E-04 
path:hsa05223 Non-small cell lung cancer 66 56 3.273 2.22E-05 5.34E-04 
path:hsa01100 Metabolic pathways 1487 861 3.266 2.42E-05 5.42E-04 
path:hsa04120 Ubiquitin mediated proteolysis 136 99 2.765 8.63E-05 1.72E-03 
path:hsa05222 Small cell lung cancer 92 72 2.765 8.69E-05 1.72E-03 
path:hsa05100 Bacterial invasion of epithelial cells 73 59 2.588 1.38E-04 2.58E-03 
path:hsa05010 Alzheimer disease 171 112 2.330 2.64E-04 4.68E-03 
path:hsa05016 Huntington disease 193 124 2.287 3.13E-04 5.17E-03 
path:hsa05163 Human cytomegalovirus infection 225 146 2.287 3.23E-04 5.17E-03 
path:hsa05034 Alcoholism 184 110 2.269 3.53E-04 5.38E-03 
path:hsa05225 Hepatocellular carcinoma 168 117 2.239 3.95E-04 5.77E-03 
path:hsa05226 Gastric cancer 149 106 2.213 4.37E-04 6.12E-03 
path:hsa03060 Protein export 23 21 2.169 5.05E-04 6.78E-03 
path:hsa04210 Apoptosis 136 94 2.148 5.65E-04 7.11E-03 
path:hsa05217 Basal cell carcinoma 63 50 2.148 5.71E-04 7.11E-03 
path:hsa04934 Cushing syndrome 155 109 2.105 6.54E-04 7.85E-03 
path:hsa05167 Kaposi sarcoma-associated herpesvirus infection 186 121 2.076 7.33E-04 8.40E-03 
path:hsa04330 Notch signaling pathway 53 42 2.076 7.50E-04 8.40E-03 
path:hsa05212 Pancreatic cancer 76 58 2.043 8.50E-04 9.05E-03 
path:hsa05224 Breast cancer 147 104 2.043 8.86E-04 9.05E-03 
path:hsa04115 p53 signaling pathway 72 55 2.043 8.89E-04 9.05E-03 
path:hsa05166 Human T-cell leukemia virus 1 infection 219 147 2.039 9.25E-04 9.14E-03 
path:hsa04140 Autophagy - animal 137 96 1.984 1.08E-03 1.04E-02 
path:hsa05215 Prostate cancer 97 71 1.930 1.26E-03 1.17E-02 
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path:hsa05161 Hepatitis B 162 107 1.834 1.61E-03 1.46E-02 
path:hsa04141 Protein processing in endoplasmic reticulum 166 111 1.760 1.96E-03 1.74E-02 
path:hsa00510 N-Glycan biosynthesis 50 39 1.740 2.21E-03 1.82E-02 
path:hsa05216 Thyroid cancer 37 30 1.740 2.22E-03 1.82E-02 
path:hsa05211 Renal cell carcinoma 69 53 1.740 2.23E-03 1.82E-02 
path:hsa00514 Other types of O-glycan biosynthesis 23 20 1.740 2.27E-03 1.82E-02 
path:hsa05213 Endometrial cancer 58 46 1.734 2.36E-03 1.84E-02 
path:hsa05202 Transcriptional misregulation in cancer 186 121 1.705 2.64E-03 1.97E-02 
path:hsa01521 EGFR tyrosine kinase inhibitor resistance 79 59 1.705 2.70E-03 1.97E-02 
path:hsa00190 Oxidative phosphorylation 133 78 1.705 2.71E-03 1.97E-02 
path:hsa04919 Thyroid hormone signaling pathway 119 85 1.705 2.80E-03 1.97E-02 
path:hsa03460 Fanconi anemia pathway 54 40 1.705 2.82E-03 1.97E-02 
path:hsa03013 RNA transport 165 101 1.704 2.88E-03 1.98E-02 
path:hsa05210 Colorectal cancer 86 63 1.638 3.42E-03 2.30E-02 
path:hsa04010 MAPK signaling pathway 295 192 1.612 3.76E-03 2.44E-02 
path:hsa04211 Longevity regulating pathway 89 64 1.612 3.78E-03 2.44E-02 
path:hsa01524 Platinum drug resistance 73 51 1.587 4.08E-03 2.59E-02 
path:hsa04520 Adherens junction 71 54 1.582 4.21E-03 2.62E-02 
path:hsa04722 Neurotrophin signaling pathway 119 84 1.576 4.36E-03 2.65E-02 
path:hsa01212 Fatty acid metabolism 57 43 1.576 4.42E-03 2.65E-02 
path:hsa05012 Parkinson disease 142 84 1.576 4.51E-03 2.66E-02 
path:hsa04068 FoxO signaling pathway 131 88 1.540 5.02E-03 2.88E-02 
path:hsa03440 Homologous recombination 41 32 1.540 5.12E-03 2.88E-02 
path:hsa03050 Proteasome 45 34 1.540 5.14E-03 2.88E-02 
path:hsa03008 Ribosome biogenesis in eukaryotes 105 55 1.498 5.77E-03 3.18E-02 
path:hsa04932 Non-alcoholic fatty liver disease (NAFLD) 149 93 1.489 5.98E-03 3.24E-02 
path:hsa04916 Melanogenesis 101 71 1.485 6.13E-03 3.27E-02 
path:hsa04070 Phosphatidylinositol signaling system 99 70 1.483 6.27E-03 3.29E-02 
path:hsa03018 RNA degradation 79 53 1.413 7.48E-03 3.87E-02 
path:hsa00513 Various types of N-glycan biosynthesis 39 31 1.406 7.72E-03 3.93E-02 
path:hsa04152 AMPK signaling pathway 120 82 1.393 8.07E-03 4.04E-02 
path:hsa05214 Glioma 75 55 1.381 8.45E-03 4.16E-02 
path:hsa03030 DNA replication 36 27 1.381 8.55E-03 4.16E-02 
path:hsa04728 Dopaminergic synapse 131 88 1.347 9.46E-03 4.50E-02 
path:hsa00280 Valine, leucine and isoleucine degradation 48 36 1.347 9.57E-03 4.50E-02 
path:hsa04725 Cholinergic synapse 112 77 1.347 9.64E-03 4.50E-02 
path:hsa00640 Propanoate metabolism 34 26 1.345 9.81E-03 4.52E-02 
path:hsa00310 Lysine degradation 61 45 1.317 1.06E-02 4.82E-02 
path:hsa03015 mRNA surveillance pathway 91 59 1.303 1.13E-02 4.98E-02 
path:hsa05219 Bladder cancer 41 32 1.303 1.13E-02 4.98E-02 




Figure 3.2. Top 10 significantly enriched gene ontologies and biological pathways associated 
with M3 LysoPC-sat.   
 
Enriched gene ontologies and biological 
pathways were classified by selected 
differentially methylated probes (FDR<0.1) 
associated with M3 LysoPC-sat for pathway 
analysis. Gene ontologies are organized into (A) 
biological processes, (B) cellular components, 
and (C) molecular functions. (D) Biological 
pathways were identified from the KEGG 
database. Fold enrichment values were 
computed using the –log adjusted p-value.   
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CHAPTER 4                                                                                                                                
Evidence for Intrinsic Mitochondrial Nutrient Utilization Underlying the Association 
between Metabolite Levels and Insulin Resistance in Adolescents. 
Abstract 
A person’s intrinsic metabolism, based on underlying physiologic conditions and reflected in the 
metabolome, may describe the relationship between nutrient intake and metabolic health. 
Untargeted metabolomics was used to identify metabolites associated with metabolic health and 
path analysis classified how habitual dietary intake influences BMI z-score (BMIz) and insulin 
resistance (IR) through changes in the metabolome among 108 girls and 98 boys aged 8-14 
years. Data on anthropometry, fasting metabolites, C-peptide, and dietary intake (via a semi-
quantitative food frequency questionnaire) were collected from adolescents in the Early Life 
Exposure in Mexico to ENvironmental Toxicants (ELEMENT) birth cohort. Sex-stratified linear 
regression identified metabolites associated BMIz and homeostatic model assessment of insulin 
resistance using C-peptide (HOMA-CP), accounting for puberty, age and muscle and fat area. 
Path analysis identified clusters of metabolites that underlie the relationship between energy-
adjusted macronutrient intake with BMIz and HOMA-CP. Metabolites associated with BMIz 
include positive associations with diglycerides among girls and positive associations with 
branched chain and aromatic amino acids in boys. Intermediates in fatty acid metabolism, 
including medium-chain acylcarnitines (AC), were inversely associated with HOMA-CP. No 
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direct relationship was observed between macronutrient intake with BMIz and IR. Carbohydrate 
intake is positively associated with HOMA-CP through decreases in levels of AC, products of β-
oxidation. Approaching significance, fat intake is positively associated with HOMA-CP through 
increases in levels of dicarboxylic fatty acids (DiC-FA), products of omega-oxidation. This 
cross-sectional analysis suggests that IR in children is associated with reduced fatty acid 
oxidation capacity. When consuming more grams of fat, there is evidence for increased extra-
mitochondrial fatty acid metabolism, while higher carbohydrate intake appears to lead to 
decreases in intermediates of β-oxidation. Thus, biomarkers of IR and mitochondrial oxidative 
capacity may depend on macronutrient intake.  
Introduction 
Obesity rates are increasing in the pediatric population in both developed and developing 
countries (1), accompanied by an increased prevalence of prediabetes and type 2 diabetes (T2D) 
(2). With recent advancements in analytical technologies, the profiling of small molecular weight 
intermediates in metabolism through metabolomics has been used to identify biomarkers and 
potential pathways associated with obesity and insulin resistance (IR). Branched chain amino 
acids (BCAA) and their short-chain acylcarnitine (AC) metabolites, propionylcarnitine and 
butyrylcarnitine, have been consistently increased in obese adolescents (3–5). However, studies 
are inconsistent regarding the relationship between BCAA and IR in adolescents with findings 
reporting positive associations (3–5), inverse associations (6), and sex differences (7–9) which 
may be due to differences in analytical methodologies as well as the variability in the size and 
characteristic in study populations. Some metabolomics analyses in youth have also identified 
divergent associations of metabolite levels and metabolic phenotypes compared to those 
observed in adults. In contrast to adults, fatty acids (FA) were not associated with BMI or IR at 
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15 years of age (10,11). Additionally, lower levels of fatty acid oxidation (FAO) intermediates, 
such as dicarboxylic fatty acids (DiC-FA) (4) and medium-chain AC (6), were reported in 
children with T2D and obesity. These results suggest less imbalance in the delivery and 
oxidation of substrates in these individuals, perhaps due to the increased substrate utilization to 
fuel tissue and linear growth in the pubertal period.   
The effect of macronutrient intake on metabolic health remains controversial with previous 
analyses describing a relationship between amount of macronutrient consumed and metabolic 
outcomes (12), while other analyses suggesting no relationship (13–15). Discrepancies in the 
results from these studies motivated us to identify molecular mechanisms, via classifying 
patterns of metabolites, which indicate how habitual diet relates to metabolic health. The ability 
to fully oxidize substrates within the mitochondria, known as the oxidative capacity, may dictate 
how nutrient intake influences BMI and IR (16,17).  
In this paper, our goal was to expand on the relationship between the metabolome with obesity 
and IR to identify potential metabolic perturbations in the pubertal period, assessing sex-specific 
alterations given differences in pubertal hormones and the accumulation of muscle and fat tissue 
(18). These results build on previous work from our group in identifying metabolites associated 
with a metabolic risk score (19) and change in metabolic risk (9). Applying an improved 
untargeted metabolomics pipeline that used new pre-processing methods, we markedly expanded 
the number of annotated features providing new insights into metabolism in the population. 
Additionally, we identified how habitual macronutrient intake, in particular energy adjusted 
carbohydrate and fat intake, is associated with the metabolome. Our final objective was to 
determine if macronutrient intake could provide additional information on the underlying 
difference in metabolism that leads to insulin resistance.  
142 
 
Subjects and Methods 
Study Population. Participants were enrolled in the Early Life Exposure in Mexico to 
ENvironmental Toxicants (ELEMENT) project which was started in 1994 and consists of three 
sequentially-enrolled birth cohorts from Mexico City Maternity Hospitals (20). A subset of these 
children, age 8-14 years, were contacted through their primary caregiver to provide urine 
samples, serum samples, anthropometry and complete an interview-based questionnaire (n=250). 
Subjects for this analysis have baseline and follow data on anthropometry, metabolic biomarkers 
and adequate serum volume for metabolomics analyses (n=206). This study was evaluated and 
approved by the Research, Ethics, and Biosafety Committees of the National Institute of Public 
Health of Mexico, the Institutional Review Board of the University of Michigan, and the 
Institutional Review Board from the Harvard School of Public Health (21). 
Metabolomics Profiling. Fasting serum samples were analyzed using an untargeted 
metabolomics platform on an Agilent 1200 HPLC/6530 quadrupole Time-of-Flight mass 
spectrometry (MS) system (Agilent Technologies, Inc., Santa Clara, CA USA) using the Waters 
Acquity HSS T3 1.8 μm column (Waters Corporation, Milford, MA) (22). The eluent was 
analyzed in both positive and negative ion mode electrospray ionization. Chromatographic peaks 
that represent features were detected using a modified version of existing commercial software 
(Agilent MassHunter Qualitative Analysis). Data normalization followed a recently described 
method (23), using “pooled” reference samples that were analyzed repeatedly throughout each 
batch (24). The incorporation of Binner, a new method to visualize closely eluting features, 
allowed for the removal of redundant features. Missing peak intensities were imputed by K-
nearest neighbor-5 in features with at least 70% detection. R package “impute” was used for 
imputation. Features with less than 70% detection across samples were removed. Annotated 
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metabolites were identified via comparing their MS/MS spectra to authentic standards, purchased 
internal or external standards ran on the same instrument. Noteworthy, these analytical 
technologies are not capable of determining the position of the double bonds and the distribution 
of carbon atoms between fatty acid side chains. All lipids will be mentioned with the 
nomenclature as X:Y, where X is the length of the carbon chain and Y is the number of double 
bonds. The final metabolomics dataset contained 550 annotated metabolites and 2722 
unannotated metabolites. 
Anthropometric Assessment. Anthropometry was obtained using standardized procedures by 
trained personnel following Lohman Methodology (25). Weight was measured with scale BAME 
Mod 420; Catálogo Médico rounded to the nearest 0.1kg; height was recorded with a stadiometer 
(Perspective Enterprises, Portage, WI, USA) to the nearest 0.5 cm; and waist circumference 
(WC) was obtained using a non-stretchable measuring tape at the level of the umbilicus (SECA) 
to the nearest 0.1 cm (21). Weight and height were used to calculate BMI (kg/m2) and 
participants were classified as obese (BMI z-score≥2) and normal weight (-2≤BMI z-score <1) 
according to the World Health Organization criteria (26), using WHO Anthro software (version 
3.2.2, January 2011, World Health Organization, Geneva, Switzerland). WC and height were 
used to calculate waist-to-height ratio (WHtR). Skinfold thickness measurements of the triceps 
(TR), subscapular (SS), and suprailiac (SP) sites were measured using Lange skinfold calipers 
(Lange, Beta Technology) to the nearest 0.1 mm. These measurements were used to quantify 
total subcutaneous adiposity (SS+TR) and central subcutaneous adiposity (SS/TR). Weight and 
height were measured in duplicate and WC and skinfold thickness were measured in triplicate. 
Arm circumference was measured to the nearest 0.1 cm and used to calculate mid-upper arm 
muscle area (MUAMA) and mid-upper arm fat area (MUAFA) using standard equations (27).   
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Metabolic Biomarkers. Metabolic biomarkers were measured using 8-hour fasting serum. 
Glucose and C-peptide were quantified using an automated chemiluminescence immunoassay 
(Immulite 1000, Siemens Medical Solutions USA, Inc., Malvern, Pennsylvania). These 
biomarkers provide a measure of glycemic control, as fasting glucose is an indicator of glucose 
metabolism and a diabetes screening tool, and C-peptide is a marker of insulin secretion from 
pancreatic β-cells (28). Insulin levels in plasma were determined by Human Insulin ELISA kit 
EZHI-14K from Millipore Corporation (Billerica, MA). Insulin measures were below the limit of 
detection for 86 subjects; therefore, C-peptide was used to assess endogenous insulin levels. 
There was a significant positive correlation between insulin and C-peptide (r2 0.7689, p <0.001) 
(Figure S4.1). C-peptide replaced insulin in an adjusted homeostatic model assessment index 
(HOMA-CP) to evaluate beta-cell function (29). 









We measured total cholesterol, triglycerides, and HDL cholesterol in fasting serum samples 
(mg/dL) using a biochemical analyzer (Cobas Mira Plus, Roche Diagnostics) and calculated 
LDL cholesterol using Friedewald’s equation (30). Leptin was measured using 
radioimmunoassay (Millipore) and insulin-like growth factor 1 (IGF-1) were measured using an 
automated chemiluminescence immunoassay (Immulite 1000). 
Blood Pressure. Systolic (SBP) and diastolic blood pressure (DBP) were measured in duplicate 




Dietary Intake. Usual dietary intake of children over the past week was determined using a semi-
quantitative food frequency questionnaire (FFQ) adapted from the 2006 Mexican Health and 
Nutrition Survey (31). Separate questionnaires were used for children ages 7-11 years and 12 
years or older. Children 7-11 years old were assisted by their mother to improve accuracy and 
precision of the self-reported intakes. Total calories and grams of macronutrients were extracted 
from all food items in the FFQ using food composition tables supplied by the United States 
Department of Agriculture and the Mexican National Institute of Nutrition and Medical Sciences 
Salvador Zubirán (32). Macronutrients were adjusted for total energy intake using the residual 
method (33). 
Puberty Status. Sexual maturation was measured using Tanner staging where stages 1 indicates 
no development and stage 5 indicates full development (34,35). Children were examined based 
on a standardized protocol by a trained pediatrician, who assessed Tanner stages in genital 
(boys), breasts (girls), and pubic hair (boys and girls) development; see reference (36). 
Participants were classified as having reached puberty onset if they had a Tanner Stage greater 
than 1 for pubic hair and genital development (boys) or breast development (girls) (37). 
Data Analysis. Prior to the main analysis, we examined sex-specific differences in adiposity 
measurements, metabolic biomarkers and dietary data. Pearson’s chi-square tests were used to 
identify differences in categorical variables. Paired t-tests were used to identify differences in 
continuous variables. Pearson’s correlations were calculated between select adiposity and 
glucose regulation measurements to determine associations among variables.   
Step 1: Linear regression was used to examine all features (p=3272) separately, and to detect 
annotated metabolites (p=550) associated with BMIz and HOMA-CP (n=206) (SAS proc 
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genmod). Important associations were with a false discovery rate (FDR) < 0.10 and nominally 
significant with an unadjusted p-value < 0.05. All models include sex, age, and puberty onset 
(dichotomous variable) (Model 1), reducing variability between exposures and outcomes, 
therefore reducing bias. Sex stratified models were run. Additional models were considered 
adjusting for specific covariates. The metabolome’s association with BMIz was adjusted for 
HOMA-CP (Model 2), MUAMA (Model 3), MUAFA (Model 4), WHtR (Model 5), or SS+TR 
(Model 6). The metabolome’s association with HOMA-CP was adjusted for BMIz (Model 2), 
MUAMA (Model 3), MUAFA (Model 4), WHtR (Model 5), or SS+TR (Model 6).  
Step 2: Subjects were stratified by sex or obese vs. normal weight to compare raw peak intensity 
of select metabolites and sums of metabolite classes (t-test).  
Step 3: Linear regression was used to classify the relationship between energy-adjusted 
carbohydrate and fat intake (grams) with HOMA-CP and BMIz, adjusting for sex, age, and 
puberty onset.  
Step 4: Annotated metabolites were correlated using Pearson’s correlations and clustered using 
hierarchical clustering. Clusters were defined using a cut-off on the height of the dendrogram 
and the tightness of the correlations of the metabolites. Defined clusters were required to have an 
average tightness r>0.2 (Pearson’s correlation) and a minimum of 5 metabolites within, resulting 
in 34 clusters and 110 singleton metabolites without clusters. A cluster score, ‘f1’, is created by a 
weighted linear sum of metabolites with weights of factor loadings of metabolites within the 
cluster.  
Step 5: In the path analysis, we identified beta coefficients describing the relationship between 
(1) energy-adjusted fat and carbohydrate intake (mean 0, std. deviation 1) with metabolome 
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clusters (β1) and (2) metabolome clusters with BMIz and standardized HOMA-CP (β2), adjusting 
for sex, age, and puberty onset. Our analysis is composed of two parts: (1) a structural part 
linking the metabolome to BMIz or HOMA-CP through a linear model such as BMIz = β0 + f1 * 
β1 + puberty onset * β2 + age * β3 + sex * β4 + e1 and (2) a confirmatory factor analysis model 
via another linear model such as f1 = γ0 + Fat * γ1 + puberty onset * γ2 + age * γ3 + sex* γ4 + e2. 
All parameters, including loadings, β values and γ parameters are estimated via a maximum 
likelihood estimation method using the R package “lavaan”. 
Step 6: Our hypothesis is that a person’s intrinsic metabolism, reflected in the metabolome, 
influences the consequence of macronutrient intake on BMIz and IR. To assess this relationship, 
we used path analysis (38), a multiple regression technique used to examine causal relationships 
between variables. The path effect of an independent variable on a dependent variable is 
expressed as products of regression parameters from the two models. To obtain confidence 
intervals for the path effect, Sobel testing was used, which is known as being a conservative but 
widely used approach for assessing the significance of a path (39). 
Unless otherwise state, statistical analyses were performed using SAS 9.4 (Cary, North 
Carolina). Heatmaps were created using an in-house software, CoolMap. Figures were created 
using GraphPad Prism version 7.4 (La Jolla, California). 
Results 
Subject Demographics 
Anthropometry, metabolic biomarkers, dietary information and background characteristics were 
compared between girls (n=108) and boys (n=98), revealing sex-specific differences (Table 4.1). 
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We observed a similar distribution of BMI categories and BMIz in girls and boys, with 
approximately 50% normal weight in both groups. Girls had greater total subcutaneous adiposity 
(TR+SS) and mid upper arm fat area (MUAFA), while boys had greater mid upper arm muscle 
area (MUAMA). Boys showed a slightly higher SBP while girls had higher triglyceride and total 
cholesterol levels as well as higher leptin and IGF-1 levels. More boys were pubertal than girls 
measured by ‘puberty onset’ (boys n=48, girls n=35, p=0.0107). Using Pearson’s Correlations, 
clinical and metabolic phenotypes exhibit strong correlations in both boys and girls, including a 
significant positive correlation between BMIz and HOMA-CP in boys (r=0.41) and girls (r=0.31) 
(Figure S4.2).   
Relationship between the Metabolome and BMIz  
Linear regression identified metabolites significantly associated with BMIz (Figure S4.3). 
Initially, we demonstrated the relationship between both annotated and unannotated features 
(p=3272) with BMIz in the entire cohort (Figure S4.3a) and sex stratified in boys (Figure 
S4.3b) and girls (Figure S4.3c) (Model 1). The analyses highlighted the associations of 66 
features with BMIz in the combined dataset, 35 features with BMIz in boys, and 34 features with 
BMIz in girls (FDR <0.1).  
Using 550 annotated features, we created a series of models that classified association between 
metabolites with BMIz in the entire cohort (Figure S4.3d) and sex stratified in boys (Figure 
S4.3e) and girls (Figure S4.3f). We reported metabolites significantly associated with BMIz in 
Model 1, adjusting for sex, age, and puberty onset, in the entire cohort (Table S4.1) and sex 
stratified in boys (Table S4.2) and girls (Table S4.3). BMIz was associated with 51 annotated 
metabolites, which were primarily composed of branched chain and aromatic amino acids and 
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various lipid species, including phospholipids/ceramides, diglycerides (DG) and FA (Model 1). 
Most of the compounds showed a positive association with BMIz. Dichotomizing the cohort into 
girls and boys demonstrated sex-specific associations with BMIz (Figure 4.1). Most notable 
associations with BMIz include the positive association with multiple DG species in girls 
(Figure 4.1a) and the positive association with BCAA and their metabolites, isovalerylcarnitine, 
AC 3:0, AC 4:0 and AC 5:0 OH, in boys (Figure 4.1b). BMIz is positively associated with the 
aromatic amino acid tyrosine in boys (β=0.4361, p=0.002) and girls (β=0.3526, p=0.0007) 
(Model 1). Of note, DHEA-S is positively associated with BMIz (β=0.3102, p=0.004) (Model 1). 
DHEA-S changes rapidly in children during adrenarche and in the pubertal period and has been 
previously found to be correlated with weight and HOMA-IR in children (40).   
To determine if the associations between metabolites and BMIz was due to confounding factors, 
we added a series of variables that correlate with BMIz into the model, considering differences 
between boys and girls via sex-stratified models (Table S4.1-3). With the addition of HOMA-
CP, we observed a reduction in the magnitude of association of metabolites with BMIz; however, 
the majority associations remained significant including the positive association between DGs 
and phospholipids with BMIz, driven by the girls (Model 2). In boys, the relationship between 
BCAA and their metabolites and BMIz was reduced with the addition of HOMA-CP (Model 2) 
and MUAMA (Model 3), suggesting that BCAAs may be related to IR and muscle mass. With 
the addition MUAFA (Model 4), WHtR (Model 5), and TR+SS (Model 6) into the model, we 
observe large shifts in beta coefficients of the metabolite-BMIz relationship overall and in both 
sexes, with most of metabolite associations becoming non-significant, though nominal p-values 
were still significant for many DGs in girls. This would suggest that both central and 
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subcutaneous adipose tissue are driving the majority of the associations observed between BMIz 
and metabolite levels in plasma.  
Of interest, adults with obesity have elevated fasting non-esterified FA levels (41), however in 
adolescents, the results are contradictory finding no associations between FA with BMIz or IR 
(10,11). Some studies have observed that overweight adolescents have higher levels of saturated 
FA and lower levels of polyunsaturated FA in comparison to lean adolescents (42). In our cohort, 
we observed very few significant associations between individual FA and BMIz in adolescents 
(Model 1). Using a sum of the peak intensities of the 55 detected fatty acids, there was a trend 
towards elevated FA in obese children (p=0.0717), but no difference between boys and girls 
(p=0.8662) (Figure S4.4a-b). Therefore, we explored how BMIz relates to FA chain length and 
number of double bonds within FA with a chain length of ≥14 carbons. Beta coefficients from 
the fatty acid-BMIz relationship (Model 1) were plotted vs. FA chain length (Figure 4.2a) and 
number of double bonds (Figure 4.2b). Distinct patterns were observed between boys and girls. 
There was an inverse association between BMIz and FA chain length in boys (r2=0.5568, 
p<0.0001) that was not observed in girls (r2=0.00638, p=0.5621) (Figure 4.2a). There was no 
trend between the number of double bond and BMIz in boys (r2=0.02262, p=0.2731), however 
an inverse relationship was observed in girls (r2=0.1810, p=0.0012) (Figure 4.2b). The majority 
of FA beta coefficients in girls are positively associated with BMIz, suggesting that in girls the 
total FA burden is higher.    
The untargeted metabolomics platform used has an extraction solvent without chloroform and a 
hard ionization method, leading to the inability to accurately detect triglycerides. However, DGs 
are highly correlated with TG levels in plasma. In our analysis, the sum peak intensities of the 19 
annotated DGs was positively correlated with clinical triglycerides (r=0.697128, p<0.0001). 
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Total DGs were significantly elevated in obese adolescents (p=0.000154) (Figure S4.4c) and 
trended towards being elevated in girls (p=0.0597) (Figure S4.4d).  
Relationship between the Metabolome and Insulin Resistance 
Despite the positive relationship between BMIz and HOMA-CP (Figure S4.2), there was 
minimal impact of adjustment for HOMA-CP on metabolite levels associated with BMIz (Model 
2, Table S4.1-3). Therefore, we used linear models to assess whether we could identify 
metabolites associated with HOMA-CP (Figure S4.5). We demonstrated the relationship 
between both annotated and unannotated features (p=3272) with HOMA-CP in the entire cohort 
(Figure S4.5a) and sex stratified in boys (Figure S4.5b) and girls (Figure S4.5c) (Model 1). 
This analysis highlighted the associations of 63 features with HOMA-CP in the combined 
dataset, 64 features with HOMA-CP in boys and 23 features with HOMA-CP in girls (FDR 
<0.1).  
Using 550 annotated features, we created a series of models that classified association between 
metabolites with HOMA-CP in the entire cohort (Figure S4.5d) and sex stratified in boys 
(Figure S4.5e) and girls (Figure S4.5f). We reported metabolites significantly associated with 
HOMA-CP in Model 1, adjusting for sex, age, and puberty onset, in the entire cohort (Table 
S4.4) and sex stratified in boys (Table S4.5) and girls (Table S4.6). In the entire cohort, HOMA-
CP was associated with 40 annotated metabolites, including positive associations with glucose, 
tyrosine, proline, multiple DGs, and bile acids; along with inverse associations with n-
acetylglycine and fatty acid metabolism intermediates, such as short- and medium-chain AC and 
DIC-FA (Model 1) (Table S4.4). There were 11 metabolites that overlapped with those 
associated with BMIz, consisting of mainly diglycerides (DG 32:0, DG 34:0, DG 30:1, DG 32:1, 
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DG 34:1, DG 36:1, DG 32:2, and DG 34:3), along with n-acetylglycine, tyrosine, and DHEA-S 
(Model 1) (Table S4.1, Table S4.4). Adding BMIz into the model greatly reduces the 
associations between DGs and HOMA-CP, especially in the boys (Model 2). The remaining 
metabolite associations with HOMA-CP, such as n-acetylglycine, proline, bile acids and fatty 
acid metabolism intermediates, remained significant in the whole group, largely driven by the 
boys (Model 2). Similar patterns were observed after adjustment for muscle mass (MUAMA) as 
well as subcutaneous and central fat distribution (MUAFA, WHtR and TR+SS) (Models 3-6).  
The inverse relationship between AC and HOMA-CP, adjusting for sex, puberty onset and age, 
is represented in Figure 4.3. Stratifying by sex reduced the number of significant associations, 
however most beta coefficients remained stable. Adjustments for muscle mass or fat mass did 
not eliminate the associations, suggesting an intrinsic factor other than weight or body 
composition drives this association (Table S4.4-6). The inverse association became stronger 
after adjustment for BMIz, primarily in males (Model 2).     
Path Analysis Highlighting the Relationship between Macronutrient Intake, the Metabolome, 
BMIz, and Insulin Resistance 
Previous results have been inconsistent when describing a relationship between habitual 
macronutrient intake and metabolic health in children. In our cohort, energy-adjusted 
carbohydrate and fat intake were not linearly related to BMIz or HOMA-CP, when adjusting for 
sex, age, and puberty onset (Path 1, Table S4.7). Conducting a path analysis, we assessed how 
macronutrient intake is reflected in the metabolome, which is associated with obesity and insulin 
resistance and calculated confidence intervals using Sobel Testing (Path 2, Figure 4.4). Due to 
biological constraints on metabolism, many metabolites are highly correlated. We took 
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advantage of this to collapse groups of highly correlated metabolites, using weighted sums for 
each group as a singular value, allowing an increase in power to identify potential causal paths. 
Individual annotated metabolites were grouped using hierarchical clustering prior to assessing 
the significance of a path of interest (Figure 4.5). We identified 34 clusters and 110 singleton 
metabolites (described in methods); clusters are classified based on their content metabolites 
(Table S4.8).  
Although sex-specific relationships were observed between the metabolome with BMIz and 
HOMA-CP (Table S4.2-3, Table S4.5-6), the majority of beta coefficients were in the same 
direction in boys and girls, with the relationship between DGs and BMIz emphasized among 
girls and the relationship between amino acids and BMIz emphasized among boys. Therefore, 
we will present the following analyses with sex as a covariate, rather than stratifying by boys and 
girls. 
The path analysis identified metabolome clusters associated with the nutrient intake (β1) and the 
outcomes (β2), BMIz (Table S4.9) and HOMA-CP (Table S4.10), adjusting for sex, age and 
puberty onset. Seven metabolite clusters were significantly associated with nutrient intake, all 
revealing positive associations with fat intake and inverse associations with carbohydrate intake 
(β1, Table S4.9-10), reflecting the inverse relationship we observe between fat and carbohydrate 
intake. The clusters were composed of BCAAs and their metabolites (Cluster 16), medium-chain 
hydroxyl-DiC-FA (Clusters 13, 14, and 15), long-chain DiC-FA (Cluster 26), long-chain 
hydroxyl-DiC-FA (Cluster 14) and medium-chain AC (Cluster 25).  
From the seven clusters that are significantly related to macronutrient intake, three of the clusters 
are associated with HOMA-CP (β2, Table S4.10). Medium-chain ACs (Cluster 25) (-
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0.833±0.240, p=0.001), intermediates of β-oxidation, and long-chain DiC-FA (Cluster 26) (-
0.383±0.141, p=0.006), intermediates of alpha-oxidation, are inversely related to HOMA-CP. 
Medium-chain DiC-FA (Cluster 15) (0.361±0.169, p=0.033), intermediates of omega-oxidation, 
are positively associated with HOMA-CP. These results suggest that intermediates of fatty acid 
oxidation have differing influences on HOMA-CP dependent on the location of oxidation. None 
of the seven clusters that are significantly related to macronutrient intake are associated with 
BMIz (β2, Table S4.9). Additional associations between metabolome clusters with BMIz and 
HOMA-CP confirmed our reported results using individual metabolites (β2, Table S4.9-10).  
Using Sobel tests, we assessed the significance of the causal path of interest. Carbohydrate intake 
is positively associated with HOMA-CP through decreases in the levels of medium-chain ACs 
(Cluster 25) (p=0.015) (Table S4.10). Fat intake is inversely associated with HOMA-CP through 
decreases in the levels of medium-chain ACs (p=0.010) (Table S4.10), supporting a protection 
from becoming insulin resistant is the ability to increase FA oxidation flux through the 
mitochondria. The pathway of macronutrient intake’s influence on HOMA-CP through medium-
chain DiC-FA (Cluster 15) and long-chain DiC-FA (Cluster 26) were marginally significant 
(Table S4.10). No pathways linking macronutrient intake to BMIz through metabolome clusters 
reached significance by Sobel tests (Table S4.9). 
Discussion 
In this cross-sectional analysis using untargeted metabolomics, we quantified the relationship 
between the metabolome with BMIz and IR among 108 girls and 98 boys, focusing on sex- 
differences in metabolism. Our findings confirm and extend previous results, emphasizing sex-
specific differences due to variations in muscle and fat tissue accumulation in puberty. Using 
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path analyses, we support our hypothesis that person’s intrinsic metabolism, reflected in the 
metabolome, influences the consequence of macronutrient intake on IR.  
Our results revealed a positive relationship between diglycerides and BMIz, driven by the girls, 
that was independent of IR and lean mass (Model 2-3), but dependent on adipose mass (Models 
4-6). DGs are building blocks in triglycerides and phospholipid biosynthesis and elevated levels 
likely reflect increased de novo lipogenesis in adipose tissue and the liver. DGs can serve as 
intracellular secondary messengers and my activate intracellular pathways leading to IR, 
defective mitochondrial activity, and endoplasmic reticulum stress (43). However, the 
relationship between DG levels and HOMA-CP was not evident once we adjusted for BMIz, 
suggesting that at least at the plasma level in children, they not contributing directly to IR.  
Plasma FAs were trending towards being elevated in obese compared to normal weight 
adolescents however, very few individual FAs were associated with BMIz. In the fasting state, 
plasma FA levels are a balance between lipolysis of triglycerides within the adipocytes and 
oxidation of FA. In adults with obesity, plasma FA levels are elevated due to an increase in 
lipolysis as adipose tissue becomes resistant to insulin action (44). This dynamic is suggested to 
differ in pubertal adolescents with elevated BMIz (11) due to increased growth hormones (i.e. 
IGF-1) (45). Increased levels of IGF-1 during puberty, as observed in our cohort (Table S4.11), 
is associated with IR and an increase in lipolysis, as well as an increase in lipid oxidation 
(46,47). The ability to increase lipid oxidation during puberty, potentially to sustain energy 
requirements during growth, may explain why plasma FA levels were not increased with BMIz. 
We noted a relationship between BMIz with the number of double bonds and the chain length of 
FAs in boys, supporting the importance of composition of FAs in their association with obesity 
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(42). Finally, we did not detect any associations of DGs or FAs with dietary macronutrient intake 
and either IR or obesity in our path analyses.  
Previous metabolomics analyses in adolescents have found tyrosine, phenylalanine, and BCAAs 
are consistently associated with obesity (3–5). In our cohort, we observed positive associations 
between BCAAs and their degradation products with BMIz, primarily in boys. Our results 
suggest that BCAAs are in part related to IR and lean mass, as adding HOMA-CP and MUAMA 
into the model reduced but did not eliminate these associations. Studies in lean adolescents 
suggest that proteolysis and protein oxidation appear to be reduced during puberty, relative to 
pre-puberty, which may be also a result of increases in IGF-1 (48). Reduced BCAA catabolism 
in adipose tissue and skeletal muscle in obesity and IR can result in elevation of plasma BCAA 
levels (49). Elevations of BCAA may be more apparent in boys due to their increased muscle 
mass and a relative inability to suppress proteolysis due to IR.  
The production of AC is due to an imbalance of entry of acyl-CoAs into the mitochondria and 
FAO rates, the latter determined by ATP need. Thus, at any ambient supply of FA, lower levels 
of MC- and LC-AC can be due to either a reduced uptake of acyl-CoAs into the mitochondria, 
for instance in the presence of elevated malonyl-CoA levels (50), or increased β-oxidation (51). 
In adults, obesity and IR are characterized by oversupply of FA to the mitochondria and 
incomplete FAO with increases in AC intermediates (52) and incompletely oxidized FA (50,53). 
In our study, we observed that MC-ACs (6-14 carbons) are inversely associated with HOMA-
CP, independent of muscle mass and BMIz, in both sexes. Previous studies have found similar 
results (6,8). Mihalik et al. observed decreases in MC-AC species in youth with obesity or T2D 
compared with normal weight, with no change in LC-AC (6) and proposed that IR in adolescents 
was associated with enhanced mitochondrial oxidation rather than reduced utilization.  
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Path analysis demonstrated positive associations between carbohydrate intake and HOMA-CP 
through decreased MC-AC, with the opposite trend found for dietary fat. These results may 
suggest that adolescents prone to IR have an increase in selection of carbohydrates for fuel, 
exacerbated by elevated habitual carbohydrate consumption. Under these conditions, elevated 
malonyl-CoA would reduce uptake of FA into the mitochondria leading to lipid accumulation in 
the cytosol, increasing FA metabolites that contribute to IR (54). Habitual fat intake is 
approaching a positive association with HOMA-CP through increased MC DiC-FA, which are 
formed from omega-oxidation in the endoplasmic reticulum (55). Our findings may reflect an 
intrinsic difference in fuel selection by mitochondria related to IR. If insulin resistant individuals 
do have a relative intrinsic selection for carbohydrate oxidation, a higher dietary fat intake could 
lead to increases in extra-mitochondrial FAO.  
These findings in young, non-diabetic individuals are reminiscent of reduced metabolic 
flexibility seen in insulin resistant individuals in the setting of obesity where tissues have 
reduced capacity to alter fuel selection in the face of changes in nutrient supply (56). We do not 
have respiratory quotient (RQ) measures in the children in this study, which could be used to test 
the hypothesis of relative differences in fuel utilization. However, Kim et al. (57) has shown that 
girls with IR associated with polycystic ovarian disease have significantly higher RQ in the 
fasting state, indicating higher carbohydrate oxidation, which was independent of adiposity and 
hormone levels. Future studies assessing RQ, metabolite patterns, and response of children to 
different diets will be needed to test this hypothesis. Additionally, future studies will assess the 
relationship between cardiorespiratory fitness (oxidative capacity) and fuel selection in children 
with a varying degree of IR. Previous analyses in humans (58) and animals (59) with higher 
oxidative capacity show a relative selection of fatty acids and a relative resistance to obesity 
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(60). In addition, adults with low oxidative capacity have a metabolite profile that is more similar 
to individuals who have a higher risk of type 2 diabetes (61).  
Conclusion 
In summary, our study highlights that intrinsic metabolism, in particular the relative ability to 
oxidize lipid in the mitochondria, may influence the consequence of nutrient intake on metabolic 
health. Strengths include the availability of a wealth of data in the ELEMENT cohort allowing 
for the incorporation of anthropometry measurements, metabolic biomarkers, puberty measures, 
and dietary intake and the use of comprehensive metabolomics methodology assessing both 
annotated and unannotated features and confirming using hierarchical clustering. The use of path 
analysis created a strong statistical platform to begin to understand mechanisms describing this 
relationship.   
Despite the strengths of this study, this work is cross sectional therefore causality cannot be 
confirmed. We are limited by the number of subjects within this study (n=206), acknowledging 
that stratifying by sex reduces power. Though within this cohort there was a strong correlation 
between C-peptide and insulin levels, we assess IR using HOMA-CP, due to the large number of 
subjects (n=86) with plasma insulin levels below the limit of detection. This suggests some 
caution in interpretation of insulin resistance. In addition, a large number of unannotated 
metabolites, generated from untargeted metabolomics, were identified to be associated with 
BMIz and HOMA-CP. These metabolites, once identified may alter or modify the conclusions in 
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Figure S4.1. Relationship between insulin and C-peptide at baseline.  

























Table 4.1. Characteristics of the ELEMENT participants, stratified by sex (n=206). Values are 
n(%) or mean±SD. ARepresents Pearson's chi-square test for categorical variables. BRepresents 





BMI Categories  
Underweight 1 (1.0) 2 (1.9) 
0.8859 
Lean 47 (48.0) 53 (49.1) 
Overweight 33 (33.7) 32 (29.6) 
Obese 17 (17.3) 21 (19.4)  
Pubic Hair Tanner Stage 
1 80 (83.3) 84 (77.8) 
0.7782 
2 12 (12.5) 18 (16.7) 
3 3 (3.2) 5 (4.6) 
4 1 (1.0) 1 (0.9) 
5 0 (0.0) 0 (0.0) 
Puberty Onset 
Yes 48 (50.0) 35 (32.4) 
0.0107 





Age  10.4±1.6 10.1±1.6 0.3781 
Anthropometry  
Weight (kg) 37.8±10.0 37.4±10.0 0.8076 
Height (cm) 139.4±10.6 138.3±10.6 0.4368 
BMI 19.2±3.2 19.3±3.5 0.7111 
BMI z-score 0.91±1.22 0.78±1.28 0.4718 
WC (cm) 69.9±9.9 70.7±10.2 0.5752 
TR + SS (mm) 25.1±11.1 30.1±11.4 0.0019 
SS/TR 0.74±0.22 0.72±0.21 0.6112 
  MUAMA (mm2) 26.5±6.9 24.0±6.3 0.0079 
  MUAFA (mm2) 15.0±7.1 17.6±7.3 0.0082 
WHtR 0.50±0.06 0.51±0.07 0.2639 
Metabolic Biomarkers  
SBP (mmHg) 104±10 101±10 0.0177 
DBP (mmHg) 65±7 65±7 0.8565 
C-peptide (ng/mL) 1.6±1.1 1.8±1.3 0.104 
Glucose (mg/dL) 87.8±8.0 87.0±10.2 0.5252 
Leptin (ng/mL) 8.4±6.6 13.3±9.3 <0.0001 
IGF-1 (ng/mL) 231.9±95.5 271.7±101.3 0.0042 
Total Cholesterol (mg/dL) 152.6±27.7 160.7±25.7 0.0314 
HDL (mg/dL) 60.0±12.1 57.4±12.2 0.1179 
Triglycerides (mg/dL) 78.4±37.0 98.3±47.5 0.0009 
LDL (mg/dL) 76.9±23.6 83.6±20.7 0.0301 
HOMA-CP 1.9±1.4 2.3±2.3 0.132 
Dietary Information (energy adjusted) 
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Calories (kcal) 2801±837 2497±842 0.0102 
Protein (g) 75.9±11.0 77.0±9.7 0.4442 
Carbohydrates (g) 345.3±40.7 341.3±31.4 0.4294 
Sugar (g) 54.2±41.3 52.8±41.7 0.8081 
Fat (g) 94.2±14.0 95.8±10.8 0.3567 
Saturated Fat (g) 28.4±9.2 31.1±10.0 0.041 
Monounsaturated Fat (g) 24.4±5.4 25.0±4.9 0.4186 
Polyunsaturated Fat (g) 15.6±4.4 15.2±4.3 0.5933 
Cholesterol (mg) 291.2±88.0 293.5±102.6 0.8587 




Figure S4.2. Clinical phenotypes and metabolic biomarkers exhibit strong correlations, sex-
stratified. 
 
Pearson correlations identified connectivity between adiposity and metabolic biomarkers in (A) 
boys (n=98) and (B) girls (n=108) and connectivity between adiposity, metabolic biomarkers, 
and energy-adjusted dietary macronutrients in (C) boys and (D) girls. Positive correlation in red 
and negative correlations in green. Nominal significance denoted with (*) (α=0.05).   
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Figure S4.3. Association of metabolite features with BMIz, within the entire cohort and sex-
stratified.  
 
Beta coefficients from linear models are plotted on the x-axis and negative log transformed p-
values are plotted on the y-axis. Association between BMIz and both annotated and unannotated 
features (p=3272) (A) within entire cohort (n=206), accounting for age, sex, and puberty onset, 
and sex stratified in (B) boys and (C) girls, accounting for age and puberty onset (Model 1). 
Using solely annotated metabolites (p=550), representing the relationship between metabolites 
and BMIz (D) within the entire cohort and sex stratified in (E) boys and (F) girls (Model 1). 
Features in red indicate significant associations after FDR correction (FDR<0.10). 
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Table S4.1. Association between annotated metabolites and BMIz (n=206). Regression models identifying annotated metabolites 
(p=550) linearly associated with BMIz. All models were adjusted for sex, age, and puberty onset (Model 1), along with additional 
phenotypic measures to identify metabolites that drive the association with BMIz including HOMA-CP (Model 2), MUAMA (Model 
3), MUAFA (Model 4), WHtR (Model 5) and TR+SS (Model 6). Values reported are β±Std Error. Metabolites with FDR<0.10 
highlighted in red and bolded. Metabolites listed have an FDR<0.10 in Model 1 in the combined model and/or the sex-stratified 
models.  
Metabolite Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
N-acetylglycine -0.2456±0.0889 -0.1135±0.0871 -0.0952±0.0643 0.0061±0.0489 0.041±0.0393 0.0238±0.0487 
isovalerylcarnitine  0.3198±0.0812 0.2565±0.0767 0.1866±0.0586 0.0448±0.0459 0.0543±0.0365 0.0288±0.0458 
isoleucine 0.3132±0.082 0.2724±0.0765 0.1945±0.0588 0.0328±0.0463 0.004±0.0373 0.0539±0.0456 
leucine 0.1858±0.082 0.1479±0.0764 0.0775±0.0587 0.0778±0.0436 0.0773±0.0348 0.0604±0.0435 
valine 0.2612±0.0839 0.2101±0.0786 0.1438±0.0602 0.0362±0.0462 0.049±0.0368 0.0317±0.0459 
phenylalanine 0.2426±0.0854 0.1842±0.0801 0.1218±0.0612 0.0486±0.0464 0.0245±0.0374 0.047±0.0461 
tyrosine 0.3852±0.0844 0.2863±0.082 0.207±0.0621 0.0906±0.0481 0.032±0.0392 0.0559±0.0485 
5-methylthioadenosine 0.3025±0.0852 0.2274±0.0808 0.1305±0.0623 0.0451±0.0475 0.0146±0.0382 0.0533±0.047 
D-ornithine 0.2128±0.0802 0.1919±0.0743 0.0939±0.0576 0.0916±0.0427 0.0164±0.035 0.1117±0.0421 
L-ornithine 0.2157±0.0803 0.1924±0.0745 0.0856±0.0579 0.0932±0.0428 0.0194±0.035 0.1202±0.042 
normethanephrine 0.2427±0.0853 0.1843±0.0801 0.1218±0.0612 0.0487±0.0464 0.0246±0.0374 0.047±0.0461 
D-lyxose -0.3152±0.0989 -0.3443±0.0907 -0.2506±0.0692 -0.0168±0.0549 0.0176±0.0441 -0.0035±0.0546 
5-phospho-alpha-D-ribose-1-
diphosphate 
0.2397±0.0899 0.1979±0.0838 0.0904±0.0649 0.0393±0.0488 0.0577±0.0388 0.0252±0.0486 
Cer t36:0(2OH) 0.3344±0.0837 0.3219±0.0772 0.2388±0.0593 0.0001±0.0482 0.0361±0.038 -0.0177±0.0481 
PE-Cer d36:1 0.1726±0.0828 0.0971±0.0782 0.129±0.0582 -0.0664±0.045 -0.0207±0.0358 -0.0411±0.0445 
PE-Cer d32:3 0.2347±0.0801 0.1768±0.0753 0.1812±0.0562 -0.0254±0.0445 0.0344±0.035 -0.0085±0.044 
PE-Cer d34:3 0.1291±0.0837 0.0884±0.0779 0.1253±0.0586 -0.0589±0.0448 0.0135±0.0357 -0.0314±0.0444 
DG 32:0 0.3822±0.0787 0.2757±0.0778 0.2117±0.058 0.05±0.0462 0.0485±0.0368 0.0588±0.0457 
DG 34:0 0.3623±0.0804 0.2646±0.0784 0.2122±0.0585 0.0508±0.0465 0.0362±0.0372 0.0599±0.0459 
DG 30:1  0.3299±0.0816 0.2388±0.0787 0.2023±0.0587 0.0627±0.046 0.0901±0.0361 0.0671±0.0456 
DG 32:1 0.368±0.0804 0.275±0.078 0.2349±0.0579 0.0419±0.0468 0.0747±0.0366 0.049±0.0463 
166 
 
DG 33:1 0.3317±0.0812 0.2585±0.0773 0.2361±0.0575 0.0068±0.0468 0.0754±0.0363 0.0043±0.0465 
DG 34:1 0.3759±0.0799 0.2887±0.0772 0.211±0.0586 0.0458±0.0467 0.0784±0.0365 0.0571±0.0461 
DG 35:1 0.3059±0.0812 0.2358±0.077 0.1743±0.0586 0.0498±0.0455 0.0557±0.0362 0.0537±0.0451 
DG 36:1 0.3543±0.0814 0.2635±0.0787 0.1546±0.0608 0.0618±0.0465 0.0525±0.0372 0.0729±0.0459 
DG 32:2 0.3805±0.0799 0.3004±0.0767 0.2359±0.0579 0.0358±0.047 0.0944±0.0363 0.0494±0.0464 
DG 34:2 0.3365±0.08 0.2673±0.076 0.2055±0.0577 0.0087±0.0464 0.0814±0.0358 0.0203±0.0458 
DG 35:2 0.3893±0.0836 0.3195±0.0793 0.24±0.0605 0.0469±0.0488 0.0929±0.0379 0.0547±0.0482 
DG 34:3 0.3405±0.0799 0.2641±0.0763 0.2143±0.0575 -0.0146±0.0468 0.0787±0.0359 0.0107±0.046 
DG 35:3 0.3738±0.0809 0.3275±0.0757 0.2543±0.0578 0.0327±0.0474 0.072±0.037 0.0358±0.0469 
DG 36:3 0.2625±0.0859 0.221±0.0801 0.1599±0.0612 0.0006±0.0476 0.079±0.0371 0.0374±0.0468 
DG 36:4 0.2937±0.084 0.2532±0.0783 0.1874±0.0599 0.0549±0.0466 0.0944±0.0365 0.0801±0.0458 
DG 38:4 0.2034±0.0851 0.1836±0.0788 0.1183±0.0604 0.0069±0.0462 0.0391±0.0367 0.0321±0.0456 
DG 36:5 0.175±0.0834 0.1414±0.0775 0.1088±0.059 -0.0738±0.0453 0.0577±0.0355 -0.0365±0.0448 
DG 38:5 0.2569±0.0865 0.1853±0.0817 0.1393±0.062 -0.0042±0.0479 0.0558±0.0376 0.0045±0.0474 
FA 17:0 0.2131±0.0814 0.1952±0.0753 0.1449±0.0575 0.0316±0.0442 0.0379±0.0353 0.0276±0.0439 
FA 18:3 0.2339±0.081 0.2231±0.0748 0.1636±0.0572 -0.005±0.0447 0.0336±0.0354 0.0145±0.0442 
AC 3:0 0.2506±0.0859 0.1874±0.0808 0.1709±0.0608 0.0699±0.0465 0.0168±0.0378 0.088±0.0459 
AC 4:0 0.2597±0.0867 0.2489±0.08 0.0723±0.0635 0.0653±0.0471 0.045±0.0379 0.0653±0.0468 
AC 8:1 0.345±0.0854 0.3466±0.0784 0.2003±0.0617 -0.0096±0.0494 0.0207±0.039 -0.0055±0.0489 
AC 5:0 (OH)  0.2855±0.087 0.2448±0.081 0.1742±0.0621 0.1145±0.0468 0.058±0.0382 0.1076±0.0466 
FA 8:1 (DiC)  0.1873±0.0861 0.1487±0.0802 0.0233±0.0624 0.05±0.0461 0.0556±0.0368 0.0562±0.0456 
FA 9:1 (DiC)  0.2294±0.0828 0.1825±0.0774 0.049±0.0606 0.1001±0.0442 0.0858±0.0354 0.0943±0.0439 
FA 12:1 (DiC) -0.2344±0.0808 -0.1672±0.0764 -0.1331±0.0577 -0.0044±0.0446 0.0238±0.0358 -0.0003±0.0443 
FA 28:2 (DiC) -0.1725±0.0864 -0.1779±0.0797 -0.0808±0.0614 -0.1118±0.0453 -0.0309±0.037 -0.0727±0.0454 
SN-glycero-3-phosphocholine 0.2019±0.084 0.199±0.0775 0.0581±0.0607 0.0605±0.045 0.0404±0.0362 0.0961±0.0442 
PC 34:0/PE 37:0 -0.2026±0.0831 -0.1622±0.0775 -0.0952±0.0595 -0.0939±0.0441 -0.0671±0.0355 -0.0694±0.0441 
PC 40:4/PE 43:4 0.2333±0.084 0.2222±0.0777 0.1808±0.059 0.0027±0.0462 -0.006±0.037 -0.0211±0.046 
PC 31:5/PE 34:5 0.2675±0.0798 0.2083±0.0752 0.1148±0.0582 0.024±0.0445 0.0752±0.0348 0.0524±0.0437 
PC 35:5/PE 38:5 -0.3013±0.0832 -0.2589±0.0777 -0.1348±0.0609 -0.1009±0.0455 -0.0573±0.0369 -0.0931±0.0453 
PE 36:2 0.2786±0.0845 0.2198±0.0795 0.1431±0.061 0.0205±0.047 0.0691±0.0369 0.0412±0.0464 
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PS 35:4 0.2429±0.0832 0.1717±0.0787 0.1682±0.0588 0.0201±0.0457 0.0191±0.0365 0.0043±0.0455 
PS 40:4 -0.2421±0.0897 -0.1936±0.0837 -0.0814±0.065 -0.0309±0.0488 -0.0634±0.0387 -0.0458±0.0483 
PS 42:6 -0.2779±0.0839 -0.2335±0.0784 -0.1004±0.0616 -0.0753±0.0459 -0.0372±0.0371 -0.093±0.0452 
PS 39:7 -0.1555±0.0862 -0.155±0.0796 -0.1432±0.0603 -0.0712±0.0456 -0.0454±0.0367 -0.0247±0.0457 
LysoPC 14:0 0.2105±0.0843 0.1276±0.0801 0.116±0.06 0.0085±0.0459 0.0717±0.036 0.0385±0.0452 
norhyodeoxycholic acid  0.1515±0.0833 0.1057±0.0778 0.1129±0.0586 0.046±0.0443 0.0483±0.0354 -0.0073±0.0444 
SM d36:2 0.2288±0.0843 0.2121±0.078 0.1854±0.0591 -0.0516±0.0467 0.0436±0.0366 -0.0373±0.0462 
DHEA sulfate 0.3102±0.1066 0.1984±0.1018 0.1064±0.0776 0.0354±0.0584 0.0577±0.0465 0.0512±0.0578 
cortisone -0.2898±0.0819 -0.2819±0.0755 -0.1509±0.0592 -0.0333±0.0458 0.0143±0.037 -0.0349±0.0454 
urate 0.2769±0.0898 0.2057±0.0848 0.1038±0.0655 0.0442±0.0493 0.0353±0.0395 0.0326±0.0491 
dipeptide (glutamate-
phenylalanine) 
0.2669±0.0848 0.2382±0.0787 0.1599±0.0606 0.0729±0.0462 -0.0608±0.038 0.048±0.0462 
dipeptide (histidine-tyrosine) 0.2307±0.0873 0.1836±0.0815 0.044±0.0638 0.1062±0.0464 0.0315±0.0379 0.1016±0.0461 






Table S4.2. Association between annotated metabolites and BMIz in boys (n=98). Sex-stratified regression models identifying 
annotated metabolites (p=550) linearly associated with BMIz. All models were adjusted for age and puberty onset (Model 1), along 
with additional phenotypic measures to identify metabolites that drive the association with BMIz including HOMA-CP (Model 2), 
MUAMA (Model 3), MUAFA (Model 4), WHtR (Model 5) and TR+SS (Model 6). Values reported are β±Std Error. Metabolites with 
FDR<0.10 highlighted in red and bolded. Metabolites listed have an FDR<0.10 in Model 1 in the combined model and/or the sex-
stratified models.  
Metabolite Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
N-acetylglycine -0.1413±0.123 -0.0142±0.1114 -0.0252±0.0873 0.0384±0.0673 0.0781±0.0557 0.0301±0.0667 
isovalerylcarnitine  0.3499±0.1185 0.2347±0.1087 0.2136±0.0849 0.0295±0.0699 0.0952±0.0559 0.0093±0.0698 
isoleucine 0.4195±0.1019 0.3175±0.0942 0.2334±0.0763 0.0346±0.0655 0.0309±0.0537 0.0525±0.0642 
leucine 0.3478±0.1022 0.2342±0.0952 0.1961±0.0747 0.0482±0.0615 0.115±0.0484 0.0564±0.0607 
valine 0.3634±0.1229 0.2164±0.1149 0.2323±0.0876 0.0238±0.0727 0.1154±0.0575 0.0117±0.0724 
phenylalanine 0.4285±0.1696 0.3005±0.1528 0.2678±0.1204 -0.0602±0.0994 0.0614±0.0801 -0.0425±0.0983 
tyrosine 0.4361±0.1412 0.1509±0.1451 0.1965±0.1047 0.086±0.0826 0.03±0.0694 0.0619±0.0826 
5-methylthioadenosine 0.549±0.1407 0.3859±0.1323 0.3513±0.1019 0.0607±0.0883 0.0691±0.0721 0.047±0.088 
D-ornithine 0.2173±0.1143 0.1916±0.1004 0.1586±0.0799 0.1114±0.0618 0.0351±0.0525 0.1483±0.0602 
L-ornithine 0.2224±0.1155 0.2105±0.1011 0.1601±0.0808 0.112±0.0625 0.033±0.0532 0.1523±0.0608 
normethanephrine 0.4286±0.1696 0.3005±0.1529 0.2678±0.1204 -0.0603±0.0994 0.0614±0.0801 -0.0425±0.0983 
D-lyxose -0.2221±0.1386 -0.2741±0.1204 -0.17±0.0967 -0.0285±0.0763 -0.0006±0.0635 -0.0774±0.0748 
5-phospho-alpha-D-ribose-1-
diphosphate 
0.1172±0.135 0.059±0.1193 0.0548±0.0947 -0.1059±0.0733 -0.011±0.0606 -0.0924±0.0727 
Cer t36:0(2OH) 0.2584±0.1268 0.2501±0.1108 0.2097±0.0881 -0.0213±0.0719 0.0187±0.0589 -0.0196±0.0713 
PE-Cer d36:1 -0.0551±0.1539 0.0119±0.1357 0.0974±0.1082 -0.1614±0.0812 -0.0846±0.068 -0.1917±0.08 
PE-Cer d32:3 0.0358±0.1177 0.0257±0.1033 0.1538±0.0815 -0.1252±0.0627 -0.008±0.0524 -0.1092±0.0623 
PE-Cer d34:3 -0.1025±0.1289 -0.0611±0.1136 0.0659±0.0916 -0.1443±0.0678 -0.0165±0.0577 -0.1108±0.0678 
DG 32:0 0.2981±0.1243 0.1609±0.1147 0.183±0.0882 -0.0201±0.0719 -0.0082±0.0592 -0.0227±0.0713 
DG 34:0 0.2236±0.1449 0.083±0.1314 0.1182±0.1023 -0.0041±0.0801 -0.0367±0.0665 -0.0085±0.0795 
DG 30:1  0.2259±0.1306 0.1292±0.1172 0.1696±0.0912 -0.0071±0.0728 0.0371±0.0597 -0.0131±0.0722 
DG 32:1 0.2309±0.1223 0.1542±0.1092 0.197±0.0847 -0.0552±0.0692 0.0274±0.0563 -0.0506±0.0686 
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DG 33:1 0.2219±0.1211 0.1859±0.1067 0.1928±0.0838 -0.0794±0.0685 0.0588±0.0551 -0.0673±0.0679 
DG 34:1 0.2891±0.1269 0.2156±0.1132 0.1867±0.0896 -0.0555±0.0734 0.0658±0.0588 -0.0405±0.0726 
DG 35:1 0.2624±0.1406 0.2045±0.1244 0.2194±0.0976 -0.0327±0.0792 0.0624±0.0642 -0.0156±0.0783 
DG 36:1 0.2892±0.1389 0.1886±0.1247 0.1246±0.0998 -0.0144±0.0788 0.0413±0.0643 -0.0062±0.078 
DG 32:2 0.1761±0.1302 0.0895±0.1162 0.1405±0.0907 -0.1067±0.072 0.0196±0.059 -0.0981±0.0714 
DG 34:2 0.1939±0.1249 0.159±0.11 0.1596±0.0869 -0.1099±0.0698 0.0513±0.0565 -0.088±0.0691 
DG 35:2 0.2933±0.129 0.2516±0.1136 0.2617±0.0886 -0.0425±0.0744 0.0774±0.0595 -0.0349±0.0736 
DG 34:3 0.1729±0.1208 0.1276±0.1067 0.1634±0.0837 -0.1205±0.0671 0.0263±0.0548 -0.0845±0.0665 
DG 35:3 0.1945±0.1216 0.1783±0.1067 0.2407±0.0826 -0.106±0.0681 0.0097±0.0557 -0.1046±0.0675 
DG 36:3 0.0779±0.1219 0.1182±0.1068 0.1124±0.0846 -0.0908±0.0658 0.0301±0.0543 -0.0711±0.0653 
DG 36:4 0.044±0.1527 0.0717±0.134 0.1446±0.1062 -0.1226±0.0817 -0.0065±0.068 -0.1064±0.0811 
DG 38:4 0.0651±0.1186 0.0983±0.104 0.0999±0.0824 -0.0703±0.0639 -0.0156±0.053 -0.0744±0.0634 
DG 36:5 -0.0094±0.1177 -0.0193±0.1033 0.0393±0.0823 -0.1612±0.0617 -0.0042±0.0524 -0.1441±0.0615 
DG 38:5 0.1965±0.1237 0.2072±0.1079 0.1481±0.0863 -0.0553±0.069 0.0496±0.056 -0.0474±0.0683 
FA 17:0 0.2106±0.1216 0.1568±0.1077 0.1926±0.084 0.0059±0.0676 0.029±0.0557 0.0035±0.0671 
FA 18:3 0.1565±0.1211 0.1812±0.1057 0.2076±0.0828 -0.0756±0.0668 0.0256±0.0547 -0.0448±0.0661 
AC 3:0 0.6012±0.1396 0.4757±0.1277 0.3931±0.1013 0.1886±0.085 0.119±0.0721 0.1561±0.0858 
AC 4:0 0.417±0.1322 0.3348±0.1182 0.1544±0.0999 0.0842±0.0775 0.104±0.0632 0.0883±0.0767 
AC 8:1 0.4749±0.1221 0.4526±0.1058 0.3039±0.0884 0.0303±0.0773 0.1123±0.0607 0.0477±0.076 
AC 5:0 (OH)  0.4027±0.1326 0.303±0.1196 0.2956±0.0928 0.0981±0.0767 0.0679±0.064 0.0823±0.0765 
FA 8:1 (DiC)  0.4792±0.1483 0.388±0.1325 0.2619±0.1083 0.0723±0.0881 0.1532±0.0699 0.0316±0.0886 
FA 9:1 (DiC)  0.484±0.1233 0.3768±0.1125 0.2216±0.0947 0.1568±0.0732 0.179±0.0587 0.1244±0.074 
FA 12:1 (DiC) -0.2281±0.1283 -0.1029±0.1166 -0.0888±0.0917 -0.073±0.0703 -0.0328±0.0588 -0.1114±0.0688 
FA 28:2 (DiC) -0.35±0.1185 -0.2814±0.1057 -0.088±0.0906 -0.172±0.0652 -0.0596±0.0569 -0.1383±0.0659 
SN-glycero-3-phosphocholine 0.024±0.1332 0.0706±0.117 -0.0773±0.0933 0.0616±0.0712 0.0282±0.0592 0.1315±0.0699 
PC 34:0/PE 37:0 -0.343±0.0998 -0.2548±0.091 -0.1616±0.0747 -0.1065±0.058 -0.1335±0.0464 -0.1146±0.0572 
PC 40:4/PE 43:4 0.2676±0.1194 0.2415±0.1048 0.1886±0.0838 0.0445±0.0672 0.0021±0.0563 0.0319±0.0669 
PC 31:5/PE 34:5 0.1287±0.1284 0.1402±0.1124 0.0774±0.0899 -0.0464±0.07 0.032±0.0575 -0.0449±0.0694 
PC 35:5/PE 38:5 -0.4873±0.1246 -0.3443±0.1169 -0.2215±0.0957 -0.128±0.0753 -0.0805±0.0633 -0.094±0.076 
PE 36:2 0.1502±0.1283 0.1731±0.1121 0.1246±0.0894 -0.0615±0.0704 0.0521±0.0575 -0.0415±0.0697 
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PS 35:4 0.3788±0.1136 0.2983±0.1021 0.2917±0.0789 0.045±0.0683 0.0463±0.0561 0.039±0.0679 
PS 40:4 -0.3207±0.1177 -0.1948±0.1086 -0.0436±0.0903 -0.0902±0.0667 -0.127±0.0538 -0.1032±0.0658 
PS 42:6 -0.2823±0.1339 -0.1918±0.12 -0.0587±0.0983 -0.0662±0.0746 -0.0125±0.0625 -0.037±0.0745 
PS 39:7 -0.4356±0.1304 -0.3915±0.1145 -0.1769±0.0987 -0.1515±0.0749 -0.1395±0.0617 -0.1769±0.0732 
LysoPC 14:0 0.0877±0.1379 0.0751±0.1211 0.1507±0.0955 -0.0735±0.0745 0.0417±0.0614 -0.0687±0.0739 
norhyodeoxycholic acid  0.3564±0.1201 0.1795±0.1154 0.1516±0.089 0.0579±0.0701 0.0425±0.0581 0.0163±0.0706 
SM d36:2 0.23±0.1334 0.2765±0.1157 0.2567±0.0909 -0.028±0.0745 0.0924±0.0599 0.0044±0.0735 
DHEA sulfate 0.4019±0.1493 0.2734±0.1356 0.2603±0.1059 0.0604±0.086 0.0733±0.0707 0.0412±0.0858 
cortisone -0.2488±0.1269 -0.306±0.1096 -0.1999±0.0882 0.0818±0.0723 0.0597±0.0594 0.0419±0.0713 
urate 0.275±0.1283 0.1759±0.1155 0.1831±0.0903 -0.0703±0.0737 0.0014±0.0601 -0.0713±0.0731 
dipeptide (glutamate-
phenylalanine) 
0.2456±0.1179 0.1739±0.1053 0.1297±0.084 0.074±0.0652 -0.0717±0.0556 0.0356±0.0655 
dipeptide (histidine-tyrosine) 0.3489±0.1363 0.2634±0.1219 0.0799±0.1021 0.1414±0.0755 0.0613±0.0642 0.1204±0.0755 






Table S4.3. Association between annotated metabolites and BMIz in girls (n=108). Sex-stratified regression models identifying 
annotated metabolites (p=550) linearly associated with BMIz. All models were adjusted for age and puberty onset (Model 1), along 
with additional phenotypic measures to identify metabolites that drive the association with BMIz including HOMA-CP (Model 2), 
MUAMA (Model 3), MUAFA (Model 4), WHtR (Model 5) and TR+SS (Model 6). Values reported are β±Std Error. Metabolites with 
FDR<0.10 highlighted in red and bolded. Metabolites listed have an FDR<0.10 in Model 1 in the combined model and/or the sex-
stratified models. 
Metabolite Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
N-acetylglycine -0.3573±0.1271 -0.2206±0.1297 -0.1855±0.0932 -0.0156±0.0708 -0.0046±0.0554 0.0271±0.0716 
isovalerylcarnitine  0.2843±0.1121 0.2325±0.1069 0.1504±0.0816 0.069±0.0603 0.0159±0.0481 0.0529±0.0608 
isoleucine 0.1539±0.1319 0.1403±0.1238 0.1286±0.0932 0.0523±0.0683 -0.0381±0.0541 0.0732±0.0681 
leucine -0.0417±0.1276 -0.0335±0.1197 -0.0766±0.0902 0.1221±0.0652 0.0302±0.0516 0.068±0.0657 
valine 0.1829±0.1131 0.1634±0.1063 0.0666±0.0816 0.05±0.0592 -0.0026±0.0469 0.0495±0.0593 
phenylalanine 0.1831±0.0982 0.1401±0.0934 0.0673±0.0713 0.086±0.0509 0.0126±0.041 0.0773±0.0512 
tyrosine 0.3526±0.1044 0.2981±0.1002 0.2067±0.0767 0.0931±0.0579 0.0334±0.0465 0.0535±0.0592 
5-methylthioadenosine 0.1845±0.1054 0.1332±0.1004 0.0143±0.0775 0.0424±0.0554 -0.01±0.044 0.0594±0.0552 
D-ornithine 0.1896±0.1124 0.1715±0.1056 0.035±0.082 0.0672±0.0586 -0.0033±0.0467 0.0738±0.0586 
L-ornithine 0.1943±0.1115 0.1683±0.105 0.0226±0.0818 0.0674±0.0582 0.0063±0.0464 0.0857±0.058 
normethanephrine 0.1832±0.0982 0.1402±0.0934 0.0674±0.0713 0.0861±0.0509 0.0127±0.041 0.0774±0.0512 
D-lyxose -0.4107±0.1425 -0.4257±0.1326 -0.3222±0.1004 -0.0259±0.0795 0.0455±0.0629 0.0712±0.0813 
5-phospho-alpha-D-ribose-1-
diphosphate 
0.3164±0.125 0.2749±0.1183 0.1176±0.0927 0.1763±0.0645 0.1166±0.0515 0.1357±0.0658 
Cer t36:0(2OH) 0.3728±0.1141 0.3615±0.1067 0.2789±0.0809 0.0085±0.0655 0.0488±0.0503 -0.0237±0.0662 
PE-Cer d36:1 0.2695±0.0958 0.1843±0.0953 0.1409±0.0702 -0.019±0.0539 0.0085±0.0417 0.0301±0.053 
PE-Cer d32:3 0.4203±0.1053 0.3479±0.1031 0.2162±0.0802 0.0836±0.0612 0.0815±0.0475 0.0998±0.0607 
PE-Cer d34:3 0.3084±0.1061 0.2462±0.1023 0.1735±0.0775 0.0105±0.0594 0.0418±0.0459 0.0339±0.059 
DG 32:0 0.4379±0.1005 0.347±0.1027 0.2268±0.0776 0.1102±0.0589 0.0907±0.0461 0.1255±0.0583 
DG 34:0 0.4175±0.0951 0.3418±0.095 0.2593±0.0708 0.0834±0.0567 0.0758±0.0441 0.1006±0.0561 
DG 30:1  0.4063±0.1021 0.3265±0.1013 0.2319±0.0764 0.1089±0.0583 0.1322±0.0441 0.1229±0.0578 
DG 32:1 0.4828±0.1039 0.3945±0.1054 0.2696±0.0799 0.1325±0.0615 0.1206±0.0477 0.1415±0.0612 
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DG 33:1 0.4256±0.1072 0.3444±0.106 0.2747±0.0785 0.084±0.0623 0.0939±0.048 0.0707±0.0629 
DG 34:1 0.4441±0.1012 0.3603±0.1017 0.2226±0.0787 0.13±0.0586 0.0913±0.0465 0.1367±0.0584 
DG 35:1 0.3381±0.0977 0.2727±0.0952 0.1509±0.0742 0.0964±0.0542 0.0562±0.0432 0.094±0.0544 
DG 36:1 0.3867±0.099 0.3077±0.0985 0.1653±0.0771 0.1103±0.0561 0.0605±0.0449 0.1225±0.0557 
DG 32:2 0.5131±0.0969 0.4455±0.0958 0.3114±0.0745 0.1435±0.0596 0.1569±0.0447 0.1617±0.0587 
DG 34:2 0.4495±0.104 0.3712±0.1031 0.2381±0.0799 0.1249±0.0603 0.1102±0.047 0.1247±0.0604 
DG 35:2 0.4552±0.1081 0.3812±0.1059 0.2255±0.0836 0.1189±0.0626 0.1072±0.0487 0.1274±0.0624 
DG 34:3 0.4785±0.1034 0.3997±0.1029 0.2647±0.0796 0.0868±0.063 0.131±0.0469 0.1035±0.0624 
DG 35:3 0.518±0.1059 0.4639±0.1017 0.2877±0.0823 0.1595±0.0627 0.1358±0.0489 0.1662±0.0625 
DG 36:3 0.4491±0.1192 0.3723±0.116 0.2105±0.0911 0.1185±0.0674 0.1368±0.0515 0.1699±0.0655 
DG 36:4 0.4041±0.0973 0.356±0.0933 0.2135±0.0742 0.1515±0.0542 0.1487±0.0415 0.1791±0.053 
DG 38:4 0.3416±0.1209 0.2944±0.1148 0.1348±0.0903 0.1036±0.0652 0.0999±0.0508 0.1577±0.0637 
DG 36:5 0.3551±0.1143 0.3112±0.1085 0.1885±0.0843 0.0179±0.0647 0.1266±0.0477 0.0777±0.0633 
DG 38:5 0.3117±0.1199 0.2054±0.1189 0.1216±0.0889 0.0527±0.0652 0.0616±0.0508 0.0604±0.0651 
FA 17:0 0.2018±0.1093 0.1947±0.1024 0.1015±0.0786 0.0559±0.0575 0.0424±0.0452 0.0495±0.0576 
FA 18:3 0.2916±0.1079 0.2664±0.1016 0.1249±0.0799 0.0604±0.0587 0.04±0.0462 0.0696±0.0585 
AC 3:0 0.0937±0.1061 0.048±0.1005 0.0664±0.0752 0.0222±0.0549 -0.0257±0.0433 0.0638±0.0545 
AC 4:0 0.1474±0.1135 0.1567±0.1062 0.0063±0.0822 0.0619±0.0587 0.0047±0.0466 0.0568±0.0589 
AC 8:1 0.2674±0.1175 0.2723±0.1098 0.1044±0.0862 -0.0271±0.0642 -0.0508±0.0503 -0.0366±0.0644 
AC 5:0 (OH)  0.1988±0.1143 0.1739±0.1076 0.0794±0.0826 0.1356±0.0582 0.049±0.047 0.1316±0.0584 
FA 8:1 (DiC)  0.0546±0.1041 0.0316±0.0979 -0.079±0.0746 0.0382±0.0535 0.0146±0.0421 0.0645±0.0533 
FA 9:1 (DiC)  0.0592±0.1087 0.0361±0.1022 -0.0488±0.0777 0.0594±0.0557 0.031±0.0439 0.0737±0.0556 
FA 12:1 (DiC) -0.2365±0.1038 -0.1831±0.0992 -0.1492±0.0744 0.0343±0.0568 0.0648±0.0445 0.0728±0.0573 
FA 28:2 (DiC) 0.0256±0.1227 -0.0149±0.1156 -0.0746±0.0872 -0.0595±0.063 0.0003±0.0496 -0.013±0.0632 
SN-glycero-3-phosphocholine 0.3025±0.1077 0.2859±0.101 0.1502±0.0792 0.0629±0.0588 0.0498±0.0462 0.0782±0.0585 
PC 34:0/PE 37:0 0.0256±0.1376 0.0384±0.1291 0.0057±0.0975 -0.0814±0.0706 0.0365±0.0555 -0.0008±0.0709 
PC 40:4/PE 43:4 0.2437±0.1205 0.2257±0.1132 0.1532±0.0862 -0.007±0.0648 -0.0161±0.0508 -0.0536±0.0654 
PC 31:5/PE 34:5 0.3597±0.1001 0.287±0.0983 0.1344±0.0777 0.0842±0.0565 0.1078±0.043 0.1283±0.055 
PC 35:5/PE 38:5 -0.1497±0.1123 -0.1478±0.1053 -0.0945±0.0799 -0.0738±0.0579 -0.0422±0.0458 -0.0874±0.0578 
PE 36:2 0.3827±0.1101 0.3023±0.1081 0.1559±0.0844 0.0953±0.0616 0.0866±0.0481 0.1157±0.061 
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PS 35:4 0.1133±0.1188 0.0406±0.1135 0.0589±0.0845 -0.0121±0.0617 -0.0045±0.0485 -0.034±0.0619 
PS 40:4 -0.114±0.1372 -0.1067±0.1287 -0.1346±0.0967 0.0562±0.0712 0.0166±0.0559 0.0337±0.0713 
PS 42:6 -0.26±0.1075 -0.2301±0.1015 -0.1235±0.0785 -0.0782±0.0573 -0.0512±0.0452 -0.1269±0.0561 
PS 39:7 0.0292±0.1131 0.0087±0.1063 -0.1621±0.0807 -0.0051±0.0582 0.0096±0.0457 0.0857±0.0578 
LysoPC 14:0 0.2963±0.1045 0.205±0.1037 0.0948±0.0789 0.0662±0.057 0.0946±0.0437 0.1105±0.0558 
norhyodeoxycholic acid  -0.0294±0.1126 -0.026±0.1056 0.084±0.0801 0.0418±0.0579 0.0495±0.0454 -0.0248±0.0579 
SM d36:2 0.2231±0.1089 0.1863±0.103 0.1293±0.0782 -0.0579±0.0592 0.0091±0.0458 -0.059±0.0593 
DHEA sulfate 0.2516±0.1502 0.1358±0.1458 -0.045±0.1116 0.0103±0.0794 0.048±0.0619 0.0605±0.0789 
cortisone -0.2959±0.1093 -0.2729±0.1028 -0.1269±0.0809 -0.1054±0.0583 -0.0157±0.0472 -0.0848±0.0589 
urate 0.2483±0.1302 0.1764±0.1246 0.0123±0.0967 0.1601±0.0665 0.0611±0.0538 0.1348±0.0672 
dipeptide (glutamate-
phenylalanine) 
0.3112±0.1215 0.2922±0.1141 0.1754±0.0881 0.0905±0.0651 -0.0517±0.0528 0.0751±0.0656 
dipeptide (histidine-tyrosine) 0.1619±0.1128 0.1222±0.1066 0.004±0.0821 0.0973±0.0579 0.0118±0.0464 0.0996±0.0579 





































Linear models identified metabolites associated with BMIz in the entire cohort, adjusting for age, 
sex, and puberty onset, and in sex-stratified models, adjusting for age and puberty onset. Beta 
coefficients representing the relationship between (A) DG metabolites and (B) BCAA 
metabolites with BMIz in the entire cohort (bars) and boys (blue dots) and girls (red dots). 
Significance in the entire cohort depicted by striped gray bars (FDR<0.10). Signficance in sex-
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T-tests were used to distinguish differences between metabolite groups. Sum of raw peak 
intensity values of FA (p=55) stratified by (A) obese and normal weight (p=0.0717) and (B) by 
sex (p=0.86662). Sum of raw peak intensity values of DG metabolites (p=19) significantly 
differs between (C) obese and normal weight (p=0.000154) and (D) trended to be elevated in 




Figure 4.2. Relationship between fatty acid chain length and number of double bonds with 
BMIz, sex-stratified.  
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(A) Relationship between beta coefficients describing models between fatty acids and BMIz and 
fatty acid chain length (14-30 carbons) in boys (r²=0.5568, p-value<0.0001) and girls (r²=0.0064, 
p-value=0.5621). (B) Relationship between beta coefficients describing models between fatty 
acids and BMIz and number of double bonds in boys (r²=0.0226, p-value=0.2731) and girls 






Figure S4.5. Association of metabolite features with HOMA-CP, within the entire cohort and 
sex-stratified.  
 
Beta coefficients from linear models are plotted on the x-axis and negative log transformed p-
values are plotted on the y-axis. Association between HOMA-CP and both annotated and 
unannotated features (p=3272) (A) within entire cohort (n=206), accounting for age, sex, and 
puberty onset, and sex stratified in (B) boys and (C) girls, accounting for age and puberty onset 
(Model 1). Using solely annotated metabolites (p=550), representing the relationship between 
metabolites and HOMA-CP (D) within the entire cohort and sex stratified in (E) boys and (F) 




Table S4.4. Association between annotated metabolites and HOMA-CP (n=206). Regression models identifying annotated 
metabolites (p=550) linearly associated with HOMA-CP. All models were adjusted for sex, age, and puberty onset (Model 1), along 
with additional phenotypic measures to identify metabolites that drive the association with HOMA-CP including BMIz (Model 2), 
MUAMA (Model 3), MUAFA (Model 4), WHtR (Model 5) and TR+SS (Model 6). Values reported are β±Std Error. Metabolites with 
FDR<0.10 highlighted in red and bolded. Metabolites listed have an FDR<0.10 in Model 1 in the combined model and/or the sex-
stratified models. 
Metabolite Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
N-acetylglycine -0.5841±0.1363 -0.4536±0.1302 -0.467±0.1292 -0.4565±0.1344 -0.4378±0.134 -0.4529±0.1353 
N-acetyl-L-leucine 0.2169±0.1364 0.1517±0.1269 0.1978±0.126 0.2118±0.1289 0.1535±0.1287 0.2088±0.1292 
creatine 0.4111±0.144 0.4385±0.1324 0.4188±0.1324 0.4306±0.1356 0.4352±0.1343 0.4297±0.1359 
lysine 0.4362±0.1317 0.3173±0.125 0.3219±0.1245 0.3303±0.128 0.3224±0.1269 0.342±0.1277 
3,4-hydroxyphenyl-lactate 0.1682±0.1428 0.0913±0.133 0.0728±0.1332 0.1286±0.1354 0.1269±0.1342 0.1315±0.1357 
tyrosine 0.476±0.1352 0.2707±0.1339 0.3315±0.1294 0.3194±0.1353 0.2882±0.1358 0.3084±0.1371 
proline 0.4877±0.1358 0.4092±0.1271 0.3938±0.1275 0.4115±0.1303 0.406±0.1292 0.41±0.1307 
glucose 0.4791±0.1556 0.4819±0.1432 0.4466±0.1437 0.5212±0.1462 0.4793±0.1453 0.5037±0.1467 
raffinose 0.2699±0.1369 0.1875±0.128 0.1779±0.128 0.2441±0.1296 0.1892±0.1298 0.2506±0.1298 
DG 32:0 0.5326±0.1251 0.3392±0.1253 0.3978±0.1202 0.3707±0.1284 0.3637±0.1264 0.3784±0.1281 
DG 34:0 0.4707±0.1283 0.2793±0.127 0.3489±0.122 0.3097±0.1299 0.2985±0.1285 0.3179±0.1297 
DG 30:1  0.4249±0.1299 0.2459±0.1269 0.3201±0.1224 0.2809±0.1291 0.2916±0.1264 0.2866±0.1291 
DG 32:1 0.4471±0.1289 0.2503±0.1276 0.3378±0.1219 0.2768±0.1311 0.2877±0.1277 0.2844±0.1309 
DG 34:1 0.4186±0.1289 0.2149±0.1278 0.2829±0.1231 0.243±0.1312 0.2547±0.1278 0.2528±0.1309 
DG 36:1 0.4301±0.1303 0.2385±0.1282 0.2686±0.1259 0.2736±0.1306 0.2654±0.1291 0.2827±0.1304 
DG 32:2 0.381±0.1296 0.1706±0.1284 0.2602±0.1228 0.1935±0.1323 0.2197±0.1278 0.2049±0.1319 
DG 34:3 0.3544±0.1287 0.1642±0.126 0.2489±0.1213 0.1613±0.1317 0.2056±0.1259 0.1783±0.1307 
FA 12:2 -0.4197±0.1334 -0.3597±0.1243 -0.3755±0.1236 -0.411±0.1259 -0.3884±0.1252 -0.4105±0.1262 
FA 14:2 -0.4426±0.1355 -0.4579±0.1245 -0.4798±0.124 -0.5153±0.1271 -0.4739±0.1261 -0.499±0.1275 
FA 14:3 0.3069±0.1273 0.2644±0.1182 0.2365±0.1187 0.2958±0.1203 0.2822±0.1195 0.2951±0.1206 
FA 16:3 -0.3824±0.1338 -0.4752±0.1226 -0.4516±0.1224 -0.536±0.1264 -0.4694±0.1245 -0.5229±0.1266 
AC 2:0 -0.4066±0.1347 -0.3824±0.1245 -0.3661±0.1247 -0.4268±0.1267 -0.3972±0.126 -0.4193±0.1271 
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AC 6:0 -0.3812±0.1402 -0.4653±0.1286 -0.4785±0.1284 -0.4795±0.132 -0.4516±0.1306 -0.4747±0.1323 
AC 8:0 -0.393±0.1382 -0.3736±0.1277 -0.4253±0.1267 -0.3942±0.1303 -0.3752±0.1294 -0.3941±0.1306 
AC 10:0 -0.461±0.1384 -0.4031±0.1288 -0.4725±0.127 -0.4232±0.1313 -0.4087±0.1305 -0.4245±0.1316 
AC 12:0 -0.3707±0.1334 -0.3465±0.1234 -0.4089±0.1223 -0.3658±0.1259 -0.3405±0.1252 -0.3589±0.1263 
AC 10:1 -0.393±0.1373 -0.3712±0.1269 -0.4286±0.1259 -0.3884±0.1295 -0.3739±0.1286 -0.3848±0.1299 
AC 12:1  -0.4827±0.1357 -0.5026±0.1244 -0.5148±0.1241 -0.5256±0.1272 -0.5026±0.1262 -0.522±0.1276 
AC 14:1  -0.4714±0.1336 -0.4302±0.1239 -0.4856±0.1225 -0.4638±0.126 -0.4375±0.1254 -0.4541±0.1265 
AC 10:2 -0.3995±0.1371 -0.3643±0.127 -0.3911±0.1263 -0.4044±0.1292 -0.3735±0.1286 -0.4035±0.1295 
AC 12:2 -0.5864±0.1267 -0.5209±0.1183 -0.57±0.1164 -0.5142±0.1218 -0.5289±0.1198 -0.5231±0.1217 
AC 14:2 -0.4589±0.1267 -0.4356±0.1171 -0.4808±0.116 -0.4694±0.1192 -0.4436±0.1185 -0.4572±0.1197 
AC 11:3 -0.234±0.1247 -0.1659±0.1163 -0.2435±0.1149 -0.1497±0.1198 -0.1917±0.1173 -0.1363±0.1207 
AC 6:0 (OH)  -0.361±0.1336 -0.3586±0.1232 -0.3701±0.1229 -0.4077±0.1257 -0.3637±0.1249 -0.4036±0.126 
AC 8:0 (OH) -0.5435±0.1346 -0.4658±0.126 -0.5285±0.1237 -0.48±0.1286 -0.4706±0.1277 -0.4829±0.1288 
AC 10:0 (OH) -0.5451±0.1373 -0.474±0.1282 -0.5547±0.1257 -0.4843±0.1311 -0.4761±0.1301 -0.4852±0.1314 
FA 8:0 (DiC) 0.2938±0.135 0.1972±0.1267 0.1123±0.1301 0.2657±0.1279 0.215±0.128 0.2676±0.1281 
FA 10:1 (DiC)  -0.0749±0.133 0±0.1238 0.0013±0.1236 -0.0031±0.1267 0.0097±0.1258 -0.0118±0.1268 
Keto 14:0 -0.4328±0.1338 -0.3808±0.1244 -0.4338±0.123 -0.4273±0.1262 -0.391±0.1259 -0.4219±0.1266 
PA 22:3 -0.3523±0.1277 -0.3199±0.1183 -0.2692±0.1195 -0.3274±0.1209 -0.3024±0.1204 -0.3327±0.121 
PC 33:3/PE 36:3 -0.4657±0.1229 -0.374±0.1159 -0.3463±0.1171 -0.4094±0.1174 -0.3902±0.117 -0.418±0.1173 
PC 38:6/PE 41:6 -0.2292±0.1402 -0.1777±0.1302 -0.1706±0.1301 -0.1988±0.1328 -0.1834±0.1319 -0.1968±0.1331 
myo-inositol 0.4666±0.1458 0.4768±0.1341 0.5007±0.1336 0.4493±0.1378 0.4886±0.1358 0.4563±0.1379 
LysoPC 14:0 0.3609±0.132 0.2423±0.1251 0.283±0.1233 0.2485±0.1284 0.2807±0.1255 0.2663±0.1278 
glycochenodeoxycholate 0.677±0.1241 0.6703±0.1136 0.6437±0.1143 0.6975±0.1158 0.6614±0.1156 0.6896±0.1163 
glycocholate 0.6307±0.1261 0.6136±0.1159 0.5882±0.1165 0.6603±0.1177 0.6199±0.1174 0.644±0.1183 
taurocholate -0.2432±0.1327 -0.285±0.1223 -0.2724±0.1222 -0.2708±0.1252 -0.2817±0.124 -0.2936±0.1255 
norhyodeoxycholic acid  0.1939±0.1313 0.105±0.1228 0.1613±0.1215 0.1315±0.1251 0.1324±0.1239 0.1029±0.1264 
DHEA sulfate 0.4953±0.1674 0.3226±0.1598 0.3308±0.159 0.3439±0.1635 0.3528±0.161 0.3553±0.1633 
cycloheptanecarboxylic acid 0.2935±0.1349 0.2084±0.1263 0.1279±0.1292 0.267±0.1278 0.2244±0.1277 0.2714±0.128 




Table S4.5. Association between annotated metabolites and HOMA-CP in boys (n=98). Sex-stratified regression models identifying 
annotated metabolites (p=550) linearly associated with HOMA-CP. All models were adjusted for age and puberty onset (Model 1), 
along with additional phenotypic measures to identify metabolites that drive the association with HOMA-CP including BMIz (Model 
2), MUAMA (Model 3), MUAFA (Model 4), WHtR (Model 5) and TR+SS (Model 6). Values reported are β±Std Error. Metabolites 
with FDR<0.10 highlighted in red and bolded. Metabolites listed have an FDR<0.10 in Model 1 in the combined model and/or the 
sex-stratified models. 
Metabolite Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
N-acetylglycine -0.2982±0.1351 -0.2255±0.1202 -0.2095±0.1185 -0.2089±0.1269 -0.1766±0.123 -0.2061±0.1248 
N-acetyl-L-leucine 0.4153±0.1205 0.2918±0.1113 0.341±0.1053 0.3437±0.113 0.2843±0.1123 0.3199±0.1128 
creatine 0.1014±0.1806 0.068±0.1587 0.073±0.1557 0.0287±0.1663 0.0589±0.1591 0.0039±0.1643 
lysine 0.2753±0.1553 0.1409±0.1403 0.1054±0.139 0.1655±0.1459 0.1588±0.1397 0.1861±0.1423 
3,4-hydroxyphenyl-lactate 0.4918±0.1302 0.4115±0.1162 0.3582±0.1176 0.4718±0.1183 0.4579±0.1136 0.4565±0.117 
tyrosine 0.7383±0.1475 0.5546±0.1415 0.5724±0.1349 0.5977±0.1461 0.5495±0.1428 0.5754±0.1455 
proline 0.3841±0.1345 0.3251±0.1189 0.3208±0.1167 0.3149±0.1252 0.3234±0.1193 0.314±0.1231 
glucose 0.4463±0.1531 0.3823±0.1352 0.3297±0.1352 0.4548±0.1385 0.3798±0.1356 0.4366±0.1368 
raffinose 0.4855±0.144 0.3368±0.1331 0.3251±0.1308 0.4177±0.1337 0.3551±0.1319 0.4088±0.1319 
DG 32:0 0.3424±0.1388 0.1936±0.1278 0.2529±0.1217 0.1899±0.1358 0.1736±0.1296 0.1755±0.134 
DG 34:0 0.3365±0.1604 0.222±0.144 0.2546±0.1397 0.2225±0.151 0.1904±0.146 0.2113±0.149 
DG 30:1  0.2333±0.1463 0.1157±0.1316 0.1888±0.1265 0.1138±0.1383 0.1237±0.1315 0.1013±0.1364 
DG 32:1 0.1854±0.138 0.064±0.1243 0.1585±0.119 0.0372±0.1324 0.0662±0.1245 0.0282±0.1302 
DG 34:1 0.1793±0.1446 0.0257±0.1313 0.0974±0.126 -0.0025±0.1404 0.0469±0.1306 -0.0083±0.1377 
DG 36:1 0.2458±0.1568 0.0949±0.1421 0.1156±0.1382 0.0897±0.15 0.1015±0.1421 0.0818±0.1475 
DG 32:2 0.2063±0.1454 0.114±0.1296 0.1781±0.1253 0.0625±0.1388 0.1152±0.1299 0.0559±0.1364 
DG 34:3 0.1076±0.1361 0.0152±0.1211 0.1±0.1172 -0.0483±0.13 0.0205±0.1212 -0.0394±0.1269 
FA 12:2 -0.1445±0.1344 -0.0861±0.1189 -0.016±0.1187 -0.1707±0.1226 -0.1227±0.1183 -0.1912±0.1207 
FA 14:2 -0.2807±0.1435 -0.2633±0.1257 -0.1697±0.1265 -0.3651±0.1298 -0.2992±0.1251 -0.3697±0.1276 
FA 14:3 0.3856±0.1309 0.3942±0.113 0.346±0.1125 0.4413±0.1172 0.4229±0.1124 0.4412±0.1151 
FA 16:3 -0.1969±0.1392 -0.2978±0.121 -0.14±0.1208 -0.4129±0.1288 -0.2932±0.1213 -0.4333±0.1263 
AC 2:0 -0.2764±0.1427 -0.3398±0.1234 -0.2856±0.1219 -0.3922±0.1292 -0.3438±0.1236 -0.3867±0.1268 
181 
 
AC 6:0 -0.2553±0.1471 -0.4295±0.1271 -0.3622±0.1245 -0.4447±0.1343 -0.3898±0.1274 -0.4654±0.1317 
AC 8:0 -0.4041±0.157 -0.4089±0.1363 -0.4234±0.1331 -0.4322±0.1419 -0.4016±0.1368 -0.4443±0.1393 
AC 10:0 -0.4648±0.1528 -0.4249±0.1338 -0.4747±0.129 -0.4444±0.1392 -0.4192±0.1343 -0.4493±0.1367 
AC 12:0 -0.3901±0.1369 -0.4087±0.118 -0.4545±0.1142 -0.4258±0.1232 -0.3931±0.1188 -0.4246±0.1211 
AC 10:1 -0.3668±0.1458 -0.3605±0.1269 -0.3739±0.1239 -0.3892±0.1319 -0.3585±0.1272 -0.3997±0.1295 
AC 12:1  -0.421±0.1432 -0.4637±0.1226 -0.4486±0.1204 -0.5026±0.1279 -0.4507±0.1233 -0.4964±0.1256 
AC 14:1  -0.4575±0.1427 -0.4665±0.1229 -0.4874±0.1195 -0.5102±0.1276 -0.4475±0.1239 -0.4883±0.1259 
AC 10:2 -0.3609±0.1513 -0.3738±0.1312 -0.354±0.1291 -0.4386±0.1362 -0.3598±0.1319 -0.4333±0.1339 
AC 12:2 -0.2957±0.1418 -0.2516±0.1249 -0.311±0.1208 -0.2609±0.1302 -0.2303±0.126 -0.2697±0.1278 
AC 14:2 -0.3378±0.1309 -0.358±0.1131 -0.4036±0.1096 -0.3888±0.1178 -0.3478±0.1136 -0.375±0.116 
AC 11:3 -0.5279±0.1228 -0.4373±0.1106 -0.4645±0.106 -0.4444±0.1163 -0.4583±0.1092 -0.4194±0.1164 
AC 6:0 (OH)  -0.1804±0.143 -0.2766±0.1245 -0.2641±0.122 -0.349±0.1317 -0.2524±0.1248 -0.3396±0.1289 
AC 8:0 (OH) -0.5216±0.1547 -0.4715±0.1356 -0.5013±0.1314 -0.4951±0.141 -0.4586±0.1366 -0.5015±0.1383 
AC 10:0 (OH) -0.5052±0.1553 -0.4684±0.1356 -0.5151±0.1308 -0.4811±0.1415 -0.4472±0.1369 -0.4867±0.1388 
FA 8:0 (DiC) 0.418±0.1427 0.2429±0.1337 0.2189±0.1323 0.3389±0.1333 0.267±0.1321 0.3203±0.1321 
FA 10:1 (DiC)  -0.3826±0.131 -0.3028±0.1171 -0.2771±0.116 -0.3373±0.1207 -0.2765±0.119 -0.3553±0.1179 
Keto 14:0 -0.2845±0.14 -0.2734±0.1223 -0.2349±0.1211 -0.3405±0.1266 -0.2729±0.1226 -0.354±0.1244 
PA 22:3 -0.2523±0.1482 -0.2229±0.1302 -0.1487±0.1301 -0.2588±0.1351 -0.2295±0.1303 -0.2741±0.1327 
PC 33:3/PE 36:3 -0.1924±0.1421 -0.0507±0.1288 -0.0566±0.1258 -0.0918±0.1331 -0.0836±0.1276 -0.0756±0.1316 
PC 38:6/PE 41:6 -0.4542±0.1404 -0.3415±0.1272 -0.3354±0.1248 -0.3575±0.1327 -0.3411±0.1275 -0.3471±0.131 
myo-inositol 0.1016±0.146 0.1201±0.1279 0.104±0.1257 0.0691±0.1339 0.1459±0.1281 0.0945±0.1315 
LysoPC 14:0 0.0296±0.1545 -0.0175±0.1359 0.0794±0.1331 -0.057±0.1426 0.0022±0.136 -0.0604±0.1404 
glycochenodeoxycholate 0.2999±0.1289 0.3624±0.1108 0.3288±0.1092 0.3568±0.1162 0.3357±0.1115 0.3212±0.1148 
glycocholate 0.365±0.1334 0.4169±0.1143 0.3532±0.1138 0.4312±0.1197 0.3705±0.1158 0.3972±0.1182 
taurocholate 0.1881±0.1245 0.069±0.1128 0.0995±0.1092 0.0947±0.1171 0.0659±0.1132 0.0736±0.1161 
norhyodeoxycholic acid  0.4594±0.1322 0.2931±0.1251 0.308±0.1205 0.3247±0.13 0.2953±0.1252 0.2953±0.1303 
DHEA sulfate 0.3231±0.17 0.1158±0.1572 0.2107±0.149 0.1487±0.1638 0.1331±0.1565 0.1244±0.1621 
cycloheptanecarboxylic acid 0.4161±0.1429 0.2629±0.1321 0.2428±0.1305 0.3454±0.1329 0.2863±0.1307 0.3285±0.1316 




Table S4.6. Association between annotated metabolites and HOMA-CP in girls (n=108). Sex-stratified regression models identifying 
annotated metabolites (p=550) linearly associated with HOMA-CP. All models were adjusted for age and puberty onset (Model 1), 
along with additional phenotypic measures to identify metabolites that drive the association with HOMA-CP including BMIz (Model 
2), MUAMA (Model 3), MUAFA (Model 4), WHtR (Model 5) and TR+SS (Model 6). Values reported are β±Std Error. Metabolites 
with FDR<0.10 highlighted in red and bolded. Metabolites listed have an FDR<0.10 in Model 1 in the combined model and/or the 
sex-stratified models. 
Metabolite Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 
N-acetylglycine -0.8848±0.2336 -0.6984±0.232 -0.7536±0.2276 -0.711±0.2374 -0.726±0.2373 -0.725±0.2424 
N-acetyl-L-leucine -0.0425±0.2538 0±0.2384 0.0034±0.2401 0.0705±0.2435 -0.0053±0.2427 0.0848±0.247 
creatine 0.5518±0.2134 0.615±0.1982 0.5938±0.2 0.6161±0.2013 0.6115±0.2023 0.6271±0.2035 
lysine 0.5171±0.1978 0.4024±0.1903 0.4368±0.1895 0.3988±0.1943 0.4054±0.1951 0.4131±0.1959 
3,4-hydroxyphenyl-lactate -0.1826±0.2508 -0.2311±0.2351 -0.2052±0.2366 -0.2313±0.2383 -0.2224±0.2394 -0.2046±0.2405 
tyrosine 0.3363±0.2047 0.1164±0.2041 0.2087±0.1983 0.1665±0.2041 0.1531±0.2075 0.1635±0.2087 
proline 0.6061±0.2297 0.5081±0.2186 0.4786±0.2226 0.5261±0.221 0.5061±0.2237 0.5222±0.2239 
glucose 0.5391±0.2662 0.6071±0.2481 0.5716±0.2503 0.6044±0.2518 0.5938±0.2531 0.5832±0.2545 
raffinose 0.1016±0.216 0.0893±0.2026 0.0813±0.2041 0.1142±0.2052 0.065±0.2066 0.129±0.2073 
DG 32:0 0.6923±0.1947 0.4767±0.2041 0.534±0.1962 0.5236±0.2027 0.5368±0.2029 0.5524±0.2028 
DG 34:0 0.548±0.1876 0.3236±0.196 0.4185±0.1846 0.3629±0.1968 0.3814±0.1959 0.3944±0.1967 
DG 30:1  0.5519±0.1995 0.3277±0.2049 0.4095±0.1965 0.3791±0.2036 0.4082±0.2011 0.4065±0.2041 
DG 32:1 0.6784±0.2048 0.4345±0.2168 0.5123±0.2056 0.4916±0.214 0.5089±0.2134 0.5212±0.2148 
DG 34:1 0.6164±0.1987 0.3836±0.2079 0.4436±0.2008 0.4414±0.2049 0.4475±0.2068 0.4674±0.2059 
DG 36:1 0.5463±0.1927 0.3343±0.1975 0.3724±0.1948 0.386±0.1958 0.3841±0.1987 0.4109±0.1964 
DG 32:2 0.5027±0.1995 0.2098±0.2152 0.3295±0.1997 0.2799±0.2118 0.313±0.2084 0.3176±0.2116 
DG 34:3 0.5746±0.2064 0.3129±0.2173 0.3996±0.2069 0.3545±0.2192 0.3973±0.2133 0.3912±0.2192 
FA 12:2 -0.6929±0.2256 -0.6261±0.213 -0.7506±0.2105 -0.6277±0.2163 -0.6491±0.2162 -0.619±0.2194 
FA 14:2 -0.5821±0.2197 -0.6161±0.2044 -0.7734±0.2057 -0.6228±0.2074 -0.6126±0.2085 -0.5945±0.21 
FA 14:3 0.2493±0.206 0.1582±0.1955 0.1496±0.1974 0.1775±0.1976 0.1774±0.1987 0.1857±0.1994 
FA 16:3 -0.5469±0.2192 -0.6168±0.2036 -0.7632±0.2059 -0.6213±0.2068 -0.6157±0.2078 -0.5945±0.2091 
AC 2:0 -0.4848±0.2236 -0.3898±0.2126 -0.4416±0.2118 -0.4139±0.2146 -0.4284±0.215 -0.4228±0.2165 
183 
 
AC 6:0 -0.4726±0.2288 -0.4687±0.2141 -0.568±0.2148 -0.4759±0.217 -0.4883±0.2178 -0.4684±0.2193 
AC 8:0 -0.3726±0.2112 -0.3329±0.1986 -0.4208±0.1986 -0.3451±0.2011 -0.3446±0.202 -0.3437±0.2031 
AC 10:0 -0.4478±0.2144 -0.375±0.2029 -0.4673±0.2016 -0.3898±0.2053 -0.392±0.2062 -0.3937±0.2073 
AC 12:0 -0.3368±0.2187 -0.2793±0.2062 -0.3755±0.2059 -0.2939±0.2086 -0.2871±0.2099 -0.2897±0.2109 
AC 10:1 -0.3984±0.2208 -0.3557±0.2077 -0.4644±0.2076 -0.3537±0.2107 -0.3672±0.2113 -0.3474±0.2132 
AC 12:1  -0.5177±0.2176 -0.5181±0.2034 -0.5639±0.2041 -0.5232±0.2061 -0.532±0.207 -0.5278±0.2081 
AC 14:1  -0.465±0.2123 -0.386±0.2012 -0.4844±0.1996 -0.4059±0.2033 -0.4191±0.2037 -0.4135±0.2051 
AC 10:2 -0.4191±0.2139 -0.3384±0.2028 -0.4069±0.2018 -0.3566±0.205 -0.3718±0.2053 -0.3693±0.2066 
AC 12:2 -0.7907±0.1953 -0.7095±0.1859 -0.7565±0.1843 -0.6873±0.1918 -0.7399±0.1878 -0.7049±0.1927 
AC 14:2 -0.5483±0.2083 -0.4857±0.1968 -0.547±0.1959 -0.5154±0.1984 -0.5161±0.1993 -0.5126±0.2006 
AC 11:3 0.0029±0.2013 0.0338±0.189 -0.0862±0.1915 0.0769±0.1925 0.0132±0.1923 0.0794±0.1946 
AC 6:0 (OH)  -0.4879±0.2149 -0.3969±0.2043 -0.4475±0.2035 -0.422±0.2062 -0.4386±0.2064 -0.4383±0.2075 
AC 8:0 (OH) -0.5417±0.2042 -0.4491±0.1947 -0.5472±0.1919 -0.4491±0.198 -0.4688±0.1977 -0.4586±0.1998 
AC 10:0 (OH) -0.5646±0.2098 -0.4745±0.1997 -0.5872±0.1968 -0.4784±0.2028 -0.4951±0.2028 -0.4834±0.205 
FA 8:0 (DiC) 0.2066±0.2135 0.188±0.2004 0.0396±0.2081 0.2311±0.2028 0.186±0.2041 0.2423±0.2048 
FA 10:1 (DiC)  0.1834±0.2274 0.2302±0.2131 0.222±0.2146 0.2583±0.2165 0.2307±0.2171 0.2657±0.2189 
Keto 14:0 -0.5488±0.218 -0.4671±0.2068 -0.6231±0.2041 -0.4897±0.2088 -0.4914±0.2098 -0.4805±0.2117 
PA 22:3 -0.4697±0.1968 -0.4428±0.1847 -0.3897±0.1885 -0.4409±0.1874 -0.4078±0.1899 -0.4392±0.1894 
PC 33:3/PE 36:3 -0.6254±0.1885 -0.5684±0.1781 -0.5312±0.1822 -0.5932±0.1795 -0.5727±0.1816 -0.6194±0.1803 
PC 38:6/PE 41:6 -0.0244±0.2298 -0.0399±0.2156 -0.0302±0.217 -0.0648±0.2187 -0.0401±0.2195 -0.0599±0.2208 
myo-inositol 0.8641±0.2443 0.8667±0.2272 0.9425±0.227 0.8729±0.2305 0.8642±0.2319 0.854±0.2336 
LysoPC 14:0 0.5803±0.1967 0.4149±0.1947 0.4263±0.1958 0.4465±0.1957 0.473±0.194 0.4811±0.1947 
glycochenodeoxycholate 1.0568±0.2013 0.9764±0.1911 0.9682±0.1938 1.0281±0.1904 0.9957±0.1941 1.0545±0.1912 
glycocholate 0.8732±0.2028 0.7845±0.1934 0.7939±0.1944 0.8528±0.192 0.84±0.1937 0.8582±0.1939 
taurocholate -0.8494±0.2319 -0.7462±0.2212 -0.7618±0.222 -0.7536±0.2246 -0.7637±0.2251 -0.7897±0.2244 
norhyodeoxycholic acid  -0.0185±0.2127 0.0007±0.1995 0.0814±0.2026 0.0301±0.2027 0.0299±0.2036 -0.0157±0.2041 
DHEA sulfate 0.6673±0.2799 0.5156±0.2683 0.4393±0.2779 0.5186±0.2729 0.5529±0.2718 0.5594±0.2731 
cycloheptanecarboxylic acid 0.2088±0.2132 0.1889±0.2001 0.0461±0.2075 0.2253±0.2024 0.1864±0.2038 0.241±0.2044 















































































































































































































Linear models identified metabolites associated with HOMA-CP in the entire cohort, adjusting 
for age, sex, and puberty onset, and in sex-stratified models, adjusting for age and puberty onset. 
Beta coefficients representing the relationship between all AC with HOMA-CP in the entire 
cohort (bars) and boys (blue dots) and girls (red dots). Significance in the entire cohort depicted 
by striped gray bars (FDR<0.10). Signficance in sex-stratified models depicted by “X” 
(FDR<0.10). 
         combined  
         combined (significant)  
● boys  
X boys (significant)  
● girls 




Table S4.7. Linear relationship between energy adjusted macronutrient intake with BMIz and HOMA-CP. Carbohydrate and fat 
intake was adjusted for total energy intake using the residual method and standardized (mean 0, std 1). Linear models assessed the 






β±SE                 Unadjusted p-value β±SE                 Unadjusted p-value 
carbohydrate 0.02872±0.085 0.7359 0.15307±0.1332 0.2519 
fat -0.05201±0.0851 0.5418 -0.18161±0.1332 0.1744 
186 
 
Figure 4.4. Structure of path analysis.  
 
Path analysis classfied the effects of macronutrient intake (independent variable) on BMIz and 
HOMA-CP (dependent variable) through metabolome clusters. The relationship between the diet 
and each metabolome cluster is described by β1. The relationship between each metabolome 
cluster and the outcome is described by β2. Path 1 describes the influence of macronutrient intake 
on BMIz and HOMA-CP. Path 2 describes the influence of macronutrient intake on BMIz and 
HOMA-CP through metabolome clusters. The independent variables, energy adjusted fat and 
carbohydrate intake, were standardized (mean 0, standard deviation 1). All models adjusted for 





















Pearson’s correlation and hierarchical clustering identified connectivity between annotated 
metabolites (p=550). Clusters were formed based on dendrogram height (red line) and tightness 







































Table S4.8. Classification of clusters. Annotated metabolites were clustered using hierarchical clustering. Cluster names and 




Cluster Name Metabolites 
1 LC and VLC-FA (DiC),VLC-FA, PC/PE 
FA 18:0 (DiC), FA 18:0 (OH), FA 24:1 (DiC), FA 26:1 (DiC), FA 26:2 (DiC), FA 26:5, estradiol 
valerate, PE-Cer d36:1, PC 34:0/PE 37:0, PC 36:5/PE 39:5, FA 27:2 (DiC), FA 28:6, FA 
28:0, FA 26:3, FA 25:0, PE-Cer d34:2, FA 28:5 
2 LC-FA 
FA 14:0, FA 16:0, FA 17:2 (DiC), FA 24:1, FA 20:2, FA 18:3, FA 15:0, FA 18:1, FA 18:0, FA 
18:2 , FA 16:1, FA 20:1, FA 20:0, FA 22:1, FA 24:2, phytanate 
3 LC-FA 
FA 22:2, FA 20:3, FA 22:5, FA 22:6, 7-oxo-11-octadecenoic acid, FA 22:3, FA 24:4, FA 
17:1, FA 24:5, FA 20:5 
4 Cer 
Cer 41:0, PC 36:5/PE 39:5, Cer 35:0, Cer d42:1 (2OH), Cer d43:1 (2OH), Cer t40:0(2OH), 
Cer t41:0(2OH), Cer d40:1 (2OH), Cer 40:0, Cer d44:1 (2OH), Cer t42:0(2OH), PE-Cer 
d34:1, Cer d38:1 (2OH), Cer t38:0(2OH) 
5 TG, Cer TG 52:8, TG 50:8, TG 49:8, Cer 42:0, Cer 43:0, Cer 44:0 
6 VLC-FA, VLC-FA (DiC), VLC-FA (OH) 
FA 27:0 (OH), FA 26:2, FA 25:0 (OH), FA 25:2, FA 30:6, FA 24:0 (DiC), FA 26:1 , FA 16:0 
(OH), LysoPC 20:4, FA 28:2 (DiC), FA 29:6, FA 26:0 (OH), FA 28:1 (DiC), FA 30:5 
7 LysoPE, FA Cer t34:0(2OH), LysoPC 18:3, FA 26:4, FA 20:4, LysoPE 16:0, LysoPE 18:0, LysoPS 21:0 
8 LC-FA, odd-chain LC-FA, Cer 
Cer 37:0, Cer 38:0, Cer t36:0(2OH), Cer 36:0, FA 17:0, FA 19:1, FA 14:1, FA 19:0, FA 16:2, 
FA 12:0, FA 14:2, FA 16:3, Keto 18:0, FA 21:5, dihomoursodeoxycholic acid , FA 24:0 
(OH), FA 20:6, FA 27:1 (DiC), 3,7-dihydroxy-5-cholestanoic acid, FA 25:1, FA 22:0 
9 bile acids, glucose, PS 
1-octadecanoyl-rac-glycerol, glucose, taurocholate, rac-glycerol-1-myristate, 
norhyodeoxycholic acid , hyodeoxycholic acid, PC 34:2/PE 37:2, PS 39:6, PS 41:6, PS 
41:7, PC 36:4/PE 39:4, traumatin 
10 
malate intermediates, PA, MC-FA 
(DiC) 
2-methylmaleate, citramalate, PA 18:3, FA 9:0, FA 16:4, 9,10,13-Trihydroxy-11-
octadecenoic acid, PG 31.4, PA 20:3, cortisol 21-acetate, FA 7:1 (DiC) , FA 8:0 (Dic, OH) , 
FA 15:4, 5-hydroxytryptophan, FA 13:4 
11 
Glucose metabolites, BCAA 
metabolites, xanthine 
S-3-methyl-2-oxopentanoate, 4-methyl-2-oxopentanoate, methyl-acetoacetate, allose, 
glyceraldehyde, malate, xanthine, possible peptide, dipeptide (HIS TYR), 
diethylstilbestrol 
12 
Glucose metabolites, acetyl-amino 
acids 
L-histidine, N-acetyl-D-glucosamine, N-acetyl-DL-serine, 3,4-hydroxyphenyl-lactate, 2-
deoxy-D-glucose, N-acetylglycine, D-lyxose 
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13 MC-FA (DiC) 
FA 11:1 (DiC,OH), 4-hydroxyphenylethanol, FA 10:0 (DiC), C8 H12 N6 O2, phenylacetic 
acid 
14 MC-FA (DiC OH), LC-FA (DiC, OH) 
C8 H14 O2, FA 9:0 (DiC,OH), FA 17:0 (DiC,OH), FA 10:1 (DiC, OH) , FA 11:0 (DiC,OH), FA 
9:1 (DiC) , FA 20:3 (DiC, diOH) , porphobilinogen, 5-methoxytryptophol, C9 H16 O2, FA 
8:1 (DiC) , FA 11:1 (DiC, OH), chlorpheniramine, FA 18:0 (DiC,OH), FA 10:0 (DiC,OH) 
15 odd-chain MC-FA (DiC) 
FA 9:0 (DiC) , FA 11:0 (DiC), FA 7:0 (DiC) , 3-hydroxybenzyl alcohol, debrisoquin, FA 5:0 
(DiC), FA 6:0 (DiC), FA 9:0 (OH), FA 13:0 (DiC), 17-alpha-hydroxyprogesterone, FA 8:0 
(DiC), cycloheptanecarboxylic acid, 3-methyladipic acid, LysoPA 20.5 
16 
BCAA, BCAA metabolite, reflect 
mitochondrial metabolism 
3-methoxytyrosine, thyroxine, isovalerylcarnitine , AC 4:0, AC 5:1 , leucine, 
glutarylcarnitine, salsolinol, methyl-jasmonate, N-undecanoylglycine, alpha-tocopherol, 




S-adenosyl-L-homocysteine, sphingosine, dipeptide (glutamate phenylalanine), 
phenylethanolamine, dipeptide (serine isoleucine/leucine) 
18 
BCAA, BCAA metabolites, aromatic 
amino acids, methionine  
isoleucine, valine, dipeptide (glutamate isoleucine/leucine), AC 3:0, tyrosine, n-gamma-
L-glutamyl-L-methionine , serine, methionine, taurolithocholate, 1-methyladenosine, 
indolelactic acid, 5-hydroxy-1,4-naphthoquinone, pantothenate, AC 5:0 (OH) , AC 11:0, 
phenylalanine, normethanephrine, L-gamma-glutamyl-L-isoleucine , 5-
methylthioadenosine, S-Allyl-L-cysteine 
19 DG, PC/PE, LysoPC 
DG 35:1, DG 36:1, DG 35:2, DG 34:1, DG 34:2, DG 34:3, DG 35:3, DG 32:0, DG 32:1, DG 
33:1, DG 38:3, DG 38:4, DG 36:3, PE 36:2, 1-oleoyl-rac-glycerol, LysoPC 16:1, LysoPC 
20:3, LysoPC 18:0, LysoPC 16:0, LysoPC 14:0, LysoPC 15:0, PC 36:2/PE 39:2, PC 36:3/PE 
39:3, PC 36:1/PE 39:1, PS 39:4, PC 34:3/PE 37:3, PS 37:6, PC 34:1/PE 37:1, PC 40:4/PE 
43:4, PC 40:5/PE 43:5, DG 38:5, PC 31:5/PE 34:5 
20 DG, PC/PE, PS 
DG 30:1 , DG 32:2, DG 34:0, PS 35:5 , PS 37:5 , PC 32:1/PE 35:1, PS 35:4, PC 32:2/PE 
35:2, PC 32:4/PE 35:4, PS 39:8 
21 polar metabolites, urate 
2-acetyl-pyrolidine, 3-amino-5-hydroxybenzoic acid, urate, 3-aminoisobutanoate, 4-
acetamidobutanoate, pinitol, methyl beta-D-galactoside, AC 7:1, AC 8:2, m-
hydroxymandelic acid, SM d36:1, dipeptide (tyrosine proline), 1,3,7-trimethyluric acid, 
C16 Sphinganine , bilirubin 
22 
dipeptides, cortisol, vitamin 
metabolites 
deoxyuridine, possible peptide, LysoPE 18:2, PC 41:7/PE 44:7, possible peptide, AC 
11:1, AC 13:1, PS 40:7, PC 33:3/PE 36:3, bis(2-ethylhexyl)phthalate, PS 42:6, 
tricarballylic acid, ascorbate, hypoxanthine, dipeptide (phenylalanine phenylalanine), 





PC 39:8/PE 42:8, PC 37:4/PE 40:4, PC 35:5/PE 38:5, PS 40:4, PC 43:8/PE 46:8, PC 
33:4/PE 36:4, PS 42:3, PS 44:3, PC 35:5/PE 38:5, PS 38:4, PC 34:5/PE 37:5, PC 34:7/PE 
37:7, PC 35:3/PE 38:3, PC 37:7/PE 40:7, PC 37:5/PE 40:5, PC 35:4/PE 38:4 
24 PC/PE, PS 
PC 41:8/PE 44:8, PS 42:3, PC 43:7/PE 46:7, PC 40:8/PE 43:8, PC 38:6/PE 41:6, AC 18:0, 
possible peptide, tripeptide (cysteine histidine lysine), PS 40:3, PS 38:7, dethiobiotin 
25 MC-AC 
AC 4:0 (OH), AC 6:0 (OH) , O-adipoylcarnitine, N-acetyl-DL-methionine, pterin, AC 8:0 
(OH), AC 10:0 (OH), AC 12:0, AC 8:0, AC 10:0, AC 10:1, AC 14:1 , AC 14:2, AC 12:1 , AC 
2:0, AC 6:0, AC 8:1, AC 10:3, AC 10:2, AC 12:2 
26 MC/LC-FA (DiC), FA (OH)  
FA 10:0 (OH) , 7-oxo-11E-tetradecenoic acid, FA 12:0 (OH), Keto 14:0, 7-oxo-11-
hexadecenoic acid, FA 12:2, FA 14:0 (DiC), FA 16:0 (DiC), FA 12:0 (DiC), FA 14:0 (OH) 
27 LC AC, SM 
SM d40:1, SM d42:1, PC 35:3/PE 38:3, PS 46:6, AC 14:0, AC 18:1, AC 16:0, AC 18:2 , PC 
42:7/PE 45:7 
28 PI, SM, PC/PE 
PI 41:1, PI 42:1, PI 43:1, SM d41:2, SM d42:2, SM d34:1, SM d34:2, SM d36:2, 
cholesterol, SM d32:1, SM d33:1, PC 34:0, PC 39:5/PE 42:5, PC 32:0/PE 35:0 
29 Krebs Cycle intermediates 
FA 18:1 (DiC), FA 18:2 (DiC), trans-aconitate, citrate, isocitrate, glucaric acid, glucuronic 
acid, salicyluric acid, AC 19:3  
30 choline, betaine  
betaine, 5-aminopentanoate, choline, fluvoxamino acid, pyridoxamine, N-acetyl-L-
alanine 
31 
lactose, MC-FA (keto), amino acids 
metabolites 
16-bromo-9E-hexadecenoic acid , FA 22:2 (DiC), AC 11:3, monoethylhexyl phthalic acid, 
LL-2,6-diaminoheptanedioate, N-(tert-Butoxycarbonyl)-L-methionine , possible peptide, 
lactose, N-acetylneuraminate, 5-oxo-7-octenoic acid 
32 PA, di-/tri-peptides 
Tripeptide (glycine proline valine), tripeptide (tryptophan tyrosine isoleucine/leucine), 
inosine, guanosine, dipeptide (isoleucine/leucine alanine) , N6,N6,N6-trimethyl-L-lysine, 
PA 17:3, FA 18:4, PA 19.3, PA 21:3, PA 23:3, PA 22:3, PA 24:3, PA 25:3, FA 15:0 (Dic, OH) 
, dipeptide (methionine isoleucine/leucine), riboflavin 
33 LC-FA (DiC, OH) 
FA 12:0 (DiC,OH), FA 16:0 (DiC,OH), FA 18:3 (DiC, diOH) , FA 13:0 (DiC,OH), FA 14:3 (DiC, 
diOH), FA 14:1 (DiC, OH), testosterone, Methyl 8-2-2-formyl-vinyl-3-hydroxy-5-oxo-
cyclopentyl]-octanoate  
34 MC-FA (DiC), PI 
FA 17:3 (DiC, diOH), PI 36:1, PI 34:1, PC 40:7/PE 43:7, PI 37:1 , PI 38:1 , FA 21:3 (DiC, 






Table S4.9. Path analysis demonstrating the relationship between macronutrient intake with BMIz through metabolome clusters, 
adjusting for age, sex and puberty onset. Association between energy-adjusted fat and carbohydrate intake (mean 0, standard deviation 
1) and metabolome clusters (β1), adjusting for age, sex and puberty onset. Association between metabolome clusters and BMIz (β2), 
adjusting for sex, age and puberty onset. Significant relationships in bold and red fill (α=0.05). Sobel testing tested the relationship 
between the independent variable and dependent variable when including the mediator, the metabolome cluster, in the model. 
Significant relationships in bold and red fill (α=0.05). 
Cluster 
Number  
Cluster Classification  
Macronutrient intake and 
the metabolome 
Metabolome and BMIz Sobel's test  
β₁±SE                 p-value  β₂±SE                 p-value  t-statistic p-value  
Carbohydrate 
1 LC and VLC-FA (DiC),VLC-FA, PC/PE -0.01±0.038 0.799 -0.148±0.164 0.368 0.244 0.807 
2 LC-FA -0.049±0.065 0.449 0.12±0.092 0.189 -0.656 0.512 
3 LC-FA -0.093±0.065 0.151 0.068±0.093 0.462 -0.654 0.513 
4 Cer -0.027±0.065 0.673 0.015±0.092 0.866 -0.156 0.876 
5 TG, Cer -0.041±0.062 0.503 0.003±0.096 0.972 -0.035 0.972 
6 VLC-FA, VLC-FA (DiC), VLC-FA (OH) -0.024±0.062 0.702 -0.108±0.096 0.260 0.363 0.717 
7 LysoPE, FA -0.021±0.062 0.736 0.032±0.096 0.739 -0.237 0.813 
8 LC-FA, odd-chain LC-FA, Cer -0.039±0.032 0.217 0.315±0.202 0.119 -0.968 0.333 
9 bile acids, glucose, PS 0.007±0.01 0.452 0.933±1.173 0.427 0.547 0.585 
10 malate intermediates, PA, MC-FA (DiC) -0.088±0.041 0.030 0.063±0.151 0.679 -0.407 0.684 
11 
Glucose metabolites, BCAA metabolites, xanthine 
-0.104±0.066 0.118 
0.063±0.091 0.487 -0.635 0.525 
12 Glucose metabolites, acetyl-amino acids -0.028±0.038 0.452 0.105±0.179 0.559 -0.461 0.645 
13 MC-FA (DiC) -0.166±0.054 0.002 0.071±0.108 0.509 -0.645 0.519 
14 MC-FA (DiC OH), LC-FA (DiC, OH) -0.18±0.055 0.001 0.15±0.107 0.159 -1.293 0.196 
15 odd-chain MC-FA (DiC) -0.114±0.055 0.037 0.201±0.108 0.062 -1.390 0.164 
16 BCAA, BCAA metabolite -0.067±0.033 0.046 0.312±0.23 0.175 -1.123 0.262 
17 homocysteine, phenylalanine metabolite -0.017±0.066 0.798 0.284±0.109 0.009 -0.255 0.799 
18 BCAA, BCAA metabolites, aromatic amino acids, 
methionine  
-0.062±0.036 0.085 
0.467±0.174 0.007 -1.450 0.147 
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19 DG, PC/PE, LysoPC -0.015±0.06 0.803 0.419±0.098 0.000 -0.250 0.803 
20 DG, PC/PE, PS 0.043±0.056 0.438 0.26±0.114 0.022 0.735 0.462 
21 polar metabolites, urate 0.015±0.013 0.226 -0.402±0.585 0.492 -0.597 0.550 
22 dipeptides, cortisol, vitamin metabolites 0±0.032 0.994 0.258±0.189 0.171 0.008 0.994 
23 PC/PE -0.055±0.063 0.386 -0.202±0.098 0.038 0.800 0.424 
24 PC/PE, PS -0.057±0.05 0.249 -0.122±0.141 0.386 0.693 0.488 
25 MC-AC -0.004±0.001 0.001 -0.08±0.149 0.591 0.531 0.596 
26 MC/LC-FA (DiC), FA (OH)  -0.132±0.065 0.043 -0.078±0.091 0.393 0.787 0.431 
27 LC AC, SM -0.028±0.038 0.455 0.138±0.163 0.398 -0.560 0.575 
28 PI, SM, PC/PE -0.052±0.045 0.244 0.17±0.138 0.220 -0.845 0.398 
29 Krebs Cycle intermediates 0.014±0.034 0.690 -0.113±0.2 0.571 -0.326 0.744 
30 choline, betaine  -0.052±0.069 0.444 -0.039±0.084 0.644 0.396 0.692 
31 
lactose, MC-FA (keto), amino acids metabolites 
0.069±0.042 0.103 
-0.278±0.216 0.197 -1.013 0.311 
32 PA, di-/tri-peptides -0.021±0.026 0.403 -0.236±0.239 0.322 0.639 0.523 
33 LC-FA (DiC, OH) -0.131±0.067 0.050 -0.043±0.088 0.628 0.470 0.638 
34 MC-FA (DiC), PI -0.111±0.058 0.057 -0.098±0.103 0.341 0.851 0.395 
Fat 
1 LC and VLC-FA (DiC),VLC-FA, PC/PE 0.01±0.038 0.789 -0.148±0.164 0.368 -0.257 0.797 
2 LC-FA 0.033±0.065 0.606 0.12±0.092 0.189 0.480 0.631 
3 LC-FA 0.09±0.065 0.169 0.068±0.093 0.462 0.648 0.517 
4 Cer 0.022±0.065 0.735 0.015±0.092 0.866 0.151 0.880 
5 TG, Cer 0.036±0.062 0.560 0.003±0.096 0.972 0.035 0.972 
6 VLC-FA, VLC-FA (DiC), VLC-FA (OH) 0.025±0.062 0.694 -0.108±0.096 0.260 -0.371 0.711 
7 LysoPE, FA 0.01±0.062 0.870 0.032±0.096 0.739 0.147 0.883 
8 LC-FA, odd-chain LC-FA, Cer 0.037±0.032 0.240 0.315±0.202 0.119 0.937 0.349 
9 bile acids, glucose, PS -0.005±0.009 0.564 0.933±1.173 0.427 -0.467 0.641 
10 malate intermediates, PA, MC-FA (DiC) 0.094±0.041 0.020 0.063±0.151 0.679 0.408 0.684 
11 
Glucose metabolites, BCAA metabolites, xanthine 
0.114±0.066 0.086 
0.063±0.091 0.487 0.644 0.519 
12 Glucose metabolites, acetyl-amino acids 0.03±0.038 0.424 0.105±0.179 0.559 0.472 0.637 
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13 MC-FA (DiC) 0.159±0.054 0.003 0.071±0.108 0.509 0.644 0.520 
14 MC-FA (DiC OH), LC-FA (DiC, OH) 0.179±0.055 0.001 0.15±0.107 0.159 1.291 0.197 
15 odd-chain MC-FA (DiC) 0.131±0.055 0.017 0.201±0.108 0.062 1.472 0.141 
16 BCAA, BCAA metabolite 0.075±0.034 0.027 0.312±0.23 0.175 1.157 0.247 
17 homocysteine, phenylalanine metabolite 0.033±0.066 0.622 0.284±0.109 0.009 0.484 0.628 
18 BCAA, BCAA metabolites, aromatic amino acids, 
methionine  
0.067±0.036 0.060 
0.467±0.174 0.007 1.539 0.124 
19 DG, PC/PE, LysoPC -0.012±0.06 0.841 0.419±0.098 0.000 -0.200 0.842 
20 DG, PC/PE, PS -0.075±0.056 0.181 0.26±0.114 0.022 -1.154 0.249 
21 polar metabolites, urate -0.01±0.012 0.380 -0.402±0.585 0.492 0.541 0.589 
22 dipeptides, cortisol, vitamin metabolites 0.005±0.032 0.869 0.258±0.189 0.171 0.164 0.870 
23 PC/PE 0.091±0.063 0.146 -0.202±0.098 0.038 -1.189 0.235 
24 PC/PE, PS 0.084±0.05 0.090 -0.122±0.141 0.386 -0.772 0.440 
25 MC-AC 0.163±0.042 0.000 -0.08±0.149 0.591 -0.532 0.595 
26 MC/LC-FA (DiC), FA (OH)  0.16±0.065 0.014 -0.078±0.091 0.393 -0.807 0.420 
27 LC AC, SM 0.036±0.038 0.350 0.138±0.163 0.398 0.627 0.531 
28 PI, SM, PC/PE 0.057±0.045 0.204 0.17±0.138 0.220 0.883 0.377 
29 Krebs Cycle intermediates -0.01±0.034 0.768 -0.113±0.2 0.571 0.262 0.794 
30 choline, betaine  0.076±0.068 0.268 -0.039±0.084 0.644 -0.426 0.670 
31 
lactose, MC-FA (keto), amino acids metabolites 
-0.059±0.042 0.160 
-0.278±0.216 0.197 0.951 0.342 
32 PA, di-/tri-peptides 0.014±0.025 0.591 -0.236±0.239 0.322 -0.473 0.636 
33 LC-FA (DiC, OH) 0.102±0.067 0.128 -0.043±0.088 0.628 -0.461 0.645 






Table S4.10. Path analysis demonstrating the relationship between macronutrient intake with HOMA-CP through metabolome 
clusters, adjusting for age, sex and puberty onset. Association between energy-adjusted fat and carbohydrate intake (mean 0, standard 
deviation 1) and metabolome clusters (β1), adjusting for age, sex and puberty onset. Association between metabolome clusters and 
HOMA-CP (β2), adjusting for sex, age and puberty onset. Significant relationships in bold and red fill (α=0.05). Sobel testing tested 
the relationship between the independent variable and dependent variable when including the mediator, the metabolome cluster, in the 
model. Significant relationships in bold and red fill (α=0.05). 
Cluster 
Number  Cluster Classification  




Sobel's test  
β₁±SE                 p-value  β₂±SE                 p-value  t-statistic p-value  
Carbohydrate 
1 LC and VLC-FA (DiC),VLC-FA, PC/PE -0.01±0.038 0.799 0.118±0.257 0.646 -0.222 0.824 
2 LC-FA -0.049±0.065 0.449 -0.052±0.145 0.717 0.327 0.744 
3 LC-FA -0.093±0.065 0.151 -0.017±0.146 0.908 0.116 0.908 
4 Cer -0.027±0.065 0.673 0.024±0.144 0.866 -0.156 0.876 
5 TG, Cer -0.041±0.062 0.503 -0.012±0.151 0.936 0.080 0.936 
6 VLC-FA, VLC-FA (DiC), VLC-FA (OH) -0.024±0.062 0.702 0.055±0.151 0.715 -0.264 0.792 
7 LysoPE, FA -0.021±0.062 0.736 -0.021±0.062 0.739 0.237 0.813 
8 LC-FA, odd-chain LC-FA, Cer -0.039±0.032 0.217 -0.556±0.319 0.081 1.008 0.314 
9 bile acids, glucose, PS 0.007±0.01 0.452 -0.941±1.628 0.563 -0.458 0.647 
10 malate intermediates, PA, MC-FA (DiC) -0.088±0.041 0.030 0.235±0.238 0.322 -0.901 0.368 
11 Glucose metabolites, BCAA metabolites, xanthine -0.104±0.066 0.118 0.056±0.143 0.695 -0.380 0.704 
12 Glucose metabolites, acetyl-amino acids -0.028±0.038 0.452 -0.026±0.281 0.927 0.091 0.927 
13 MC-FA (DiC) -0.166±0.054 0.002 -0.023±0.17 0.894 0.133 0.894 
14 MC-FA (DiC OH), LC-FA (DiC, OH) -0.18±0.055 0.001 0.178±0.168 0.288 -1.010 0.312 
15 odd-chain MC-FA (DiC) -0.114±0.055 0.037 0.361±0.169 0.033 -1.490 0.136 
16 BCAA, BCAA metabolite -0.067±0.033 0.046 0.282±0.354 0.427 -0.739 0.460 
17 homocysteine, phenylalanine metabolite -0.017±0.066 0.798 0.155±0.168 0.356 -0.247 0.805 
18 BCAA, BCAA metabolites, aromatic amino acids, 
methionine  
-0.062±0.036 0.085 0.487±0.268 0.070 -1.250 0.211 
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19 DG, PC/PE, LysoPC -0.015±0.06 0.803 0.423±0.156 0.007 -0.249 0.803 
20 DG, PC/PE, PS 0.043±0.056 0.438 0.435±0.179 0.015 0.739 0.460 
21 polar metabolites, urate 0.015±0.013 0.226 -0.848±0.952 0.373 -0.717 0.473 
22 dipeptides, cortisol, vitamin metabolites 0±0.032 0.994 -0.271±0.294 0.356 -0.008 0.994 
23 PC/PE -0.055±0.063 0.386 -0.23±0.154 -0.136 0.750 0.453 
24 PC/PE, PS -0.057±0.05 0.249 -0.294±0.221 0.184 0.870 0.384 
25 MC-AC -0.004±0.001 0.001 -0.833±0.24 0.001 2.439 0.015 
26 MC/LC-FA (DiC), FA (OH)  -0.132±0.065 0.043 -0.383±0.141 0.006 1.625 0.104 
27 LC AC, SM -0.028±0.038 0.455 -0.418±0.258 0.105 0.679 0.497 
28 PI, SM, PC/PE -0.052±0.045 0.244 0.036±0.216 0.870 -0.162 0.871 
29 Krebs Cycle intermediates 0.014±0.034 0.690 0.175±0.316 0.579 0.324 0.746 
30 choline, betaine  -0.052±0.069 0.444 -0.114±0.132 0.389 0.572 0.567 
31 lactose, MC-FA (keto), amino acids metabolites 0.069±0.042 0.103 -0.241±0.342 0.480 -0.649 0.517 
32 PA, di-/tri-peptides -0.021±0.026 0.403 -0.481±0.379 0.205 0.699 0.485 
33 LC-FA (DiC, OH) -0.131±0.067 0.050 0.004±0.139 0.979 -0.026 0.979 
34 MC-FA (DiC), PI -0.111±0.058 0.057 -0.196±0.162 0.225 1.023 0.307 
Fat 
1 LC and VLC-FA (DiC),VLC-FA, PC/PE 0.01±0.038 0.789 0.118±0.257 0.646 0.231 0.817 
2 LC-FA 0.033±0.065 0.606 -0.052±0.145 0.717 -0.296 0.767 
3 LC-FA 0.09±0.065 0.169 -0.017±0.146 0.908 -0.116 0.908 
4 Cer 0.022±0.065 0.735 0.024±0.144 0.866 0.151 0.880 
5 TG, Cer 0.036±0.062 0.560 -0.012±0.151 0.936 -0.080 0.936 
6 VLC-FA, VLC-FA (DiC), VLC-FA (OH) 0.025±0.062 0.694 0.055±0.151 0.715 0.267 0.789 
7 LysoPE, FA 0.01±0.062 0.870 -0.021±0.062 0.739 -0.147 0.883 
8 LC-FA, odd-chain LC-FA, Cer 0.037±0.032 0.240 -0.556±0.319 0.081 -0.974 0.330 
9 bile acids, glucose, PS -0.005±0.009 0.564 -0.941±1.628 0.563 0.408 0.683 
10 malate intermediates, PA, MC-FA (DiC) 0.094±0.041 0.020 0.235±0.238 0.322 0.911 0.363 
11 Glucose metabolites, BCAA metabolites, xanthine 0.114±0.066 0.086 0.056±0.143 0.695 0.382 0.702 
12 Glucose metabolites, acetyl-amino acids 0.03±0.038 0.424 -0.026±0.281 0.927 -0.091 0.927 
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13 MC-FA (DiC) 0.159±0.054 0.003 -0.023±0.17 0.894 -0.133 0.894 
14 MC-FA (DiC OH), LC-FA (DiC, OH) 0.179±0.055 0.001 0.178±0.168 0.288 1.010 0.313 
15 odd-chain MC-FA (DiC) 0.131±0.055 0.017 0.361±0.169 0.033 1.592 0.111 
16 BCAA, BCAA metabolite 0.075±0.034 0.027 0.282±0.354 0.427 0.748 0.454 
17 homocysteine, phenylalanine metabolite 0.033±0.066 0.622 0.155±0.168 0.356 0.435 0.664 
18 BCAA, BCAA metabolites, aromatic amino acids, 
methionine  
0.067±0.036 0.060 0.487±0.268 0.070 1.305 0.192 
19 DG, PC/PE, LysoPC -0.012±0.06 0.841 0.423±0.156 0.007 -0.199 0.842 
20 DG, PC/PE, PS -0.075±0.056 0.181 0.435±0.179 0.015 -1.171 0.242 
21 polar metabolites, urate -0.01±0.012 0.380 -0.848±0.952 0.373 0.625 0.532 
22 dipeptides, cortisol, vitamin metabolites 0.005±0.032 0.869 -0.271±0.294 0.356 -0.162 0.871 
23 PC/PE 0.091±0.063 0.146 -0.23±0.154 -0.136 -1.041 0.298 
24 PC/PE, PS 0.084±0.05 0.090 -0.294±0.221 0.184 -1.045 0.296 
25 MC-AC 0.163±0.042 0.000 -0.833±0.24 0.001 -2.587 0.010 
26 MC/LC-FA (DiC), FA (OH)  0.16±0.065 0.014 -0.383±0.141 0.006 -1.824 0.068 
27 LC AC, SM 0.036±0.038 0.350 -0.418±0.258 0.105 -0.809 0.418 
28 PI, SM, PC/PE 0.057±0.045 0.204 0.036±0.216 0.870 0.163 0.871 
29 Krebs Cycle intermediates -0.01±0.034 0.768 0.175±0.316 0.579 -0.260 0.794 
30 choline, betaine  0.076±0.068 0.268 -0.114±0.132 0.389 -0.680 0.496 
31 lactose, MC-FA (keto), amino acids metabolites -0.059±0.042 0.160 -0.241±0.342 0.480 0.632 0.528 
32 PA, di-/tri-peptides 0.014±0.025 0.591 -0.481±0.379 0.205 -0.495 0.620 
33 LC-FA (DiC, OH) 0.102±0.067 0.128 0.004±0.139 0.979 0.026 0.979 





Table S4.11. Differences in IGF-1 levels between pubteral and pre-pubertal children. Puberty 




Pubertal Pre-Pubertal t-test 
Mean StdDev Mean  StdDev t-value 
unadjusted p-
value 
Combined 306 112 217 73 -6.83 <0.0001 
Boys 269 109 196 63 -4.00 0.0001 
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CHAPTER 5                                                                                                                           
Conclusion 
Significance of Research Findings  
The global prevalence of obesity, type 2 diabetes (T2D), and metabolic disease continues to rise; 
influencing children and adolescents at an earlier age. In the United States, 39.8% of adults have 
obesity and 18.5% of children and adolescents aged 2-19 years have obesity (1). In part, this is 
due to increased intake of calorically dense foods, in particular highly processed foods, paired 
with increases in sedentary activity (2). A top public health priority worldwide is to reduce the 
prevalence of obesity, with an emphasis on prevention in childhood. Childhood obesity is 
associated with obesity (3) and T2D (4) in adulthood. There is a high economic burden of 
obesity and T2D (5,6), presenting an urgent need for public health efforts to save societal 
resources. In the United States, public health efforts and funding towards combatting obesity are 
focused on improving lifestyles, such as eating a healthier diet (e.g. MyPlate) and increasing 
physical activity (e.g. Let’s Move!). These programs are valuable for teaching children how to 
lead healthy lifestyles, however, there are other avenues for intervention and prevention.  
This dissertation suggests that the intrauterine environment can have profound implications on 
the offspring’s metabolic health, potentially programming risk to adult cardiometabolic disease. 
The infant cord blood lipidome and DNA methylome in cord blood leukocytes was correlated 
with the maternal lipidome across gestation, identifying unique lipid profiles related to growth. 
Harnessing the findings from our studies, I propose that interventions should be targeted to 
204 
 
women prior to conception to prevent the intergenerational cycle of obesity. Additionally, this 
dissertation highlights the intrinsic differences in nutrient utilization between individuals, which 
is related to insulin resistance (IR). In adolescence, we observed differential metabolite profiles 
associated with obesity and IR. The metabolome is influenced by habitual carbohydrate or fat 
intake, suggesting that biomarkers of IR may depend on macronutrient intake. Overall, I propose 
a shift from a “one-size-fits-all” nutrition approach to classifying mitochondrial oxidative 
capacity to create a precise “dietary prescription” for each individual.  
Implications from the pregnancy studies  
Fifty years ago, the Developmental Origins of Health and Disease (DOHaD) field originated 
with the work of David Barker and his colleagues from their epidemiological studies of infant 
and adult mortality published in The Lancet (7–9). Stemming from these results, dietary 
manipulation studies during pregnancy have demonstrated changes in the risk of adult metabolic 
disease (10). These studies have demonstrated that nutrient factors including energy intake, fatty 
acids (10,11), protein (12,13), micronutrients (14), and vitamins, including folic acid (15), have 
profound influences on fetal programming, varying by timing of exposure. However, in 
epidemiologic studies, measuring food and nutrient intake is challenging due to random and 
systematic errors in dietary assessment tools. To assess food intake, researchers rely on memory-
based dietary assessment methodologies, such as Food Frequency Questionnaires and 24-hour 
dietary recalls, which have been debated over their value and validity (16). Therefore, it is 
necessary to have objective measurements of the maternal intrauterine environment to which the 
developing fetus is exposed. For this dissertation, the maternal plasma lipidome was measured 
during first trimester (M1) and at delivery (M3), providing an objective view of maternal nutrient 
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availability across gestation. Profiling the lipidome presents the opportunity to classify 
biomarkers and metabolic pathways associated with offspring growth and metabolic health.  
Chapter 2 identified maternal lipids related to the development of the infant, measured by birth 
weight (BW) and the umbilical cord blood (CB) lipidome, a representation of placental transfer 
and infant metabolism. At each time-point, the maternal and CB lipidome displayed unique 
correlations between differing lipid classes. The increased number of significant Pearson’s 
correlations in CB compared to M1 and M3 may suggest differences in lipid connectivity, 
warranting further analyses to recognize biological implications. Most classes of lipids increased 
in levels from M1 to M3, consistent with previous observations of generalized increases in 
lipoproteins and associated lipids with advancing pregnancy (17,18). Shifts in the maternal and 
CB lipidome were consistent with the transport of long-chain (LC) polyunsaturated fatty acids 
(PUFA) as well as lysophosphatidylcholine (LysoPC) and lysophosphatidylethanolamine 
(LysoPE) species into CB. These results suggest the selective transfer of PUFAs across the 
placenta to the fetus (19), seemingly mediated in part by lysophospholipids (LysoPL) (20). 
Maternal characteristics, such as gestational weight gain (GWG) and baseline BMI, influenced 
the metabolome, including positive association between BMI and maternal plasma 
sphingomyelins (SM) as well as GWG and maternal plasma LysoPLs. 
Most of the lipids that increased in CB compared to M3 plasma were associated with infant BW 
with significant positive associations between all classes of CB LysoPC and LysoPE groups 
(both saturated and unsaturated fatty acid-containing LysoPLs) and Fenton BW z-score. Inverse 
association were observed between CB diglycerides (DGs) and triglycerides (TGs) containing 
PUFA and Fenton BW z-score. Maternal first trimester PUFA-containing TGs and phospholipids 
were inversely correlated with CB LysoPC and LysoPE species, suggesting that early gestational 
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maternal lipid levels influence the development of the CB lipidome and its relationship with BW. 
Figure 5.1 demonstrates the relationship between maternal and CB lipids with BW. While 
PUFA-containing dietary interventions have been studied in pregnancy, many of these clinical 
trials started supplements in mid-gestation. Our results suggest the importance of early gestation 
PUFA levels, therefore, I am proposing that supplementation should begin prior to conception 
(see Future Studies and Applications section). 
Chapter 3 identified epigenetic mechanisms that may contribute to developmental programming 
of offspring growth and metabolic health (21). We classified how the maternal lipidome at first 
trimester and delivery is related to altered DNA methylation patterns in umbilical CB leukocytes. 
Genome-wide DNA methylation was analyzed using the Infinium HumanMethylation850K 
(EPIC) bead array. Differential methylation at CpG probes and within CpG region was classified 
using empirical Bayes modeling, adjusting for batch differences, infant sex, and white blood cell 
types. Our findings provide support that the maternal metabolic environment during gestation 
influences infant DNA methylation, potentially by fetal programming. M3 saturated LysoPC and 
LysoPE are associated with differential methylation in CpG islands, with the majority of CpG 
sites having increased methylation with increased lipid exposure. Biological pathways pertaining 
to differentially methylated CpGs associated with M3 saturated LysoPCs are involved in cell 
proliferation. The role of maternal lysophospholipids in the establishment of the infant CB 
lipidome and epigenome, as well as birth weight, needs further elucidation to understand the 
biological implications.  
Implications in the adolescent periods  
Within adults, metabolomics analyses have identified biomarkers of obesity (22) and IR (23), 
increasing the understanding of the disease pathogenesis. With the increases in obesity (24) and 
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T2D (25) in the pediatric population, it is important to classify metabolome fluctuations in 
children and adolescents; a period of physical transition marked by the onset of puberty. We 
hypothesized the relationship between the metabolome with BMI and IR in the pediatric 
population will differ from the adult population, due to metabolic changes occurring with 
puberty. For instance, IR increases across puberty, exhibiting sex-specific changes, potentially in 
response to changes in muscle and fat mass (26). In parallel, insulin growth factor-1 (IGF-1) 
increases across puberty (27) and is directly correlated with insulin levels (28). Chapter 4 
determines how the metabolome during adolescence is related to obesity and IR, assessing sex-
specific alterations given differences in pubertal hormones and the accumulation of muscle and 
fat tissue (29). 
Sex-stratified linear regression identified metabolites associated BMI z-score (BMIz) and 
homeostatic model assessment of insulin resistance using C-peptide (HOMA-CP), accounting for 
puberty, age and muscle and fat area. Metabolites associated with BMIz include positive 
associations with DGs among girls and positive associations with branched chain and aromatic 
amino acids in boys. Intermediates in fatty acid metabolism, including medium-chain 
acylcarnitines (AC), were inversely associated with HOMA-CP. These results suggest less 
imbalance in the delivery and oxidation of substrates in these individuals, perhaps due to the 
increased substrate utilization to fuel tissue and linear growth in the pubertal period, as observed 
in previous studies (30).     
The effect of macronutrient intake on metabolic health remains controversial with previous 
analyses describing a relationship between amount of macronutrient consumed and metabolic 
outcomes (31), while other analyses suggesting no relationship (32–34). In the ELEMENT 
cohort, no direct relationship was observed between macronutrient intake with BMIz and IR. 
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Path analysis identified clusters of metabolites that underlie the relationship between energy-
adjusted macronutrient intake with BMIz and HOMA-CP. Carbohydrate intake is positively 
associated with HOMA-CP through decreases in levels of AC, products of β-oxidation. 
Approaching significance, fat intake is positively associated with HOMA-CP through increases 
in levels of dicarboxylic fatty acids (DiC-FA), products of omega-oxidation. When consuming 
more grams of fat, there is evidence for increased extra-mitochondrial fatty acid metabolism, 
while higher carbohydrate intake appears to lead to decreases in intermediates of β-oxidation. 
These results may suggest that adolescents prone to IR have an increase in selection of 
carbohydrates for fuel, exacerbated by elevated habitual carbohydrate consumption. Under these 
conditions, elevated malonyl-CoA would reduce uptake of FA into the mitochondria leading to 
lipid accumulation in the cytosol, increasing FA metabolites that contribute to IR (35) (Figure 
5.2A). Adolescents that are not prone to insulin resistance tend to have a higher mitochondrial 
oxidative capacity and an increase selection of fatty acids, represented in in humans (36) and 
animals (37). In these individuals, β-oxidation in the mitochondrial is associated with increases 
in medium-chain ACs, a reflection of enhanced oxidation (Figure 5.2B).  
Study Strengths and Limitations  
Pregnancy Study  
The Michigan Mother-Infant Pairs (MMIP) cohort is an established birth cohort with studies 
assessing the effect of environmental toxicants on maternal and newborn health (38). This cohort 
is mainly composed of white women with a high socioeconomic status, limiting the implications 
of our results to other populations. A strength of this study is the recruitment of women during 
their first prenatal appointment between 8 and 14 weeks of gestation, as other metabolomics 
studies assess the influence of the metabolome on offspring health starting at mid-gestation (39). 
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Fetal organ development is occurring during the first trimester, marking a critical period where 
the fetus is plastic to exposures. Profiling of the maternal lipidome during the first trimester can 
suggest the implications of particular lipid classes. Using an established liquid 
chromatography/mass spectrometry platform, we profiled almost 600 lipids, providing an 
objective view of the maternal metabolic environment, compared to dietary recall or a targeted 
lipid platform. Additionally, we have incorporated maternal baseline BMI and GWG to assess 
how phenotypic differences influence the lipidome.  
Infant metabolic health was classified using a variety of measurements including BW, the 
umbilical CB lipidome, and umbilical CB leukocytes DNA methylation. Infant BW is the most 
common health outcome studied to determine if the maternal intrauterine environment influences 
the development of the fetus, allowing for validation of other metabolome analyses. The 
umbilical CB lipidome is a reflection of infant metabolism as well as maternal metabolite levels, 
placental transfer, and interaction with other metabolites, such as inhibition by competition or 
metabolite-induced changes in placental transport activity. The EPIC bead array is a genome-
wide measurement of DNA methylation. Applying all three of these methods creates a strong 
platform to assess how maternal lipid levels across gestation influence infant health. Strong 
statistical methods were incorporated including clustering techniques of the lipidome by lipid 
class and number of double bonds. Empirical Bayes models were adjusted for relevant covariates 
and batch influences when assessing differential methylation, probe-wise and regionally. The 
novelty of this dissertation is the incorporation of multiple metabolome measurements with the 
epigenome to gain a broader understanding of a biological system.  
Future longitudinal studies with a larger sample size are desired to confirm results in this 
dissertation. Our sample size of approximately 100 mother-infant dyads was small for an ‘omics 
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data analysis. Further, maternal blood collection at delivery may not be representative of the 
metabolic states during the third trimester due to the stress of parturition. Future studies should 
include a mid-gestation maternal plasma sample. Umbilical CB is not a true representation of 
infant blood, as it represents placental transport and metabolism. Additional, umbilical CB 
leukocytes DNA methylation may not be the relevant tissue to examine for risk of metabolic 
disease and additional epigenetic processes, such as histone modifications, may be more 
relevant. We did not include a measure of gene expression in this dissertation. Therefore, we 
cannot be sure if differential methylation is associated with changes in transcription.  
Adolescent Study  
The Early Life Exposures in Mexico to ENvironmental Toxicants (ELEMENT) project (40) 
started in 1994 and consists of three sequentially-enrolled birth cohorts from Mexico City 
Maternity Hospitals (41). This mother-child pregnancy and birth cohort originated to explore if 
lead exposure and mobilization during pregnancy influences fetal development and whether 
maternal calcium supplementation can mitigate these adverse effects. A subset of offspring, age 
8-14 years, of the original mothers recruited were selected for the metabolomics analyses. 
Strengths include the availability of a wealth of data in the ELEMENT cohort allowing for the 
incorporation of anthropometry measurements, metabolic biomarkers, puberty measures, and 
dietary intake. The liquid chromatography/mass spectrometry based untargeted metabolomics 
platform is well-established and external standards were run, confirming annotations of 
metabolites. Linear models were used for both the unannotated and annotated features, 
incorporating the step-wise addition of covariates such as muscle and fat mass. These models 
allowed for a deeper understanding of the metabolome’s relationship with BMIz and insulin 
resistance. The use of path analysis created a strong statistical platform to begin to understand 
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mechanisms describing this relationship. A validated food frequency questionnaire quantified 
macronutrient intake (42), which was adjusted for total energy intake using the residual method 
(43). For the path analysis, hierarchical clustering grouped highly correlated metabolites, 
reducing the number of comparisons.    
Despite the strengths of this study, this work is cross sectional therefore causality cannot be 
confirmed. We are limited by the number of subjects within this study (n=206), acknowledging 
that stratifying by sex reduces power. The relationship between the metabolome and obesity was 
measured by BMIz, acknowledging that BMI does not distinguish between muscle and fat tissue. 
Previous studies have acknowledged the ratio of subcutaneous fat to visceral fat influences risk 
of IR and T2D (44). Future analyses should consider using dual-energy X-ray absorptiometry 
(DEXA) to assess the relationship between body composition and the metabolome. A more 
accurate measurement of insulin resistance would have been using insulin to calculate HOMA-
IR, instead of using C-peptide. Lastly, a measure of oxidative capacity would strengthen our 
findings from path analysis, indicating changes in mitochondrial fatty acid oxidation in 
adolescents who are prone to IR.   
Future Studies and Applications  
Molecular Study: Understanding the Transfer of Fatty Acids across the Placenta via MFSD2a 
The placenta plays a crucial role in pregnancy connecting the fetus via the umbilical cord to the 
uterine wall, supporting nutrient transfer, gas exchange, and waste elimination. Therefore, the 
placenta is a key regulator of fetal growth. This dissertation classified the relationship between 
maternal plasma lipids and umbilical cord plasma lipids without considering the implications of 
the placenta. To address, future analyses should quantify expression of lipid transporters on the 
placenta to understand mechanisms regulating nutrient transport. It is hypothesized that the 
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placenta might have a crucial role in modulating lipid transport depending on maternal supply 
and fetal demands (45). A better understanding of placental lipid transfer in relation to the 
maternal lipidome, as well as phenotypes (e.g. BMI, gestational diabetes), may help provide 
suggestions for dietary modifications to support fetal development.  
Maternal lipids are transported to the fetus across the placenta via a variety of fatty acid transport 
proteins as well as passive diffusion (46,47). Lipid species are hydrolyzed at the maternal surface 
of the placenta for transport (48). TGs are hydrolyzed by placental lipoprotein lipase and 
phospholipids are hydrolyzed by placental endothelial lipase. Previous studies have 
demonstrated the importance of the phospholipid fraction for the transport of essential LC-PUFA 
during late gestation (46). Since the sn-2 position of phospholipids tend to be occupied by 
PUFAs (49), it has been hypothesized that specific placental endothelial lipases cleave sn-1 fatty 
acids, allowing transport of the PUFA-containing LysoPC to the fetal circulation, perhaps 
enhancing delivery to the developing fetal brain (20,50). The Major Facilitator Super Family 
Domain Containing 2a (MFSD2a) protein has been proposed as a NA+-dependent LysoPL 
transporter in the brain (51) and placenta (52). This transporter provides a mechanism for the 
active transport of LysoPL from maternal plasma, preferentially transferring LysoPCs with 
PUFAs (53). Collecting placenta samples, trophoblast cells will be isolated (54) and RNA 
extracted to quantify MFSD2a gene expression.  
Clinical Study: Optimizing the Maternal Intrauterine Environment in a Pre-Conception 
Weight Loss Study 
Through a collaboration between Michigan Weight Management Program and the MMIP cohort, 
this research has fueled the start of a clinical trial assessing the influence of pre-conception 
weight loss on the health of the mother-infant dyad. The results from this dissertation have 
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indicated the importance of the maternal lipidome throughout gestation in establishing the 
umbilical CB lipidome and infant BW, potentially through fetal programming via epigenetic 
modifications. Obesity during pregnancy has increased risk of complications including 
gestational diabetes, hypertensive disorders, and preterm birth (55). Both the metabolome and 
lipidome are altered with obesity (22). To encourage the best health outcomes for the mother-
infant dyad, it is critical to optimize the intrauterine environment. Therefore, in collaboration 
with Dr. Amy Rothberg, Dr. Vasantha Padmanabhan, Dr. Dana Dolinoy, and Dr. Charles Burant, 
we hypothesize that pre-conception weight loss will normalize the maternal metabolic 
environment resulting in more favorable mother-infant health outcomes.  
Weight loss is associated with improvements in insulin sensitivity in adipose tissue, the liver, and 
muscles (56). During a 2-year intensive weight management program at the University of 
Michigan using a very low energy diet, decreases in BMI and waist circumference were 
associated with improvements in components of metabolic risk measurements (57). Table 5.1 
represents components influenced by the weight management program, including BMI, fat mass, 
and HOMA-IR.  
Within the Michigan Weight Management program, the lipidome has been analyzed in women 
that are lean and obese before and after weight loss (Figure 5.3). In comparison to lean women, 
pre-weight loss obese women have higher levels of multiple lipid species including ceramides 
(Cer), DGs, lysophospholipids (LysoPC, LysoPE), SMs, and TGs (Figure 5.3a). After weight 
loss, many of these lipid species “normalized” closer to the levels seen in lean women. For 
instance, saturated TGs in women post-weight loss were comparable to the saturated TG levels 
in lean women (Figure 5.3b), even those the women post-weight loss are still obese (Table 5.1). 
Other studies have suggested the metabolome is altered with weight loss (58). Relevant to this 
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dissertation’s findings, others have demonstrated that LysoPLs are decreased in response to 
weight loss in obese subjects (59). We hypothesize that the LysoPL lipid fraction will be 
important to modify in obese women prior to pregnancy due to the results of this dissertation and 
other studies (60–62).  
The modification of the metabolome with weight loss must be paired with incorporation of 
certain nutrients to ensure optimal health for the mother-infant dyad. In a recent review of 
omega-3 fatty acid supplementation during pregnancy, 70 randomized control trials were 
compiled to evaluate the influence of PUFA supplementation on maternal-offspring health 
outcomes (63). In offspring, supplementation reduced preterm birth, perinatal death, and low BW 
while increased prolonged gestation and large-for-gestational age babies. The influence of 
omega-3 supplementation on offspring adult body mass was uncertain. In mothers, 
supplementation was only associated with an increase in gestation length. However, most of the 
trials started omega-3 supplementations in the second or third trimester. The results of this 
dissertation suggest the importance of early gestational maternal PUFA levels for modulating the 
CB lipidome and its relationship with BW. Therefore, PUFA supplementation must begin prior 
to conception to potentially improve offspring cardiometabolic health. Maternal characteristics 
may attenuate the effect of PUFA supplementation on mother-infant pregnancy outcomes, 
including pre-pregnancy BMI (64). This is important to consider when adjusting the dosage of 
the supplement to fit the study population.  
To support placental transport of PUFAs, participants must have adequate choline levels for the 
formation of LysoPCs. Choline is an essential nutrient during fetal development, which supports 
cell membrane formation and supplies methyl groups for one carbon metabolism (65). During 
pregnancy, the dynamics of choline metabolism shifts to increase production of 
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phosphatidylcholine via the Kennedy pathway and the phosphatidylethanolamine N-
methyltransferase (PEMT) pathway (66). The relationship between docosahexaenoic acid (DHA) 
and choline supplementation during pregnancy needs to be understood. Previous 
neurodevelopment studies found enhanced hippocampal development with the supplementation 
of both DHA and choline (67). Monitoring of choline dietary intake and choline blood levels 
should begin prior to conception. Insufficient evidence is available to suggest addition of a 
choline supplement.   
After conception, participants will meet with a Registered Dietitian to monitor dietary intake. 
Physicians will monitor GWG in accordance to the recommendations produced by The Institute 
of Medicine (IOM), which are based on pre-pregnancy BMI (68). The MMIP participants 
included in this dissertation were stratified based on lean, overweight, and obese baseline BMIs 
(Figure 5.4a). Each BMI baseline group contained women that gained inadequate and excess 
gestational weight based on the IOM recommendations. In this dissertation, excess GWG was 
associated with increased in LysoPC and LysoPE in the maternal plasma, suggesting importance 
in monitoring. Both inadequate and excess GWG is associated with complications for the 
offspring, including childhood obesity, hypertension, and IR (69). Additionally, we observed a 
relationship between GWG and infant Fenton BW percentile in lean women (Figure 5.4b). A 
relationship was not observed in overweight nor obese, potentially due to the small sample size 
within these groups.   
Clinical Study: Moving Away from One-Size-Fits-All Nutrition Recommendations to 
Classifying Intrinsic Differences in Mitochondrial Oxidative Capacity.  
Using a cross-sectional study design in the ELEMENT cohort, we identified clusters of 
metabolites that underlie the relationship between habitual carbohydrate and fat intake with IR, 
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measured by HOMA-CP. Based on our results, we hypothesize that there are intrinsic differences 
in fuel selection and the ability to fully oxidize fatty acids, having implications on the 
development of IR. VO2 max during exhaustive physical activity corresponds to muscle 
mitochondrial oxidative capacity (70). Previous analyses in humans (36) and animals (37) with 
higher oxidative capacity show a relative selection of fatty acids and a relative resistance to 
obesity (71). Therefore, we propose to analyze fuel selection and oxidative capacity in children 
undergoing a controlled feeding study following these Specific Aims:  
Specific Aim 1. Investigate the correlation between VO2max, fuel selection, and metabolite 
profiles during exercise in children. We will recruit metabolically healthy children with a 
variety of BMI z-scores, including both lean and obese children. Children with T2D will be 
excluded from this study. All participants will undergo a 3-day standard diet. The day after the 
standard diet, fasted participants will undergo a treadmill stress test following the Bruce Protocol 
to obtain maximal oxygen uptake (VO2 max) (72) with regular blood sampling through an IV 
catheter. Samples will be analyzed using untargeted metabolomics and lipidomics to determine 
phenotypes that influence metabolic exercise-responses. We will analyze metabolic processes 
that are correlated with oxidative capacity and fuel selection, identifying metabolites and 
metabolic pathways biomarkers of disease risk. 
Specific Aim 2. Through a controlled feeding study, classify fasting blood metabolome 
alterations in response to two different diets (one high in carbohydrates and one high in 
fat). The metabolome is dynamic and reflective of macronutrient intake derived from diet (73). 
Post the 3-day standard diet, participants will consume one of two diets, either a high 
carbohydrate or a high fat diet, for 14-days. Following the first dietary treatment, all participants 
will consume a 3-day standard diet prior to crossover to other dietary treatment for 14-days. 
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Blood will be collected before, during, and after this study to assess how the metabolome reflects 
macronutrient intake. We hypothesize that the metabolome will respond to a feeding study 
differently in the pediatric population than in adults.  
Specific Aim 3. Identify intrinsic and phenotypic differences that influence metabolic 
response to dietary intervention. Utilizing the information gathered in Specific Aims 1 and 2, 
models will classify if fuel selection and/or oxidative capacity modulates response to dietary 
intervention. Saliva samples will be collected to assess genetic influences of fuel selection and 
oxidative capacity. Results from these models will indicate how intrinsic differences in children 
may influence metabolic response to dietary interventions allowing for the creation of tailored 
dietary recommendations.  
Public Health Relevance  
The results of these Developmental Origins of Health and Disease (DOHaD) studies suggest that 
the maternal metabolic environment has influences the establishment of the umbilical CB 
lipidome and infant birth weight, potentially through modulating DNA methylation. Modifying 
the intrauterine environment paired with dietary recommendations in the postnatal life may 
prevent adult metabolic disease. Grant funding should be aimed towards understanding 
mechanisms of the development of disease and assessing clinical relevance of interventions. 






Figure 5.1. Proposed influence of the maternal and cord blood lipidome on birth weight.  
 
Infant umbilical cord blood lipids associated with birth weight are potentially modulated by the 
maternal lipidome, beginning in early gestation. CB LysoPC and LysoPE lipid classes are 
positively associated with infant BW. CB PUFA containing TGs are inversely associated with 
BW. In the first trimester, maternal PUFA containing TGs are positive associated with CB PUFA 
containing TGs and inversely associated with CB LysoPLs. At delivery, maternal PUFA 
containing PCs and PEs are positively association with CB PUFA containing TGs, suggesting 
the importance in the phospholipid fraction for the transfer of PUFAs late in gestation. Maternal 
delivery PUFA containing SMs are inversely associated with CB PUFA containing TGs. Across 
gestation, maternal LysoPL levels are positively associated with CB LysoPL levels. Red arrows 




Figure 5.2. Proposed differences in mitochondrial oxidation in an insulin resistance and insulin 
sensitive cell.  
 
(A) In an insulin resistant cell, carbohydrates are the preferred fuel source. An increased glucose 
flux into the TCA cycle produces excess malonyl-CoA, inhibiting fatty acid entry into the 
mitochondria via CPT-1 and reducing β-oxidation. Fatty acids will accumulate in the cytosol. 
Very long-chain fatty acids can be shuttled to the peroxisomes for alpha-oxidation, producing 
long-chain dicarboxylic fatty acids. (B) In an insulin sensitive cell, fatty acids are the preferred 
fuel source. Fatty acids are shuttled from the cytosol into the mitochondria via CPT-1 to undergo 
β-oxidation. Increases in β-oxidation produce medium-chain acylcarnitines. Rescue pathways of 
fatty acids oxidation, alpha oxidation and omega oxidation, are able to oxidize fatty acid 
oxidation intermediates. Habitual dietary intake may exacerbate intrinsic mitochondrial 
differences in individuals.      
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Table 5.1. Effect of weight loss on clinical measures. Clinical characteristics of 11 lean and 31 
obese women, pre-weight loss and post-weight loss.  
 



















Age  40.3±1.2 41.4±0.5 41.4±0.5 1.00E-18 2.10E-11 3.00E-09 
BMI (kg/m2) 22.0±0.3 40.8±0.3 33.8±0.4 4.00E-07 0.0001 0.013 
Total fat mass (kg) 16.6±0.9 55.2±0.9 41.9±0.8 2.80E-07 5.50E-06 0.02 
Total FFM (kg) 42.7±0.8 55.7±0.6 51.8±0.5 7.10E-17 1.03E-10 3.00E-05 
% fat 27.7±1.2 49.6±0.3 44.3±0.5 7.10E-17 1.03E-10 3.00E-05 
REE/FFM (kcal/kg) 31.7±1.2 33.4±0.3 33.2±0.3 NS NS NS 
VO2max/FFM (mL/kg/min) 52.2±1.5 41.2±0.6 44.7±0.8 4.00E-05 1.50E-02 0.074 
Fasting glucose (mg/dL) 88.8±1.4 104.1±1.4 92.3±1.9 3.30E-01 NS 0.0006 
Fasting insulin (mIU/I) 9.5±0.6 22.0±0.6 13.3±0.3 2.10E-06 5.00E-03 1.50E-07 






























































































































































































































































































































































obese pre-WL - lean
obese post-WL - lean
B 
(A) Heat Map of standardized peak intensity for individual lipids (mean 0, standard deviation 
1). Lipids are grouped by lipid class with increasing total chain length and double bond from 
left to right in each lipid class. Beneath metabolite labels, colored bar indicate significantly 
changed metabolites (t-test, α=0.05) and direction of change (red denotes a significant 
increase, green denotes a significant decrease). (B) Individual triglycerides sorted by the 
number of double bonds. Plot of mean differences between obese, pre-WL minus lean (red) 
and obese, post-WL minus lean (blue). 
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Figure 5.4. Relationship between the Institute of Medicine gestational weight gain 



















































(A) Percentage of women that are below, within, or above IOM recommendations stratified 
by pre-pregnancy BMI. Number of women within each category listed above columns. (B) 
Comparison of Fenton BW percentile within BMI categories between women who were 
below, within, or above IOM GWG recommendations. There was a significant effect of IOM 
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